Puerto Rico
|
66-0555678
|
|
(STATE OF INCORPORATION)
|
(I.R.S. ID)
|
Title of each class
|
Name of each exchange on which registered
|
|
Class B common stock, $1.00 par value
|
New York Stock Exchange
|
Large accelerated filer ☐
|
Accelerated filer ☑
|
Non-accelerated filer ☐
|
Smaller reporting company ☐
|
Emerging growth company ☐
|
3
|
||
3
|
||
29
|
||
54
|
||
54
|
||
54
|
||
54
|
||
55
|
||
55
|
||
57
|
||
58
|
||
86
|
||
89
|
||
91
|
||
92
|
||
93
|
||
93
|
||
93
|
||
93
|
||
93
|
||
93
|
||
94
|
||
94
|
||
94
|
||
94
|
||
99
|
Market Sector
|
Enrollment at
December 31, 2017
|
Percentage of
Total Enrollment
|
||||||
Commercial
|
475,026
|
48.6
|
%
|
|||||
Medicare
|
118,451
|
12.1
|
%
|
|||||
Medicaid
|
384,462
|
39.3
|
%
|
|||||
Total
|
977,939
|
100.0
|
%
|
• |
failure to maintain our total adjusted capital at or above 375% of Health Risk-Based Capital (“HRBC”) Authorized Control Level (“ACL”) as defined by the
National Association of Insurance Commissioners
(“NAIC”) for the for Primary Licensee (TSM) and Larger BCBS Controlled Affiliate (TSS) and 100% HRBC ACL for the Smaller BCBS Controlled Affiliate (TSA);
|
• |
failure to maintain liquidity of greater than one month of underwritten claims and administrative expenses, as defined by the BCBSA, for two consecutive quarters;
|
• |
failure to satisfy state-mandated statutory net worth requirements;
|
• |
impending financial insolvency; and
|
• |
a change of control not otherwise approved by the BCBSA or a violation of the BCBSA voting and ownership limitations on our capital stock.
|
• |
grant, suspend and revoke licenses to transact business;
|
• |
regulate many aspects of the products and services we offer, including the review and approval of health insurance rates in the individual and small group markets;
|
• |
assess fines, penalties and/or sanctions;
|
• |
monitor our solvency and the adequacy of our financial reserves; and
|
• |
regulate our investment activities based on quality, diversification and other quantitative criteria, within the parameters of a list of permitted investments set forth in the insurance laws and regulations.
|
• |
initiatives to provide greater access to coverage for uninsured and under-insured populations without adequate funding to health plans or to be funded through taxes or other negative financial levies on health plans;
|
• |
other efforts or specific legislative changes to the Medicare or Medicaid program, including changes in the bidding process or other means that materially reduce premiums;
|
• |
local government regulatory changes;
|
• |
increased government enforcement, or changes in interpretation or application of fraud and abuse laws; and
|
• |
regulation that increase the operational burden on health plans or laws that increase a health plan’s exposure to liabilities, including efforts to expand the tort liability of health care plans.
|
• |
licensure;
|
• |
policy forms, including plan design and disclosures;
|
• |
premium rates and rating methodologies;
|
• |
underwriting rules and procedures;
|
• |
benefit mandates;
|
• |
eligibility requirements;
|
• |
security of electronically transmitted individually identifiable health information;
|
• |
geographic service areas;
|
• |
market conduct;
|
• |
utilization review;
|
• |
payment of claims, including timeliness and accuracy of payment;
|
• |
special rules on contracts to administer government programs;
|
• |
transactions with affiliated entities;
|
• |
limitations on the ability to pay dividends;
|
• |
payment rates to healthcare providers;
|
•
|
rate review and approval;
|
• |
transactions resulting in a change of control;
|
• |
member rights and responsibilities;
|
• |
fraud and abuse;
|
• |
sales and marketing activities;
|
• |
quality assurance procedures;
|
• |
privacy of medical and other information and permitted disclosures;
|
• |
surcharges on payments to providers;
|
• |
provider contract forms;
|
• |
delegation of financial risk and other financial arrangements in rates paid to healthcare providers;
|
• |
agent licensing;
|
• |
financial condition (including reserves);
|
• |
reinsurance;
|
• |
issuance of new capital stock shares;
|
• |
corporate governance;
|
• |
permissible investments; and
|
•
|
guaranteed issue and renewability.
|
• |
Part A covers, among other things, inpatient hospital stays, skilled nursing facility stays, home health visits (also covered under Part B), and hospice care.
|
• |
Part B covers physician visits, outpatient services, laboratory services, durable medical equipment, certain preventive services, and home health visits. Enrollment in Part B is voluntary and subject to an annual deductible.
|
• |
Part C, also known as Medicare Advantage, allows beneficiaries to enroll in private health plans and receive Medicare-covered benefits. Currently, about 17 million Medicare beneficiaries are enrolled in the United States in a Medicare Advantage plan. Under the Patient Protection and Affordable Care Act of 2010 (Pub. L No. 111-148), as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. No. 111-152), on March 30, 2010 (referred to herein as “ACA”), payments to Medicare Advantage plans are generally being reduced over time, and bonus payments are available to certain plans based on quality ratings. Medicare Advantage plans are required to maintain a medical loss ratio (“MLR”) of at least 85%, meaning, very basically, that if Medicare Advantage plans do not spend at least 85% of their revenue on patient care costs, may face various sanctions, including refunds, prohibition on enrolling new members, and contract termination. The Part C premium varies by plan.
|
• |
Part D is the voluntary, subsidized outpatient prescription drug benefit created under the Medicare Modernization Act of 2003 (the “MMA”). Part D includes subsidies for beneficiaries with low incomes that do not apply to Puerto Rico. Part D is offered through private plans that contract with Medicare, including stand-alone prescription drug plans and Medicare Advantage prescription drug plans. Part D plans are also subject to MLR requirements and their premium varies by plan.
|
• |
Provisions requiring greater access to coverage for certain uninsured and under-insured populations and the elimination of certain underwriting practices without adequate funding to health plans or with negative financial levies on health plans such as restrictions in the ability to charge additional premium for additional risk. These include, among others, (i) extending dependent coverage for unmarried individuals until age 26 under their parents’ health coverage, (ii) limiting a health plan’s ability to rescind coverage and restricting the plan’s ability to establish annual and lifetime financial caps, (iii) eliminating the use of gender as a ratings factor, and (iv) limiting a health plan’s ability to deny or limit coverage on grounds of a person’s pre-existing medical condition;
|
• |
Provisions restricting medical loss ratios and requiring premium refunds for non-compliance;
|
• |
Provisions requiring health plans to report to their members and HHS certain quality performance measures and their wellness promotion activities;
|
• |
Provisions that reduce premium payments to Medicare Advantage health plans and that tie such premium to the local Medicare fee for service costs. The adjustment began in 2012 and is being phased in over 5 to 7 years;
|
• |
Provisions that tie Medicare Advantage premiums to achievement of certain quality performance measures;
|
• |
Other efforts or specific legislative changes to the Medicare and Medicaid programs, including changes in the bidding process, authority of CMS to deny bids, or other means of materially reducing premiums such as through further adjustments to the risk adjustment methodology;
|
• |
Increased federal funding to the Medicaid program;
|
• |
Funding provided to the government of Puerto Rico to enable it to fund the expansion of its Medicaid program, rather than establish a health insurance exchange;
|
• |
Provisions that impose annual fees on health insurers;
|
• |
Increased government funding to enforcement agencies and/or changes in interpretation or application of fraud and abuse laws;
|
• |
Expanded scope of authority and/or funding to audit Medicare Advantage health plans and recoup premiums or other funds by the government or its representatives; and the increase in persons eligible for coverage under the Medicaid program in Puerto Rico, which may result in some persons currently insured by us in our commercial programs becoming eligible for, and thus moving to, the Medicaid program.
|
• |
trends in health care costs and utilization rates;
|
• |
ability to secure sufficient premium rate increases;
|
• |
competitor pricing below market trends of increasing costs;
|
• |
re-estimates of our policy and contract liabilities;
|
• |
changes in government regulation of managed care, life insurance or property and casualty insurance;
|
• |
significant acquisitions or divestitures by major competitors;
|
• |
introduction and use of new prescription drugs and technologies;
|
• |
a downgrade in our financial strength ratings;
|
• |
litigation or legislation targeted at managed care, life insurance or property and casualty insurance companies;
|
• |
ability to contract with providers and government agencies consistent with past practice;
|
• |
ability to successfully implement our disease management and utilization management programs;
|
• |
volatility in the securities markets and investment losses and defaults; and
|
• |
general economic downturns, major disasters and epidemics.
|
• |
Commercial:
One of our managed care subsidiaries is a qualified contractor to provide managed care coverage to federal government employees within Puerto Rico. Such coverage is provided pursuant to a contract with the OPM that is subject to termination in the event of non-compliance not corrected to the satisfaction of the OPM. During each of the years ended December 31, 2017, 2016, and 2015 premiums generated under this contract represented 5.7%, 5.8% and 5.6% of our consolidated premiums earned, net, respectively.
|
• |
Medicare:
We provide services through our Medicare Advantage products pursuant to a limited number of contracts with CMS. These contracts generally have terms of one year and must be renewed each year. Each of our contracts with CMS is cancellable for cause if we breach a material provision of the contract or violate relevant laws or regulations. If we are unable to renew, or to successfully re-bid or compete for any of these contracts, or if the process for bidding materially changes or if any of these contracts are terminated, our business could be materially impaired. During each of the years ended December 31, 2017, 2016, and 2015, contracts with CMS represented 36.6%, 35.4% and 39.4% of our consolidated premiums earned, net, respectively.
|
•
|
Medicaid:
We participate in the government of Puerto Rico Health Reform Program (similar to Medicaid) to provide health coverage to medically indigent citizens in Puerto Rico. Under the current agreement, TSS offers healthcare services on a fully-insured basis to Medicaid subscribers in the Metro North and West regions. TSS is also responsible for providing medical, mental, pharmacy and dental healthcare services to Medicaid subscribers in these service regions on an at-risk basis. The current agreement ends on June 30, 2018. The current agreement with ASES contains certain termination rights for both TSS and ASES, including ASES’s right to terminate the agreement as a result of insufficient government funds to pay ASES’s obligations under the contract and TSS’s right to terminate the agreement within 45 days before the end of each fiscal year if TSS and ASES have not agreed to the per member per month rate. For the years ended December 31, 2017, 2016 and 2015, premiums generated under our current agreement represented 26.6%, 27.1% and 21.8% of our consolidated premiums earned, net, respectively. In early February 2018, the Government of Puerto Rico issued a Request for Proposal (“RFP”) for the administration of its Medicaid program that will introduce significant changes to the model, including the elimination of geographical areas and allowing participants to select insurance carriers. The Company is thoroughly evaluating the RFP and all aspects of the new model, including financial, clinical, operational and systems requirements and risks.
|
• |
rising levels of actual costs that are not known by companies at the time they price their products;
|
• |
volatile and unpredictable developments, including man-made and natural catastrophes;
|
• |
changes in reserves resulting from the general claims and legal environments as different types of claims arise and judicial interpretations relating to the scope of insurers’ liability develop; and
|
• |
fluctuations in interest rates, inflationary pressures and other changes in the investment environment, which affect returns on invested capital.
|
• |
Significantly reducing the value of the debt securities we hold in our investment portfolio, and creating net realized capital losses that reduce our operating results and/or net unrealized capital losses that reduce our shareholders’ equity.
|
• |
Lowering interest rates on high quality short-term debt securities and thereby materially reducing our net investment income and operating results.
|
• |
Making it more difficult to value certain of our investment securities, for example if trading becomes less frequent, which could lead to significant period-to-period changes in our estimates of the fair values of those securities and cause period-to-period volatility in our operating results and shareholders’ equity.
|
• |
Reducing our ability to issue other securities.
|
• |
identify profitable growth opportunities in current and additional markets;
|
• |
transact successful acquisitions, capital investments and other growth initiatives;
|
• |
determine the correct value of assets and investments;
|
• |
implement adequate pricing and operational structure, including underwriting and claim management processes;
|
• |
design attractive and profitable insurance and health products and services;
|
• |
recruit required personnel for expanded operations, including officers, agents, brokers, medical providers, and other key personnel;
|
• |
obtain regulatory permission required to operate in other jurisdictions or lines of business;
|
• |
comply with regulatory requirements;
|
• |
integrate acquired business to our operations, including integration of information technology, management and personnel, and administrative systems;
|
• |
create the expected return over time; and
|
• |
Implement new, or modify existing internal monitoring and control systems.
|
• |
initiatives to provide greater access to coverage for uninsured and under-insured populations without adequate funding to health plan or to be funded through taxes or other negative financial levy on health plans;
|
• |
payments to health plans that are tied to achievement of certain quality performance measures and by health plans that do not satisfy applicable medical loss ratio requirements;
|
• |
other efforts or specific legislative changes to the Medicare or Medicaid programs, including changes in the bidding process or other means of materially reducing premiums;
|
• |
local government regulatory changes;
|
• |
increased government enforcement, or changes in interpretation or application, of fraud and abuse and health information privacy laws; and
|
• |
regulations that increase the operational burden on health plans that increase a health plan’s exposure to liabilities, including efforts to expand the tort liability of health plans.
|
• |
recoupment of amounts we have been paid pursuant to our government contracts;
|
• |
mandated changes in our business practices;
|
• |
imposition of significant civil or criminal penalties, fines or other sanctions on us and/or our key employees;
|
• |
additional reporting requirements and oversight and mandated corrective action or remediation plans;
|
• |
loss or non-renewal of our government contracts or loss of our ability to participate in Medicare or other federal or local governmental payor programs; damage to our reputation;
|
• |
increased difficulty in marketing our products and services;
|
• |
inability to obtain approval for future services or geographic expansions; and
|
• |
loss of one or more of our licenses to act as an insurance company, preferred provider or managed care organization or other licensed entity or to otherwise provide a service.
|
• |
permit our board of directors to issue one or more series of preferred stock;
|
• |
divide our board of directors into three classes serving staggered three-year terms;
|
• |
limit the ability of shareholders to remove directors;
|
• |
impose restrictions on shareholders’ ability to fill vacancies on our board of directors;
|
• |
impose advance notice requirements for shareholder proposals and nominations of directors to be considered at meetings of shareholders; and
|
• |
impose restrictions on shareholders’ ability to amend our articles and bylaws.
|
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
High
|
Low
|
|||||||
2017
|
||||||||
First quarter
|
$
|
21.47
|
$
|
16.60
|
||||
Second quarter
|
18.62
|
16.09
|
||||||
Third quarter
|
24.71
|
15.16
|
||||||
Fourth quarter
|
28.87
|
23.37
|
||||||
2016
|
||||||||
First quarter
|
$
|
26.83
|
$
|
19.99
|
||||
Second quarter
|
27.50
|
21.60
|
||||||
Third quarter
|
26.55
|
21.51
|
||||||
Fourth quarter
|
23.68
|
19.00
|
Ticker
|
Name
|
1/2/2013
|
12/31/2013
|
12/31/2014
|
12/31/2015
|
12/31/2016
|
12/31/2017
|
||||||||||||||||||
GTS US Equity
|
TRIPLE-S MANAGEMENT CORP
|
100.00
|
100.31
|
123.37
|
123.37
|
106.81
|
128.22
|
||||||||||||||||||
SPX Index
|
S&P 500 INDEX
|
100.00
|
126.39
|
140.79
|
139.76
|
153.09
|
182.82
|
||||||||||||||||||
S5MANH Index
|
S&P MHC Index
|
100.00
|
144.98
|
191.26
|
230.34
|
271.88
|
387.22
|
(Dollar amounts in millions, except per share data)
|
Total Number
of Shares
Purchased
|
Average
Price
Paid per
Share
|
Total Number of
Shares
Purchased as
Part of Publicly
Announced
Programs ¹
|
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
|
||||||||||||
October 1, 2017 to October 31, 2017
|
310,481
|
$
|
23.79
|
310,481
|
$
|
10.0
|
||||||||||
November 1, 2017 to November 30, 2017
|
11,900
|
23.95
|
11,900
|
9.8
|
||||||||||||
December 1, 2017 to December 31, 2017
|
-
|
-
|
-
|
9.8
|
2017
|
2016
|
2015
|
2014
|
2013
|
||||||||||||||||
(Dollar amounts in millions, except per share data)
|
||||||||||||||||||||
Years ended December 31,
|
||||||||||||||||||||
Premiums earned, net
|
$
|
2,826.9
|
$
|
2,890.6
|
$
|
2,783.2
|
$
|
2,128.6
|
$
|
2,203.0
|
||||||||||
Administrative service fees
|
16.5
|
17.9
|
44.7
|
119.3
|
108.7
|
|||||||||||||||
Net investment income
|
51.6
|
48.9
|
45.2
|
47.5
|
47.3
|
|||||||||||||||
Other operating revenues
|
3.7
|
3.5
|
3.7
|
4.2
|
4.8
|
|||||||||||||||
Total operating revenues
|
2,898.7
|
2,960.9
|
2,876.8
|
2,299.6
|
2,363.8
|
|||||||||||||||
Net realized investments gains
|
10.8
|
17.4
|
18.9
|
18.2
|
2.6
|
|||||||||||||||
Other income, net
|
6.6
|
6.5
|
7.0
|
2.3
|
15.3
|
|||||||||||||||
Total revenues
|
2,916.1
|
2,984.8
|
2,902.7
|
2,320.1
|
2,381.7
|
|||||||||||||||
Benefits and expenses:
|
||||||||||||||||||||
Claims incurred
|
2,353.1
|
2,472.2
|
2,318.7
|
1,747.6
|
1,836.2
|
|||||||||||||||
Operating expenses
|
477.2
|
493.9
|
518.7
|
497.2
|
478.2
|
|||||||||||||||
Total operating costs
|
2,830.3
|
2,966.1
|
2,837.4
|
2,244.8
|
2,314.4
|
|||||||||||||||
Interest expense
|
6.8
|
7.6
|
8.2
|
9.3
|
9.5
|
|||||||||||||||
Total benefits and expenses
|
2,837.1
|
2,973.7
|
2,845.6
|
2,254.1
|
2,323.9
|
|||||||||||||||
Income before taxes
|
79.0
|
11.1
|
57.1
|
66.0
|
57.8
|
|||||||||||||||
Income tax expense (benefit)
|
24.5
|
(6.3
|
)
|
5.1
|
0.7
|
2.3
|
||||||||||||||
Net income
|
54.5
|
17.4
|
52.0
|
65.3
|
55.5
|
|||||||||||||||
Net loss attributable to non-controlling interest
|
-
|
-
|
(0.1
|
)
|
(0.4
|
)
|
(0.4
|
)
|
||||||||||||
Net income attributable to TSM
|
$
|
54.5
|
$
|
17.4
|
$
|
52.1
|
$
|
65.7
|
$
|
55.9
|
||||||||||
Basic net income per share (1):
|
$
|
2.27
|
$
|
0.71
|
$
|
2.03
|
$
|
2.42
|
$
|
2.02
|
||||||||||
Diluted net income per share:
|
$
|
2.26
|
$
|
0.71
|
$
|
2.02
|
$
|
2.41
|
$
|
2.01
|
2017
|
2016
|
2015
|
2014
|
2013
|
||||||||||||||||
Years ended December 31,
|
||||||||||||||||||||
Cash and cash equivalents
|
$
|
198.9
|
$
|
103.4
|
$
|
197.8
|
$
|
110.0
|
$
|
74.4
|
||||||||||
Total assets
|
$
|
3,116.8
|
$
|
2,219.0
|
$
|
2,206.1
|
$
|
2,145.7
|
$
|
2,047.6
|
||||||||||
Long-term borrowings
|
$
|
32.1
|
$
|
35.1
|
$
|
36.8
|
$
|
74.5
|
$
|
89.3
|
||||||||||
Total stockholders' equity
|
$
|
913.4
|
$
|
863.2
|
$
|
847.5
|
$
|
858.6
|
$
|
785.4
|
|
2017
|
2016
|
2015
|
2014
|
2013
|
|||||||||||||||
Years ended December 31,
|
||||||||||||||||||||
Medical loss ratio
|
85.6
|
%
|
88.6
|
%
|
86.2
|
%
|
85.9
|
%
|
86.7
|
%
|
||||||||||
Operating expense ratio
|
13.6
|
%
|
14.0
|
%
|
15.1
|
%
|
18.5
|
%
|
17.0
|
%
|
||||||||||
Medical membership (period end)
|
977,939
|
1,017,372
|
1,094,444
|
2,139,484
|
2,187,939
|
(1) |
Further details of the calculation of basic and diluted earnings per share are set forth
in Notes 2 and 21 of the audited consolidated financial statements for the years ended December 31, 2017, 2016 and 2015.
|
(2) |
Does not reflect inter-segment eliminations.
|
· |
Consolidated premiums earned, net decreased 2.2% year over year, to $2.8 billion, primarily reflecting lower Managed Care and Property and Casualty premiums.
|
· |
The lower Managed Care premiums reflect lower membership in the segment’s Medicaid and Commercial businesses, the impact of the suspension of the HIP fee pass through in 2017, and lower Medicare additional risk score revenue. These decreases were partially offset by higher average premium rates in the Commercial and Medicaid businesses, as well as by higher Medicare membership.
|
· |
Consolidated claims for the year were $2.4 billion, down 4.8% over last year, primarily reflecting lower Managed Care membership, the ongoing improvement in our managed care operations, and the estimated decrease in the utilization of Managed Care services caused by Hurricanes Irma and Maria in September 2017. These decreases were offset in part by the estimated $14.8 million net retained losses incurred by the Property and Casualty segment caused by the aforementioned Hurricanes. The consolidated loss ratio was down 230 basis points, to 83.2%, and the Medical Loss Ratio (“MLR”) decreased 300 basis points, to 85.6%.
|
· |
Consolidated operating expenses for the year were $477.2 million and the operating expense ratio was 16.8%.
|
· |
Net income for the year was $54.5 million, an increase from a net income of $17.4 million in the prior year, primarily reflecting improvements in the Managed Care segment’s MLR.
|
Years ended December 31, | ||||||||||||
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Premiums earned, net:
|
||||||||||||
Managed care
|
$
|
2,590.0
|
$
|
2,648.5
|
$
|
2,549.5
|
||||||
Life insurance
|
161.8
|
156.9
|
148.1
|
|||||||||
Property and casualty insurance
|
77.2
|
87.9
|
87.6
|
|||||||||
Intersegment premiums earned
|
(2.1
|
)
|
(2.7
|
)
|
(2.0
|
)
|
||||||
Consolidated premiums earned, net
|
$
|
2,826.9
|
$
|
2,890.6
|
$
|
2,783.2
|
||||||
Administrative service fees:
|
||||||||||||
Managed care
|
$
|
21.6
|
$
|
22.4
|
$
|
49.3
|
||||||
Intersegment administrative service fees
|
(5.1
|
)
|
(4.5
|
)
|
(4.6
|
)
|
||||||
Consolidated administrative service fees
|
$
|
16.5
|
$
|
17.9
|
$
|
44.7
|
||||||
Operating income (loss):
|
||||||||||||
Managed care
|
$
|
55.0
|
$
|
(36.8
|
)
|
$
|
20.5
|
|||||
Life insurance
|
19.4
|
21.5
|
20.0
|
|||||||||
Property and casualty insurance
|
(6.0
|
)
|
12.1
|
8.3
|
||||||||
Intersegment and other
|
-
|
(2.0
|
)
|
(9.4
|
)
|
|||||||
Consolidated operating income (loss)
|
$
|
68.4
|
$
|
(5.2
|
)
|
$
|
39.4
|
As of December 31, | ||||||||||||
2017
|
2016
|
2015
|
||||||||||
Commercial
(1)
|
475,026
|
509,157
|
547,634
|
|||||||||
Medicare
|
118,451
|
110,297
|
123,888
|
|||||||||
Medicaid
|
384,462
|
397,918
|
422,922
|
|||||||||
Total
|
977,939
|
1,017,372
|
1,094,444
|
(1) |
Commercial membership includes corporate accounts, self-funded employers, individual accounts, Medicare Supplement, federal government employees and local government employees.
|
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Years ended December 31,
|
||||||||||||
Revenues:
|
||||||||||||
Premiums earned, net
|
$
|
2,826.9
|
$
|
2,890.6
|
$
|
2,783.2
|
||||||
Administrative service fees
|
16.5
|
17.9
|
44.7
|
|||||||||
Net investment income
|
51.6
|
48.9
|
45.2
|
|||||||||
Other operating revenues
|
3.7
|
3.5
|
3.7
|
|||||||||
Total operating revenues
|
2,898.7
|
2,960.9
|
2,876.8
|
|||||||||
Net realized investment gains
|
10.8
|
17.4
|
18.9
|
|||||||||
Other income, net
|
6.6
|
6.5
|
7.0
|
|||||||||
Total revenues
|
2,916.1
|
2,984.8
|
2,902.7
|
|||||||||
Benefits and expenses:
|
||||||||||||
Claims incurred
|
2,353.1
|
2,472.2
|
2,318.7
|
|||||||||
Operating expenses
|
477.2
|
493.9
|
518.7
|
|||||||||
Total operating costs
|
2,830.3
|
2,966.1
|
2,837.4
|
|||||||||
Interest expense
|
6.8
|
7.6
|
8.2
|
|||||||||
Total benefits and expenses
|
2,837.1
|
2,973.7
|
2,845.6
|
|||||||||
Income before taxes
|
79.0
|
11.1
|
57.1
|
|||||||||
Income (benefit) tax expense
|
24.5
|
(6.3
|
)
|
5.1
|
||||||||
Net income
|
54.5
|
17.4
|
52.0
|
|||||||||
Net loss attributable to non-controlling interest
|
-
|
-
|
(0.1
|
)
|
||||||||
Net income attributable to TSM
|
$
|
54.5
|
$
|
17.4
|
$
|
52.1
|
• |
For the 2016 period the Managed Care segment, which has a higher effective tax rate than our other segments, incurred in a loss before taxes, resulting in the recording of a tax benefit during the period.
|
• |
During the 2015 period, the Company executed a Closing Agreement between TSM and its subsidiaries and the Puerto Rico Treasury Department in connection with a local law that provided a temporary preferential tax rate in capital asset transactions. These events allowed the Company to record a $3.1 million benefit in the 2015 period resulting from the enacted lower taxable rate and the reassessment of the realizability of some of its deferred taxes.
|
• |
The Property and Casualty segment reassessed the tax rate used to measure several temporary differences; as a consequence such rate was increased from 20% to 39%, resulting in an increase to its deferred tax expense of approximately $3.6 million in 2016
|
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Operating revenues:
|
||||||||||||
Medical premiums earned, net:
|
||||||||||||
Commercial
|
$
|
803.3
|
$
|
841.4
|
$
|
844.6
|
||||||
Medicare
|
1,035.3
|
1,023.9
|
1,097.7
|
|||||||||
Medicaid
|
751.4
|
783.2
|
607.2
|
|||||||||
Medical premiums earned, net
|
2,590.0
|
2,648.5
|
2,549.5
|
|||||||||
Administrative service fees
|
21.6
|
22.4
|
49.3
|
|||||||||
Net investment income
|
16.6
|
15.1
|
11.8
|
|||||||||
Total operating revenues
|
2,628.2
|
2,686.0
|
2,610.6
|
|||||||||
Medical operating costs:
|
||||||||||||
Medical claims incurred
|
2,218.3
|
2,347.5
|
2,196.7
|
|||||||||
Medical operating expenses
|
354.9
|
375.3
|
393.4
|
|||||||||
Total medical operating costs
|
2,573.2
|
2,722.8
|
2,590.1
|
|||||||||
Medical operating income (loss)
|
$
|
55.0
|
$
|
(36.8
|
)
|
$
|
20.5
|
|||||
Additional data:
|
||||||||||||
Member months enrollment:
|
||||||||||||
Commercial:
|
||||||||||||
Fully-insured
|
3,981,347
|
4,209,920
|
4,492,395
|
|||||||||
Self-funded
|
1,967,668
|
2,144,621
|
2,221,327
|
|||||||||
Total Commercial member months
|
5,949,015
|
6,354,541
|
6,713,722
|
|||||||||
Medicare member months
|
1,457,363
|
1,394,272
|
1,447,420
|
|||||||||
Medicaid:
|
||||||||||||
Fully-insured
|
4,631,316
|
4,829,729
|
3,855,945
|
|||||||||
Self-funded
|
-
|
-
|
4,229,082
|
|||||||||
Total Medicaid member months
|
4,631,316
|
4,829,729
|
8,085,027
|
|||||||||
Total member months
|
12,037,694
|
12,578,542
|
16,246,169
|
|||||||||
Medical loss ratio
|
85.6
|
%
|
88.6
|
%
|
86.2
|
%
|
||||||
Operating expense ratio
|
13.6
|
%
|
14.1
|
%
|
15.1
|
%
|
· |
Medical premiums generated by the Commercial business decreased by $38.1 million, or 4.5%, to $803.3 million. This fluctuation primarily reflects lower fully-insured enrollment during the year of approximately 228,600 member months and $14.5 million related to the suspension of the HIP fee pass-through; offset by an increase in average premium rates of approximately 5%.
|
· |
Medical premiums generated by the Medicare business increased by $11.4 million, or 1.1%, to $1,035.3 million, primarily reflecting an increase in member months enrollment of approximately 63,100 lives. This increase is partially offset by lower additional risk score revenue by $30.9 million as well as lower average premium rates due to a reduction in the 2017 Medicare reimbursement rates.
|
· |
Medical premiums generated by the Medicaid business decreased by $31.8 million to $751.4 million. This decrease primarily reflects lower fully-insured member months enrollment by approximately 198,400 lives, $10.8 million related to the suspension of the HIP fee pass-through as a result of the 2017 moratorium and, the impact of the 2.5% excess profit accrual that increased 2016 premiums by $10.9 million. Decreases are partially offset by a $12.2 million increase in premium collections related to our compliance with the contract’s quality incentive metrics and the impact of the new premium rates that were effective July 1st 2017, which increased average premium rates by approximately 9%.
|
· |
The medical claims incurred of the Commercial business decreased by $94.5 million, or 13.2%, during the 2017 period and its MLR, at 77.5%, was 770 basis points lower than the same period last year. Adjusting for the effect of prior period reserve developments, the Commercial MLR would have been 77.9%, 590 basis points lower than the adjusted MLR for last year, primarily reflecting the estimated decrease in utilization caused by Hurricanes Irma and Maria in September 2017 as well as the ongoing claim trends that are lower than our premium trends following the continuity of our underwriting discipline. The estimated decrease in utilization related to the aforementioned hurricanes account for approximately 310 of the 590 basis-points decrease in the adjusted MLR.
|
· |
The medical claims incurred of the Medicare business decreased by $16.6 million, or 1.8%, during the 2017 period and its MLR decreased by 260 basis points, to 87.7 %. Adjusting for the effect of prior period reserve developments in 2017 and 2016 and moving the additional risk score revenue adjustments to their corresponding period, the Medicare MLR would have been approximately 88.4%, about 80 basis points lower than last year. The estimated decrease in utilization caused by Hurricanes Irma and Maria mitigated the impact of the higher trends in Part B drugs and pharmacy benefits experienced by this business as well as the improvement of benefits in 2017 products taking advantage of the HIP fee moratorium. The estimated decrease in utilization related to the aforementioned hurricanes lowered by approximately 270 basis points the adjusted MLR.
|
· |
The medical claims incurred of the Medicaid business decreased by $18.2 million, or 2.6%, during the 2017 period
and its MLR increased by 140 basis points, to 91.5%. Adjusting for the effect of prior period reserve developments in 2017 and 2016, as well as for the impact of the 2.5% excess profit accrual and this year’s quality incentive premiums, the Medicaid MLR would have been approximately 91.8%, about 180 basis points higher than last year. The higher MLR primarily reflects increased pharmacy and outpatient claim trends, partially offset by the estimated decrease in utilization caused by Hurricanes Irma and Maria, which lowered the adjusted MLR by 30 basis points, and
the impact of the higher premium rates that were effective July 1
st
2017.
|
· |
Medical premiums generated by the Commercial business decreased by $3.2 million, or 0.4%, to $841.4 million primarily resulting from a decrease in fully-insured member months enrollment, partially offset by an approximately 5% year over year increase in average premium rates.
|
· |
Medical premiums generated by the Medicare business decreased by $73.8 million, or 6.7%, to $1,000 million. This fluctuation primarily results from lower risk score revenue as compared with 2015, lower member months enrollment, and a reduction in 2016 Medicare reimbursement rates.
|
· |
Medical premiums generated by the Medicaid business increased by $176.0 million to $783.2 million, primarily as the result of the change in the Medicaid service model, from an ASO agreement to a fully-insured model effective April 1, 2015.
|
· |
The medical claims incurred of the Commercial business increased by $4.3 million, or 0.6%, during 2016, mostly reflecting the impact of prior period reserve developments, partially offset by lower member months enrollment. The Commercial MLR was 85.2%, which is 100 basis points higher than the MLR for the prior year. Excluding the effect of prior period reserve developments in 2016 and 2015, the MLR would have decreased by 270 basis points, reflecting the continuity of our underwriting discipline and premium trends higher than claims trends.
|
· |
The medical claims incurred of the Medicare business decreased by $4.1 million, or 0.4%, during the 2016 period reflecting the previously mentioned decrease in membership and changes in benefit design included in 2016 products as the result of the decrease in reimbursement rates. This decrease is offset by unfavorable prior period reserve developments. The Medicare MLR was 90.3%, which is 570 basis points higher than the MLR for the prior year. Adjusting for the effect of prior period reserve developments, and moving the 2015 final risk score revenue adjustments to its corresponding period, our Medicare MLR would have been 90.0%, about 530 basis points higher than last year. The higher MLR primarily reflects higher Part B drug costs mainly related to cancer and rheumatoid arthritis, additional deterioration in the experience of End Stage Renal Disease (ESRD) and the effect of the decrease in 2016 Medicare reimbursement rates.
|
· |
The medical claims incurred of the Medicaid business increased by $150.7 million during the 2016 period reflecting the previously mentioned change in the Medicaid contract effective April 1, 2015.
|
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Years ended December 31,
|
||||||||||||
Operating revenues:
|
||||||||||||
Premiums earned, net:
|
||||||||||||
Premiums earned
|
$
|
166.4
|
$
|
161.3
|
$
|
153.8
|
||||||
Assumed earned premiums
|
4.2
|
4.4
|
3.9
|
|||||||||
Ceded premiums earned
|
(8.8
|
)
|
(8.8
|
)
|
(9.6
|
)
|
||||||
Premiums earned, net
|
161.8
|
156.9
|
148.1
|
|||||||||
Net investment income
|
24.8
|
24.9
|
24.5
|
|||||||||
Total operating revenues
|
186.6
|
181.8
|
172.6
|
|||||||||
Operating costs:
|
||||||||||||
Policy benefits and claims incurred
|
87.3
|
86.9
|
82.6
|
|||||||||
Underwriting and other expenses
|
79.9
|
73.4
|
70.0
|
|||||||||
Total operating costs
|
167.2
|
160.3
|
152.6
|
|||||||||
Operating income
|
$
|
19.4
|
$
|
21.5
|
$
|
20.0
|
||||||
Additional data:
|
||||||||||||
Loss ratio
|
54.0
|
%
|
55.4
|
%
|
55.8
|
%
|
||||||
Expense ratio
|
49.4
|
%
|
46.8
|
%
|
47.3
|
%
|
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Years ended December 31,
|
||||||||||||
Operating revenues:
|
||||||||||||
Premiums earned, net:
|
||||||||||||
Premiums written
|
$
|
143.8
|
$
|
133.1
|
$
|
134.4
|
||||||
Premiums ceded
|
(62.3
|
)
|
(46.0
|
)
|
(48.7
|
)
|
||||||
Change in unearned premiums
|
(4.3
|
)
|
0.8
|
1.9
|
||||||||
Premiums earned, net
|
77.2
|
87.9
|
87.6
|
|||||||||
Net investment income
|
9.5
|
8.9
|
8.7
|
|||||||||
Total operating revenues
|
86.7
|
96.8
|
96.3
|
|||||||||
Operating costs:
|
||||||||||||
Claims incurred
|
50.8
|
40.8
|
42.6
|
|||||||||
Underwriting and other operating expenses
|
41.9
|
43.9
|
45.4
|
|||||||||
Total operating costs
|
92.7
|
84.7
|
88.0
|
|||||||||
Operating (loss) income
|
$
|
(6.0
|
)
|
$
|
12.1
|
$
|
8.3
|
|||||
Additional data:
|
||||||||||||
Loss ratio
|
65.8
|
%
|
46.4
|
%
|
48.6
|
%
|
||||||
Expense ratio
|
54.3
|
%
|
49.9
|
%
|
51.8
|
%
|
(Dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Sources (uses) of cash:
|
||||||||||||
Cash provided by operating activities
|
$
|
286.2
|
$
|
6.5
|
$
|
229.1
|
||||||
Net purchases of investment securities
|
(154.6
|
)
|
(80.9
|
)
|
(41.6
|
)
|
||||||
Net capital expenditures
|
(21.4
|
)
|
(4.8
|
)
|
(9.1
|
)
|
||||||
Proceeds from long-term borrowoings
|
24.3
|
-
|
-
|
|||||||||
Payments of long-term borrowings
|
(27.1
|
)
|
(1.7
|
)
|
(37.6
|
)
|
||||||
Proceeds from policyholder deposits
|
13.6
|
18.2
|
16.5
|
|||||||||
Surrenders of policyholder deposits
|
(22.1
|
)
|
(21.9
|
)
|
(18.8
|
)
|
||||||
Repurchase and retirement of common stock
|
(20.2
|
)
|
(21.4
|
)
|
(48.3
|
)
|
||||||
Other
|
12.2
|
11.6
|
(2.4
|
)
|
||||||||
Net increase (decrease) in cash and cash equivalents
|
$
|
90.9
|
$
|
(94.4
|
)
|
$
|
87.8
|
·
|
The table below describes the payments due under our contractual obligations, aggregated by type of contractual obligation, including the maturity profile of our debt, operating leases and other long-term liabilities, but excludes an estimate of the future cash outflows related to the following:
|
o
|
Alternative investments
– The Company has $117.6 million of unfunded capital commitments related to alternative investments. These commitments were excluded from this disclosure due to the undeterminate nature of their cash flows.
|
o
|
Unearned premiums – This amount accounts for the premiums collected prior to the end of coverage period and does not represent a future cash outflow. As of December 31, 2017, we had $86.3 million in unearned premiums.
|
o
|
Policyholder deposits – The cash outflows related to these instruments are not included because they do not have defined maturities, such that the timing of payments and withdrawals is uncertain. There are currently no significant policyholder deposits in paying status. As of December 31, 2017, our policyholder deposits had a carrying amount of $176.5 million.
|
o
|
Other long-term liabilities – Due to the indeterminate nature of their cash outflows, $107.9 million of other long-term liabilities are not reflected in the following table, including $33.7 million of liability for pension benefits, $21.9 million in deferred tax liabilities, and $52.3 million in liabilities to the Federal Employees’ Health Benefits Plan Program.
|
Contractual obligations by year
|
||||||||||||||||||||||||||||
(Dollar amounts in millions)
|
Total
|
2018
|
2019
|
2020
|
2021
|
2022
|
Thereafter
|
|||||||||||||||||||||
Long-term borrowings (1)
|
$
|
37.4
|
$
|
4.2
|
$
|
4.3
|
$
|
4.2
|
$
|
4.0
|
$
|
3.9
|
$
|
16.8
|
||||||||||||||
Operating leases
|
11.6
|
4.2
|
3.8
|
2.0
|
0.6
|
1.0
|
-
|
|||||||||||||||||||||
Purchase obligations (2)
|
297.9
|
236.2
|
42.0
|
5.4
|
4.5
|
2.3
|
7.5
|
|||||||||||||||||||||
Claim liabilities (3)
|
464.4
|
370.1
|
56.6
|
11.6
|
8.1
|
7.4
|
10.6
|
|||||||||||||||||||||
Estimated obligation for future policy benefits (4)
|
657.9
|
133.1
|
116.6
|
108.6
|
102.0
|
96.2
|
101.4
|
|||||||||||||||||||||
$
|
1,469.2
|
$
|
747.8
|
$
|
223.3
|
$
|
131.8
|
$
|
119.2
|
$
|
110.8
|
$
|
136.3
|
(1)
|
As of December 31, 2017, our long-term borrowings consist of a credit agreement entered with a commercial bank in Puerto Rico. See the “Financing and Financing Capacity” section for additional information regarding our long-term borrowings.
|
(2)
|
Purchase obligations represent payments required by us under material agreements to purchase goods or services that are enforceable and legally binding and where all significant terms are specified, including: quantities to be purchased, price provisions and the timing of the transaction. Other purchase orders made in the ordinary course of business for which we are not liable are excluded from the table above. Estimated pension plan contributions amounting to $2.0 million were included within the total purchase obligations. However, this amount is an estimate which may be subject to change in view of the fact that contribution decisions are affected by various factors such as market performance, regulatory and legal requirements and plan funding policy.
|
(3)
|
Claim liabilities represent the amount of our claims processed and incomplete as well as an estimate of the amount of incurred but not reported claims and loss-adjustment expenses. This amount does not include an estimate of claims to be incurred subsequent to December 31, 2017. The expected claims payments are an estimate and may differ materially from the actual claims payments made by us in the future. Also, claim liabilities are presented gross, and thus do not reflect the effects of reinsurance under which $642.5 million of reserves had been ceded at December 31, 2017.
|
(4)
|
Our life insurance segment establishes, and carries as liabilities, actuarially determined amounts that are calculated to meet its policy obligations when a policy matures or surrenders, an insured dies or becomes disabled or upon the occurrence of other covered events. A significant portion of the estimated obligation for future policy benefits to be paid included in this table considers contracts under which we are currently not making payments and will not make payments until the occurrence of an insurable event not under our control, such as death, illness, or the surrender of a policy. We have estimated the timing of the cash flows related to these contracts based on historical
experience as well as expectations of future payment patterns. The amounts presented in the table above represent the estimated cash payments for benefits under such contracts based on assumptions related to the receipt of future premiums and assumptions related to mortality, morbidity, policy lapses, renewals, retirements, disability incidence and other contingent events as appropriate for the respective product type. All estimated cash payments included in this table are not discounted to present value nor do they take into account estimated future premiums on policies in-force as of December 31, 2017 and are gross of any reinsurance recoverable. The $657.9 million total estimated cash flows for all years in the table is different from the liability of future policy benefits of $339.5
million included in our audited consolidated financial statements principally due to the time value of money. Actual cash payments to policyholders could differ significantly from the estimated cash payments as presented in this table due to differences between actual experience and the assumptions used in the estimation of these payments.
|
(Dollar amounts in millions)
|
||||
Managed care
|
$
|
367.0
|
||
Property and casualty insurance
|
694.4
|
|||
Life insurance
|
45.5
|
|||
Consolidated
|
$
|
1,106.9
|
(1) |
Assumes (decrease) increase in the completion factors for the most recent twelve months.
|
(2) |
Assumes (decrease) increase in the claims trend factors for the most recent twelve months.
|
(Dollar amounts in millions)
|
2016
|
2015
|
2014
|
|||||||||
Years ended December 31,
|
||||||||||||
Total incurred claims:
|
||||||||||||
As reported
(1)
|
$
|
2,356.6
|
$
|
2,216.3
|
$
|
1,665.3
|
||||||
On a retrospective basis
|
2,343.8
|
2,207.3
|
1,645.6
|
|||||||||
Variance
|
$
|
12.8
|
$
|
9.0
|
$
|
19.7
|
||||||
Variance to total incurred claims as reported
|
0.5
|
%
|
0.4
|
%
|
1.2
|
%
|
(1) |
Includes total claims incurred less adjustments for prior year reserve development.
|
· |
Through the management of our cash flows and investment portfolio.
|
· |
In the Commercial business we have the ability to increase the premium rates throughout the year in the monthly renewal process, when renegotiating the premiums for the following contract year of each group as they become due. We consider the actual claims trend of each group when determining the premium rates for the following contract year.
|
· |
We have available short-term borrowing facilities that from time to time address differences between cash receipts and disbursements.
|
· |
the market risk information is limited by the assumptions and parameters established in creating the related sensitivity analysis, including the impact of prepayment rates on mortgages; and
|
· |
the model assumes that the composition of assets and liabilities remains unchanged throughout the year.
|
(Dollar amounts in millions)
|
|||||||||||||
Change in Interest Rates
|
Expected
Fair Value
|
Amount of
Decrease
|
%
Change
|
||||||||||
December 31, 2017:
|
|||||||||||||
Base Scenario
|
$
|
1,219.3
|
|||||||||||
+100 bp
|
|
1,163.4
|
(55.9
|
)
|
(4.6
|
)%
|
|||||||
+200 bp
|
|
1,111.7
|
(107.6
|
)
|
(8.8
|
)%
|
|||||||
+300 bp
|
|
1,062.4
|
(156.9
|
)
|
(12.9
|
)%
|
|||||||
December 31, 2016:
|
|||||||||||||
Base Scenario
|
$
|
1,154.6
|
|||||||||||
+100 bp
|
|
1,102.0
|
(52.6
|
)
|
(4.6
|
)%
|
|||||||
+200 bp
|
|
1,053.2
|
(101.4
|
)
|
(8.9
|
)%
|
|||||||
+300 bp
|
|
1,007.1
|
(147.5
|
)
|
(13.0
|
)%
|
2017
|
||||||||||||||||||||
March 31
|
June 30
|
September 30
|
December 31
|
Total
|
||||||||||||||||
Revenues
|
||||||||||||||||||||
Premiums earned, net
|
$
|
702,273
|
$
|
722,891
|
$
|
714,325
|
$
|
687,443
|
$
|
2,826,932
|
||||||||||
Administrative service fees
|
4,379
|
4,548
|
3,391
|
4,196
|
16,514
|
|||||||||||||||
Net investment income
|
12,016
|
12,698
|
12,395
|
14,506
|
51,615
|
|||||||||||||||
Other operating revenues
|
965
|
1,121
|
941
|
633
|
3,660
|
|||||||||||||||
Total operating revenues
|
719,633
|
741,258
|
731,052
|
706,778
|
2,898,721
|
|||||||||||||||
Net realized investment gains (losses):
|
||||||||||||||||||||
Total other-than-temporary impairment losses on securities
|
-
|
-
|
-
|
(49
|
)
|
(49
|
)
|
|||||||||||||
Net realized gains, excluding other-than-temporary impairment losses on securities
|
336
|
4,054
|
3,753
|
2,737
|
10,880
|
|||||||||||||||
Total net realized investment gains
|
336
|
4,054
|
3,753
|
2,688
|
10,831
|
|||||||||||||||
Other income, net
|
2,525
|
587
|
3,409
|
12
|
6,533
|
|||||||||||||||
Total revenues
|
722,494
|
745,899
|
738,214
|
709,478
|
2,916,085
|
|||||||||||||||
Benefits and expenses
|
||||||||||||||||||||
Claims incurred
|
620,863
|
611,297
|
583,625
|
537,316
|
2,353,101
|
|||||||||||||||
Operating expenses
|
110,946
|
118,720
|
119,145
|
128,402
|
477,213
|
|||||||||||||||
Total operating costs
|
731,809
|
730,017
|
702,770
|
665,718
|
2,830,314
|
|||||||||||||||
Interest expense
|
1,686
|
1,721
|
1,709
|
1,678
|
6,794
|
|||||||||||||||
Total benefits and expenses
|
733,495
|
731,738
|
704,479
|
667,396
|
2,837,108
|
|||||||||||||||
(Loss) income before taxes
|
(11,001
|
)
|
14,161
|
33,735
|
42,082
|
78,977
|
||||||||||||||
Income tax (benefit) expense
|
(6,658
|
)
|
1,456
|
11,824
|
17,874
|
24,496
|
||||||||||||||
Net (loss) income
|
(4,343
|
)
|
12,705
|
21,911
|
24,208
|
54,481
|
||||||||||||||
Less: Net loss attributable to non-controlling interest
|
1
|
-
|
1
|
3
|
5
|
|||||||||||||||
Net (loss) income attributable to TSM
|
$
|
(4,342
|
)
|
$
|
12,705
|
$
|
21,912
|
$
|
24,211
|
$
|
54,486
|
|||||||||
Basic net (loss) income per share
|
$
|
(0.18
|
)
|
$
|
0.52
|
$
|
0.91
|
$
|
1.02
|
$
|
2.27
|
|||||||||
Diluted net (loss) income per share
|
$
|
(0.18
|
)
|
$
|
0.52
|
$
|
0.91
|
$
|
1.01
|
$
|
2.26
|
2016
|
||||||||||||||||||||
March 31
|
June 30
|
September 30
|
December 31
|
Total
|
||||||||||||||||
Revenues
|
||||||||||||||||||||
Premiums earned, net
|
$
|
738,534
|
$
|
729,049
|
$
|
721,187
|
$
|
701,871
|
$
|
2,890,641
|
||||||||||
Administrative service fees
|
5,083
|
4,520
|
4,146
|
4,094
|
17,843
|
|||||||||||||||
Net investment income
|
11,358
|
12,875
|
12,337
|
12,343
|
48,913
|
|||||||||||||||
Other operating revenues
|
812
|
915
|
871
|
863
|
3,461
|
|||||||||||||||
Total operating revenues
|
755,787
|
747,359
|
738,541
|
719,171
|
2,960,858
|
|||||||||||||||
Net realized investment gains (losses):
|
||||||||||||||||||||
Total other-than-temporary impairment losses on securities
|
-
|
(1,434
|
)
|
-
|
-
|
(1,434
|
)
|
|||||||||||||
Net realized gains, excluding other-than-temporary impairment losses on securities
|
58
|
2,954
|
5,376
|
10,425
|
18,813
|
|||||||||||||||
Total net realized investment gains
|
58
|
1,520
|
5,376
|
10,425
|
17,379
|
|||||||||||||||
Other income, net
|
875
|
3,859
|
734
|
1,101
|
6,569
|
|||||||||||||||
Total revenues
|
756,720
|
752,738
|
744,651
|
730,697
|
2,984,806
|
|||||||||||||||
Benefits and expenses
|
||||||||||||||||||||
Claims incurred
|
626,694
|
622,087
|
629,169
|
594,241
|
2,472,191
|
|||||||||||||||
Operating expenses
|
122,980
|
121,112
|
123,406
|
126,396
|
493,894
|
|||||||||||||||
Total operating costs
|
749,674
|
743,199
|
752,575
|
720,637
|
2,966,085
|
|||||||||||||||
Interest expense
|
1,882
|
1,954
|
1,893
|
1,906
|
7,635
|
|||||||||||||||
Total benefits and expenses
|
751,556
|
745,153
|
754,468
|
722,543
|
2,973,720
|
|||||||||||||||
Income (loss) before taxes
|
5,164
|
7,585
|
(9,817
|
)
|
8,154
|
11,086
|
||||||||||||||
Income tax expense (benefit)
|
1,709
|
3,707
|
(7,873
|
)
|
(3,888
|
)
|
(6,345
|
)
|
||||||||||||
Net income (loss)
|
3,455
|
3,878
|
(1,944
|
)
|
12,042
|
17,431
|
||||||||||||||
Less: Net loss attributable to non-controlling interest
|
1
|
2
|
3
|
1
|
7
|
|||||||||||||||
Net income (loss) attributable to TSM
|
$
|
3,456
|
$
|
3,880
|
$
|
(1,941
|
)
|
$
|
12,043
|
$
|
17,438
|
|||||||||
Basic net income (loss) per share
|
$
|
0.14
|
$
|
0.16
|
$
|
(0.08
|
)
|
$
|
0.49
|
$
|
0.71
|
|||||||||
Diluted net income (loss) per share
|
$
|
0.14
|
$
|
0.16
|
$
|
(0.08
|
)
|
$
|
0.49
|
$
|
0.71
|
· |
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
|
· |
provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
|
· |
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.
|
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Financial Statements
|
Description
|
F-1
|
Report of Independent Registered Public Accounting Firm
|
F-2
|
Consolidated Balance Sheets as of December 31, 2017 and 2016
|
F-3
|
Consolidated Statements of Earnings for the years ended December 31, 2017, 2016 and 2015
|
F-4
|
Consolidated Statements of Comprehensive Income for the years ended December 31, 2017, 2016 and 2015
|
F-5
|
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2017, 2016 and 2015
|
F-6
|
Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016 and 2015
|
F-7
|
Notes to Consolidated Financial Statements – December 31, 2017, 2016 and 2015
|
Financial Statements
Schedules
|
Description
|
S-1
|
Schedule II – Condensed Financial Information of the Registrant
|
S-2
|
Schedule III – Supplementary Insurance Information
|
S-3
|
Schedule IV – Reinsurance
|
S-4
|
Schedule V – Valuation and Qualifying Accounts
|
S-5
|
Schedule VI – Supplementary Information Concerning Consolidated Property and Casualty Insurance Operations
|
Exhibits
|
Description
|
Amended and Restated Articles of Incorporation (incorporated herein by reference to Exhibit 3(i)(d) to TSM’s Annual Report on Form 10-K for the Year Ended December 31, 2007 (File No. 001-33865).
|
|
Amendment to Article Tenth of the Amended and Restated Articles of Incorporation of Triple-S Management Corporation, incorporated by reference to Exhibit 3(i)(b) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 (File No. 001-33865).
|
Exhibits
|
Description
|
Articles of Incorporation of Triple-S Management Corporation, as currently in effect, incorporated by reference to Exhibit 3(i)(c) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 (File No. 001-33865).
|
|
Amendments to Article Tenth and Thirteenth of the Amended and Restated Articles of Incorporation of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3(i)(d) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-33865)).
|
|
Composite Amended and Restated Articles of Incorporation of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3(i)(e) to TSM’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-33865)).
|
|
Amended and Restated Bylaws of Triple-S Management Corporation (incorporated herein by reference to Exhibit 3.1 to TSM’s Current Report on Form 8-K filed on June 11, 2010 (File No. 001-33865)).
|
|
Amendment to the Contract between Administración de Seguros de Salud de Puerto Rico (ASES) and Triple-S Salud, Inc. to administer the provision of physical & behavioral health services under the Government Health Plan Program (File No. 001-33865).
|
|
Amended and Restated Agreement between the Puerto Rico Health Insurance Administration and TSS to administer the provision of the physical health component of the Medicaid program in designated service regions (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q filed on August 8, 2013 (File No. 001-33865)).
|
|
Federal Employees Health Benefits Contract (incorporated herein by reference to Exhibit 10.5 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
|
|
Credit Agreement with FirstBank Puerto Rico in the amount of $41,000,000 (incorporated herein by reference to Exhibit 10.6 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
|
|
Credit Agreement with FirstBank Puerto Rico in the amount of $20,000,000 (incorporated herein by reference to Exhibit 10.7 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
|
|
Non-Contributory Retirement Program (incorporated herein by reference to Exhibit 10.8 to TSM's General Form of Registration of Securities on Form 10 (File No. 001-33865)).
|
|
Blue Shield License Agreement by and between BCBSA and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.11 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
|
|
Blue Shield Controlled Affiliate License Agreement by and among BCBSA, TSS and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.12 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
|
Exhibits
|
Description
|
Blue Cross License Agreements by and between BCBSA and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.13 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
|
|
Blue Cross Controlled Affiliate License Agreement by and among BCBSA, TSS and TSM, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting (incorporated herein by reference to Exhibit 10.14 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2009 (File No. 001-33865)).
|
|
6.30% Senior Unsecured Notes Due September 2019 Note Purchase Agreement, dated September 30, 2004, between Triple-S Management Corporation, Triple-S, Inc. and various institutional accredited investors (incorporated herein by reference to Exhibit 10.15 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2005 (File No. 001-33865)).
|
|
6.60% Senior Unsecured Notes Due December 2020 Note Purchase Agreement, dated December 15, 2005, between Triple-S Management Corporation and various institutional accredited investors (incorporated herein by reference to Exhibit 10.16 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2005 (File No. 001-33865)).
|
|
6.70% Senior Unsecured Notes Due December 2021 Note Purchase Agreement, dated January 23, 2006, between Triple-S Management Corporation and various institutional accredited investors (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2006 (File No. 001-33865)).
|
|
TSM 2007 Incentive Plan, dated October 16, 2007 (incorporated herein by reference to Exhibit C to TSM’s 2007 Proxy Statement (File No. 001-33865)).
|
|
Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS dated August 16, 2007 (incorporated herein by reference to Exhibit 10.15 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
|
|
Addendum Number One to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(a) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
|
|
Addendum Number Two to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(b) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
|
|
Addendum Number Three to the Software License and Maintenance Agreement between Quality Care Solutions, Inc, and TSS (incorporated herein by reference to Exhibit 10.15(c) to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
|
|
Work Order Agreement between Quality Care Solutions, Inc. and TSS (incorporated herein by reference to Exhibit 10.16 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2007 (File No. 001-33865)).
|
Exhibits
|
Description
|
Employment Contract between Ramón M. Ruiz Comas and TSM (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K filed on November 5, 2012 (File No. 001-33865)).
|
|
Agreement between the Puerto Rico Health Insurance Administration and TSS for the provision of the physical & behavioral health services under the Government Health Plan Program (incorporated herein by reference to Exhibit 10.1 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2014 (File No. 001-33865)).
|
|
Settlement and Release Agreement between Triple-S Management Corporation, Triple-S Salud, Inc., and the Health Insurance Administration of Puerto Rico (incorporated herein by reference to Exhibit 10.22 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2015 (File No. 001-33865)).
|
|
Resolution Agreement between Triple-S Management Corporation, Triple-S Salud, Inc., and the Department of Health and Human Services (incorporated herein by reference to Exhibit 10.23 to TSM’s Annual Report on Form 10-K for the year ended December 31, 2015 (File No. 001-33865)).
|
|
Employment Contract between Roberto García-Rodríguez and TSM (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K/A filed on January 6, 2016 (File No. 001-33865)).
|
|
Credit Agreement dated December 28, 2016 by and between Triple-S Management Corporation and FirstBank Puerto Rico (incorporated herein by reference to Exhibit 10.1 to TSM’s Current Report on Form 8-K filed on December 30, 2016 (File No. 001-33865)).
|
|
TSM 2017 Incentive Plan (incorporated herein by reference to Exhibit 99.1 to TSM’s Form S-8 dated May 11, 2017 (File No. 001-33865)).
|
|
Amendment to Extend Contract for the Provision of Physical & Behavioral Health Services under the Government Health Plan Program (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (File No. 001-33865)).
|
|
Master Services Agreement, dated as of August 29, 2017, by and between Triple-S Salud, Inc. and OptumInsight, Inc. (incorporated herein by reference to Exhibit 10.2 to TSM’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (File No. 001-33865)).
|
|
Amendment to Extend Contract for the Provision of Physical & Behavioral Health Services under the Government Health Plan Program dated as of September 28, 2017, by and between the Administracion de Seguros de Salud de Puerto Rico and Triple-S Salud, Inc. (incorporated herein by reference to Exhibit 10.1 to TSM’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (File No. 001-33865)).
|
|
11.1
|
Statement re computation of per share earnings; an exhibit describing the computation of the earnings per share has been omitted as the detail necessary to determine the computation of earnings per share can be clearly determined from the material contained in Part II of this Annual Report on Form 10-K.
|
List of Subsidiaries of TSM
|
Exhibits
|
Description
|
Consent of Independent Registered Public Accounting Firm (Deloitte & Touche LLP).
|
|
Certification of the President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a).
|
|
Certification of the Vice President of Finance and Chief Financial Officer required by Rule 13a-14(a)/15d-14(a).
|
|
Certification of the President and Chief Executive Officer required pursuant to 18 U.S. Section 1350.
|
|
Certification of the Vice President of Finance and Chief Financial Officer required pursuant to 18 U.S. Section 1350.
|
|
Incentive Compensation Recoupment Policy
(incorporated herein by reference to Exhibit 99.1 to TSM’s Annual Report on Form 10-K for the
year ended December 31, 2010 (File No. 001-33865))
.
|
By:
|
/s/ Roberto García-Rodríguez
|
Date:
|
March 7, 2018
|
||
Roberto García-Rodríguez
|
|||||
President and Chief Executive Officer
|
By:
|
/s/ Juan J. Román-Jiménez
|
Date:
|
March 7, 2018
|
||
Juan J. Román-Jiménez
|
|||||
Executive Vice President
|
|||||
and Chief Financial Officer
|
By:
|
/s/ Luis A. Clavell-Rodríguez
|
Date:
|
March 7, 2018
|
||
Luis A. Clavell-Rodríguez
|
|||||
Director and Chairman of the Board
|
By:
|
/s/ Cari M. Domínguez
|
Date:
|
March 7, 2018
|
||
Cari M. Domínguez
|
|||||
Director and Vice-Chairman of the Board
|
By:
|
/s/
David H. Chafey, Jr
|
Date:
|
March 7, 2018
|
||
David H. Chafey, Jr.
|
|||||
Director
|
By:
|
/s/ Jorge L. Fuentes-Benejam
|
Date:
|
March 7, 2018
|
||
Jorge L. Fuentes-Benejam
|
|||||
Director
|
By:
|
/s/ Antonio F. Faría-Soto
|
Date:
|
March 7, 2018
|
||
Antonio F. Faría-Soto
|
|||||
Director
|
By:
|
/s/ Manuel Figueroa-Collazo
|
Date:
|
March 7, 2018
|
||
Manuel Figueroa-Collazo
|
|||||
Director
|
By:
|
/s/
Joseph A. Frick
|
Date:
|
March 7, 2018
|
||
Joseph A. Frick
|
|||||
Director
|
By:
|
/s/ Roberto Santa María-Ros
|
Date:
|
March 7, 2018
|
||
Roberto Santa María-Ros
|
|||||
Director
|
By:
|
/s/ Gail B. Marcus
|
Date:
|
March 7, 2018
|
||
Gail B. Marcus
|
|||||
Director
|
Report of Independent Registered Public Accounting Firm
|
1
|
Consolidated Financial Statements
|
2 |
Consolidated Balance Sheets
|
2
|
Consolidated Statements of Earnings
|
3
|
Consolidated Statements of Comprehensive Income
|
4
|
Consolidated Statements of Stockholders’ Equity
|
5
|
Consolidated Statements of Cash Flows
|
6
|
Notes to Consolidated Financial Statements
|
8–77
|
Assets
|
2017
|
2016
|
||||||
Investments and cash
|
||||||||
Securities available for sale, at fair value:
|
||||||||
Fixed maturities (amortized cost of $1,171,651 in 2017 and $1,104,303 in 2016)
|
$
|
1,216,788
|
$
|
1,151,643
|
||||
Equity securities (cost of $327,129 in 2017 and
$240,699 in 2016)
|
377,293
|
270,349
|
||||||
Securities held to maturity, at amortized cost:
|
||||||||
Fixed maturities (fair value of $2,475 in 2017 and
$3,012 in 2016)
|
2,319
|
2,836
|
||||||
Policy loans
|
9,077
|
8,564
|
||||||
Cash and cash equivalents
|
198,941
|
103,428
|
||||||
Total investments and cash
|
1,804,418
|
1,536,820
|
||||||
Premium and other receivables, net
|
899,327
|
286,365
|
||||||
Deferred policy acquisition costs and value of business acquired
|
200,788
|
194,787
|
||||||
Property and equipment, net
|
74,716
|
66,369
|
||||||
Deferred tax asset
|
65,123
|
57,768
|
||||||
Goodwill
|
25,397
|
25,397
|
||||||
Other assets
|
46,996
|
51,493
|
||||||
Total assets
|
$
|
3,116,765
|
$
|
2,218,999
|
||||
Liabilities and Stockholders’ Equity
|
||||||||
Claim liabilities
|
1,106,876
|
487,943
|
||||||
Liability for future policy benefits
|
339,507
|
321,232
|
||||||
Unearned premiums
|
86,349
|
79,310
|
||||||
Policyholder deposits
|
176,534
|
179,382
|
||||||
Liability to Federal Employees’ Health Benefits and Federal Employees' Programs
|
52,287
|
34,370
|
||||||
Accounts payable and accrued liabilities
|
354,894
|
169,449
|
||||||
Deferred tax liability
|
21,891
|
18,850
|
||||||
Long term borrowings
|
32,073
|
35,085
|
||||||
Liability for pension benefits
|
33,672
|
30,892
|
||||||
Total liabilities
|
2,204,083
|
1,356,513
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity
|
||||||||
Triple-S Management Corporation stockholders' equity Common stock Class A, $1 par value. Authorized 100,000,000 shares; issued and outstanding 950,968 at December 31, 2017 and 2016
|
951
|
951
|
||||||
Common stock Class B, $1 par value. Authorized 100,000,000 shares; issued and outstanding 22,627,077 and 23,321,163 shares at December 31, 2017 and 2016, respectively
|
22,627
|
23,321
|
||||||
Additional paid-in capital
|
53,142
|
65,592
|
||||||
Retained earnings
|
785,390
|
730,904
|
||||||
Accumulated other comprehensive income, net
|
51,254
|
42,395
|
||||||
Total Triple-S Management Corporation stockholders' equity
|
913,364
|
863,163
|
||||||
Non-controlling interest in consolidated subsidiary
|
(682
|
)
|
(677
|
)
|
||||
Total stockholders' equity
|
912,682
|
862,486
|
||||||
Total liabilities and stockholders’ equity
|
$
|
3,116,765
|
$
|
2,218,999
|
2017
|
2016
|
2015
|
||||||||||
Revenues:
|
||||||||||||
Premiums earned, net
|
$
|
2,826,932
|
$
|
2,890,641
|
$
|
2,783,154
|
||||||
Administrative service fees
|
16,514
|
17,843
|
44,705
|
|||||||||
Net investment income
|
51,615
|
48,913
|
45,174
|
|||||||||
Other operating revenues
|
3,660
|
3,461
|
3,719
|
|||||||||
Total operating revenues
|
2,898,721
|
2,960,858
|
2,876,752
|
|||||||||
Net realized investment gains (losses):
|
||||||||||||
Total other-than-temporary impairment losses on securities
|
(49
|
)
|
(1,434
|
)
|
(5,212
|
)
|
||||||
Net realized gains, excluding other-than-temporary impairment losses on securities
|
10,880
|
18,813
|
24,153
|
|||||||||
Total net realized investment gains
|
10,831
|
17,379
|
18,941
|
|||||||||
Other income, net
|
6,533
|
6,569
|
7,043
|
|||||||||
Total revenues
|
2,916,085
|
2,984,806
|
2,902,736
|
|||||||||
Benefits and expenses:
|
||||||||||||
Claims incurred (net of reinsurance of $683,421, $11,319 and $15,738)
|
2,353,101
|
2,472,191
|
2,318,715
|
|||||||||
Operating expenses
|
477,213
|
493,894
|
518,721
|
|||||||||
Total operating costs
|
2,830,314
|
2,966,085
|
2,837,436
|
|||||||||
Interest expense
|
6,794
|
7,635
|
8,169
|
|||||||||
Total benefits and expenses
|
2,837,108
|
2,973,720
|
2,845,605
|
|||||||||
Income before taxes
|
78,977
|
11,086
|
57,131
|
|||||||||
Income tax expense (benefit)
|
24,496
|
(6,345
|
)
|
5,099
|
||||||||
Net income
|
54,481
|
17,431
|
52,032
|
|||||||||
Less: Net loss attributable to non-controlling interest
|
5
|
7
|
89
|
|||||||||
Net income attributable to Triple-S Management Corporation
|
$
|
54,486
|
$
|
17,438
|
$
|
52,121
|
||||||
Earnings per share attributable to Triple-S Management Corporation
|
||||||||||||
Basic net income per share
|
$
|
2.27
|
$
|
0.71
|
$
|
2.03
|
||||||
Diluted net income per share
|
$
|
2.26
|
$
|
0.71
|
$
|
2.02
|
2017
|
2016
|
2015
|
||||||||||
Net income
|
$
|
54,481
|
$
|
17,431
|
$
|
52,032
|
||||||
Other comprehensive income (loss), net of tax:
|
||||||||||||
Net unrealized change in fair value of available for sale securities, net of taxes
|
13,867
|
(107
|
)
|
(38,989
|
)
|
|||||||
Defined benefit pension plan:
|
||||||||||||
Actuarial (loss) gain, net
|
(5,028
|
)
|
18,232
|
16,105
|
||||||||
Prior service credit, net
|
20
|
(1,353
|
)
|
(269
|
)
|
|||||||
Total other comprehensive income (loss), net of tax
|
8,859
|
16,772
|
(23,153
|
)
|
||||||||
Comprehensive income
|
63,340
|
34,203
|
28,879
|
|||||||||
Comprehensive loss attributable to non-controlling interest
|
5
|
7
|
89
|
|||||||||
Comprehensive income attributable to Triple-S Management Corporation
|
$
|
63,345
|
$
|
34,210
|
$
|
28,968
|
Class A
Common
Stock
|
Class B
Common
Stock
|
Additional
Paid-in
Capital
|
Retained
Earnings
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Triple-S
Management
Corporation
Stockholders’
Equity
|
Non-controlling
Interest in
Consolidated
Subsidiary
|
Total
Stockholders’
Equity
|
|||||||||||||||||||||||||
Balance, December 31, 2014
|
$
|
2,378
|
$
|
24,654
|
$
|
121,405
|
$
|
661,345
|
$
|
48,776
|
$
|
858,558
|
$
|
(532
|
)
|
$
|
858,026
|
|||||||||||||||
Share-based compensation
|
-
|
202
|
8,088
|
-
|
-
|
8,290
|
-
|
8,290
|
||||||||||||||||||||||||
Stock issued upon exercise of stock options
|
-
|
13
|
166
|
-
|
-
|
179
|
-
|
179
|
||||||||||||||||||||||||
Common stock conversion
|
(1,427
|
)
|
1,427
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||
Repurchase and retirement of common stock
|
-
|
(2,248
|
)
|
(46,221
|
)
|
-
|
-
|
(48,469
|
)
|
-
|
(48,469
|
)
|
||||||||||||||||||||
Non-controlling interest decrease related to retirement of consolidated subsidiary common stock
|
-
|
-
|
-
|
-
|
-
|
-
|
(49
|
)
|
(49
|
)
|
||||||||||||||||||||||
Net change in comprehensive income (loss)
|
-
|
-
|
-
|
52,121
|
(23,153
|
)
|
28,968
|
(89
|
)
|
28,879
|
||||||||||||||||||||||
Balance, December 31, 2015
|
$
|
951
|
$
|
24,048
|
$
|
83,438
|
$
|
713,466
|
$
|
25,623
|
$
|
847,526
|
$
|
(670
|
)
|
$
|
846,856
|
|||||||||||||||
Share-based compensation
|
-
|
223
|
2,576
|
-
|
-
|
2,799
|
-
|
2,799
|
||||||||||||||||||||||||
Stock issued upon exercise of stock options
|
-
|
4
|
51
|
-
|
-
|
55
|
-
|
55
|
||||||||||||||||||||||||
Repurchase and retirement of common stock
|
-
|
(954
|
)
|
(20,473
|
)
|
-
|
-
|
(21,427
|
)
|
-
|
(21,427
|
)
|
||||||||||||||||||||
Net change in comprehensive income (loss)
|
-
|
-
|
-
|
17,438
|
16,772
|
34,210
|
(7
|
)
|
34,203
|
|||||||||||||||||||||||
Balance, December 31, 2016
|
$
|
951
|
$
|
23,321
|
$
|
65,592
|
$
|
730,904
|
$
|
42,395
|
$
|
863,163
|
$
|
(677
|
)
|
$
|
862,486
|
|||||||||||||||
Share-based compensation
|
-
|
167
|
6,909
|
-
|
-
|
7,076
|
-
|
7,076
|
||||||||||||||||||||||||
Repurchase and retirement of common stock
|
-
|
(861
|
)
|
(19,359
|
)
|
-
|
-
|
(20,220
|
)
|
-
|
(20,220
|
)
|
||||||||||||||||||||
Net change in comprehensive income (loss)
|
-
|
-
|
-
|
54,486
|
8,859
|
63,345
|
(5
|
)
|
63,340
|
|||||||||||||||||||||||
Balance, December 31, 2017
|
$
|
951
|
$
|
22,627
|
$
|
53,142
|
$
|
785,390
|
$
|
51,254
|
$
|
913,364
|
$
|
(682
|
)
|
$
|
912,682
|
2017
|
2016
|
2015
|
||||||||||
Cash flows from operating activities
|
||||||||||||
Net income
|
$
|
54,481
|
$
|
17,431
|
$
|
52,032
|
||||||
Adjustments to reconcile net income to net cash provided by operating activities
|
||||||||||||
Depreciation and amortization
|
13,198
|
14,120
|
16,379
|
|||||||||
Net amortization of investments
|
10,114
|
8,671
|
6,854
|
|||||||||
Additions to the allowance for doubtful receivables
|
1,462
|
1,601
|
16,121
|
|||||||||
Deferred tax benefit
|
(9,916
|
)
|
(8,326
|
)
|
(5,070
|
)
|
||||||
Net realized investment gains on sale of securities
|
(10,831
|
)
|
(17,379
|
)
|
(18,941
|
)
|
||||||
Interest credited to policyholder deposits
|
5,677
|
3,794
|
5,690
|
|||||||||
Share-based compensation
|
7,076
|
2,463
|
8,290
|
|||||||||
(Increase) decrease in assets
|
||||||||||||
Premium and other receivables, net
|
(614,424
|
)
|
(5,320
|
)
|
6,399
|
|||||||
Deferred policy acquisition costs and value of business acquired
|
(6,596
|
)
|
(7,286
|
)
|
(6,548
|
)
|
||||||
Deferred taxes
|
4,946
|
(4,799
|
)
|
3,616
|
||||||||
Other assets
|
5,117
|
(9,009
|
)
|
(2,630
|
)
|
|||||||
Increase (decrease) in liabilities
|
||||||||||||
Claim liabilities
|
618,933
|
(3,822
|
)
|
101,679
|
||||||||
Liability for future policy benefits
|
18,275
|
31,702
|
18,146
|
|||||||||
Unearned premiums
|
7,039
|
(950
|
)
|
(2,396
|
)
|
|||||||
Liability to FEHBP
|
17,917
|
7,675
|
11,029
|
|||||||||
Accounts payable and accrued liabilities
|
166,450
|
(24,095
|
)
|
18,444
|
||||||||
Net cash provided by operating activities
|
288,918
|
6,471
|
229,094
|
2017
|
2016
|
2015
|
||||||||||
Cash flows from investing activities
|
||||||||||||
Proceeds from investments sold or matured
Securities available for sale
|
||||||||||||
Fixed maturities sold
|
$
|
463,232
|
$
|
400,848
|
$
|
355,045
|
||||||
Fixed maturities matured
|
18,893
|
56,988
|
67,615
|
|||||||||
Equity securities sold
|
59,963
|
109,049
|
100,152
|
|||||||||
Securities held to maturity
|
||||||||||||
Fixed maturities matured
|
2,712
|
1,538
|
640
|
|||||||||
Acquisition of investments
|
||||||||||||
Securities available for sale
|
||||||||||||
Fixed maturities
|
(560,304
|
)
|
(482,252
|
)
|
(469,198
|
)
|
||||||
Equity securities
|
(134,834
|
)
|
(163,119
|
)
|
(92,844
|
)
|
||||||
Securities held to maturity
|
||||||||||||
Fixed maturities
|
(2,197
|
)
|
(1,445
|
)
|
(624
|
)
|
||||||
Other investments
|
(2,064
|
)
|
(2,493
|
)
|
(2,427
|
)
|
||||||
Net disbursements for policy loans
|
(513
|
)
|
(663
|
)
|
(641
|
)
|
||||||
Net capital expenditures
|
(21,359
|
)
|
(4,750
|
)
|
(9,094
|
)
|
||||||
Net cash used in investing activities
|
(176,471
|
)
|
(86,299
|
)
|
(51,376
|
)
|
||||||
Cash flows from financing activities
|
||||||||||||
Repurchase and retirement of common stock
|
(20,220
|
)
|
(21,371
|
)
|
(48,287
|
)
|
||||||
Change in outstanding checks in excess of bank balances
|
12,683
|
12,250
|
(1,786
|
)
|
||||||||
Repayments of long-term borrowings
|
(2,836
|
)
|
(1,742
|
)
|
(37,640
|
)
|
||||||
Net proceeds from revolving line of credit
|
1,964
|
-
|
-
|
|||||||||
Proceeds from policyholder deposits
|
13,557
|
18,224
|
16,563
|
|||||||||
Surrenders of policyholder deposits
|
(22,082
|
)
|
(21,923
|
)
|
(18,787
|
)
|
||||||
Net cash used in financing activities
|
(16,934
|
)
|
(14,562
|
)
|
(89,937
|
)
|
||||||
Net increase (decrease) in cash and cash equivalents
|
95,513
|
(94,390
|
)
|
87,781
|
||||||||
Cash and cash equivalents
|
||||||||||||
Beginning of year
|
103,428
|
197,818
|
110,037
|
|||||||||
End of year
|
$
|
198,941
|
$
|
103,428
|
$
|
197,818
|
1.
|
Nature of Business
|
2.
|
Significant Accounting Policies
|
a.
|
Managed Care
|
b.
|
Life and Accident and Health Insurance
|
c.
|
Property and Casualty Insurance
|
Asset Category
|
Estimated
Useful Life
|
|
Buildings
|
20 to 50 years
|
|
Building improvements
|
3 to 5 years
|
|
Leasehold improvements
|
Shorter of estimated useful
|
|
life or lease term
|
||
Office furniture
|
5 years
|
|
Computer software
|
3 to 10 years
|
|
Computer equipment, equipment,
|
||
and automobiles
|
3 years
|
3.
|
Investment in Securities
|
2017
|
||||||||||||||||
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
|||||||||||||
Securities available for sale
|
||||||||||||||||
Fixed maturities
|
||||||||||||||||
Obligations of government- sponsored enterprises
|
$
|
1,431
|
$
|
13
|
$
|
-
|
$
|
1,444
|
||||||||
U.S. Treasury securities and obligations of U.S. government instrumentalities
|
118,858
|
41
|
(550
|
)
|
118,349
|
|||||||||||
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
|
8,059
|
34
|
-
|
8,093
|
||||||||||||
Municipal securities
|
771,789
|
30,468
|
(1,467
|
)
|
800,790
|
|||||||||||
Corporate bonds
|
217,046
|
17,767
|
(489
|
)
|
234,324
|
|||||||||||
Residential mortgage-backed securities
|
32,465
|
2
|
(355
|
)
|
32,112
|
|||||||||||
Collateralized mortgage obligations
|
22,003
|
10
|
(337
|
)
|
21,676
|
|||||||||||
Total fixed maturities
|
1,171,651
|
48,335
|
(3,198
|
)
|
1,216,788
|
|||||||||||
Equity securities
|
||||||||||||||||
Mutual Funds
|
292,459
|
50,072
|
(223
|
)
|
342,308
|
|||||||||||
Alternative investments
|
34,670
|
559
|
(244
|
)
|
34,985
|
|||||||||||
Total equity securities
|
327,129
|
50,631
|
(467
|
)
|
377,293
|
|||||||||||
Total
|
$
|
1,498,780
|
$
|
98,966
|
$
|
(3,665
|
)
|
$
|
1,594,081
|
2016
|
||||||||||||||||
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
|||||||||||||
Securities available for sale
|
||||||||||||||||
Fixed maturities
|
||||||||||||||||
Obligations of government-sponsored enterprises
|
$
|
41,442
|
$
|
87
|
$
|
(15
|
)
|
$
|
41,514
|
|||||||
U.S. Treasury securities and obligations of U.S. government instrumentalities
|
85,652
|
157
|
(9
|
)
|
85,800
|
|||||||||||
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
|
17,930
|
2,189
|
(68
|
)
|
20,051
|
|||||||||||
Municipal securities
|
650,175
|
34,187
|
(559
|
)
|
683,803
|
|||||||||||
Corporate bonds
|
263,351
|
12,182
|
(661
|
)
|
274,872
|
|||||||||||
Residential mortgage-backed securities
|
684
|
34
|
-
|
718
|
||||||||||||
Collateralized mortgage obligations
|
45,069
|
58
|
(242
|
)
|
44,885
|
|||||||||||
Total fixed maturities
|
1,104,303
|
48,894
|
(1,554
|
)
|
1,151,643
|
|||||||||||
Equity securities-Mutual funds and alternative investments
|
240,699
|
30,101
|
(451
|
)
|
270,349
|
|||||||||||
Total
|
$
|
1,345,002
|
$
|
78,995
|
$
|
(2,005
|
)
|
$
|
1,421,992
|
2017
|
||||||||||||||||
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
|||||||||||||
Securities held to maturity
|
||||||||||||||||
U.S. Treasury securities and obligations of U.S. government instrumentalties
|
$
|
617
|
$
|
154
|
$
|
-
|
$
|
771
|
||||||||
Residential mortgage-backed securities
|
191
|
2
|
-
|
193
|
||||||||||||
Certificates of deposits
|
1,511
|
-
|
-
|
1,511
|
||||||||||||
$
|
2,319
|
$
|
156
|
$
|
-
|
$
|
2,475
|
2016
|
||||||||||||||||
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
|||||||||||||
Securities held to maturity
|
||||||||||||||||
U.S. Treasury securities and obligations of U.S. government instrumentalties
|
$
|
619
|
$
|
158
|
$
|
-
|
$
|
777
|
||||||||
Residential mortgage-backed securities
|
191
|
18
|
-
|
209
|
||||||||||||
Certificates of deposits
|
2,026
|
-
|
-
|
2,026
|
||||||||||||
$
|
2,836
|
$
|
176
|
$
|
-
|
$
|
3,012
|
2017
|
||||||||||||||||||||||||||||||||||||
Less than 12 months
|
12 months or longer
|
Total
|
||||||||||||||||||||||||||||||||||
|
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
|||||||||||||||||||||||||||
Securites available for sale
|
||||||||||||||||||||||||||||||||||||
Fixed maturities
|
||||||||||||||||||||||||||||||||||||
U.S. Treasury securities and obligations of U.S. governmental instrumentalities
|
$
|
96,617
|
$
|
(550
|
)
|
7
|
$
|
-
|
$
|
-
|
-
|
$
|
96,617
|
$
|
(550
|
)
|
7
|
|||||||||||||||||||
Municipal securities
|
162,731
|
(1,467
|
)
|
27
|
-
|
-
|
-
|
162,731
|
(1,467
|
)
|
27
|
|||||||||||||||||||||||||
Corporate bonds
|
80,374
|
(489
|
)
|
16
|
-
|
-
|
-
|
80,374
|
(489
|
)
|
16
|
|||||||||||||||||||||||||
Residential mortgage-backed securities
|
31,736
|
(355
|
)
|
19
|
-
|
-
|
-
|
31,736
|
(355
|
)
|
19
|
|||||||||||||||||||||||||
Collateralized mortgage obligations
|
13,630
|
(239
|
)
|
3
|
7,294
|
(98
|
)
|
2
|
20,924
|
(337
|
)
|
5
|
||||||||||||||||||||||||
Total fixed maturities
|
385,088
|
(3,100
|
)
|
72
|
7,294
|
(98
|
)
|
2
|
392,382
|
(3,198
|
)
|
74
|
||||||||||||||||||||||||
Equity securities
|
||||||||||||||||||||||||||||||||||||
Mutual funds
|
42,983
|
(223
|
)
|
6
|
-
|
-
|
-
|
42,983
|
(223
|
)
|
6
|
|||||||||||||||||||||||||
Alternative investments
|
9,986
|
(212
|
)
|
5
|
3,162
|
(32
|
)
|
1
|
13,148
|
(244
|
)
|
6
|
||||||||||||||||||||||||
Total equity securities
|
52,969
|
(435
|
)
|
11
|
3,162
|
(32
|
)
|
1
|
56,131
|
(467
|
)
|
12
|
||||||||||||||||||||||||
Total for securities available for sale
|
$
|
438,057
|
$
|
(3,535
|
)
|
83
|
$
|
10,456
|
$
|
(130
|
)
|
3
|
$
|
448,513
|
$
|
(3,665
|
)
|
86
|
2016
|
||||||||||||||||||||||||||||||||||||
Less than 12 months
|
12 months or longer
|
Total
|
||||||||||||||||||||||||||||||||||
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
Estimated
Fair Value
|
Gross
Unrealized
Loss
|
Number of
Securities
|
||||||||||||||||||||||||||||
Securites available for sale
|
||||||||||||||||||||||||||||||||||||
Fixed maturities
|
||||||||||||||||||||||||||||||||||||
Obligations of government-sponsored enterprises
|
$
|
9,483
|
$
|
(15
|
)
|
1
|
$
|
-
|
$
|
-
|
-
|
$
|
9,483
|
$
|
(15
|
)
|
1
|
|||||||||||||||||||
U.S. Treasury securities and obligations of U.S. governmental instrumentalities
|
12,937
|
(9
|
)
|
1
|
-
|
-
|
-
|
12,937
|
(9
|
)
|
1
|
|||||||||||||||||||||||||
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
|
7,758
|
(68
|
)
|
5
|
-
|
-
|
-
|
7,758
|
(68
|
)
|
5
|
|||||||||||||||||||||||||
Municipal securities
|
84,252
|
(559
|
)
|
13
|
-
|
-
|
-
|
84,252
|
(559
|
)
|
13
|
|||||||||||||||||||||||||
Corporate bonds
|
105,054
|
(661
|
)
|
22
|
-
|
-
|
-
|
105,054
|
(661
|
)
|
22
|
|||||||||||||||||||||||||
Collateralized mortgage obligations
|
32,120
|
(239
|
)
|
8
|
784
|
(3
|
)
|
1
|
32,904
|
(242
|
)
|
9
|
||||||||||||||||||||||||
Total fixed maturities
|
251,604
|
(1,551
|
)
|
50
|
784
|
(3
|
)
|
1
|
252,388
|
(1,554
|
)
|
51
|
||||||||||||||||||||||||
Equity securities-Mutual funds and alternative investments
|
22,615
|
(451
|
)
|
4
|
-
|
-
|
-
|
22,615
|
(451
|
)
|
4
|
|||||||||||||||||||||||||
Total for securities available for sale
|
$
|
274,219
|
$
|
(2,002
|
)
|
54
|
$
|
784
|
$
|
(3
|
)
|
1
|
$
|
275,003
|
$
|
(2,005
|
)
|
55
|
• |
Identification and evaluation of securities that have possible indications of other-than-temporary impairment, which includes an analysis of all investments with gross unrealized investment losses that represent 20% or more of their cost and all investments with an unrealized loss greater than $100.
|
• |
For any other securities with a gross unrealized investment loss we might review and evaluate investee’s current financial condition, liquidity, near-term recovery prospects, implications of rating agency actions, the outlook for the business sectors in which the investee operates and other factors.
|
• |
Consideration of evidential matter, including an evaluation of factors or triggers that may or may not cause individual investments to qualify as having other-than-temporary impairments.
|
• |
Determination of the status of each analyzed security as other-than-temporary or not, with documentation of the rationale for the decision; and
|
• |
Equity securities are considered to be impaired
based on market conditions and the length of time the funds have been in a loss position
.
|
Amortized
Cost
|
Estimated
Fair Value
|
|||||||
Securities available for sale
|
||||||||
Due in one year or less
|
$
|
10,696
|
$
|
10,792
|
||||
Due after one year through five years
|
279,086
|
280,249
|
||||||
Due after five years through ten years
|
286,990
|
290,696
|
||||||
Due after ten years
|
540,411
|
581,263
|
||||||
Residential mortgage-backed securities
|
32,465
|
32,112
|
||||||
Collateralized mortgage obligations
|
22,003
|
21,676
|
||||||
$
|
1,171,651
|
$
|
1,216,788
|
|||||
Securities held to maturity
|
||||||||
Due in one year or less
|
$
|
1,511
|
$
|
1,511
|
||||
Due after ten years
|
617
|
771
|
||||||
Residential mortgage-backed securities
|
191
|
193
|
||||||
$
|
2,319
|
$
|
2,475
|
2017
|
2016
|
2015
|
||||||||||
Realized gains (losses)
|
||||||||||||
Fixed maturity securities
|
||||||||||||
Securities available for sale
|
||||||||||||
Gross gains
|
$
|
1,460
|
$
|
3,086
|
$
|
8,208
|
||||||
Gross losses
|
(2,176
|
)
|
(2,744
|
)
|
(646
|
)
|
||||||
Gross losses from other-than-temporary impairments
|
-
|
-
|
(4,267
|
)
|
||||||||
Total fixed maturity securities
|
(716
|
)
|
342
|
3,295
|
||||||||
Equity securities
|
||||||||||||
Securities available for sale
|
||||||||||||
Gross gains
|
12,154
|
19,674
|
17,903
|
|||||||||
Gross losses
|
(558
|
)
|
(1,203
|
)
|
(1,312
|
)
|
||||||
Gross losses from other-than-temporary impairments
|
(49
|
)
|
(1,434
|
)
|
(945
|
)
|
||||||
Total equity securities
|
11,547
|
17,037
|
15,646
|
|||||||||
Net realized gains on securities
|
$
|
10,831
|
$
|
17,379
|
$
|
18,941
|
2017
|
2016
|
2015
|
||||||||||
Changes in unrealized gains (losses)
|
||||||||||||
Recognized in accumulated other comprehensive income (loss)
|
||||||||||||
Fixed maturities – available for sale
|
(2,203
|
)
|
1,953
|
(25,227
|
)
|
|||||||
Equity securities – available for sale
|
20,514
|
2,172
|
(19,479
|
)
|
||||||||
$
|
18,311
|
$
|
4,125
|
$
|
(44,706
|
)
|
||||||
Not recognized in the consolidated financial statements
|
||||||||||||
Fixed maturities – held to maturity
|
$
|
(20
|
)
|
$
|
(19
|
)
|
$
|
(24
|
)
|
4.
|
Net Investment Income
|
2017
|
2016
|
2015
|
||||||||||
Fixed maturities
|
$
|
38,414
|
$
|
37,139
|
$
|
36,256
|
||||||
Equity securities
|
10,728
|
9,666
|
7,146
|
|||||||||
Policy loans
|
709
|
619
|
557
|
|||||||||
Cash equivalents and interest-bearing deposits
|
798
|
257
|
143
|
|||||||||
Other
|
966
|
1,232
|
1,072
|
|||||||||
Total
|
$
|
51,615
|
$
|
48,913
|
$
|
45,174
|
5.
|
Premium and Other Receivables, Net
|
2017
|
2016
|
|||||||
Premium
|
$
|
103,027
|
$
|
91,528
|
||||
Self-funded group receivables
|
39,859
|
57,728
|
||||||
FEHBP
|
13,346
|
14,321
|
||||||
Agent balances
|
32,818
|
25,495
|
||||||
Accrued interest
|
14,331
|
13,668
|
||||||
Reinsurance recoverable
|
661,679
|
58,295
|
||||||
Other
|
70,150
|
62,637
|
||||||
935,210
|
323,672
|
|||||||
Less allowance for doubtful receivables:
|
||||||||
Premium
|
26,490
|
27,320
|
||||||
Other
|
9,393
|
9,987
|
||||||
35,883
|
37,307
|
|||||||
Premium and other receivables, net
|
$
|
899,327
|
$
|
286,365
|
6.
|
Deferred Policy Acquisition Costs and Value of Business Acquired
|
DPAC
|
VOBA
|
Total
|
||||||||||
Balance, December 31, 2014
|
$
|
151,756
|
$
|
32,344
|
$
|
184,100
|
||||||
Additions
|
48,599
|
-
|
48,599
|
|||||||||
VOBA interest at an average rate of 5.15%
|
-
|
1,543
|
1,543
|
|||||||||
Amortization
|
(38,624
|
)
|
(4,970
|
)
|
(43,594
|
)
|
||||||
Net change
|
9,975
|
(3,427
|
)
|
6,548
|
||||||||
Balance, December 31, 2015
|
161,731
|
28,917
|
190,648
|
|||||||||
Additions
|
47,742
|
-
|
47,742
|
|||||||||
VOBA interest at an average rate of 5.15%
|
-
|
1,381
|
1,381
|
|||||||||
Amortization
|
(40,848
|
)
|
(4,136
|
)
|
(44,984
|
)
|
||||||
Net change
|
6,894
|
(2,755
|
)
|
4,139
|
||||||||
Balance, December 31, 2016
|
168,625
|
26,162
|
194,787
|
|||||||||
Additions
|
48,701
|
-
|
48,701
|
|||||||||
VOBA interest at an average rate of 5.17%
|
-
|
1,253
|
1,253
|
|||||||||
Amortization
|
(39,605
|
)
|
(4,348
|
)
|
(43,953
|
)
|
||||||
Net change
|
9,096
|
(3,095
|
)
|
6,001
|
||||||||
Balance, December 31, 2017
|
$
|
177,721
|
$
|
23,067
|
$
|
200,788
|
Year ending December 31:
|
||||
2018
|
$
|
3,019
|
||
2019
|
2,269
|
|||
2020
|
2,003
|
|||
2021
|
2,073
|
|||
2022
|
1,478
|
7.
|
Property and Equipment, Net
|
2017
|
2016
|
|||||||
Land
|
$
|
10,976
|
$
|
10,976
|
||||
Buildings and leasehold improvements
|
64,856
|
64,828
|
||||||
Office furniture and equipment
|
35,070
|
24,234
|
||||||
Computer equipment and software
|
116,244
|
114,749
|
||||||
Automobiles
|
701
|
593
|
||||||
227,847
|
215,380
|
|||||||
Less accumulated depreciation and amortization
|
153,131
|
149,011
|
||||||
Property and equipment, net
|
$
|
74,716
|
$
|
66,369
|
8.
|
Goodwill
|
9.
|
Fair Value Measurements
|
Level 1 |
Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
|
Level 2 |
Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
|
Level 3 |
Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
|
2017
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Securities available for sale
|
||||||||||||||||
Fixed maturity securities
|
||||||||||||||||
Obligations of government-sponsored enterprises
|
$
|
-
|
$
|
1,444
|
$
|
-
|
$
|
1,444
|
||||||||
U.S. Treasury securities and obligations of U.S. government instrumentalities
|
118,349
|
-
|
-
|
118,349
|
||||||||||||
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
|
-
|
8,093
|
-
|
8,093
|
||||||||||||
Municipal securities
|
-
|
800,790
|
-
|
800,790
|
||||||||||||
Corporate bonds
|
-
|
234,324
|
-
|
234,324
|
||||||||||||
Residential agency mortgage-backed securities
|
-
|
32,112
|
-
|
32,112
|
||||||||||||
Collaterized mortgage obligations
|
-
|
21,676
|
-
|
21,676
|
||||||||||||
Total fixed maturities
|
118,349
|
1,098,439
|
-
|
1,216,788
|
||||||||||||
Equity securities - Mutual funds
|
193,159
|
149,149
|
-
|
342,308
|
||||||||||||
Alternative investments - measured at net asset value
|
-
|
-
|
-
|
34,985
|
||||||||||||
Total equity securities
|
193,159
|
149,149
|
-
|
377,293
|
||||||||||||
$
|
311,508
|
$
|
1,247,588
|
$
|
-
|
$
|
1,594,081
|
2016
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Securities available for sale
|
||||||||||||||||
Fixed maturity securities
|
||||||||||||||||
Obligations of government-sponsored enterprises
|
$
|
-
|
$
|
41,514
|
$
|
-
|
$
|
41,514
|
||||||||
U.S. Treasury securities and obligations of U.S. government instrumentalities
|
85,800
|
-
|
-
|
85,800
|
||||||||||||
Obligations of the Commonwealth of Puerto Rico and its instrumentalities
|
-
|
20,051
|
-
|
20,051
|
||||||||||||
Municipal securities
|
-
|
683,803
|
-
|
683,803
|
||||||||||||
Corporate bonds
|
-
|
274,872
|
-
|
274,872
|
||||||||||||
Residential agency mortgage-backed securities
|
-
|
718
|
-
|
718
|
||||||||||||
Collaterized mortgage obligations
|
-
|
44,885
|
-
|
44,885
|
||||||||||||
Total fixed maturities
|
85,800
|
1,065,843
|
-
|
1,151,643
|
||||||||||||
Equity securities - Mutual funds and alternative investments
|
166,595
|
76,222
|
-
|
242,817
|
||||||||||||
Alternative investments - measured at net asset value
|
-
|
-
|
27,532
|
27,532
|
||||||||||||
Total equity securities
|
166,595
|
76,222
|
27,532
|
270,349
|
||||||||||||
$
|
252,395
|
$
|
1,142,065
|
$
|
27,532
|
$
|
1,421,992
|
2017
|
||||||||||||||||||||
Carrying
Value
|
Fair Value
|
|||||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||||||
Assets:
|
||||||||||||||||||||
Policy loans
|
$
|
9,077
|
$
|
-
|
$
|
9,077
|
$
|
-
|
$
|
9,077
|
||||||||||
Liabilities:
|
||||||||||||||||||||
Policyholder deposits
|
$
|
176,534
|
$
|
-
|
$
|
176,534
|
$
|
-
|
$
|
176,534
|
||||||||||
Long-term borrowings - loans payable to bank - variable
|
32,350
|
-
|
32,350
|
-
|
32,350
|
|||||||||||||||
Total liabilities
|
$
|
217,961
|
$
|
-
|
$
|
217,961
|
$
|
-
|
$
|
217,961
|
2016
|
||||||||||||||||||||
Carrying
Value
|
Fair Value
|
|||||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||||||
Assets:
|
||||||||||||||||||||
Policy loans
|
$
|
8,564
|
$
|
-
|
$
|
8,564
|
$
|
-
|
$
|
8,564
|
||||||||||
Liabilities:
|
||||||||||||||||||||
Policyholder deposits
|
$
|
179,382
|
$
|
-
|
$
|
179,382
|
$
|
-
|
$
|
179,382
|
||||||||||
Long-term borrowings:
|
||||||||||||||||||||
Loans payable to bank - variable
|
11,187
|
-
|
11,187
|
-
|
11,187
|
|||||||||||||||
6.6% senior unsecured notes payable
|
24,000
|
-
|
24,000
|
-
|
24,000
|
|||||||||||||||
Total long-term borrowings
|
35,187
|
-
|
35,187
|
-
|
35,187
|
|||||||||||||||
Total liabilities
|
$
|
214,569
|
$
|
-
|
$
|
214,569
|
$
|
-
|
$
|
214,569
|
10.
|
Claim Liabilities and Claim Adjustment Expenses
|
2017
|
||||||||||||
Managed
Care
|
Other
Business
Segments *
|
Consolidated
|
||||||||||
Claim liabilities at beginning of year
|
$
|
349,047
|
$
|
138,896
|
$
|
487,943
|
||||||
Reinsurance recoverable on claim liabilities
|
-
|
(38,998
|
)
|
(38,998
|
)
|
|||||||
Net claim liabilities at beginning of year
|
349,047
|
99,898
|
448,945
|
|||||||||
Claims incurred
|
||||||||||||
Current period insured events
|
2,231,052
|
118,012
|
2,349,064
|
|||||||||
Prior period insured events
|
(12,782
|
)
|
(8,975
|
)
|
(21,757
|
)
|
||||||
Total
|
2,218,270
|
109,037
|
2,327,307
|
|||||||||
Payments of losses and loss-adjustment expenses
|
||||||||||||
Current period insured events
|
1,940,410
|
64,051
|
2,004,461
|
|||||||||
Prior period insured events
|
259,550
|
38,536
|
298,086
|
|||||||||
Total
|
2,199,960
|
102,587
|
2,302,547
|
|||||||||
Net claim liabilities at end of year
|
367,357
|
106,348
|
473,705
|
|||||||||
Reinsurance recoverable on claim liabilities
|
-
|
633,171
|
633,171
|
|||||||||
Claim liabilities at end of year
|
$
|
367,357
|
$
|
739,519
|
$
|
1,106,876
|
2016
|
||||||||||||
Managed
Care
|
Other
Business
Segments *
|
Consolidated
|
||||||||||
Claim liabilities at beginning of year
|
$
|
348,297
|
$
|
143,468
|
$
|
491,765
|
||||||
Reinsurance recoverable on claim liabilities
|
-
|
(40,714
|
)
|
(40,714
|
)
|
|||||||
Net claim liabilities at beginning of year
|
348,297
|
102,754
|
451,051
|
|||||||||
Claims incurred
|
||||||||||||
Current period insured events
|
2,356,594
|
103,049
|
2,459,643
|
|||||||||
Prior period insured events
|
(9,047
|
)
|
(7,157
|
)
|
(16,204
|
)
|
||||||
Total
|
2,347,547
|
95,892
|
2,443,439
|
|||||||||
Payments of losses and loss-adjustment expenses
|
||||||||||||
Current period insured events
|
2,083,552
|
58,091
|
2,141,643
|
|||||||||
Prior period insured events
|
263,245
|
40,657
|
303,902
|
|||||||||
Total
|
2,346,797
|
98,748
|
2,445,545
|
|||||||||
Net claim liabilities at end of year
|
349,047
|
99,898
|
448,945
|
|||||||||
Reinsurance recoverable on claim liabilities
|
-
|
38,998
|
38,998
|
|||||||||
Claim liabilities at end of year
|
$
|
349,047
|
$
|
138,896
|
$
|
487,943
|
2015
|
||||||||||||
Managed
Care
|
Other
Business
Segments *
|
Consolidated
|
||||||||||
Claim liabilities at beginning of year
|
$
|
249,330
|
$
|
140,756
|
$
|
390,086
|
||||||
Reinsurance recoverable on claim liabilities
|
-
|
(40,635
|
)
|
(40,635
|
)
|
|||||||
Net claim liabilities at beginning of year
|
249,330
|
100,121
|
349,451
|
|||||||||
Claims incurred
|
||||||||||||
Current period insured events
|
2,216,330
|
98,279
|
2,314,609
|
|||||||||
Prior period insured events
|
(19,637
|
)
|
(1,211
|
)
|
(20,848
|
)
|
||||||
Total
|
2,196,693
|
97,068
|
2,293,761
|
|||||||||
Payments of losses and loss-adjustment expenses
|
||||||||||||
Current period insured events
|
1,868,607
|
52,369
|
1,920,976
|
|||||||||
Prior period insured events
|
229,119
|
42,066
|
271,185
|
|||||||||
Total
|
2,097,726
|
94,435
|
2,192,161
|
|||||||||
Net claim liabilities at end of year
|
348,297
|
102,754
|
451,051
|
|||||||||
Reinsurance recoverable on claim liabilities
|
-
|
40,714
|
40,714
|
|||||||||
Claim liabilities at end of year
|
$
|
348,297
|
$
|
143,468
|
$
|
491,765
|
*
|
Other Business Segments include the Life Insurance and Property and Casualty segments, as well as intersegment eliminations.
|
Incurred Claims and Allocated Claim
Adjustment Expenses, Net of Reinsurance
|
As of December 31, 2017
|
|||||||||||||||
(in thousands)
|
||||||||||||||||
Incurred Year
|
2016
|
2017
|
Total of IBNR Liabilities
Plus Expected
Development on
Reported Claims
|
Cumulative
Number of
Reported Claims
|
||||||||||||
2016
|
$ |
2,356,592
|
2,343,812
|
798
|
20,270
|
|||||||||||
2017
|
2,231,052
|
290,642
|
17,577
|
|||||||||||||
Total
|
$
|
4,574,864
|
Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
|
|||||||||
Incurred Year
|
|
2016
|
2017
|
||||||
2016
|
$ |
2,083,552
|
2,343,014
|
||||||
2017
|
1,940,410
|
||||||||
Total
|
$
|
4,283,424
|
|||||||
All outstanding liabilities before 2016, net of reinsurance |
75,917
|
||||||||
Liabilities for claims and claim adjustment expenses, net of reinsurance |
$
|
367,357
|
Incurred Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
|
As of December 31, 2017
|
|||||||||||||||||||||||||||||||||||||||||||||||
Incurred
Year
|
Incurred amount
|
Total of IBNR Plus
Expected Development
on Reported Claims
|
Cumulative Number
of reported claims
|
|||||||||||||||||||||||||||||||||||||||||||||
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||||||||||||
2008
|
2009
|
2010
|
2011
|
2012
|
2013
|
2014
|
2015
|
2016
|
2017
|
|||||||||||||||||||||||||||||||||||||||
2008
|
$
|
49,095
|
$
|
48,812
|
$
|
46,443
|
$
|
45,941
|
$
|
45,541
|
$
|
47,658
|
$
|
45,909
|
$
|
45,535
|
$
|
45,571
|
$
|
45,471
|
24
|
15,762
|
||||||||||||||||||||||||||
2009
|
51,778
|
51,760
|
50,848
|
51,298
|
51,564
|
51,315
|
51,485
|
51,293
|
51,563
|
188
|
16,089
|
|||||||||||||||||||||||||||||||||||||
2010
|
54,226
|
54,090
|
55,266
|
56,400
|
57,115
|
57,386
|
57,242
|
56,960
|
174
|
18,010
|
||||||||||||||||||||||||||||||||||||||
2011
|
51,315
|
50,287
|
51,105
|
50,776
|
51,895
|
52,099
|
51,729
|
342
|
20,914
|
|||||||||||||||||||||||||||||||||||||||
2012
|
49,040
|
49,856
|
48,900
|
49,817
|
48,945
|
48,186
|
750
|
20,212
|
||||||||||||||||||||||||||||||||||||||||
2013
|
52,343
|
51,030
|
49,606
|
49,168
|
48,229
|
1,104
|
22,351
|
|||||||||||||||||||||||||||||||||||||||||
2014
|
48,430
|
45,410
|
43,707
|
42,547
|
1,924
|
22,026
|
||||||||||||||||||||||||||||||||||||||||||
2015
|
45,067
|
40,175
|
37,271
|
2,944
|
20,044
|
|||||||||||||||||||||||||||||||||||||||||||
2016
|
48,127
|
44,294
|
6,766
|
19,251
|
||||||||||||||||||||||||||||||||||||||||||||
2017
|
60,694
|
16,958
|
33,917
|
|||||||||||||||||||||||||||||||||||||||||||||
Total
|
$
|
486,944
|
Cumulative Paid claims and Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||||||||||||
Incurred
Year
|
||||||||||||||||||||||||||||||||||||||||
(unaudited)
2008
|
(unaudited)
2009
|
(unaudited)
2010
|
(unaudited)
2011
|
(unaudited)
2012
|
(unaudited)
2013
|
(unaudited)
2014
|
(unaudited)
2015
|
2016
|
2017
|
|||||||||||||||||||||||||||||||
2008
|
$
|
23,715
|
$
|
32,835 |
$
|
37,420
|
$
|
40,332 |
$
|
41,847
|
$
|
43,787
|
$
|
44,426
|
$
|
44,703
|
$
|
44,867
|
$
|
44,911
|
||||||||||||||||||||
2009
|
23,843 |
35,327
|
41,810 |
45,838
|
48,637
|
49,709
|
50,196
|
50,371
|
50,594
|
|||||||||||||||||||||||||||||||
2010
|
27,118
|
38,964 |
45,409
|
49,808
|
52,890
|
54,027
|
54,996
|
55,715
|
||||||||||||||||||||||||||||||||
2011
|
24,534 |
34,835
|
41,606
|
44,996
|
47,908
|
49,598
|
50,457
|
|||||||||||||||||||||||||||||||||
2012
|
22,677 |
33,620
|
40,406
|
43,663
|
45,607
|
46,094
|
||||||||||||||||||||||||||||||||||
2013
|
21,376 |
33,249
|
38,979
|
42,840
|
44,252
|
|||||||||||||||||||||||||||||||||||
2014
|
18,752 |
28,657
|
33,809
|
36,875
|
||||||||||||||||||||||||||||||||||||
2015
|
17,063
|
24,935
|
28,040
|
|||||||||||||||||||||||||||||||||||||
2016
|
20,099
|
28,996
|
||||||||||||||||||||||||||||||||||||||
2017
|
28,414
|
|||||||||||||||||||||||||||||||||||||||
$
|
414,348
|
|||||||||||||||||||||||||||||||||||||||
All Outstanding liabilities before 2008, net of reinsurance |
1,568
|
|||||||||||||||||||||||||||||||||||||||
Liabilities for claims and claims adjustment expenses, net of reinsurance |
$
|
74,164
|
(unaudited)
2008
|
(unaudited)
2009
|
(unaudited)
2010
|
(unaudited)
2011
|
(unaudited)
2012
|
(unaudited)
2013
|
(unaudited)
2014
|
(unaudited)
2015
|
(unaudited)
2016
|
(unaudited)
2017
|
|||||||||||||||||||||||||||||||
Average
|
46.7
|
%
|
21.7
|
%
|
11.7
|
%
|
7.2
|
%
|
4.5
|
%
|
2.5
|
%
|
1.4
|
%
|
0.7
|
%
|
0.4
|
%
|
0.1
|
%
|
As of December 31, 2017
|
||||
Net outstanding liabilities
|
||||
Managed Care
|
$
|
367,357
|
||
Property and Casualty
|
74,164
|
|||
Other short-duration insurance lines
|
3,696
|
|||
Liabilities for unpaid claims and claim adjustment expenses, net of reinsurance
|
445,217
|
|||
Reinsurance recoverable on unpaid claims - Property and Casualty
|
620,280
|
|||
Insurance lines other than short-duration
|
41,822
|
|||
Intersegment elimination
|
(443
|
)
|
||
Total gross liability for unpaid claims and claim adjustment expense
|
$
|
1,106,876
|
11.
|
Federal Employees’ Health Benefits (FEHBP) and Federal Employees’ (FEP) Programs
|
12. |
Long-Term Borrowings
|
2017
|
2016
|
|||||||
Senior unsecured notes payable of $60,000 issued on December 2005; due December 2020. Interest was payable monthly at a fixed rate of 6.60%, fully paid in January 2017.
|
$
|
-
|
$
|
24,000
|
||||
Secured loan payable of $11,187, payable in monthly installments of $137 through October 1, 2023, plus interest at a rate reset periodically of 100 basis points over selected LIBOR maturity (which was 2.37% at December 31, 2017).
|
9,547
|
11,187
|
||||||
Secured loan payable of $20,150, payable in monthly installments of $84 through January 1, 2024, plus interest at a rate reset periodically of 275 basis points over selected LIBOR maturity (which was 4.08% at December 31, 2017).
|
19,226
|
-
|
||||||
Secured loan payable of $4,116, payable in monthly installments of $49 through January 1, 2024, plus interest at a rate reset periodically of 325 basis points over selected LIBOR maturity (which was 4.58% at December 31, 2017).
|
3,577
|
-
|
||||||
Total borrowings
|
32,350
|
35,187
|
||||||
Less: unamortized debt issuance costs
|
277
|
102
|
||||||
$
|
32,073
|
$
|
35,085
|
Year ending December 31
|
||||
2018
|
$
|
3,236
|
||
2019
|
3,236
|
|||
2020
|
3,236
|
|||
2021
|
3,236
|
|||
2022
|
3,236
|
|||
Thereafter
|
16,170
|
|||
$
|
32,350
|
13. |
Reinsurance Activity
|
Premiums Earned
|
Claims Incurred
(1)
|
|||||||||||||||||||||||
2017
|
2016
|
2015
|
2017
|
2016
|
2015
|
|||||||||||||||||||
Gross
|
$
|
2,893,765
|
$
|
2,945,017
|
$
|
2,843,086
|
$
|
3,010,728
|
$
|
2,454,758
|
$
|
2,309,499
|
||||||||||||
Ceded
|
(71,295
|
)
|
(59,032
|
)
|
(64,134
|
)
|
(687,520
|
)
|
(15,008
|
)
|
(19,430
|
)
|
||||||||||||
Assumed
|
4,462
|
4,656
|
4,202
|
4,099
|
3,689
|
3,692
|
||||||||||||||||||
Net
|
$
|
2,826,932
|
$
|
2,890,641
|
$
|
2,783,154
|
$
|
2,327,307
|
$
|
2,443,439
|
$
|
2,293,761
|
(1) |
The claims incurred disclosed in this table exclude the portion of the change in the liability for future policy benefits amounting to $25,794, $28,752, and $24,954 that is included within the consolidated claims incurred during the years ended December 31, 2017, 2016 and 2015, respectively.
|
· |
For group policies, 80% of the claims up to a maximum of $800 (80% of $1,000), per person, per life. For other group policies with other options, the agreement covers 80% of the claims up to a maximum of $400 (80% of $500), per person, per life, or 80% of the claims up to a maximum of $200 (80% of $250), per person, per life.
|
· |
For policies provided to the active and retired employees of the Commonwealth of Puerto Rico and its instrumentalities, the treaty covers 100% of the claims up to a maximum of $1,000 per person, per life with major medical coverage, only if the covered person uses providers that are members of TSS network.
|
· |
For policies provided to the municipalities of Puerto Rico, the treaty covers 100% of the claims up to a maximum of $250, per person, per life, with plans with lifetime limits and all other plans 100% of the claims up to a maximum of $1,000, per person, per life.
|
· |
Casualty excess of loss treaty. This treaty provides reinsurance for losses up to $12,000, subject to a retention of $225.
|
· |
Medical malpractice excess of loss. This treaty provides reinsurance for losses up to $3,000, subject to a retention of $150.
|
· |
Surety quota share treaty covering contract and miscellaneous surety bond business. This treaty provides reinsurance of up to $5,000 for contract surety bonds, subject to an aggregate of $10,000 per contractor and $3,000 per miscellaneous surety bond.
|
· |
Commercial Property quota share contract
. This treaty covers a maximum of $30,000 for any one risk. Under this treaty 30% of the risk is ceded to reinsurers. The remaining exposure is covered by a
Property Per Risk excess of loss contract
that provides reinsurance in excess of $350 up to a maximum of $21,000, or the remaining 70% for any one risk.
|
· |
Builders’ risk quota share and first surplus covering contractors’ risk. This treaty provides protection on a 20/80 quota share basis for the initial $2,500 and a first surplus of $12,500 for a maximum of $14,500 for any one risk.
|
· |
The commercial property quota share contract described above provides coverage for losses from a single event up to $200,000.
|
· |
Personal property catastrophe excess of loss. This treaty provides protection from losses up to a maximum of $125,000, subject to a $5,000 retention.
|
· |
Commercial property catastrophe excess of loss. This treaty provides protection for losses up to a maximum of $135,000, subject to a $10,000 retention.
|
· |
Property catastrophe excess of loss. This treaty provides a protection of $285,000 in excess of the Personal and Commercial lines Catastrophe contracts.
|
· |
In addition, the above combined $15,000 retention is further reduced to $10,000 by the
Clash Cover Property Catastrophe excess of loss contract.
The losses would be net of any Facultative reinsurance. Also, the Company purchases personal and commercial
Reinstatement Premium Protection contracts
to cover the necessity of reinstating the catastrophe program in the event it is activated.
|
· |
Group life insurance facultative agreement, reinsuring risk in excess of $25 of certain group life policies and a combined pro rata and excess of loss agreement effective July 1, 2008, reinsuring 50% of the risk up to $200 and ceding the excess.
|
· |
Facultative pro rata agreements for the long‑term disability insurance, reinsuring 65% of the risk.
|
· |
Several reinsurance agreements, mostly on an excess of loss basis up to a maximum retention of $50. For certain new life products that have been issued after 1999, the retention limit is $175, and for others issued after January 1, 2015, the retention limit is $200.
|
· |
A quota share agreement for group major medical and an excess of loss agreements for group and individual major medical, where TSV cedes 40% of all claims up to a maximum retention of $100 and 70% of all claims over $100 up to a maximum of $2,000.
|
· |
Excess of loss agreement for the Major Medical Business in Costa Rica reinsuring 100% of all claims over $25.
|
14. |
Income Taxes
|
2017
|
2016
|
2015
|
||||||||||
Current income tax expense
|
$
|
34,412
|
$
|
1,981
|
$
|
10,169
|
||||||
Deferred income tax benefit
|
(9,916
|
)
|
(8,326
|
)
|
(5,070
|
)
|
||||||
Total income tax expense (benefit)
|
$
|
24,496
|
$
|
(6,345
|
)
|
$
|
5,099
|
2017
|
2016
|
2015
|
||||||||||
Income before taxes
|
$
|
78,977
|
$
|
11,086
|
$
|
57,131
|
||||||
Statutory tax rate
|
39.00
|
%
|
39.00
|
%
|
39.00
|
%
|
||||||
Income tax expense at statutory rate
|
30,801
|
4,324
|
22,281
|
|||||||||
(Decrease) increase in taxes resulting from
|
||||||||||||
Exempt interest income, net
|
(5,364
|
)
|
(5,158
|
)
|
(6,041
|
)
|
||||||
Effect of taxing life insurance operations as a qualified domestic life insurance company instead of as a regular corporation
|
(4,871
|
)
|
(5,033
|
)
|
(4,936
|
)
|
||||||
Effect of taxing capital gains at a preferential rate
|
(2,116
|
)
|
(3,799
|
)
|
(7,432
|
)
|
||||||
Dividends received deduction
|
-
|
-
|
270
|
|||||||||
Adjustment to deferred tax assets and liabilities for changes in effective tax rates
|
(120
|
)
|
1,669
|
(1,576
|
)
|
|||||||
Other adjustments to deferred tax assets and liabilities
|
836
|
2,852
|
(58
|
)
|
||||||||
Effect of extraordinary dividend distribution from the JUA Association - reported net of taxes in other income
|
(922
|
)
|
(151
|
)
|
(875
|
)
|
||||||
Charges against the catastrophe loss reserve
|
1,567
|
-
|
-
|
|||||||||
Allowance for doubtful receivables recapture
|
2,688
|
-
|
-
|
|||||||||
Effect of net operating loss limitations
|
1,511
|
-
|
-
|
|||||||||
Tax credit benefit
|
(555
|
)
|
(709
|
)
|
(537
|
)
|
||||||
Tax returns to provision true up
|
363
|
(181
|
)
|
(1,084
|
)
|
|||||||
Subtotal
|
(6,983
|
)
|
(10,510
|
)
|
(22,269
|
)
|
||||||
Other permanent disallowances, net:
|
||||||||||||
Disallowed resolution agreements expense
|
-
|
-
|
1,716
|
|||||||||
Disallowance of expenses related to exempt interest income
|
-
|
58
|
-
|
|||||||||
Disallowed dividend received deduction
|
-
|
-
|
3,598
|
|||||||||
Disallowed interest expense
|
-
|
8
|
12
|
|||||||||
Other
|
50
|
-
|
61
|
|||||||||
Total other permanent differences
|
50
|
66
|
5,387
|
|||||||||
Other adjustments
|
628
|
(225
|
)
|
(300
|
)
|
|||||||
Total income tax expense (benefit)
|
$
|
24,496
|
$
|
(6,345
|
)
|
$
|
5,099
|
2017
|
2016
|
|||||||
Deferred tax assets
|
||||||||
Allowance for doubtful receivables
|
$
|
11,787
|
$
|
10,070
|
||||
Liability for pension benefits
|
13,826
|
10,624
|
||||||
Employee benefits plan
|
-
|
1,580
|
||||||
Postretirement benefits
|
662
|
772
|
||||||
Deferred compensation
|
2,168
|
2,041
|
||||||
Accumulated depreciation
|
1,296
|
1,137
|
||||||
Impairment loss on investments
|
950
|
2,035
|
||||||
Contingency reserves
|
1,950
|
-
|
||||||
Share-based compensation
|
6,795
|
4,393
|
||||||
Alternative minimum income tax credit
|
1,874
|
1,991
|
||||||
Purchased tax credits
|
2,767
|
6,062
|
||||||
Net operating loss
|
38,839
|
33,081
|
||||||
Difference in tax basis of investments portfolio
|
-
|
3,049
|
||||||
Accrued liabilities
|
3,271
|
2,133
|
||||||
Other
|
873
|
772
|
||||||
Gross deferred tax assets
|
87,058
|
79,740
|
||||||
Less: valuation allowance
|
(8,283
|
)
|
(8,016
|
)
|
||||
Deferred tax assets
|
78,775
|
71,724
|
||||||
Deferred tax liabilities
|
||||||||
Deferred policy acquisition costs
|
(7,323
|
)
|
(6,621
|
)
|
||||
Catastrophe loss reserve
|
(6,371
|
)
|
(8,020
|
)
|
||||
Unrealized gain on securities available for sale
|
(19,440
|
)
|
(15,804
|
)
|
||||
Difference in tax basis of investments portfolio
|
(220
|
)
|
-
|
|||||
Unamortized debt issue costs
|
(108
|
)
|
(152
|
)
|
||||
Intangible asset
|
(1,546
|
)
|
(2,195
|
)
|
||||
Employee benefits plan
|
(535
|
)
|
-
|
|||||
Accumulated depreciation
|
-
|
(14
|
)
|
|||||
Gross deferred tax liabilities
|
(35,543
|
)
|
(32,806
|
)
|
||||
Net deferred tax asset
|
$
|
43,232
|
$
|
38,918
|
15. |
Pension Plans
|
2017
|
2016
|
|||||||
Change in benefit obligation
|
||||||||
Benefit obligation at beginning of year
|
$
|
163,877
|
$
|
184,782
|
||||
Service cost
|
223
|
3,640
|
||||||
Interest cost
|
7,186
|
8,749
|
||||||
Benefit payments
|
(10,503
|
)
|
(12,911
|
)
|
||||
Actuarial loss
|
24,269
|
14,709
|
||||||
Liability gain due to curtailment
|
-
|
(35,092
|
)
|
|||||
Benefit obligation at end of year
|
$
|
185,052
|
$
|
163,877
|
||||
Accumulated benefit obligation at end of year
|
$
|
185,052
|
$
|
163,877
|
||||
Change in fair value of plan assets
|
||||||||
Fair value of plan assets at beginning of year
|
$
|
140,398
|
$
|
130,061
|
||||
Actual return on assets
|
24,984
|
13,248
|
||||||
Employer contributions
|
4,000
|
10,000
|
||||||
Benefit payments
|
(10,503
|
)
|
(12,911
|
)
|
||||
Fair value of plan assets at end of year
|
$
|
158,879
|
$
|
140,398
|
||||
Funded status at end of year
|
$
|
(26,173
|
)
|
$
|
(23,479
|
)
|
||
Amounts in accumulated other comprehensive income not yet recognized as a component of net periodic pension cost
|
||||||||
Development of prior service credit
|
||||||||
Balance at beginning of year
|
$
|
-
|
$
|
(2,223
|
)
|
|||
Amortization
|
-
|
450
|
||||||
Curtailment/Settlement
|
-
|
1,773
|
||||||
Net prior service credit
|
-
|
-
|
||||||
Development of actuarial loss
|
||||||||
Balance at beginning of year
|
27,060
|
55,716
|
||||||
Amortization
|
(369
|
)
|
(4,028
|
)
|
||||
Loss arising during the year
|
8,025
|
10,464
|
||||||
Curtailment/Settlement gain during the year
|
-
|
(35,092
|
)
|
|||||
Actuarial net loss
|
34,716
|
27,060
|
||||||
Sum of deferrals
|
$
|
34,716
|
$
|
27,060
|
||||
Net amount recognized
|
$
|
8,543
|
$
|
3,581
|
2017
|
2016
|
|||||||
Discount rate
|
3.75
|
%
|
4.50
|
%
|
||||
Rate of compensation increase
|
N/A
|
N/A
|
2017
|
2016
|
|||||||
Pension liability
|
$
|
26,173
|
$
|
23,479
|
||||
Accumulated other comprehensive loss, net of a deferred tax of $10,176 and $7,191 in 2017 and 2016, respectively
|
24,540
|
19,869
|
2017
|
2016
|
2015
|
||||||||||
Components of net periodic benefit cost
|
||||||||||||
Service cost
|
$
|
223
|
$
|
3,640
|
$
|
4,137
|
||||||
Interest cost
|
7,186
|
8,749
|
8,281
|
|||||||||
Expected return on plan assets
|
(8,740
|
)
|
(9,003
|
)
|
(8,380
|
)
|
||||||
Prior service benefit
|
-
|
(450
|
)
|
(450
|
)
|
|||||||
Actuarial loss
|
369
|
4,028
|
5,939
|
|||||||||
Net periodic benefit cost
|
$
|
(962
|
)
|
$
|
6,964
|
$
|
9,527
|
2017
|
2016
|
2015
|
||||||||||
Discount rate
|
4.50
|
%
|
4.75
|
%
|
4.25
|
%
|
||||||
Expected return on plan assets
|
6.50
|
%
|
7.00
|
%
|
7.00
|
%
|
||||||
Rate of compensation increase
|
N/A
|
Graded; 3.50
|
% |
Graded; 3.50
|
% | |||||||
to 8.00
|
% |
to 8.00
|
% |
2017
|
||||||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
NAV
|
Total
|
||||||||||||||||
Government obligations
|
$
|
-
|
$
|
7,131
|
$
|
-
|
$
|
-
|
$
|
7,131
|
||||||||||
Non-agency backed securities
|
-
|
641
|
-
|
-
|
641
|
|||||||||||||||
Corporate obligations
|
-
|
8,560
|
-
|
-
|
8,560
|
|||||||||||||||
Limited Liability Corporations
|
-
|
-
|
-
|
119,581
|
-
|
|||||||||||||||
Real estate
|
-
|
-
|
-
|
7,568
|
-
|
|||||||||||||||
Registered investments
|
3,388
|
659
|
-
|
-
|
4,047
|
|||||||||||||||
Hedge funds
|
-
|
8,808
|
-
|
1,972
|
8,808
|
|||||||||||||||
Common stocks
|
1,920
|
-
|
-
|
-
|
1,920
|
|||||||||||||||
Preferred stocks
|
23
|
17
|
-
|
-
|
40
|
|||||||||||||||
Interest-bearing cash
|
501
|
-
|
-
|
-
|
501
|
|||||||||||||||
Derivatives
|
(1
|
)
|
17
|
-
|
-
|
16
|
||||||||||||||
$
|
5,831
|
$
|
25,833
|
$
|
-
|
$
|
129,121
|
$
|
31,664
|
2016
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Government obligations
|
$
|
-
|
$
|
6,276
|
$
|
-
|
$
|
6,276
|
||||||||
Non-agency backed securities
|
-
|
715
|
-
|
715
|
||||||||||||
Corporate obligations
|
-
|
7,243
|
-
|
7,243
|
||||||||||||
Partnership/Joint venture
|
-
|
-
|
932
|
932
|
||||||||||||
Limited Liability Corporations
|
-
|
98,188
|
-
|
98,188
|
||||||||||||
Real estate
|
-
|
-
|
6,617
|
6,617
|
||||||||||||
Registered investments
|
3,839
|
1,869
|
-
|
5,708
|
||||||||||||
Common/Collective trusts
|
-
|
7,334
|
-
|
7,334
|
||||||||||||
Hedge funds
|
-
|
4,581
|
-
|
4,581
|
||||||||||||
Common stocks
|
1,515
|
1
|
-
|
1,516
|
||||||||||||
Preferred stocks
|
107
|
12
|
-
|
119
|
||||||||||||
Forward foreign currency contracts
|
-
|
(1
|
)
|
-
|
(1
|
)
|
||||||||||
Interest-bearing cash
|
2,224
|
-
|
-
|
2,224
|
||||||||||||
Derivatives
|
-
|
27
|
-
|
27
|
||||||||||||
$
|
7,685
|
$
|
126,245
|
$
|
7,549
|
$
|
141,479
|
Government
Obligations
|
Corporate
Obligations
|
Partnership/
Joint
Venture
|
Real
Estate
|
Hedge
Funds
|
Total
|
|||||||||||||||||||
Beginning balance at December 31, 2015
|
$
|
-
|
$
|
-
|
$
|
567
|
$
|
5,929
|
$
|
-
|
$
|
6,496
|
||||||||||||
Actual return on program assets:
|
||||||||||||||||||||||||
Relating to assets still held at the reporting date
|
-
|
-
|
19
|
501
|
-
|
520
|
||||||||||||||||||
Relating to assets sold during the period
|
-
|
-
|
1
|
72
|
-
|
73
|
||||||||||||||||||
Purchases, issuances, and settlements
|
-
|
-
|
345
|
324
|
-
|
669
|
||||||||||||||||||
Transfer in and/or out
|
-
|
-
|
-
|
(209
|
)
|
-
|
(209
|
)
|
||||||||||||||||
Ending balance at December 31, 2016
|
-
|
-
|
932
|
6,617
|
-
|
7,549
|
||||||||||||||||||
Actual return on program assets:
|
||||||||||||||||||||||||
Transfer in and/or out
|
-
|
-
|
(932
|
)
|
(6,617
|
)
|
-
|
(7,549
|
)
|
|||||||||||||||
Ending balance at December 31, 2017
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
· |
Increasing risk is rewarded with compensating returns over time, and therefore, prudent risk taking is justifiable for long-term investors.
|
· |
Risk can be controlled through diversification of asset classes and investment approaches, as well as diversification of individual securities.
|
· |
Risk is reduced by time, and over time the relative performance of different asset classes is reasonably consistent. Over the long-term, equity investments have provided and should continue to provide superior returns over other security types. Fixed-income securities can dampen volatility and provide liquidity in periods of depressed economic activity. Lengthening duration of fixed income securities may reduce surplus volatility.
|
· |
The strategic or long-term allocation of assets among various asset classes is an important driver of long‑term returns.
|
· |
Relative performance of various asset classes is unpredictable in the short‑term and attempts to shift tactically between asset classes are unlikely to be rewarded.
|
· |
To ensure assets are available to meet current and future obligations of the participating programs when due.
|
· |
To earn the maximum return that can be realistically achieved in the markets over the long‑term at a specified and controlled level of risk in order to minimize future contributions.
|
· |
To invest assets with consideration of the liability characteristics in order to better align assets and liabilities.
|
· |
To invest the assets with the care, skill, and diligence that a prudent person acting in a like capacity would undertake. In the process, the Administration of the Trust has the objective of controlling the costs involved with administering and managing the investments of the National Retirement Trust.
|
Year ending December 31
|
||||
2018
|
$
|
9,048
|
||
2019
|
9,253
|
|||
2020
|
9,585
|
|||
2021
|
9,830
|
|||
2022
|
9,799
|
|||
2023 – 2027
|
51,294
|
16. |
Catastrophe Loss Reserve and Trust Fund
|
17. |
Stockholders’ Equity
|
a. |
Common Stock
|
b. |
Preferred Stock
|
c. |
Liquidity Requirements
|
d. |
Dividends
|
18. |
Stock Repurchase Programs
|
· |
In October 2014 the Company’s Board of Directors authorized a $50,000 repurchase program (2014 $50,000 program) of its Class B common stock. This program was completed on October 7, 2015.
|
· |
In November 2015 the Company’s Board of Directors authorized a $25,000 repurchase program (2015 $25,000 program) of its Class B common stock. This program was completed on September 14, 2016.
|
· |
In August 2017 the Company’s Board of Directors authorized a $30,000 repurchase program (2017 $30,000 program) of its Class B common stock.
|
2017
|
2016
|
2015
|
||||||||||||||||||||||||||||||||||
Shares
Repurchased
|
Average
Share
Price
|
Amount
Repurchased
|
Shares
Repurchased
|
Average
Share
Price
|
Amount
Repurchased
|
Shares
Repurchased
|
Average
Share
Price
|
Amount
Repurchased
|
||||||||||||||||||||||||||||
2017 $30,000 program
|
861,415
|
$
|
23.38
|
$
|
20,220
|
-
|
$
|
-
|
$
|
-
|
-
|
$
|
-
|
$
|
-
|
|||||||||||||||||||||
2015 $25,000 program
|
-
|
-
|
-
|
951,831
|
22.54
|
21,370
|
154,554
|
23.72
|
3,629
|
|||||||||||||||||||||||||||
2014 $50,000 program
|
-
|
-
|
-
|
-
|
-
|
-
|
2,086,532
|
21.69
|
44,658
|
|||||||||||||||||||||||||||
Total
|
861,415
|
$
|
23.38
|
$
|
20,220
|
951,831
|
$
|
22.54
|
$
|
21,370
|
2,241,086
|
$
|
21.87
|
$
|
48,287
|
19. |
Comprehensive Income
|
Unrealized
Gains on
Securities
|
Liability
for Pension
Benefits
|
Accumulated
Other
Comprehensive
Income
|
||||||||||
Beginning balance at December 31, 2016
|
$
|
62,371
|
$
|
(19,976
|
)
|
$
|
42,395
|
|||||
Net current period change
|
22,836
|
(5,011
|
)
|
17,825
|
||||||||
Reclassification adjustments for gains and losses reclassified in income
|
(8,969
|
)
|
3
|
(8,966
|
)
|
|||||||
Ending balance at December 31, 2017
|
$
|
76,238
|
$
|
(24,984
|
)
|
$
|
51,254
|
2017
|
||||||||||||
Before-Tax
Amount
|
Deferred Tax
(Expense)
Benefit
|
Net-of-Tax
Amount
|
||||||||||
Unrealized holding gains on securities arising during the period
|
$
|
28,544
|
$
|
(5,708
|
)
|
$
|
22,836
|
|||||
Less reclassification adjustment for gains and losses realized in income
|
(10,831
|
)
|
1,862
|
(8,969
|
)
|
|||||||
Net change in unrealized gain
|
17,713
|
(3,846
|
)
|
13,867
|
||||||||
Liability for pension benefits:
|
||||||||||||
Reclassification adjustment for amortization of net losses from past experience and prior service costs
|
5
|
(2
|
)
|
3
|
||||||||
Net change arising from assumptions and plan changes and experience
|
(8,215
|
)
|
3,204
|
(5,011
|
)
|
|||||||
Net change in liability for pension benefits
|
(8,210
|
)
|
3,202
|
(5,008
|
)
|
|||||||
Net current period change
|
$
|
9,503
|
$
|
(644
|
)
|
$
|
8,859
|
2016
|
||||||||||||
Before-Tax
Amount
|
Deferred Tax
(Expense)
Benefit
|
Net-of-Tax
Amount
|
||||||||||
Unrealized holding gains on securities arising during the period
|
$
|
18,357
|
$
|
(3,596
|
)
|
$
|
14,761
|
|||||
Less reclassification adjustment for gains and losses realized in income
|
(17,379
|
)
|
2,511
|
(14,868
|
)
|
|||||||
Net change in unrealized gain
|
978
|
(1,085
|
)
|
(107
|
)
|
|||||||
Liability for pension benefits:
|
||||||||||||
Reclassification adjustment for amortization of net losses from past experience and prior service costs
|
1,888
|
(737
|
)
|
1,151
|
||||||||
Net change arising from assumptions and plan changes and experience
|
25,783
|
(10,055
|
)
|
15,728
|
||||||||
Net change in liability for pension benefits
|
27,671
|
(10,792
|
)
|
16,879
|
||||||||
Net current period change
|
$
|
28,649
|
$
|
(11,877
|
)
|
$
|
16,772
|
2015
|
||||||||||||
Before-Tax
Amount
|
Deferred Tax
(Expense)
Benefit
|
Net-of-Tax
Amount
|
||||||||||
Unrealized holding gains on securities arising during the period
|
$
|
(25,765
|
)
|
$
|
3,153
|
$
|
(22,612
|
)
|
||||
Less reclassification adjustment for gains and losses realized in income
|
(18,941
|
)
|
2,564
|
(16,377
|
)
|
|||||||
Net change in unrealized gain
|
(44,706
|
)
|
5,717
|
(38,989
|
)
|
|||||||
Liability for pension benefits:
|
||||||||||||
Reclassification adjustment for amortization of net losses from past experience and prior service costs
|
6,020
|
(2,348
|
)
|
3,672
|
||||||||
Net change arising from assumptions and plan changes and experience
|
19,940
|
(7,776
|
)
|
12,164
|
||||||||
Net change in liability for pension benefits
|
25,960
|
(10,124
|
)
|
15,836
|
||||||||
Net current period change
|
$
|
(18,746
|
)
|
$
|
(4,407
|
)
|
$
|
(23,153
|
)
|
20. |
Share-Based Compensation
|
Restricted Awards
|
Performance Awards
|
|||||||||||||||
Number of
Shares
|
Weighted
Average
Fair
Value
|
Number of
Shares
|
Weighted
Average
Exercise
Price
|
|||||||||||||
Outstanding balance at January 1, 2017
|
161,824
|
$
|
21.94
|
458,195
|
$
|
21.44
|
||||||||||
Granted
|
154,367
|
17.78
|
338,577
|
18.18
|
||||||||||||
Lapsed
|
(90,583
|
)
|
21.51
|
(234,954
|
)
|
19.49
|
||||||||||
Forfeited (due to termination)
|
(7,921
|
)
|
19.48
|
(38,990
|
)
|
20.10
|
||||||||||
Quantity adjusted (due to performance payout more than 100%), net of forfeited
|
-
|
-
|
13,296
|
27.18
|
||||||||||||
Outstanding balance at December 31, 2017
|
217,687
|
$
|
19.26
|
536,124
|
$
|
20.47
|
21. |
Net
Income Available to Stockholders and Basic Net Income per Share
|
2017
|
2016
|
2015
|
||||||||||
Numerator for earnings per share
|
||||||||||||
Net income attributable to TSM available to stockholders
|
$
|
54,486
|
$
|
17,438
|
$
|
52,121
|
||||||
Denominator for basic earnings per share –
|
||||||||||||
Weighted average of common shares
|
23,996,503
|
24,454,435
|
25,674,079
|
|||||||||
Effect of dilutive securities
|
71,083
|
56,658
|
87,662
|
|||||||||
Denominator for diluted earnings per share
|
24,067,586
|
24,511,093
|
25,761,741
|
|||||||||
Basic net income per share attributable to TSM
|
$
|
2.27
|
$
|
0.71
|
$
|
2.03
|
||||||
Diluted net income per share attributable to TSM
|
$
|
2.26
|
$
|
0.71
|
$
|
2.02
|
22. |
Commitments
|
Year ending December 31
|
||||
2018
|
$
|
4,178
|
||
2019
|
3,817
|
|||
2020
|
2,027
|
|||
2021
|
605
|
|||
2022
|
939
|
|||
Total
|
$
|
11,566
|
23. |
Contingencies
|
24. |
Statutory Accounting
|
(dollar amounts in millions)
|
2017
|
2016
|
2015
|
|||||||||
Net admitted assets
|
$
|
2,102
|
$
|
1,829
|
$
|
1,881
|
||||||
Capital and surplus
|
647
|
638
|
691
|
|||||||||
RBC requirement
|
301
|
278
|
301
|
|||||||||
Net income
|
87
|
24
|
73
|
25. |
Supplementary Information on Cash Flow Activities
|
2017
|
2016
|
2015
|
||||||||||
Supplementary information
|
||||||||||||
Noncash transactions affecting cash flow activities
|
||||||||||||
Change in net unrealized (gain) loss on securities available for sale, including deferred income tax liability (asset) of $3,846, $1,085, and $(5,717) in 2017, 2016, and 2015, respectively
|
$
|
(13,867
|
)
|
$
|
107
|
$
|
38,989
|
|||||
Change in liability for pension benefits, and deferred income tax (asset) liability of $(3,202), $10,792, $10,124, in 2017, 2016, and 2015, respectively
|
$
|
5,008
|
$
|
(16,879
|
)
|
$
|
(15,836
|
)
|
||||
Repurchase and retirement of common stock
|
$
|
(89
|
)
|
$
|
(56
|
)
|
$
|
(182
|
)
|
|||
Exercise of stock options
|
$
|
-
|
$
|
55
|
$
|
179
|
||||||
Other
|
||||||||||||
Income taxes paid
|
$
|
10,363
|
$
|
11,549
|
$
|
6,437
|
||||||
Interest paid
|
$
|
6,794
|
$
|
7,635
|
$
|
4,792
|
26. |
Segment Information
|
· |
Managed Care segment
– This segment is engaged in the sale of managed care products to the Commercial, Medicare and Medicaid market sectors. The Commercial accounts sector includes corporate accounts, U.S. federal government employees, individual accounts, local government employees, and Medicare supplement. The following represents a description of the major contracts by sector:
|
– |
The segment is a qualified contractor to provide health coverage to federal government employees within Puerto Rico and the USVI. Earned premiums revenue related to this contract amounted to $156,417, $163,556 and $155,821 for the years ended December 31, 2017, 2016, and 2015, respectively (see note 11).
|
– |
Under its commercial business, the segment also provides health coverage to certain employees of the Commonwealth of Puerto Rico and its instrumentalities. Earned premium revenue related to such health plans amounted to $28,149, $29,475 and $30,607 for years ended December 31, 2017, 2016, and 2015, respectively.
|
– |
The segment provides services through its Medicare health plans pursuant to a limited number of contracts with CMS. Earned premium revenue related to the Medicare business amounted to $1,035,285, $1,023,904, and $1,097,657 for the years ended December 31, 2017, 2016, and 2015, respectively.
|
– |
The segment also participates in the Medicaid program to provide health coverage to medically indigent citizens in Puerto Rico, as defined by the laws of the government of Puerto Rico.
We served all eight service regions on an administrative service only basis (ASO) until March 31, 2015.
Administrative service fees for the period ended December 31, 2015 amounted to $24,266. Beginning on April 1, 2015, the segment began providing managed care services to two service regions on a fully-insured basis, earned premium revenue related to this business amounted to $751,393, $783,231, and $607,216 for the years ended December 31, 2017, 2016, and 2015, respectively.
|
· |
Life Insurance segment
– This segment offers primarily life and accident and health insurance coverage, and annuity products. The premiums for this segment are mainly subscribed through an internal sales force and a network of independent brokers and agents.
|
·
|
Property and Casualty Insurance segment
–The predominant insurance products of this segment commercial package, commercial auto, and personal package. The premiums for this segment are originated through a network of independent insurance agents and brokers. Agents or general agencies collect the premiums from the insureds, which are subsequently remitted to the segment, net of commissions. Remittances are generally due 60 days after the closing date of the general agent’s account current.
|
2017
|
2016
|
2015
|
||||||||||
Operating revenues
|
||||||||||||
Managed care
|
||||||||||||
Premiums earned, net
|
$
|
2,588,692
|
$
|
2,647,169
|
$
|
2,548,270
|
||||||
Fee revenue
|
16,514
|
17,843
|
44,705
|
|||||||||
Intersegment premiums/fee revenue
|
6,362
|
5,918
|
5,860
|
|||||||||
Net investment income
|
16,659
|
15,102
|
11,779
|
|||||||||
Total managed care
|
2,628,227
|
2,686,032
|
2,610,614
|
|||||||||
Life
|
||||||||||||
Premiums earned, net
|
161,628
|
156,140
|
147,864
|
|||||||||
Intersegment premiums
|
218
|
716
|
251
|
|||||||||
Net investment income
|
24,819
|
24,877
|
24,457
|
|||||||||
Total life
|
186,665
|
181,733
|
172,572
|
|||||||||
Property and casualty
|
||||||||||||
Premiums earned, net
|
76,612
|
87,332
|
87,020
|
|||||||||
Intersegment premiums
|
613
|
613
|
613
|
|||||||||
Net investment income
|
9,489
|
8,891
|
8,706
|
|||||||||
Total property and casualty
|
86,714
|
96,836
|
96,339
|
|||||||||
Other segments*
|
||||||||||||
Intersegment service revenues
|
8,677
|
9,907
|
10,863
|
|||||||||
Operating revenues from external sources
|
3,763
|
3,563
|
3,875
|
|||||||||
Total other segments
|
12,440
|
13,470
|
14,738
|
|||||||||
Total business segments
|
2,914,046
|
2,978,071
|
2,894,263
|
|||||||||
TSM operating revenues from external sources
|
545
|
19
|
53
|
|||||||||
Elimination of intersegment premiums
|
(7,193
|
)
|
(7,247
|
)
|
(6,724
|
)
|
||||||
Elimination of intersegment service revenue
|
(8,677
|
)
|
(9,907
|
)
|
(10,863
|
)
|
||||||
Other intersegment eliminations
|
-
|
(78
|
)
|
23
|
||||||||
Consolidated operating revenues
|
$
|
2,898,721
|
$
|
2,960,858
|
$
|
2,876,752
|
* |
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
|
2017
|
2016
|
2015
|
||||||||||
Operating income (loss)
|
||||||||||||
Managed care
|
$
|
55,040
|
$
|
(36,777
|
)
|
$
|
20,514
|
|||||
Life
|
19,434
|
21,458
|
20,012
|
|||||||||
Property and casualty
|
(6,034
|
)
|
12,074
|
8,273
|
||||||||
Other segments*
|
(391
|
)
|
(1,784
|
)
|
(301
|
)
|
||||||
Total business segments
|
68,049
|
(5,029
|
)
|
48,498
|
||||||||
TSM operating revenues from external sources
|
545
|
19
|
53
|
|||||||||
TSM unallocated operating expenses
|
(9,787
|
)
|
(9,739
|
)
|
(18,858
|
)
|
||||||
Elimination of TSM charges
|
9,600
|
9,522
|
9,623
|
|||||||||
Consolidated operating income (loss)
|
68,407
|
(5,227
|
)
|
39,316
|
||||||||
Consolidated net realized investment gains
|
10,831
|
17,379
|
18,941
|
|||||||||
Consolidated interest expense
|
(6,794
|
)
|
(7,635
|
)
|
(8,169
|
)
|
||||||
Consolidated other income, net
|
6,533
|
6,569
|
7,043
|
|||||||||
Consolidated income before taxes
|
$
|
78,977
|
$
|
11,086
|
$
|
57,131
|
2017
|
2016
|
2015
|
||||||||||
Depreciation and amortization expense
|
||||||||||||
Managed care
|
$
|
10,007
|
$
|
11,114
|
$
|
13,268
|
||||||
Life
|
1,203
|
1,030
|
1,094
|
|||||||||
Property and casualty
|
528
|
544
|
673
|
|||||||||
Other segments*
|
673
|
645
|
556
|
|||||||||
Total business segments
|
12,411
|
13,333
|
15,591
|
|||||||||
TSM depreciation expense
|
787
|
787
|
788
|
|||||||||
Consolidated depreciation and amortization expense
|
$
|
13,198
|
$
|
14,120
|
$
|
16,379
|
* |
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
|
2017
|
2016
|
2015
|
||||||||||
Assets
|
||||||||||||
Managed care
|
$
|
1,092,715
|
$
|
1,013,872
|
$
|
1,034,725
|
||||||
Life
|
853,289
|
816,920
|
770,721
|
|||||||||
Property and casualty
|
1,094,773
|
349,159
|
350,514
|
|||||||||
Other segments*
|
19,027
|
26,034
|
25,629
|
|||||||||
Total business segments
|
3,059,804
|
2,205,985
|
2,181,589
|
|||||||||
Unallocated amounts related to TSM
|
||||||||||||
Cash, cash equivalents, and investments
|
81,169
|
17,033
|
12,304
|
|||||||||
Property and equipment, net
|
22,257
|
22,380
|
23,219
|
|||||||||
Other assets
|
22,763
|
21,646
|
31,732
|
|||||||||
126,189
|
61,059
|
67,255
|
||||||||||
Elimination entries – intersegment receivables and others
|
(69,228
|
)
|
(48,045
|
)
|
(42,699
|
)
|
||||||
Consolidated total assets
|
$
|
3,116,765
|
$
|
2,218,999
|
$
|
2,206,145
|
2017
|
2016
|
2015
|
||||||||||
Significant noncash items
|
||||||||||||
Net change in unrealized gain (loss) on securities available for sale
|
||||||||||||
Managed care
|
$
|
3,932
|
$
|
104
|
$
|
(15,505
|
)
|
|||||
Life
|
7,142
|
2,659
|
(13,005
|
)
|
||||||||
Property and casualty
|
2,691
|
(2,984
|
)
|
(10,482
|
)
|
|||||||
Other segments*
|
-
|
105
|
(10
|
)
|
||||||||
Total business segments
|
13,765
|
(116
|
)
|
(39,002
|
)
|
|||||||
Amount related to TSM
|
102
|
9
|
13
|
|||||||||
Consolidated net change in unrealized gain (loss) on securities available for sale
|
$
|
13,867
|
$
|
(107
|
)
|
$
|
(38,989
|
)
|
* |
Includes segments that are not required to be reported separately, primarily the data processing services organization and the health clinic.
|
27. |
Subsequent Events
|
As of December 31,
|
||||||||
2017
|
2016
|
|||||||
Assets:
|
||||||||
Cash and cash equivalents
|
17,541
|
$
|
14,153
|
|||||
Securities available for sale, at fair value:
|
||||||||
Equity Securities (cost of $63,490 in 2017 and $2,869 in 2016)
|
63,628
|
2,880
|
||||||
Investment in subsidiaries
|
836,427
|
866,010
|
||||||
Notes receivable and accrued interest from subsidiaries
|
42,869
|
47,153
|
||||||
Due from subsidiaries
|
8,927
|
5,255
|
||||||
Deferred tax assets
|
18,186
|
14,976
|
||||||
Other assets
|
26,834
|
29,050
|
||||||
Total assets
|
$
|
1,014,412
|
$
|
979,477
|
||||
Liabilities:
|
||||||||
Notes payable and accrued interest to subsidiary
|
17,267
|
16,475
|
||||||
Due to subsidiaries
|
66
|
22,661
|
||||||
Long-term borrowings
|
32,073
|
35,085
|
||||||
Liability for pension benefits
|
33,672
|
30,892
|
||||||
Other liabilities
|
17,970
|
11,201
|
||||||
Total liabilities
|
101,048
|
116,314
|
||||||
Stockholders' equity:
|
||||||||
Common stock, class A
|
951
|
951
|
||||||
Common stock, class B
|
22,627
|
23,321
|
||||||
Additional paid-in-capital
|
53,142
|
65,592
|
||||||
Retained earnings
|
785,390
|
730,904
|
||||||
Accumulated other comprehensive income, net
|
51,254
|
42,395
|
||||||
Total stockholders' equity
|
913,364
|
863,163
|
||||||
Total liabilities and stockholders' equity
|
$
|
1,014,412
|
$
|
979,477
|
2017
|
2016
|
2015
|
||||||||||
Investment income
|
$
|
545
|
$
|
19
|
$
|
53
|
||||||
Other revenues
|
10,836
|
11,644
|
12,015
|
|||||||||
Total revenues
|
11,381
|
11,663
|
12,068
|
|||||||||
Operating expenses:
|
||||||||||||
General and administrative expenses
|
9,787
|
9,739
|
18,858
|
|||||||||
Interest expense
|
1,196
|
1,763
|
2,435
|
|||||||||
Total operating expenses
|
10,983
|
11,502
|
21,293
|
|||||||||
Income (loss) before income taxes
|
398
|
161
|
(9,225
|
)
|
||||||||
Income tax expense (benefit)
|
295
|
1,183
|
(1,071
|
)
|
||||||||
Loss of parent company
|
103
|
(1,022
|
)
|
(8,154
|
)
|
|||||||
Equity in net income of subsidiaries
|
54,383
|
18,460
|
60,275
|
|||||||||
Net income
|
$
|
54,486
|
$
|
17,438
|
$
|
52,121
|
2017
|
2016
|
2015
|
||||||||||
Net income
|
$
|
54,486
|
$
|
17,438
|
$
|
52,121
|
||||||
Adjustment to reconcile net income to net cash provided by operating activities:
|
||||||||||||
Equity in net income of subsidiaries
|
(54,383
|
)
|
(18,460
|
)
|
(60,275
|
)
|
||||||
Depreciation and amortization
|
880
|
839
|
872
|
|||||||||
Shared- based compensation
|
7,076
|
2,799
|
8,290
|
|||||||||
Deferred income tax expense (benefit)
|
(33
|
)
|
1,042
|
(1,227
|
)
|
|||||||
Dividends received from subsidiaries
|
90,000
|
19,000
|
47,000
|
|||||||||
Return of investment due to closing of subsidiary
|
7,731
|
-
|
-
|
|||||||||
Other
|
-
|
-
|
42
|
|||||||||
Changes in assets and liabilities:
|
||||||||||||
Accrued interest from subsidiaries, net
|
5,076
|
(646
|
)
|
(1,046
|
)
|
|||||||
Due from subsidiaries
|
(3,672
|
)
|
(1,525
|
)
|
4,869
|
|||||||
Other assets
|
1,917
|
(1,751
|
)
|
(1,953
|
)
|
|||||||
Due to subsidiaries
|
(22,595
|
)
|
10,801
|
(2,162
|
)
|
|||||||
Other liabilities
|
1,339
|
(4,812
|
)
|
4,614
|
||||||||
Net cash provided by operating activities
|
87,822
|
24,725
|
51,145
|
|||||||||
Cash flows from investing activities:
|
||||||||||||
Acquisition of investment in securities classified as available for sale
|
(61,747
|
)
|
(2,869
|
)
|
-
|
|||||||
Proceeds from sale and maturities of investment in securities classified as available for sale
|
1,126 | - | 27,500 | |||||||||
Collection of note receivable from subsidiary
|
-
|
4,500
|
9,000
|
|||||||||
Issuance of note receivable to subsidiary
|
-
|
(1,394
|
)
|
(2,369
|
)
|
|||||||
Net acquisition of property and equipment
|
(757
|
)
|
-
|
(3,676
|
)
|
|||||||
Net cash provided by (used in) investing activities
|
(61,378
|
)
|
237
|
30,455
|
||||||||
Cash flow from financing activities:
|
||||||||||||
Repayments of long-term borrowings
|
(2,836
|
)
|
(1,742
|
)
|
(37,640
|
)
|
||||||
Repurchase of common stock
|
(20,220
|
)
|
(21,371
|
)
|
(48,287
|
)
|
||||||
Net cash used in financing activities
|
(23,056
|
)
|
(23,113
|
)
|
(85,927
|
)
|
||||||
Net increase (decrease) in cash and cash equivalents
|
3,388
|
1,849
|
(4,327
|
)
|
||||||||
Cash and cash equivalents, beginning of year
|
14,153
|
12,304
|
16,631
|
|||||||||
Cash and cash equivalents, end of year
|
$
|
17,541
|
$
|
14,153
|
$
|
12,304
|
(1)
|
For purposes of these condensed financial statements, Triple‑S Management Corporation’s (the Company or TSM) investment in its wholly owned subsidiaries is recorded using the equity method of accounting.
|
(2)
|
Significant Accounting Policies
|
(3)
|
Long‑Term Borrowings
|
|
2017
|
2016
|
||||||
Senior unsecured notes payable of $60,000 issued on December 2005; due December 2020. Interest was payable monthly at a fixed rate of 6.60%, fully paid in January 2017.
|
$
|
-
|
$
|
24,000
|
||||
Secured loan payable of $11,187, payable in monthly installments of $137 through October 1, 2023, plus interest at a rate reset periodically of 100 basis points over selected LIBOR maturity (which was 2.37% at December 31, 2017).
|
9,547
|
11,187
|
||||||
Secured loan payable of $20,150, payable in monthly installments of $84 through January 1, 2024, plus interest at a rate reset periodically of 275 basis points over selected LIBOR maturity (which was 4.08% at December 31, 2017).
|
19,226
|
-
|
||||||
Secured loan payable of $4,116, payable in monthly installments of $49 through January 1, 2024, plus interest at a rate reset periodically of 325 basis points over selected LIBOR maturity (which was 4.58% at December 31, 2017).
|
3,577
|
-
|
||||||
Total borrowings
|
32,350
|
35,187
|
||||||
Less: unamortized debt issuance costs
|
277
|
102
|
||||||
|
$
|
32,073
|
$
|
35,085
|
Year ending December 31
|
||||
2018
|
$
|
3,236
|
||
2019
|
3,236
|
|||
2020
|
3,236
|
|||
2021
|
3,236
|
|||
2022
|
3,236
|
|||
Thereafter
|
16,170
|
|||
|
$
|
32,350
|
(4) |
Transactions with Related Parties
|
2017
|
2016
|
2015
|
||||||||||
Rent charges to subsidiaries
|
$
|
7,807
|
$
|
7,801
|
$
|
7,801
|
||||||
Interest charged to subsidiaries on notes receivable
|
2,032
|
2,258
|
2,758
|
|||||||||
Interest charged from subsidiary on note payable
|
791
|
755
|
720
|
(Dollar amounts in thousands)
|
||||||||||||||||||||||||||||||||||||||||||||
Segment
|
Deferred
Policy
Acquisition
Costs and Value
of Business
Acquired
|
Claim
Liabilities
|
Liability for
Future
Policy
Benefits
|
Unearned
Premiums
|
Other
Policy Claims
and Benefits
Payable
|
Premium
Revenue
|
Net
Investment
Income
|
Claims
Incurred
|
Amortization of
Deferred Policy
Acquisition
Costs and Value
of Business
Acquired
|
Other
Operating
Expenses
|
Net
Premiums
Written
|
|||||||||||||||||||||||||||||||||
2017
|
||||||||||||||||||||||||||||||||||||||||||||
Managed care
|
$
|
-
|
$
|
367,357
|
$
|
-
|
$
|
1,813
|
$
|
-
|
$
|
2,589,987
|
$
|
16,659
|
$
|
2,218,270
|
$
|
-
|
$
|
354,917
|
$
|
2,589,987
|
||||||||||||||||||||||
Life insurance
|
182,010
|
45,518
|
339,507
|
8,751
|
-
|
161,846
|
24,819
|
87,348
|
18,511
|
61,372
|
161,846
|
|||||||||||||||||||||||||||||||||
Property and casualty insurance
|
18,778
|
694,444
|
-
|
75,785
|
-
|
77,225
|
9,489
|
50,761
|
23,595
|
18,392
|
81,520
|
|||||||||||||||||||||||||||||||||
Other non-reportable segments, parent company operations and net consolidating entries.
|
-
|
(443
|
)
|
-
|
-
|
-
|
(2,126
|
)
|
648
|
(3,278
|
)
|
-
|
426
|
(2,126
|
)
|
|||||||||||||||||||||||||||||
-
|
||||||||||||||||||||||||||||||||||||||||||||
Total
|
$
|
200,788
|
$
|
1,106,876
|
$
|
339,507
|
$
|
86,349
|
$
|
-
|
$
|
2,826,932
|
$
|
51,615
|
$
|
2,353,101
|
$
|
42,106
|
$
|
435,107
|
$
|
2,831,227
|
||||||||||||||||||||||
2016
|
||||||||||||||||||||||||||||||||||||||||||||
Managed care
|
$
|
-
|
$
|
349,047
|
$
|
-
|
$
|
2,889
|
$
|
-
|
$
|
2,648,469
|
$
|
15,102
|
$
|
2,347,547
|
$
|
-
|
$
|
375,262
|
$
|
2,648,469
|
||||||||||||||||||||||
Life insurance
|
177,811
|
42,858
|
321,232
|
8,122
|
-
|
156,856
|
24,877
|
86,924
|
12,530
|
60,821
|
152,506
|
|||||||||||||||||||||||||||||||||
Property and casualty insurance
|
16,976
|
96,977
|
-
|
68,299
|
-
|
87,945
|
8,891
|
40,766
|
25,170
|
18,826
|
87,158
|
|||||||||||||||||||||||||||||||||
Other non-reportable segments, parent company operations and net consolidating entries.
|
-
|
(939
|
)
|
-
|
-
|
-
|
(2,629
|
)
|
43
|
(3,046
|
)
|
-
|
1,285
|
(2,629
|
)
|
|||||||||||||||||||||||||||||
-
|
||||||||||||||||||||||||||||||||||||||||||||
Total
|
$
|
194,787
|
$
|
487,943
|
$
|
321,232
|
$
|
79,310
|
$
|
-
|
$
|
2,890,641
|
$
|
48,913
|
$
|
2,472,191
|
$
|
37,700
|
$
|
456,194
|
$
|
2,885,504
|
||||||||||||||||||||||
2015
|
||||||||||||||||||||||||||||||||||||||||||||
Managed care
|
$
|
-
|
$
|
348,297
|
$
|
-
|
$
|
3,489
|
$
|
-
|
$
|
2,549,522
|
$
|
11,779
|
$
|
2,196,693
|
$
|
-
|
$
|
393,407
|
$
|
2,549,173
|
||||||||||||||||||||||
Life insurance
|
172,284
|
44,601
|
352,370
|
6,596
|
-
|
148,115
|
24,457
|
82,561
|
17,661
|
52,338
|
144,262
|
|||||||||||||||||||||||||||||||||
Property and casualty insurance
|
18,364
|
99,796
|
-
|
70,175
|
-
|
87,633
|
8,706
|
42,600
|
25,933
|
19,533
|
85,734
|
|||||||||||||||||||||||||||||||||
Other non-reportable segments, parent company operations and net consolidating entries.
|
-
|
(929
|
)
|
-
|
-
|
-
|
(2,116
|
)
|
232
|
(3,139
|
)
|
-
|
9,849
|
(2,116
|
)
|
|||||||||||||||||||||||||||||
-
|
||||||||||||||||||||||||||||||||||||||||||||
Total
|
$
|
190,648
|
$
|
491,765
|
$
|
352,370
|
$
|
80,260
|
$
|
-
|
$
|
2,783,154
|
$
|
45,174
|
$
|
2,318,715
|
$
|
43,594
|
$
|
475,127
|
$
|
2,777,053
|
Gross
Amount (1)
|
Ceded to
Other
Companies
|
Assumed
from Other
Companies
|
Net
Amount
|
Percentage
of Amount
Assumed
to Net
|
||||||||||||||||
2017
|
||||||||||||||||||||
Life insurance in force
|
$
|
10,307,506
|
$
|
10,307,506
|
0.0
|
%
|
||||||||||||||
Premiums:
|
||||||||||||||||||||
Life insurance
|
$
|
166,280
|
$
|
8,826
|
$
|
4,174
|
$
|
161,628
|
2.6
|
%
|
||||||||||
Accident and health insurance
|
2,591,796
|
3,392
|
288
|
2,588,692
|
0.0
|
%
|
||||||||||||||
Property and casualty insurance
|
135,689
|
59,077
|
-
|
76,612
|
0.0
|
%
|
||||||||||||||
Total premiums
|
$
|
2,893,765
|
$
|
71,295
|
$
|
4,462
|
$
|
2,826,932
|
0.2
|
%
|
||||||||||
|
|
|
||||||||||||||||||
2016
|
||||||||||||||||||||
Life insurance in force
|
$
|
10,178,956
|
$
|
10,178,956
|
0.0
|
%
|
||||||||||||||
Premiums:
|
||||||||||||||||||||
Life insurance
|
$
|
160,628
|
$
|
8,838
|
$
|
4,350
|
$
|
156,140
|
2.8
|
%
|
||||||||||
Accident and health insurance
|
2,650,011
|
3,148
|
306
|
2,647,169
|
0.0
|
%
|
||||||||||||||
Property and casualty insurance
|
134,378
|
47,046
|
-
|
87,332
|
0.0
|
%
|
||||||||||||||
Total premiums
|
$
|
2,945,017
|
$
|
59,032
|
$
|
4,656
|
$
|
2,890,641
|
0.2
|
%
|
||||||||||
|
|
|
||||||||||||||||||
2015
|
||||||||||||||||||||
Life insurance in force
|
$
|
10,129,123
|
$
|
10,129,123
|
0.0
|
%
|
||||||||||||||
Premiums:
|
||||||||||||||||||||
Life insurance
|
$
|
153,607
|
$
|
9,596
|
$
|
3,853
|
$
|
147,864
|
2.6
|
%
|
||||||||||
Accident and health insurance
|
2,552,699
|
4,778
|
349
|
2,548,270
|
0.0
|
%
|
||||||||||||||
Property and casualty insurance
|
136,780
|
49,760
|
-
|
87,020
|
0.0
|
%
|
||||||||||||||
Total premiums
|
$
|
2,843,086
|
$
|
64,134
|
$
|
4,202
|
$
|
2,783,154
|
0.2
|
%
|
(1) |
Gross premiums amount is presented net of intercompany eliminations of $2,126, $3,457 and $4,402 for the years ended December 31, 2017, 2016, and 2015, respectively.
|
Additions
|
||||||||||||||||||||
Balance at
Beginning of
Period
|
Charged to
Costs and
Expenses
|
Charged (Reversal)
To Other Accounts
- Describe (1)
|
Deductions -
Describe (2)
|
Balance at
End of
Period
|
||||||||||||||||
2017
|
||||||||||||||||||||
Allowance for doubtful receivables
|
$
|
37,307
|
5,210
|
(3,748
|
)
|
(2,886
|
)
|
$
|
35,883
|
|||||||||||
2016
|
||||||||||||||||||||
Allowance for doubtful receivables
|
$
|
37,244
|
1,295
|
306
|
(1,538
|
)
|
$
|
37,307
|
||||||||||||
2015
|
||||||||||||||||||||
Allowance for doubtful receivables
|
$
|
36,368
|
15,781
|
340
|
(15,245
|
)
|
$
|
37,244
|
(1) |
Represents premiums adjustment to provide for unresolved reconciliation items with the Government of Puerto Rico and other entities.
|
(2) |
Deductions represent the write-off of accounts deemed uncollectible.
|
As of December 31,
|
For the Years Ended December 31,
|
|||||||||||||||||||||||||||||||||||||||
Deferred
Policy
|
Reserve for
Unpaid Claims
and Claims
|
Net
|
Claims and Claim Adjustment
Expenses Incurred
Related to
|
Amortization of
Deferred Policy
|
Paid Claims and
|
|||||||||||||||||||||||||||||||||||
Year
|
Acquisition
Costs
|
Ajustment
Expenses
|
Unearned
Premiums
|
Earned
Premiums
|
Investment
Income
|
Current
Year
|
Prior
Years
|
Acquisition
Costs
|
Claim Adjustment
Expenses
|
Premiums
Written
|
||||||||||||||||||||||||||||||
2017
|
$
|
18,778
|
$
|
694,444
|
$
|
75,785
|
$
|
77,225
|
$
|
9,489
|
$
|
60,696
|
$
|
(9,935
|
)
|
$
|
23,595
|
$
|
47,689
|
$
|
143,787
|
|||||||||||||||||||
2016
|
$
|
16,976
|
$
|
96,977
|
$
|
68,299
|
$
|
87,945
|
$
|
8,891
|
$
|
48,127
|
$
|
(7,361
|
)
|
$
|
25,170
|
$
|
42,887
|
$
|
133,115
|
|||||||||||||||||||
2015
|
$
|
18,364
|
$
|
99,796
|
$
|
70,175
|
$
|
87,633
|
$
|
8,706
|
$
|
45,067
|
$
|
(2,467
|
)
|
$
|
25,933
|
$
|
41,612
|
$
|
134,410
|
I. |
RENEWAL OF CONTRACT
|
II. |
DISCONTINUATION OF HIGH UTILIZERS PROGRAM
|
III. |
AMENDMENTS
|
1. |
Immediately following Section 1.1.6, a new Section 1.1.7 shall be inserted stating as follows:
|
2. |
The following definitions in Article 2 shall be amended as follows:
|
3. |
The following definitions in Article 2 shall be inserted as follows:
|
4. |
The definition of Preferred Drug List (“PDL”) in Article 2 shall be deleted in its entirety. The acronym of PDL in Article 3 shall be deleted in its entirety.
|
5. |
The following acronyms in Article 3 shall be inserted as follows:
|
FMC
|
Formulary of Medications Covered
|
LME
|
List of Medications by Exception
|
6. |
The following acronyms in Article 3 shall be amended as follows:
|
QIP
|
Quality Incentive Program
|
US or USA
|
United States of America
|
7. |
All subsequent references within the Contract to the following defined terms and acronyms shall be replaced as follows, unless otherwise stated in this Amendment:
|
a. |
All references to the defined term “Action” shall be deleted and replaced with the defined term “Adverse Benefit Determination.”
|
b. |
All references to the defined term “Preferred Drug List” shall be deleted and replaced with the defined term “Formulary of Medications Covered.” All references to the acronym “PDL” shall be deleted and replaced with the acronyms
|
c. |
All references to the defined term “Master Formulary” shall be deleted and replaced with the defined term “List of Medications by Exception” or the acronym “LME.”
|
d. |
All references to the former “Quality Improvement Procedure” shall be deleted and replaced with “Quality Incentive Program.”
|
8. |
Section 4.5.1 shall be amended and replaced in its entirety as follows:
|
4.5.1
|
ASES shall conduct readiness reviews of the Contractor’s operations three (3) months before the start of a new managed care program and when the Contractor will provide or arrange for the provision of covered benefits to new eligibility groups. Such review will include, at a minimum, one (1) on-site review, at dates and times to be determined by ASES. These reviews may include, but are not limited to, desk and on-site reviews of documents provided by the Contractor, walk-through(s) of the Contractor’s facilities, Information System demonstrations, and interviews with the Contractor’s staff. ASES will conduct the readiness review to confirm that the Contractor is capable and prepared to perform all Administrative Functions and to provide high-quality services to GHP Enrollees.
|
9. |
Section 4.5.3.12 shall be amended and replaced in its entirety as follows:
|
4.5.3.12
|
Financial management, including financial reporting and monitoring and financial solvency;
|
10. |
Section 4.5.3.14 shall be amended and replaced in its entirety as follows:
|
4.5.3.14 |
Information Systems management, including claims management, encounter data and enrollment information management, systems performance, interfacing capabilities, and security management functions and capabilities; and
|
11. |
Section 5.2.1.1 shall be amended and replaced in its entirety as follows:
|
5.2.1.1
|
The Contractor shall accept all Potential Enrollees into its Plan without restrictions. The Contractor shall not discriminate against individuals eligible to enroll on the basis of religion, race, color, national origin, sex, sexual orientation, gender identity, or disability, and will not use any policy or practice that has the effect of discriminating on the basis of religion, race, color, national origin, sex, sexual orientation, gender identity, or disability on the basis of health, health status, pre-existing condition, or need for health care services.
|
12. |
Section 5.2.2 shall be amended and replaced in its entirety as follows:
|
5.2.2
|
Effective Date of Enrollment
|
5.2.2.1 |
Except as provided below, Enrollment, whether chosen or automatic, will be effective (hereinafter referred to as the “Effective Date of Enrollment”) the same date as the period of eligibility specified on the MA-10.
|
5.2.2.2 |
Effective Date of Enrollment for Newborns.
The Effective Date of Enrollment for Medicaid and CHIP Eligible newborns is the date of his or her birth. The Effective Date of Enrollment for Commonwealth Population newborns is the date the newborn is registered with the Puerto Rico Medicaid Program. A newborn shall be Auto-Enrolled pursuant to the procedures set forth in Section 5.2.6.
|
5.2.2.3 |
Re-Enrollment Policy and Effective Date of Re-Enrollment for Mothers Who are Minor Dependents
. In the event that a female Enrollee who is included in a family group for coverage under the GHP as a Dependent child becomes pregnant, the Enrollee shall be referred to the Puerto Rico Medicaid Program. She will effectively establish a new family with the diagnosis of her pregnancy and will become the Contact Member of the new family. The eligibility period of the new family will begin on the date of the first diagnosis of the pregnancy, and the Enrollee shall be AutoEnrolled, effective as of this date. The mother shall be Auto-Assigned to the PMG and PCP to which she was assigned before the Re-Enrollment.
|
5.2.2.4 |
Effective
Date of Re-Enrollment for Enrollees Who Lose Eligibility.
If an Enrollee who is a Medicaid- or - CHIP Eligible Person or member of the Commonwealth Population loses eligibility for the GHP for a period of two (2) months or less, Enrollment in the Contractor’s Plan shall be reinstated. Upon notification from ASES of the Recertification, the Contractor shall Auto-Enroll the person, with Enrollment effective as of the eligibility period specified on the MA-10.
|
13. |
Section 5.2.4.2 shall be amended and replaced in its entirety as follows:
|
5.2.4.2
|
The Auto-Enrollment process will include Auto-Assignment of a PMG and a PCP (see Section 5.4 of this Contract). A new Enrollee who is a Dependent of a current GHP Enrollee (the “Contact Member’) shall be automatically assigned to the same PMG as his or her Contact Member, as identified by the Contact Member number.
|
14. |
Section 5.2.5.2 shall be amended and replaced in its entirety as follows:
|
5.2.5.2
|
Once the Enrollee calls or visits the Contractor’s office to execute the right of changing the assigned PMG, PCP, or both, the Contractor shall request that the Enrollee select a new PMG and PCP. During the visit or call, the Contractor shall issue to the Enrollee an Enrollee ID Card and a notice of Enrollment, as well as an Enrollee Handbook and Provider Directory either in paper or electronic form, subject to requirements of Sections 6.9.8 and 6.9.9; or, such notice of Enrollment, an ID Card, a Handbook, and a Provider Directory may be sent to the Enrollee via surface mail or electronically, subject to the requirements of Sections 6.9.8 and 6.9.9 within five (5) Business Days of the Enrollee’s request to change the Auto-Enrollment assignments.
|
15. |
Immediately following Section 5.2.5.3, a new Section 5.2.2.3.1 shall be inserted stating as follows:
|
5.2.5.3.1
|
All Enrollees must also be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56. Such notification must clearly explain the process for exercising this disenrollment right, as well as the alternatives available to the Enrollee based on their specific circumstance.
|
16. |
Section 5.2.6.4 shall be amended and replaced in its entirety as follows:
|
5.2.6.4
|
If the mother has not made a PCP and PMG selection at the time of the child’s birth, the Contractor shall, within one (1) Business Day of the birth, auto-assign the newborn to a PCP who is a pediatrician and to the Contact Member’s PMG.
|
17. |
Section 5.3.3.3 shall be amended and replaced in its entirety as follows:
|
5.3.3.3
|
If what would otherwise be the Effective Date of Disenrollment under this Section 5.3.3 falls:
|
5.3.3.3.1 |
When the Enrollee is an inpatient at a hospital, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the Enrollee is discharged from the hospital, or the last day of the month following the month in which Disenrollment would otherwise be effective, whichever occurs earlier;
|
5.3.3.3.2 |
During a month in which a Medicaid, CHIP or Commonwealth Enrollee is pregnant, or on the date the pregnancy ends, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the 60-day post-partum period ends;
|
5.3.3.3.3 |
When the Enrollee is in the process of appealing a Disenrollment though either the Grievance System, ASES’s Administrative Law Hearing process, or the Puerto Rico Medicaid Department’s dedicated hearing process on Disenrollments, as applicable, then ASES shall postpone the Effective Date of Disenrollment until a decision is rendered after the hearing; or
|
5.3.3.3.4 |
During a month in which an Enrollee is diagnosed with a Terminal Condition, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the following month.
|
18. |
Immediately following Section 5.3.5, a new Section 5.3.5.1 shall be inserted stating as follows, and the remaining Section 5.3.5 shall be renumbered accordingly, including any references thereto:
|
5.3.5.1
|
All Enrollees must be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56. Such notification must clearly explain the process for exercising this disenrollment right, as well as the coverage alternatives available to the Enrollee based on their specific circumstance.
|
19. |
Original Section 5.3.5.2, renumbered by this Amendment as 5.3.5.3, shall be amended and replaced in its entirety as follows:
|
5.3.5.3
|
An Enrollee may request Disenrollment from the Contractor’s Plan without cause during the ninety (90) Calendar Days following the Effective Date of Enrollment with the Plan or the date that the Contractor sends the Enrollee notice of the Enrollment, whichever is later. An Enrollee may request Disenrollment without cause every twelve (12) months thereafter or if, upon automatic re-enrollment of an Enrollee disenrolled solely because he or she loses eligibility for a period of two (2) months or less, the temporary loss of Medicaid eligibility has caused the Enrollee to miss the annual disenrollment opportunity. In addition, an Enrollee may request Disenrollment without cause in the event that ASES notifies the Enrollee that ASES has imposed or intends to impose on the Contractor the intermediate sanctions set forth in 42 CFR 438.702(a)(3).
|
20. |
Immediately following Original Section 5.3.5.3.1, renumbered by this Amendment as 5.3.5.4.1, a new Section 5.3.5.4.2 shall be inserted stating as follows, and the remaining Section 5.3.5.4 shall be renumbered accordingly, including any references thereto:
|
5.3.5.4.2
|
The Contractor’s Plan does not, due to moral or religious objections, cover the health service the Enrollee seeks.
|
21. |
Original Section 5.3.5.4, renumbered by this Amendment as 5.3.5.5, shall be amended and replaced in its entirety as follows:
|
5.3.5.5
|
If the Contractor fails to refer a Disenrollment request within the timeframe specified in Section 5.3.3, or if ASES fails to make a Disenrollment determination so that the Enrollee may be disenrolled by the first day of the second month following the month when the Disenrollment request was made, per Section 5.3.3, the Disenrollment shall be deemed approved for the effective date that would have been established had ASES or the Contractor complied with Section 5.3.3.
|
22. |
Section 5.3.8.2 shall be amended and replaced in its entirety as follows:
|
5.3.8.2
|
The Contractor shall notify the Puerto Rico Medicaid Program Immediately when the Enrollment database is updated to reflect a change in the place of residence of an Enrollee or an Enrollee’s death.
|
23. |
Section 6.1.1 shall be amended and replaced in its entirety as follows:
|
6.1.1
|
The Contractor shall have policies and procedures, prior approved by ASES and submitted in accordance with Attachment 12, that explain how it will ensure that Enrollees and Potential Enrollees:
|
6.1.1.1 |
Are aware of their rights and responsibilities;
|
6.1.1.2 |
How to obtain physical and Behavioral Health Services;
|
6.1.1.3 |
What to do in an emergency or urgent medical situation;
|
6.1.1.4 |
How to request a Grievance, Appeal, or Administrative Law Hearing;
|
6.1.1.5 |
How to report suspected Incident of Fraud, Waste, and Abuse;
|
6.1.1.6 |
Have basic information on the basic features of managed care; and
|
6.1.1.7 |
Understand the MCO’s responsibilities to coordinate Enrollee care.
|
24. |
Section 6.1.2 shall be amended and replaced in its entirety as follows:
|
6.1.2
|
The Contractor’s informational materials must convey to Enrollees and Potential Enrollees that GHP is an integrated program that includes both physical and Behavioral Health Services, and must also explain the concepts of Primary Medical Groups and Preferred Provider Networks.
|
25. |
Immediately following Section 6.1.6, a new Section 6.1.7 shall be inserted stating as follows:
|
6.1.6
|
The Contractor shall use the definitions for managed care terminology set forth by ASES in all of its written and verbal communications with Enrollees, in accordance with 42 CFR 438.10(c)(4)(i).
|
26. |
Section 6.2.4.3 shall be amended and replaced in its entirety as follows:
|
6.2.4.3
|
Standard letters and notifications, such as the notice of Enrollment required in Section 5.2.5.3, the notice of Redetermination required in Section 5.2.7.1, and the notice of Disenrollment required in Section 5.3.2. The Contractor shall use model Enrollee notices developed by ASES.
|
27. |
Section 6.3.2 shall be amended and replaced in its entirety as follows:
|
6.3.2
|
The Contractor shall make all written materials available through auxiliary aids and services or alternative formats, and in a manner that takes into consideration the Enrollee’s or Potential Enrollee’s special needs, including Enrollees and Potential Enrollees who are visually impaired or have limited reading proficiency. The Contractor shall notify all Enrollees and Potential Enrollees that Information is available in alternative formats, and shall instruct them on how to access those formats. Consistent with Section 1557 of PPACA and 42 C.F.R. 438.10(d)(3), all written materials must also include taglines in the prevalent languages, as well as large print, with a font size of no smaller than 18 point, to explain the availability of written and oral translation to understand the Information provided and the toll-free and TTY/TDY telephone number of the GHP Service Line.
|
28. |
Section 6.3.3 shall be amended and replaced in its entirety as follows:
|
6.3.3 |
Once an Enrollee has requested a written material in an alternative format or language, the Contractor shall at no cost to the Enrollee or Potential Enrollee (i) make a notation of the Enrollee or Potential Enrollee’s preference in the Contractor’s system and (ii) provide all subsequent written materials to the Enrollee or Potential Enrollee in such format unless the Enrollee or Potential Enrollee requests otherwise.
|
29. |
Section 6.3.4 shall be amended and replaced in its entirety as follows:
|
6.3.4
|
Except as provided in Sections 1.1.5 and 6.4 (Enrollee Handbook) and subject to Section 6.3.8, the Contractor shall make all written information available in Spanish on other applicable Prevalent Non-English Language, as defined in Section 6.3.8 below, with a language block in English, explaining that (i) Enrollees may access an English translation of the Information if needed, and (ii) the Contractor will provide oral interpretation services into any language other than Spanish or English, if needed. Such translation or interpretation shall be provided by the Contractor at no cost to the Enrollee. The language block and all other content shall comply with 42 CFR 438.10(d)(2) and Section 1557 of PPACA.
|
30. |
Section 6.3.5 shall be amended and replaced in its entirety as follows:
|
6.3.5
|
If oral interpretation services are required in order to explain the Benefits covered under the GHP to a Potential Enrollee who does not speak either English or Spanish, the Contractor must, at its own cost, make such services available in a third language, in compliance with 42 CFR 438.10(d)(4).
|
31. |
Section 6.3.8 shall be amended and replaced in its entirety as follows:
|
6.3.8
|
Within ninety (90) Calendar Days of a notification from ASES that ASES has identified a Prevalent Non-English Language other than Spanish or English (with “Prevalent Non-English Language” defined as a language that is the primary language of more than five percent (5%) of the population of Puerto Rico), all written materials provided to Enrollees and Potential Enrollees shall be translated into and made available in such language.
|
32. |
Section 6.4.1 shall be amended and replaced in its entirety as follows:
|
6.4.1
|
The Contractor shall produce at its sole cost, and shall mail or make electronically available, subject to the requirements of Section 6.9.8 and 6.9.9, to all new Enrollees, an Enrollee Handbook including information on physical health, Behavioral Health, and all other Covered Services offered under the GHP. The Contractor shall distribute the Handbook either simultaneously with the notice of Enrollment referenced in Section 5.2.5.3 or within five (5) Calendar Days of sending the notice of Enrollment via surface mail.
|
33. |
Section 6.4.3 shall be amended and replaced in its entirety as follows:
|
6.4.3
|
The Contractor shall either:
|
6.4.3.1 |
Mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9, to all Enrollees an Enrollee Handbook on at least an annual basis, after the initial distribution of the Handbook at Enrollment; or
|
6.4.3.2 |
At least annually, as required by 42 CFR 438.10, mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9, to all Enrollees a Handbook supplement that includes Information on the following:
|
6.4.3.2.1 |
The Contractor’s service area;
|
6.4.3.2.2 |
Benefits covered under the GHP;
|
6.4.3.2.3 |
Any cost-sharing imposed by the Contractor; and
|
6.4.3.2.4 |
To the extent available, quality and performance indicators, including Enrollee satisfaction.
|
6.4.3.3
|
The Contractor is not required to mail an Enrollee Handbook to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided a Enrollee Handbook within the past year. The Contractor is also not required to mail an Enrollee Handbook to new Enrollees under the age of twenty-one (21) if an Enrollee Handbook has been mailed within the past year to a member of that Enrollee’s household. However, this exception does not apply to pregnant Enrollees under the age of twenty-one (21).
|
34. |
Section 6.4.5.9 shall be amended and replaced in its entirety as follows:
|
6.4.5.9
|
Information on the amount, duration and scope of Benefits and Covered Services, including how the scope of Benefits and services differs between Medicaid- and CHIP Eligibles and Other Eligible Persons. This must include Information on the EPSDT Benefit and how Enrollees under the age of twentyone (21) and entitled to the EPSDT Benefit may access component services;
|
35. |
Section 6.4.5.12 shall be amended and replaced in its entirety as follows:
|
6.4.5.12
|
An explanation of any service limitations or exclusions from coverage, including any restrictions on the Enrollee’s freedom of choice among network Providers;
|
36. |
Section 6.4.5.27.3.2 shall be amended and replaced in its entirety as follows:
|
6.4.5.27.3.2
|
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years under any circumstances.
|
37. |
Section 6.4.5.29.9 shall be amended and replaced in its entirety as follows:
|
6.4.5.29.9
|
Information on the family planning services and supplies, including the extent to which, and how, Enrollees may obtain such services or supplies from out-of-network providers, and that an Enrollee cannot be required to obtain a referral before choosing a family planning Provider.
|
38. |
Immediately following Section 6.4.5.29.9, new Sections 6.4.5.29.10 and 6.4.5.29.11 shall be inserted stating as follows:
|
6.4.5.29.10 |
Information on non-coverage of counseling or referral services based on Contractor’s moral or religious objections, as specified in Section 7.13 and how to access these services from ASES; and
|
6.4.5.29.11 |
Instructions on how to access oral or written translation services, Information in alternative formats, and auxiliary aids and services, as specified in Sections 6.3 and 6.11.
|
39. |
Section 6.5.1.16 shall be amended and replaced in its entirety as follows:
|
6.5.1.16
|
Only be responsible for cost-sharing in accordance with 42 CFR 447.50 through 42 CFR 447.82 and as permitted by the Puerto Rico Medicaid and CHIP State Plans and Puerto Rico law as applicable to the Enrollee.
|
40. |
Section 6.6.1 shall be amended and replaced in its entirety as follows:
|
6.6.1
|
The Contractor shall develop, maintain, and mail or make electronically available, subject to the requirements of Sections 6.9.8 and 6.9.9 to all new Enrollees a Provider Directory that includes Information on both physical and Behavioral Health Providers under the GHP. The Contractor shall distribute the Provider Directory, within five (5) Calendar Days of sending the notice of Enrollment referenced in Section 5.2.5.3.
|
6.6.1.1
|
The Contractor is not required to mail a Provider Directory to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided a Provider Directory within the past year. The Contractor is also not required to mail a Provider Directory to new Enrollees under the age of twenty-one (21) if a Provider Directory has been mailed within the past year to a member of that Enrollee’s household. However, this exception does not apply to pregnant Enrollees under the age of twentyone (21).
|
41. |
Section 6.6.2 shall be amended and replaced in its entirety as follows:
|
6.6.2
|
The Contractor shall update the paper Provider Directory once a month and distribute it to Enrollees upon Enrollee request.
|
42. |
Section 6.6.3 shall be amended and replaced in its entirety as follows:
|
6.6.3
|
The Contractor shall make the Provider Directory available on its website in a machine readable file and format as specified by CMS.
|
43. |
Section 6.6.4 shall be amended and replaced in its entirety as follows:
|
6.6.4
|
The Provider Directory shall include the names, provider group affiliations, locations, office hours, telephone numbers, websites, cultural and linguistic capabilities, completion of Cultural Competency training, and accommodations for people with physical disabilities of current Network Providers. This includes, at a minimum, Information sorted by Service Region on PCPs, specialists, dentists, FQHCs and RHCs, Behavioral Health Providers, and pharmacies in each Service Region, hospitals, including locations of emergency settings and Post-Stabilization Services, with the name, location, hours of operation, and telephone number of each facility/setting. The Provider Directory shall also identify all Network Providers that are not accepting new patients. Any subcontractors of ASES, such as the PBM, will collaborate with the Contractor to provide information in a format mutually agreed upon for the generation of the Provider Directory.
|
44. |
Section 6.7.2.10 shall be amended and replaced in its entirety as follows:
|
6.7.2.10
|
The applicable Co-Payment levels for various services outside the Enrollee’s PPN and the assurance that no Co-Payment will be charged for a Medicaid Eligible Person and for CHIP children under twenty-one (21) years under any circumstances;
|
45. |
Immediately following Section 6.9.7, new Sections 6.9.8 and 6.9.9 shall be inserted stating as follows:
|
6.9.8 |
Any Enrollee Information required under 42 CFR 438.10, including the Enrollee Handbook, Provider Directory, and Enrollee notices, may not be provided electronically or on the Contractor’s website unless such Information (1) is readily accessible, (2) is placed on the Contractor’s website in a prominent location, (3) is provided in a form that can be electronically retained and printed, and (4) includes notice to the Enrollee that the Information is available in paper form without charge and can be provided upon request within five (5) Business Days.
|
6.9.9 |
The Enrollee Handbook and Provider Directory may be provided electronically instead of paper form if all required elements of Section 6.9.8 are satisfied. However, the Contractor must provide the Enrollee Handbook and Provider Directory in paper form upon request by the Enrollee at no charge and within five (5) Business Days. If the Enrollee Handbook is provided by e-mail, the Contractor must first obtain the Enrollee’s agreement to receive the Enrollee Handbook by e-mail. If the Enrollee Handbook is posted on the Contractor’s website, the Contractor must first advise the Enrollee in paper or electronic form that the information is available on the internet, and must include the applicable website address, provided that Enrollees with disabilities who cannot access this information online are provided auxiliary aids and services upon request and at no cost.
|
46. |
Section 6.10.1 shall be amended and replaced in its entirety as follows:
|
6.10.1
|
In accordance with 42 CFR 438.206, the Contractor shall have a comprehensive written Cultural Competency plan describing how the Contractor will ensure that services are provided in a culturally competent manner to all Enrollees. The Cultural Competency plan must describe how the Providers, individuals, and systems within the Contractor’s Plan will effectively provide services to people of all diverse cultural and ethnic backgrounds, disabilities, and regardless of gender, sexual orientation, gender identity, or religion in a manner that recognizes values, affirms, and respects the worth of the individual Enrollees and protects and preserves the dignity of each individual.
|
47. |
Section 6.11.1 shall be amended and replaced in its entirety as follows:
|
6.11.1
|
The Contractor shall provide oral interpreter services to any Enrollee or Potential Enrollee who speaks any language other than English or Spanish as his or her primary language, regardless of whether the Enrollee or Potential Enrollee speaks a language that meets the threshold of a Prevalent Non-English Language. This also includes the use of auxiliary aids and services such as TTY/TDY and the use of American Sign Language. The Contractor is required to notify its Enrollees of the availability of oral interpretation services and to inform them of how to access oral interpretation services. There shall be no charge to an Enrollee or Potential Enrollee for interpreter services or other auxiliary aids.
|
48. |
Section 6.14.1 shall be amended and replaced in its entirety as follows:
|
6.14.1
|
Prohibited Activities. The Contractor is prohibited from engaging in the following activities:
|
6.14.1.1 |
Directly or indirectly engaging in door-to-door, telephone, e-mail, texting or other Cold-Call Marketing activities;
|
6.14.1.2 |
Offering any favors, inducements or gifts, promotions, or other insurance products that are designed to induce Enrollment in the Contractor’s Plan;
|
6.14.1.3 |
Distributing plans and materials that contain statements that ASES determines are inaccurate, false, or misleading. Statements considered false or misleading include, but are not limited to, any assertion or statement (whether written or oral) that the Contractor’s plan is endorsed by the Federal Government or Commonwealth, or similar entity;
|
6.14.1.4 |
Distributing materials that, according to ASES, mislead or falsely describe
|
6.14.1.5 |
Seeking to influence Enrollment in conjunction with the sale or offering of any private insurance; and
|
6.14.1.6 |
Asserting or stating in writing or verbally that the Enrollee or Potential Enrollee must enroll in the Contractor’s plan to obtain or retain Benefits.
|
49. |
Section 7.1.4.1 shall be amended and replaced in its entirety as follows:
|
7.1.4.1
|
The Enrollee paid the Provider for the service. This rule does not apply in circumstances where a Medicaid or CHIP Eligible Enrollee incurs out-ofpocket expenses for Emergency Services provided in the other USA jurisdictions. In such a case, the expenses will be reimbursed under the GHP; or
|
50. |
Section 7.5.2.1.19 shall be amended and replaced in its entirety as follows:
|
7.5.2.1.19
|
Organ and tissue transplants, except skin, bone and corneal transplants. Such skin, bone and corneal transplants shall be covered only in accordance with ASES’s written standards providing for similarly situated individuals to be treated alike, and, for any restriction on facilities or practitioners providing such services, to be consistent with the accessibility of high quality care to Enrollees; and
|
51. |
Section 7.5.7.11 shall be amended and replaced in its entirety as follows:
|
7.5.7.11
|
The Contractor shall be responsible for timely payment for emergency transportation services in the other USA jurisdictions for Enrollees who are Medicaid or CHIP Eligibles, if the emergency transportation is associated with an Emergency Service in the other USA jurisdictions covered under Section 7.5.9.3.1.2 of this Contract. If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for emergency transportation services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.
|
52. |
Section 7.5.8.4.7 shall be amended and replaced in its entirety as follows:
|
7.5.8.4.7
|
Other FDA approved contraceptive medications or methods not covered by sections 7.5.8.4.5 or 7.5.8.4.6 of the Contract, when it is Medically Necessary and approved through a Prior Authorization or through an exception process and the prescribing Provider can demonstrate at least one of the following situations:
|
7.5.8.4.7.1 |
Contra-indication with drugs that are in the FMC or LME that the Enrollee is already taking, and no other methods available in the FMC or LME that can be used by the Enrollee.
|
7.5.8.4.7.2 |
History of adverse reaction by the Enrollee to the contraceptive methods covered as specified by ASES; or
|
7.5.8.4.7.3 |
History of adverse reaction by the Enrollee to the contraceptive medications that are on the FMC or LME.
|
53. |
Immediately following Section 7.5.8.4.7.3, a new Section 7.5.8.5 shall be inserted stating as follows:
|
7.5.8.5
|
Maternity services, including family planning and postpartum services, must be covered for a sixty (60) day period, beginning on the day the pregnancy ends. These services will also be covered for any remaining days in the month in which the sixtieth (60
th
) day falls.
|
54. |
Section 7.5.9.1 shall be amended and replaced in its entirety as follows:
|
7.5.9.1
|
The Contractor shall cover and pay for Emergency Services where necessary to treat an Emergency Medical Condition or a Psychiatric Emergency. The Contractor shall ensure that Medical and Psychiatric Emergency Services are available twenty-four (24) hours a day, seven (7) days per Week. The Contractor shall ensure that emergency rooms and other Providers qualified to furnish Emergency Services have appropriate personnel to provide physical and Behavioral Health Services. All Emergency Services must be billed appropriately to the Contractor based on the applicable treatment and site of care. No Prior Authorization will be required for Emergency Services, and the Contractor shall not deny payment for treatment if a representative of the Contractor instructed the Enrollee to seek Emergency Services.
|
55. |
Section 7.5.9.2 shall be amended and replaced in its entirety as follows:
|
7.5.9.2
|
Emergency Services shall include, but are not limited to, the following:
|
7.5.9.2.1 |
Emergency room visits, including medical attention and routine and necessary services;
|
7.5.9.2.2 |
Trauma services;
|
7.5.9.2.3 |
Operating room use;
|
7.5.9.2.4 |
Respiratory therapy;
|
7.5.9.2.5 |
Specialist and sub-specialist treatment when required by the emergency room physician;
|
7.5.9.2.6 |
Anesthesia;
|
7.5.9.2.7 |
Surgical material;
|
7.5.9.2.8 |
Laboratory tests and X-Rays;
|
7.5.9.2.9 |
Post-Stabilization Services, as provided in Section 7.5.9.4 below;
|
7.5.9.2.10 |
Care as necessary in the case of a Psychiatric Emergency in an emergency room setting;
|
7.5.9.2.11 |
Drugs, medicine and intravenous solutions used in the emergency room; and
|
7.5.9.2.12 |
Transfusion of blood and blood plasma services, without limitations, including:
|
7.5.9.2.12.1 |
Authologal and irradiated blood;
|
7.5.9.2.12.2 |
Monoclonal factor IX with a certified hematologist Referral;
|
7.5.9.2.12.3 |
Intermediate purity concentrated ant hemophilic factor (Factor VIII);
|
7.5.9.2.12.4 |
Monoclonal type anti-hemophilic factor with a certified hematologist’s authorization; and
|
7.5.9.2.12.5 |
Activated protrombine complex (Autoflex and Feiba) with a certified hematologist’s authorization.
|
56. |
Section 7.5.9.3 shall be amended and replaced in its entirety as follows:
|
7.5.9.3
|
Emergency Services Within and Outside Puerto Rico
|
7.5.9.3.1
|
The Contractor shall make Emergency Services available:
|
7.5.9.3.1.1 |
For all Enrollees, throughout Puerto Rico, including outside the Contractor’s Service Regions, and notwithstanding whether the Emergency Services Provider is a Network Provider; and
|
7.5.9.3.1.2 |
For Medicaid and CHIP Eligibles, in Puerto Rico or in the other USA jurisdictions, when the services are Medically Necessary and could not be anticipated, notwithstanding that Emergency Services Providers outside of Puerto Rico are not Network Providers. The Contractor shall be responsible for fulfilling payment for Emergency Services rendered in the other USA jurisdictions in a timely manner. If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for Emergency Services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.
|
7.5.9.3.2
|
In covering Emergency Services provided by Puerto Rico Providers outside the Contractor’s Network, or by Providers in the other USA jurisdictions, the Contractor shall pay the Provider at least the average rate paid to Network Providers.
|
57. |
Section 7.5.9.4.2 shall be amended and replaced in its entirety as follows:
|
7.5.9.4.2
|
An Enrollee who has been treated for an Emergency Medical Condition or Psychiatric Emergency shall not be held liable for any subsequent screening or treatment necessary to stabilize or diagnose the specific condition in order to stabilize the Enrollee.
|
58. |
Immediately following Section 7.5.9.4.3.1, a new Section 7.5.9.4.3.2 shall be inserted stating as follows, and the remaining Section 7.5.9.4.3 shall be renumbered accordingly, including any references thereto:
|
7.5.9.4.3.2
|
The Contractor must limit cost-sharing for Post-Stabilization Services upon inpatient admission to Enrollees to amounts no greater than what the Contractor would charge Enrollee if services were obtained through the Contractor’s General Network.
|
59. |
Section 7.5.9.6.2 shall be amended and replaced in its entirety as follows:
|
7.5.9.6.2
|
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.
|
60. |
Section 7.5.9.7.2 shall be amended and replaced in its entirety as follows:
|
7.5.9.7.2
|
The Contractor shall not refuse to cover an Emergency Medical Condition or a Psychiatric Emergency based on the emergency room Provider, hospital, or fiscal Agent not notifying the Enrollee’s PCP or the Contractor of the Enrollee’s screening or treatment within ten (10) Calendar Days following the Enrollee’s presentation for Emergency Services.
|
61. |
Section 7.5.12.1 shall be amended and replaced in its entirety as follows:
|
7.5.12.1
|
The Contractor shall provide in accordance with Section 1927 of the Social Security Act pharmacy services under the GHP, including the following:
|
7.5.12.1.1 |
All costs related to prescribed medications for Enrollees, excluding the Enrollee’s Co-Payment where applicable;
|
7.5.12.1.2 |
Drugs on the Formulary of Medications Covered (FMC);
|
7.5.12.1.3 |
Drugs included on the LME, but not in the FMC (through the exceptions process explained in Section 7.5.12.10); and
|
7.5.12.1.4 |
In some instances, through the exceptions process, drugs that are not included on either the FMC or the LME.
|
62. |
Section 7.5.12.4.1 shall be amended and replaced in its entirety as follows:
|
7.5.12.4.1
|
Consistent with the requirements of Section 1927(d)(5) of the Social Security Act, some or all prescription drugs may be subject to Prior Authorization, which shall be implemented and managed by the PBM or the Contractor, according to policies and procedures established by the ASES Pharmacy and Therapeutic (“P&T”) Committee and decided upon in consultation with the Contractor when applicable.
|
63. |
Section 7.5.12.4.2.1 shall be amended and replaced in its entirety as follows:
|
7.5.12.4.2.1
|
The decision whether to grant a Prior Authorization of a prescription must not exceed twenty-four (24) hours from the receipt of the Enrollee’s Service Authorization Request and the standard information needed to make a determination is provided. Such standard information to make a determination includes the following: the prescription, a supporting statement setting forth the clinical justification and medical necessity for the prescribed medication, and expected duration of treatment, as required by the protocol for the medication. The Contractor shall provide notice on a Prior Authorization request by telephone or other telecommunication device in the required timeframes. In circumstances where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing the prescription drug, the Contractor shall provide at least a seventy-two (72) hour supply of the prescription drug unless the drug is statutorily excluded from coverage under Section 1927(d)(2) of the Social Security Act. In such cases, Prior Authorization must be provided as expeditiously as the Enrollee’s health requires, and no later than within twenty-four (24) hours following the Service Authorization Request.
|
64. |
Section 7.5.12.10.1.2 shall be amended and replaced in its entirety as follows:
|
7.5.12.10.1.2
|
The Contractor shall cover a drug that is not included on either the FMC or the LME, only as part of an exceptions process, provided that the drug is being prescribed for a use approved by the FDA or for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act for the treatment of the condition.
|
65. |
Section 7.5.12.10.2 shall be amended and replaced in its entirety as follows:
|
7.5.12.10.2
|
In addition to demonstrating that the drug is being prescribed for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act and as referenced in Section 7.5.12.10.1.2 above, a Provider prescribing a drug not on the FMC or LME must provide the Contractor with the necessary medical documentation to demonstrate that:
|
7.5.12.10.2.1 |
The drug does not have any bioequivalent on the market; and
|
7.5.12.10.2.2 |
The drug is clinically indicated because of:
|
7.5.12.10.2.2.1 |
Contra-indication with drugs that are in the FMC or LME that the Enrollee is already taking, and scientific literature’s indication of the possibility of serious adverse health effects related to the taking the drug;
|
7.5.12.10.2.2.2 |
History of adverse reaction by the Enrollee to drugs that are on the FMC or LME;
|
7.5.12.10.2.2.3 |
Therapeutic failure of all available alternatives on the FMC or LME; or
|
7.5.12.10.2.2.4 |
Other special circumstances.
|
66. |
Section 7.5.12.14 shall be amended and replaced in its entirety as follows:
|
7.5.12.14
|
Formulary Management Program
|
7.5.12.14.1 |
The Contractor shall
select two (2) members of its staff to serve on a cross-functional committee, the Pharmacy Benefit Financial Committee, tasked with rebate maximization and/or evaluating recommendations regarding the FMC and LME from the P&T Committee and the PPA and PBM as applicable. The Pharmacy Benefit Financial Committee will also review the FMC and LME from time to time and evaluate additional recommendations on potential cost-saving pharmacy initiatives, under the direction and approval of ASES.
|
7.5.12.14.2 |
The Contractor shall select a member of its staff to serve on a crossfunctional subcommittee tasked with assisting in the evaluation of additional potential cost-saving pharmacy initiatives as needed.
|
67. |
Section 7.5.12.15 shall be amended and replaced in its entirety as follows:
|
7.5.12.15
|
Utilization Management and Reports. The Contractor shall:
|
7.5.12.15.1 |
Perform drug Utilization reviews that meet the standards established by both ASES and Federal authorities, including the operation of a drug utilization review program as required in 42 CFR Part 456, Subpart K;
|
7.5.12.15.2 |
Develop and distribute protocols that will be subject to ASES approval, when necessary; and
|
7.5.12.15.3 |
Provide to ASES annually a detailed description of its drug utilization program activities.
|
68. |
Section 7.5.12.16.2 shall be amended and replaced in its entirety as follows:
|
7.5.12.16.2
|
The Contractor shall advise Providers that they may not outright deny medication because it is not included on ASES’s FMC or LME. A medication not on the FMC or LME may be provided through the exceptions process described in Section 7.5.12.10.
|
69. |
Section 7.5.12.17 shall be amended and replaced in its entirety as follows:
|
7.5.12.17
|
Cooperation with the Pharmacy Program Administrator (“PPA”)
|
7.5.12.17.1 |
The Contractor shall receive updates to the FMC and LME from the PPA. The Contractor shall adhere to these updates.
|
7.5.12.17.2 |
Any rebates shall be negotiated by the PPA and retained in their entirety by ASES. The Contractor shall neither negotiate, collect, nor retain any pharmacy rebate for Enrollee Utilization of brand drugs included on ASES’s FMC or LME.
|
70. |
Immediately following Section 7.5.12.17.2, a new Section 7.5.12.18 shall be inserted stating as follows:
|
7.5.12.18
|
Information on Pharmacy Benefits Coverage. The Contractor shall provide Information on the FMC and LME in electronic or paper form, including which generic or brand medications are covered, and what formulary tier each medication is on. Drug lists that are published on the Contractor’s website must be in a machine readable file and format as specified by CMS.
|
71. |
Section 7.7.8 shall be amended and replaced in its entirety as follows:
|
7.7.8
|
The Contractor shall complete, monitor, and routinely update a treatment plan for each Enrollee who is registered for Special Coverage at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee.
|
7.7.8.1
|
The treatment plan shall be developed by the Enrollee’s PCP, with the Enrollee’s participation, and in consultation with any specialists caring for the Enrollee. The Contractor shall require, in its Provider Contracts with PCPs, that Special Coverage registration treatment plans be submitted to the Contractor for review and approval in a timely manner.
|
72. |
Section 7.8.2.3 shall be amended and replaced in its entirety as follows:
|
7.8.2.3
|
The Contractor’s Care Management system shall emphasize prevention, continuity of care, and coordination of care, including between settings of care and appropriate discharge planning for short- and long-term hospital and institutional stays. The system will advocate for, and link Enrollees to, services as necessary across Providers, including community and social support Providers, and settings. Care Management functions include:
|
7.8.2.3.1 |
Assignment of a specific Care Manager to each enrollee qualified for Care Management;
|
7.8.2.3.2 |
Management of Enrollee to Care Manager ratios that have been reviewed and approved by ASES;
|
7.8.2.3.3 |
Identification of Enrollees who have or may have chronic or severe Behavioral Health needs, including through use of the screening tools MCHAT for the detection of Autism, ASQ, ASQ-SE, Conners Scale (ADHD screen), DAST-10, GAD, and PC-PTSD, and other tools available for diagnosis of Behavioral Health disorders;
|
7.8.2.3.4 |
Assessment of an Enrollee’s physical and Behavioral Health needs utilizing a standardized needs assessment within thirty (30) Calendar Days of Referral to Care Management that has been reviewed and given written approval by ASES. The Contractor shall also make its best efforts to perform this needs assessment for all new Enrollees within ninety (90) Calendar Days of the Effective Date of Enrollment, and to comply with all other requirements for such assessments set forth in 42 CFR 438.208(b);
|
7.8.2.3.5 |
Development of a plan of care within sixty (60) Calendar Days of the needs assessment;
|
7.8.2.3.6 |
Referrals and assistance to ensure timely Access to Providers;
|
7.8.2.3.7 |
Coordination of care actively linking the Enrollee to Providers, medical services, residential, social, and other support services where deemed necessary;
|
7.8.2.3.8 |
Monitoring of the Enrollees needs for assistance and additional services via face-to-face or telephonic contact at least quarterly (based on high- or low-risk;
|
7.8.2.3.9 |
Continuity and transition of care; and
|
7.8.2.3.10 |
Follow-up and documentation, including the review and/or revision of a plan of care upon reassessment of need, at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee.
|
73. |
Section 7.10.1 shall be amended and replaced in its entirety as follows:
|
7.10.1
|
In compliance with 42 CFR 438.3 (j)(1) and (2), 42 CFR 422.128(a), 42 CFR 422.128(b), 42 CFR 489.102(a), and Law No. 160 of November 17, 2001, the Contractor shall maintain written policies and procedures for Advance Directives. Such Advance Directives shall be included in each Enrollee’s Medical Record. The Contractor shall provide these policies and procedures written at a fourth (4
th
) grade reading level in English and Spanish to all Enrollees eighteen (18) years of age and older and shall advise Enrollees of:
|
7.10.1.1 |
Their rights under the laws of Puerto Rico, including the right to accept or refuse medical or surgical treatment and the right to formulate Advance Directives;
|
7.10.1.2 |
The Contractor’s written policies respecting the implementation of those rights, including a statement of any limitation that incorporates the requirements set forth under 42 CFR 422.128(b)(1)(ii) regarding the implementation of Advance Directives as a matter of conscience; and
|
7.10.1.3 |
The Enrollee’s right to file Complaints concerning noncompliance with Advance Directive requirements directly with ASES or with the Puerto Rico Office of the Patient Advocate.
|
74. |
Section 7.11.4.2 shall be amended and replaced in its entirety as follows:
|
7.11.4.2
|
No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.
|
75. |
Immediately following Section 7.12.2, new Sections 7.12.3 and 7.12.3.1 shall be inserted stating as follows:
|
7.12.3
|
The Contractor must enter into a Coordination of Benefits Agreement with Medicare within sixty (60) days from the Effective Date of the Contract and participate in the automated claims crossover process in order to appropriately allocate reimbursement for Dual Eligible Beneficiaries. Any crossover claims not appropriately reimbursed by the applicable Medicaid program will be considered an Overpayment and shall be reported and returned in accordance with Section 22.1.19.
|
7.12.3.1
|
ASES may extend the sixty (60) day time frame set forth in Section 7.12.3 if the Contractor can provide evidence, satisfactory to ASES, that documents the Contractor’s reasonable efforts to enter into a Coordination of Benefits Agreement with Medicare.
|
76. |
Section 7.13.2 shall be amended and replaced in its entirety as follows:
|
7.13.2
|
The Contractor shall furnish information about the services it does not cover based on a moral or religious objection to ASES with its GHP Program application. The Contractor acknowledges that such objections will be factored into the calculation of rates paid to the Contractor and, when made during the course of the Contract period, may serve as grounds for recalculation of the rates paid.
|
77. |
Section 10.3.1.22 shall be amended and replaced in its entirety as follows:
|
10.3.1.22
|
Specify that ASES, CMS, the Office of Inspector General, the Comptroller General, the Medicaid Fraud Control Unit, and their designees, shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents, and may inspect the premises, physical facilities, and equipment where activities or work related to the GHP program is conducted. The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later;
|
78. |
Section 10.4.3 shall be amended and replaced in its entirety as follows:
|
10.4.3
|
The Contractor shall, within fifteen (15) Calendar Days of issuance of a notice of termination to a Provider, provide written notice of the termination to Enrollees who received his or her Primary Care from, or was seen on a regular basis by, the terminated Provider, and shall assist the Enrollee as needed in finding a new Provider.
|
79. |
Section 10.5.1.5 shall be amended and replaced in its entirety as follows:
|
10.5.1.5
|
With the exceptions noted below, the Contractor shall negotiate rates with Providers, and such rates shall be specified in the Provider Contract. Payment arrangements may take any form allowed under Federal law and the laws of Puerto Rico, including Capitation payments, Fee-for-Service payment, and salary, if any, subject to Section 10.6 concerning permitted risk arrangements. However, the Contractor must consider the use of maximum provider reimbursement rates equaling eighty percent (80%) of the 2016 Medicare fee schedule for the reimbursement of non-facility professional services related to cardiology and nuclear medicine services, and seventy percent (70%) of the 2016 Medicare fee schedule for the reimbursement of non-facility professional services related to all other specialties except radiation oncology, hematology/oncology, urology, interventional radiology and dialysis services. Any use of the 2016 Medicare fee schedule to set maximum provider reimbursement rates shall not obligate the Contractor to increase current provider reimbursement rates that have been previously negotiated. The Contractor shall inform ASES in writing when it enters any Provider payment arrangement other than Fee-for-Service.
|
80. |
Section 10.5.1.6 shall be amended and replaced in its entirety as follows:
|
10.5.1.6
|
Any Capitation payment made by the Contractor to Providers shall be based on sound actuarial methods in accordance with 42 C.F.R. 438.4. The Contractor shall submit data on the basis of which ASES will certify the actuarial soundness of Capitation payments, including the base data generated by the Contractor. All Provider payments by the Contractor shall be reasonable, and the amount paid shall not jeopardize or infringe upon the quality of the services provided.
|
81. |
Section 11.2.5 shall be amended and replaced in its entirety as follows:
|
11.2.5
|
If the Contractor delegates any of its utilization management responsibilities under this Section 11.2 or 11.4 to any delegated Utilization Management agent or Subcontractor, such agent or Subcontractor must also comply with written policies and procedures for processing requests for authorizations of services in accordance with 42 CFR 438.210(b)(1).
|
82. |
Section 11.4.1.5 shall be amended and replaced in its entirety as follows:
|
11.4.1.5
|
Neither the Contractor nor any Provider or Subcontractor may impose a requirement that Referrals be submitted for the approval of committees, boards, Medical Directors, etc. The Contractor shall strictly enforce this directive and shall issue Administrative Referrals (see Section 11.4.1.4) whenever it deems medically necessary.
|
83. |
Section 11.4.2.1.1 shall be amended and replaced in its entirety as follows:
|
11.4.2.1.1
|
With the exception of Prior Authorization of covered prescription drugs as described in Section 7.5.12.4.2, the decision to grant or deny a Prior Authorization must not exceed seventy-two (72) hours from the time of the Enrollee’s Service Authorization Request for all Covered Services; except that, where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing services, the Prior Authorization must be provided as expeditiously as the Enrollee’s health requires, and no later than twenty-four (24) hours from the Service Authorization Request.
|
84. |
Section 11.4.6.1 shall be amended and replaced in its entirety as follows:
|
11.4.6.1
|
Neither a Referral nor Prior Authorization shall be required for any Emergency Service, no matter whether the Provider is within the PPN, and notwithstanding whether there is ultimately a determination that the condition for which the Enrollee sought treatment from an Emergency Services Provider was not an Emergency Medical Condition or Psychiatric Emergency.
|
85. |
Section 12.1.4 shall be amended and replaced in its entirety as follows:
|
12.1.4
|
ASES, in strict compliance with 42 CFR 438.340 and other Federal and Puerto Rico regulations, shall evaluate the delivery of health care by the Contractor. Such quality monitoring shall include monitoring of
all the Contractor’s Quality Management/Quality Improvement (“QM/QI”) programs described in this Article 12 of this Contract.
|
86. |
Section 12.2.2 shall be amended and replaced in its entirety as follows:
|
12.2.2
|
For Medicaid and CHIP Eligibles, the QAPI program shall be in compliance with Federal requirements specified at 42 CFR 438.330.
|
87. |
Section 12.2.3.1 shall be amended and replaced in its entirety as follows:
|
12.2.3.1
|
A method of monitoring, analyzing, evaluating, and improving the delivery, quality and appropriateness of health care furnished to all Enrollees (including over, under, and inappropriate Utilization of services) and including those with special health care needs, as defined by ASES in the quality strategy;
|
88. |
Immediately following Section 12.2.6, a new Section 12.2.7 shall be inserted stating as follows:
|
12.2.7
|
As per 42 CFR 438.332(a) and (b), the Contractor shall inform ASES as to whether it has been accredited by a private, independent accrediting entity, and if so, shall provide or authorize the accrediting entity to provide ASES, as applicable, a copy of its most recent accreditation review (including its accreditation status, expiration date of the accreditation, and survey type and level) recommended actions or improvements, corrective action plans, and summaries of findings.
|
89. |
Section 12.3.1 shall be amended and replaced in its entirety as follows:
|
12.3.1
|
At a minimum, the Contractor shall have a PIPs work plan and activities that are consistent with Federal and Puerto Rico statutes, regulations, and Quality Assessment and Performance Improvement Program requirements for pursuant to 42 C.F.R. 438.330. For more detailed information refer to the “EQR Managed Care Organization Protocol” available at http://www.medicaid.gov/ Medicaid-CHIP-Program-Information/By-Topics/Quality-of-Care/Quality-ofCare-External- Quality-Review.html.
|
90. |
Section 12.7.1 shall be amended and replaced in its entirety as follows:
|
12.7.1
|
In compliance with Federal requirements at 42 CFR 438.358, ASES will contract with an External Quality Review Organization (“EQRO”) to conduct annual, external, independent reviews of the quality outcomes, timeliness of, and Access to, the services covered in this Contract. The Contractor shall collaborate with ASES’s EQRO to develop studies, surveys, and other analytic activities to assess the quality of care and services provided to Enrollees and to identify opportunities for program improvement. To facilitate this process the Contractor shall supply Data, including but not limited to Claims Data and Medical Records, to the EQRO. Upon the request of ASES, the Contractor shall provide its protocols for providing Information, participating in review activities, and using the results of the reviews to improve the quality of the services and programs provided to Enrollees.
|
91. |
Section 13.1.2 shall be amended and replaced in its entirety as follows:
|
13.1.2
|
For Medicaid and CHIP Eligibles, the Contractor’s internal controls, policies, and procedures shall comply with all Federal requirements regarding Fraud, Waste, and Abuse and program integrity, including but not limited to Sections 1128, 1128A, 1156, 1842(j)(2), and 1902(a)(68) of the Social Security Act, Section 6402(h) of PPACA, 42 CFR 438.608, the CMS Medicaid Integrity program, and the Deficit Reduction Act of 2005. The Contractor shall exercise diligent efforts to ensure that no payments are made to any person or entity that has been excluded from participation in Federal health care programs. (See State Medicaid Director Letter #09-001, January 16, 2009.)
|
92. |
Section 13.2.2.2 shall be amended and replaced in its entirety as follows:
|
13.2.2.2
|
Require the designation of a compliance officer and a compliance committee that are accountable to the Contractor’s senior management. The compliance officer must have express authority to provide unfiltered reports directly to the Contractor’s most senior leader and governing body;
|
93. |
Section 13.2.3 shall be amended and replaced in its entirety as follows:
|
13.2.3
|
The Contractor, and any Subcontractors delegated the responsibility by the Contractor for coverage of services and payment of claims under this Contract, shall include in all employee handbooks a specific discussion of the False Claims Act and its Fraud, Waste, and Abuse policies and procedures, the rights of employees to be protected as whistleblowers, and the Contractor and Subcontractor’s procedures for detecting and preventing Fraud, Waste, and Abuse.
|
94. |
Section 13.4.1.2.3 shall be amended and replaced in its entirety as follows:
|
13.4.1.2.3
|
Any Subcontractor or other person with an employment, consulting, or other arrangement with the Contractor for the provision of items or services that are significant and material the Contractor’s obligations under this Contract.
|
95. |
Section 13.5.3 shall be amended and replaced in its entirety as follows:
|
13.5.3
|
The Contractor shall Immediately report to ASES the identity of any Provider or other person who is debarred, suspended, or otherwise prohibited from participating in procurement activities. ASES shall promptly notify the Secretary of Health and Human Services of the noncompliance, as required by 42 CFR 438.610(d).
|
96. |
Section 14.1.1 shall be amended and replaced in its entirety as follows:
|
14.1.1
|
In accordance with 42 CFR Part 438, Subpart F, the Contractor shall establish an internal Grievance System under which Enrollees, or Providers acting on their behalf, may express dissatisfaction with the Contractor or challenge the denial of coverage of, or payment for, Covered Services.
|
97. |
Section 14.1.10 shall be amended and replaced in its entirety as follows:
|
14.1.10
|
The Contractor shall include information regarding the Grievance System in the Provider Guidelines and upon joining the Contractor’s Network, all Providers and Subcontractors, as applicable shall receive training and education regarding the Contractor’s Grievance System, which includes but is not limited to:
|
14.1.10.1 |
The Enrollee’s right to file Complaints, Grievances and, Appeals and the requirements and timeframes for filing;
|
14.1.10.2 |
The Enrollee’s right to file a Complaint, Grievance, or Appeal with the Patient Advocate Office;
|
14.1.10.3 |
The Enrollee’s right to an Administrative Law Hearing, how to obtain an Administrative Law Hearing, and representation rules at an Administrative Law Hearing;
|
14.1.10.4 |
The availability of assistance in filing a Complaint, Grievance, or Appeal;
|
14.1.10.5 |
The toll-free numbers to file oral Complaints, Grievances, and Appeals;
|
14.1.10.6 |
The Enrollee’s right to request continuation of Benefits during an Appeal, or an Administrative Law Hearing filing, and that if the Contractor’s Adverse Benefit Determination is upheld in an Administrative Law Hearing, the Enrollee may be liable for the cost of any continued Benefits; and
|
14.1.10.7 |
Any Puerto Rico-determined Provider Appeal rights to challenge the failure of the Contractor to cover a service.
|
98. |
Section 14.1.14 shall be amended and replaced in its entirety as follows:
|
14.1.14
|
The Contractor shall ensure that the individuals who make decisions on Grievances and Appeals are individuals:
|
14.1.14.1 |
Who were not involved in any previous level of review or decisionmaking, or who were subordinates of any individual involved in a previous review or decision-making;
|
14.1.14.2 |
Who, if deciding any of the following, are Providers who have the appropriate clinical expertise, as determined by ASES, in treating the Enrollee’s condition or disease if deciding any of the following:
|
14.1.14.2.1 |
An Appeal of a denial that is based on lack of Medical Necessity;
|
14.1.14.2.2 |
A Grievance regarding denial of expedited resolutions of Appeal; and
|
14.1.14.2.3 |
Any Grievance or Appeal that involves clinical issues; and
|
14.1.14.3
|
Who take into account all comments, documents, records and other information submitted by Enrollee without regard to whether such information was submitted or considered in the initial Adverse Benefit Determination.
|
99. |
Section 14.1.16 shall be amended and replaced in its entirety as follows:
|
14.1.16
|
The Contractor and Subcontractors, as applicable, shall have a system in place to collect, analyze, and integrate Data regarding Complaints, Grievances, and Appeals. At a minimum, the record must be accessible to ASES and available upon request to CMS and include the following information:
|
14.1.16.1 |
Date Complaint, Grievance, or Appeal was received;
|
14.1.16.2 |
Enrollee’s name;
|
14.1.16.3 |
Enrollee’s Medicaid ID number, if applicable;
|
14.1.16.4 |
Name of the individual filing the Complaint, Grievance, or Appeal on behalf of the Enrollee;
|
14.1.16.5 |
Date of acknowledgement that receipt of Grievance or Appeal was mailed to the Enrollee;
|
14.1.16.6 |
Summary of Complaint, Grievance, or Appeal;
|
14.1.16.7 |
Date of each review or review meeting and resolution at each level, if applicable;
|
14.1.16.8 |
Date Notice of Disposition or Notice of Adverse Benefit Determination was mailed to the Enrollee;
|
14.1.16.9 |
Corrective Action required; and
|
14.1.16.10 |
Date of resolution.
|
100. |
Section 14.2.3 shall be amended and replaced in its entirety as follows:
|
14.2.3
|
An Enrollee or Enrollee’s Authorized Representative shall file a Complaint within fifteen (15) Calendar Days after the date of occurrence that initiated the Complaint. If the Enrollee or Enrollee’s Authorized Representative attempts to file a Complaint beyond the fifteen (15) Calendar Days, the Contractor shall instruct the Enrollee or Enrollee’s Authorized Representative to file a Grievance.
|
101. |
Section 14.2.5 shall be amended and replaced in its entirety as follows:
|
14.2.5
|
The Contractor shall resolve each Complaint within seventy-two (72) hours of the time the Contractor received the initial Complaint, whether orally or in writing. If the Complaint is not resolved within this timeframe, the Complaint shall be treated as a Grievance. The Contractor cannot require the Enrollee to file a separate Grievance before proceeding to Appeal.
|
102. |
Section 14.3.2 shall be amended and replaced in its entirety as follows:
|
14.3.2
|
An Enrollee may file a Grievance at any time.
|
103. |
Section 14.3.4 shall be amended and replaced in its entirety as follows:
|
14.3.4
|
The Contractor shall provide written notice of the disposition of the Grievance as expeditiously as the Enrollee’s health condition requires, but in any event, within ninety (90) Calendar Days from the day the Contractor receives the Grievance. If the Grievance originated from a Complaint that was not resolved within the seventy-two (72) hour timeframe set forth in Section 14.2.5, the time already spent by the Contractor to resolve the original Complaint must be deducted from this ninety (90) Calendar Day timeframe.
|
104. |
Section 14.3.6 shall be amended and replaced in its entirety as follows:
|
14.3.6
|
The Contractor may extend the timeframe to provide a written notice of disposition of a Grievance for up to fourteen (14) Calendar Days if the Enrollee requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is a need for additional Information and how the delay is in the Enrollee’s interest. If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:
|
14.3.6.1 |
Make reasonable efforts to provide Enrollee prompt oral notice of the delay;
|
14.3.6.2 |
Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days; and
|
14.3.6.3 |
Inform the Enrollee of the right to file a Grievance if the Enrollee disagrees with the decision to extend the timeframe; and .
|
105. |
Section 14.4.1 shall be amended and replaced in its entirety as follows:
|
14.4.1
|
Pursuant to 42 CFR 438.210(a), the Contractor shall provide written notice to the requesting Provider and the Enrollee of any decision by the Contractor to deny a Service Authorization Request, or to authorize a service in an amount, duration, or scope that is less than requested. The Contractor’s notices shall meet the requirements of 42 CFR 438.404.
|
106. |
Immediately following Section 14.4.3.2, a new Section 14.4.3.3 shall be inserted stating as follows, and the remaining Section 14.4.3 shall be renumbered accordingly, including any references thereto:
|
14.3.3.3
|
The right of Enrollee to be provided, upon request and at no expense to Enrollee, reasonable access to and copies of all documents, records and other information relevant to the Adverse Benefit Determination.
|
107. |
Section 14.4.4.4 shall be amended and replaced in its entirety as follows:
|
14.4.4.4
|
If the Contractor extends the timeframe for the authorization decision and issuance of Notice of Adverse Benefit Determination according to Section 14.4.3, the Contractor shall give the Enrollee written notice of the reasons for the decision to extend if he or she did not request the extension and the Enrollee’s right to file a Grievance if he or she disagrees with that decision. The Contractor shall issue and carry out its determination as expeditiously as the Enrollee’s health requires and no later than the date the extension expires.
|
108. |
Section 14.5.3 shall be amended and replaced in its entirety as follows:
|
14.5.3
|
The requirements of the Appeal process shall be binding for all types of Appeals, including expedited Appeals, unless otherwise established for expedited Appeals. Only one (1) level of Appeal is permitted before proceeding to an Administrative Law Hearing.
|
109. |
Section 14.5.7 shall be amended and replaced in its entirety as follows:
|
14.5.7
|
The Appeals process shall provide the Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, opportunity, before and during the Appeals process, to examine the Enrollee’s case file, including Medical Records, and any other documents and records considered during the Appeals process and provide copies of documents contained therein without charge and sufficiently in advance of the resolution timeframe for the Appeal.
|
110. |
Section 14.5.9 shall be amended and replaced in its entirety as follows:
|
14.5.9
|
The Contractor shall resolve each standard Appeal and provide written notice of the disposition, as expeditiously as the Enrollee’s health condition requires but no more than thirty (30) Calendar Days from the date the Contractor receives the Appeal.
|
111. |
Section 14.5.11 shall be amended and replaced in its entirety as follows:
|
14.5.11
|
The Contractor shall resolve each expedited Appeal and provide a written Notice of Disposition, as expeditiously as the Enrollee’s health condition requires, but no longer than seventy-two (72) hours after the Contractor receives the Appeal and make reasonable efforts to provide oral notice.
|
112. |
Section 14.5.12 shall be amended and replaced in its entirety as follows:
|
14.5.12
|
If the Contractor denies an Enrollee’s request for expedited review, it shall utilize the timeframe for standard Appeals specified herein and shall make reasonable efforts to give the Enrollee prompt oral notice of the denial, and follow-up within two (2) Calendar Days with a written notice. If the Enrollee disagrees with the decision to extend the prescribed timeframe, he or she shall be informed of the right to file a Grievance and the Grievance shall be resolved within twenty-four (24) hours. The Contractor shall also make reasonable efforts to provide oral notice for resolution of an expedited review of an Appeal.
|
113. |
Section 14.5.13 shall be amended and replaced in its entirety as follows:
|
14.5.13
|
The Contractor may extend the timeframe for standard or expedited resolution of the Appeal by up to fourteen (14) Calendar Days if the Enrollee, Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is need for additional information and how the delay is in the Enrollee’s interest. If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:
|
14.5.13.1 |
Make reasonable efforts to provide Enrollee prompt oral notice of the delay;
|
14.5.13.2 |
Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days;
|
14.5.13.3 |
Inform the Enrollee of the right to file a Grievance if the Enrollee disagrees with the decision to extend the timeframe; and
|
14.5.13.4 |
Resolve the Appeal as expeditiously as the Enrollee’s health condition requires, and no later than the date the extension expires.
|
114. |
Section 14.5.15 shall be amended and replaced in its entirety as follows:
|
14.5.15
|
The written notice of Disposition shall be in a format and language that, at a minimum, meets applicable notification standards and shall include:
|
14.5.15.1 |
The results and date of the Appeal resolution; and
|
14.5.15.2 |
For decisions not wholly in the Enrollee’s favor:
|
14.5.15.3 |
The right to request an Administrative Law Hearing;
|
14.5.15.4 |
How to request an Administrative Law Hearing;
|
14.5.15.5 |
The right to continue to receive Benefits pending an Administrative Law Hearing;
|
14.5.15.6 |
How to request the continuation of Benefits; and
|
14.5.15.7 |
Notification that if the Contractor’s Adverse Benefit Determination is upheld in a hearing, the Enrollee may liable for the cost of any continued Benefits.
|
115. |
Section 14.6.1 shall be amended and replaced in its entirety as follows:
|
14.6.1
|
The Contractor is responsible for explaining the Enrollee’s right to and the procedures for an Administrative Law Hearing, including that the Enrollee must exhaust the Contractor’s Grievance, Complaints, and Appeals process before requesting an Administrative Law Hearing. However, if the Contractor fails to adhere to all notice and timing requirements set forth in 42 CFR 438.408, the Enrollee is deemed to have exhausted the Contractor’s Appeals process and may proceed with initiating an Administrative Law Hearing.
|
116. |
Section 14.6.4 shall be amended and replaced in its entirety as follows:
|
14.6.4
|
ASES shall permit the Enrollee to request an Administrative Law Hearing within one hundred and twenty (120) Calendar Days of the Notice of Resolution of the Appeal.
|
117. |
Section 14.7.2 shall be amended and replaced in its entirety as follows:
|
14.7.2
|
The Contractor shall continue the Enrollee’s Benefits if the Enrollee or the Enrollee’s Authorized Representative files the Appeal within sixty (60) Calendar Days following the date on the Adverse Benefit Determination notice; the Appeal involves the termination, suspension, or reduction of a previously authorized course of treatment; the services were ordered by an authorized Provider; the period covered by the original authorization has not expired; and the Enrollee timely files for continuation of the Benefits.
|
118. |
Section 14.7.5 shall be amended and replaced in its entirety as follows:
|
14.7.5
|
If the Contractor or ASES reverses a decision to deny, limit, or delay services that were not furnished while the Appeal / Administrative Law Hearing was pending, the Contractor shall authorize or provide the disputed services promptly and as expeditiously as the Enrollee’s health condition requires but no later than seventy-two (72) hours from the date the Contractor receives notice reversing the determination.
|
119. |
Section 16.4 shall be amended and replaced in its entirety as follows:
|
16.4
|
The Contractor shall not pay any Claim submitted by a Provider during the period of time when such Provider is excluded or suspended from the Medicare, Medicaid, CHIP or Title V Maternal and Child Health Services Block Grant programs for Fraud, Waste, or Abuse or otherwise included on the Department of Health and Human Services Office of the Inspector General exclusions list, or employs someone on this list, and when the Contractor knew, or had reason to know, of that exclusion, after a reasonable time period after reasonable notice has been furnished to the Contractor. The Contractor shall not pay any Claim submitted by a Provider that is on Payment Hold.
|
120. |
Section 16.6 shall be amended and replaced in its entirety as follows:
|
16.6
|
Network Providers may not receive payment other than by the Contractor for services covered under this Agreement, except when such payments are specifically required to be made by ASES under Title XIX of the Social Security Act, or its implementing regulations, or when ASES makes direct payments to Network Providers for graduate medical education costs approved under the Medicaid State Plan. The Contractor is prohibited from making payment on any amount expended for any item or service not covered under the Medicaid State Plan.
|
121. |
Section 16.13.2 shall be amended and replaced in its entirety as follows:
|
16.13.2
|
The Provider will have a period of sixty (60) Calendar Days to make the requested payment, to agree to Contractor retention of said payment, or to dispute the recovery action following the process described in Section 16.11.6.
|
122. |
Section 17.2.4.6 shall be amended and replaced in its entirety as follows:
|
17.2.4.6
|
Be maintained for ten (10) years in either live and/or archival systems. The duration of the retention period may be extended at the discretion of and as indicated to the Contractor by ASES as needed for ongoing audits or other purposes.
|
123. |
Section 17.3.3 shall be amended and replaced in its entirety as follows:
|
17.3.3
|
Each month the Contractor shall generate Encounter Data files from its Claims management system(s) and/or other sources. Such files must be submitted in standardized Accredited Standards Committee (ASC) X12N 837 and National Council for Prescription Drug Programs (NCPDP) formats, and the ASC X12N 835 format as appropriate. The files will contain settled Claims and Claim adjustments and Encounter Data from Providers for the most recent month for which all such transactions were completed. The Contractor shall provide these files electronically to ASES and/or its Agent at a frequency and level of detail to be specified by CMS and ASES based on program administration, oversight, and program integrity needs, and in adherence to the procedure, content standards and format indicated in Attachment 9. The Contractor shall make changes or corrections to any systems, processes or Data transmission formats as needed to comply with Encounter Data quality standards as originally defined or subsequently amended.
|
124. |
Immediately following Section 17.3.5, a new Section 17.3.6 shall be inserted stating as follows:
|
17.3.6
|
Revisions to the Modified Adjusted Gross Income (“MAGI”) are expected to be implemented on July 1, 2017. To comply with MAGI requirements, Contractor must update its Information Systems in accordance with the procedures and timelines set forth in Attachment 9 and any other subsequent guidance issued by ASES.
|
125. |
Section 18.1.1 shall be amended and replaced in its entirety as follows:
|
18.1.1
|
ASES may, at its discretion, require the Contractor to submit additional reports or any other data, documentation or information relating to the performance of the Contractor’s obligations both on an ad hoc and recurring basis as required by ASES or CMS. If ASES requests any revisions to the reports already submitted, the Contractor shall make the changes and re-submit the reports, according to the time period and format specified by ASES.
|
126. |
Immediately following Section 18.2.5.6, a new Section 18.2.5.7 shall be inserted stating as follows:
|
18.2.5.7
|
The Contractor shall submit a quarterly
Provider Preventable Conditions Report
describing any identified Provider preventable conditions as defined in Sections 7.1.1.1.1 and 7.1.1.1.2 of this Contract. The report shall include but not be limited to, a description of each identified instance of a provider preventable condition, the name of the applicable Provider, and a summary of corrective actions taken by the Contractor or Provider to address any underlying causes of the provider preventable condition.
|
127. |
Section 19.1.4.3.3 shall be amended and replaced in its entirety as follows:
|
19.1.4.3.3
|
The Contractor has taken actions that have caused substantial risk to Enrollees’ health;
|
128. |
Section 19.4.1 shall be amended and replaced in its entirety as follows:
|
19.4.1
|
The Contractor has the right within fifteen (15) Calendar Days following receipt of the notice of imposition of intermediate sanctions to seek administrative review in writing of ASES’s determination and any such intermediate sanctions, pursuant to Act 72 or under any other applicable law or regulation. This time period can be extended for an additional fifteen (15) days if the Contractor submits a written request that includes a credible explanation of why it needs additional time, the request is received by ASES before the end of the initial period, and ASES has determined that the Contractor’s conduct does not pose a threat to an Enrollee’s health or safety.
|
129. |
Section 19.4.5 shall be amended and replaced in its entirety as follows:
|
19.4.5
|
In addition to the actions described under Section 19.4.3, the examining officer may recommend the delivery and implementation of a Corrective Action Plan with respect to Contractor’s failure to comply with the terms of this Contract as set forth in ASES’ notice of intermediate sanctions.
|
130. |
Section 19.5 shall be amended and replaced in its entirety as follows:
|
19.5
|
Judicial Review -
To the extent administrative review is sought by the Contractor pursuant to Section 19.4, the Contractor has the right to seek judicial review of ASES’s actions by the Puerto Rico Court of Appeals, San Juan Panel, within thirty (30) Calendar Days of the notice of final determination issued by ASES.
|
131. |
Section 22.1.2 shall be amended and replaced in its entirety as follows:
|
22.1.2
|
ASES will have the discretion to recoup payments made to the Contractor for ineligible Enrollees, including, but not limited to, the following:
|
22.1.2.1 |
Enrollees incorrectly enrolled with more than one Contractor;
|
22.1.2.2 |
Enrollees who die prior to the Enrollment month for which the payment was made;
|
22.1.2.3 |
Enrollees whom ASES later determines were not eligible for Medicaid during the Enrollment month for which payment was made.
|
22.1.2.4 |
Enrollees whom were not domiciled in Puerto Rico during the Enrollment month for which payment was made; or
|
22.1.2.5 |
Enrollees whom were incarcerated during the Enrollment month for which payment was made.
|
132. |
Section 22.1.5 shall be amended and replaced in its entirety as follows:
|
22.1.5
|
The PMPM Payment for Enrollees not enrolled for the full month shall be determined on a pro rata basis by dividing the monthly Capitation amount by the number of days in the month and multiplying the result by the number of days including and following the Effective Date of Enrollment or the number of days prior to and including the Effective Date of Disenrollment, as applicable. The Contractor is entitled to a PMPM Payment for each Enrollee as of the Effective Date of Enrollment, including the period referred to in Section 5.2.2. The Contractor is entitled to a PMPM Payment for each Enrollee up to the Effective Date of Disenrollment, including the period referred to in Section 5.3.
|
133. |
Section 22.1.17 shall be amended and replaced in its entirety as follows:
|
22.1.17
|
The profit of the Contractor and Subcontractors for each fiscal year of the Contract Term shall not exceed two point five percent (2.5 %) of the PMPM Payment (Excess Profit). In the event that the profit exceeds this amount as a result of the positive impact the high quality services provided by the Contractor and Sub-Contractors had on the Enrollees Health, the Parties shall share the Excess Profit in proportions of fifty percent (50%) for the Contractor and Subcontractors, and fifty percent (50%) for ASES. For the purpose of this section high quality services will be measured on the Contractor’s compliance with eighty-five percent (85%) of the QIP quality metrics as established by ASES in Attachment 19. In the event ASES discovers the existence of Excess Profit by means of an audit during the Control and Supervision Plan or the Contractor does not meet the high quality services standard mentioned in this section, ASES is entitled to one hundred percent (100%) of the Excess Profit.
|
22.1.17.1
|
Excess Profit and any other incentive arrangements between ASES and the Contractor must comply the requirements set forth by CMS in 42 CFR 438.6(b)(2).
|
134. |
Section 22.1.18 shall be amended and replaced in its entirety as follows:
|
22.1.18
|
The Contractor shall initially determine its Excess Profit for each fiscal year and shall submit a sworn certification annually to attest to the truth and accuracy of its Excess Profit and the assumptions on which it is calculated to ASES. After receipt of the Contractor’s sworn certification, ASES will audit the Contractor’s Excess Profit based on the Contractor’s sworn certification and the Contractor’s and Subcontractors’ audited financial statements submitted annually to ASES pursuant to Sections 23.1.3 and 18.2.9.8 of this Contract, and the validation of the IBNR reserve by ASES’s actuary. The Excess Profit calculation will include the entire fiscal year (total aggregated earned premium for all Service Regions). ASES will audit the Excess Profit certified by the Contractor using the actual medical expenses and the contracted administrative fee portion of the PMPM. ASES shall notify the Contractor of ASES’s determination of the Contractor’s Excess Profit within forty-five (45) Calendar Days of receipt by ASES of the Contractor’s audited financial statement. The Contractor shall remit the portion of Excess Profit payable to ASES within fifteen (15) Calendar Days of receiving the notice of Excess Profit determination from ASES. The same regulations shall apply to any and all Subcontractors.
|
135. |
Immediately following Section 22.1.18, a new Section 22.1.19 shall be inserted stating as follows, and the remaining Section 22.1 shall be renumbered accordingly, including any references thereto:
|
22.1.19
|
The Contractor shall include in its calculation of Excess Profit, as reported under this Section 22.1, all of the profit of its partially- or wholly-owned subsidiaries or Affiliates realized from services rendered in relation to this contract (the “Affiliated Profit”), unless the Contractor demonstrates and ASES agrees that the Affiliated Profit did not result from preferential contractual terms included in the Contractor’s contracts or arrangements with its partially- or wholly-owned subsidiaries and Affiliates.
|
22.1.19.1 |
Preferential contractual terms are those that result in a cost or expense that exceeds fair market value, or those that exceed any other terms for the provisioning of same or similar goods and services as would be agreed to by a reasonable person under the same or similar circumstances prevailing at the time the decision was made for that same or similar good or service. In determining whether preferential contract terms exist, consideration must be given to factors including “sound business practices,” “arm’slength bargaining” and “market prices for comparable goods and services for the geographical area.” Contractual terms shall also be deemed preferential if the Contractor’s partially- or wholly-owned subsidiaries or Affiliates charge the Contractor a higher price for the same or similar goods or services than the lowest price charged by the Contractor’s partially- or wholly-owned subsidiaries or Affiliates to any and all other clients.
|
22.1.19.2 |
Notwithstanding the above, if a Contractor’s subsidiary or Affiliate charges the Contractor for goods or services provided under or associated with the GHP program, and such charges exceed 60% of the total revenue of the subsidiary or Affiliate, such charges must be at cost. If such charges are not at cost, any excess amounts above cost must be included in the calculation of the Contractor’s Excess Profit.
|
22.1.19.3 |
Contractor shall report to ASES’s Office of Finance all related-party transactions within thirty (30) Calendar Days and provide a copy of the contract for each transaction detailing the amounts paid or to be paid, charged or transferred and goods or services to be provided under the contract. A certification under penalty from criminal perjury from the Contractor’s President, Vice-President, Chief Financial Officer, or Treasurer specifying what are the “at cost” and/or “fair market value” amounts of the contract, as applicable, shall be included with each submission.
|
136. |
Original Section 22.1.18, renumbered by this Amendment as 22.1.20, shall be amended and replaced in its entirety as follows:
|
22.1.20
|
To comply with 42 CFR 438.608(d) and 433.312, the Contractor shall, consistent with the procedures set forth in Attachment 23, refund (i) the share
of the Overpayment due to ASES within eleven (11) months of the discovery and (ii) the share of an Overpayment due to ASES within fifteen (15) Calendar Days from a final judgment on a Fraud, Waste,
or Abuse Action. The Contractor must also require and have a mechanism for a Provider to report to the Contractor when it has received an Overpayment, to return that Overpayment to the Contractor with a written reason for the Overpayment within sixty (60) Calendar Days after the date on which the Overpayment was identified. The Contractor shall report annually to ASES on their recoveries of all Overpayments.
|
137. |
Immediately following Section 22.1, a new Section 22.2 shall be inserted stating as follows, and the remaining Article 22 shall be renumbered accordingly, including any references thereto:
|
22.2
|
Medical Loss Ratio
|
22.2.1 |
The Contractor shall report a Medical Loss Ratio and related data, including the data on the basis of which ASES will determine the compliance of the Contractor with the Medical Loss Ratio Requirement, as required under 42 CFR 438.8(k) for each rating period. Such reporting shall be provided to ASES no later than March 31
st
of the following year.
|
22.2.2 |
The Contractor shall calculate its Medical Loss Ratio and related data based on the methodology set forth in 42 CFR 438.8 and any other instructions issued by CMS or ASES. Effective July 1, 2017, the Contractor is expected to achieve a target medical loss ratio standard, as calculated under 42 CFR 438.8, of at least ninety-one percent (91%) for the contract year.
|
22.2.3 |
The calculation of administrative expenses for the purposes of determining the Medical Loss Ratio in accordance with 42 CFR 438.8 shall not be affected by the methodology used to calculate Excess Profit as set forth in Sections 22.1.18 and 22.1.19.
|
138. |
Original Section 22.3.1, renumbered by this Amendment as 22.4.1, shall be amended and replaced in its entirety as follows:
|
22.4.1
|
ASES shall maintain a Retention Fund of the PMPM Payment each month as part of the Quality Incentive Program described in Section 12.5 according to the following table:
|
Retention Fund Percentage (RFP) Breakdown
|
||||
Baseline FY 2016
|
||||
Time Period (Incurred service
from Contract Term)
|
Retention Fund
Percentage
|
Performance
Measures
|
Preventive Clinical
Programs
|
Emergency Room
Use Indicators
|
7/1/2017 through 9/30/2017
|
2% of PMPM
|
40% of RFP
|
30% of RFP
|
30% of RFP
|
10/31/2017 through 12/31/2017
|
2% of PMPM
|
40% of RFP
|
30% of RFP
|
30% of RFP
|
1/31/2018 through 3/30/2018
|
2% of PMPM
|
40% of RFP
|
30% of RFP
|
30% of RFP
|
4/30/2018 through 6/30/2018
|
2% of PMPM
|
40% of RFP
|
30% of RFP
|
30% of RFP
|
139. |
Original Section 22.3.2.1, renumbered by this Amendment as 22.4.2.1, shall be amended and replaced in its entirety as follows:
|
22.4.2.1
|
The Contractor shall submit a quarterly report no later than ninety (90) Calendar Days after the end of each quarter regarding each of the performance indicators to be evaluated, as determined by ASES (from those listed in Section 12.5);
|
140. |
Immediately following Original Section 22.3.2.3, renumbered by this Amendment as 22.4.2.3, a new Section 22.4.3 shall be inserted stating as follows:
|
22.4.3
|
The Quality Incentive Program and any other withhold incentive arrangements between ASES and the Contractor must comply the requirements set forth by CMS in 42 CFR 438.6(b)(3).
|
141. |
Section 23.1.4 shall be amended and replaced in its entirety as follows:
|
23.1.4
|
The Contractor shall provide to ASES a copy of its Annual Report required to be filed with the Puerto Rico Office of the Insurance Commissioner (OIC Report), as applicable, in the format agreed upon by the National Association of Insurance Commissioners (NAIC), for the year ended on December 31, 2014, and subsequently thereafter, during the Contract Term and any renewals, not later than March 31 of each year. The Contractor shall submit to ASES a reconciliation of the OIC Report with its annual audited financial statements filed pursuant to Section 23.1.3 and Section 18.2.9.8.
|
142. |
Section 23.2.3 shall be amended and replaced in its entirety as follows:
|
23.2.3
|
The Contractor shall provide assurances to ASES that its provision against the risk of insolvency is adequate, in compliance with the Federal standards set forth in 42 CFR 438.116, and shall submit data on the basis of which ASES will determine that the Contractor has made adequate provision against the risk of insolvency. In particular, the Contractor shall, according to the timeframe specified in Attachment 12 to this Contract, furnish documentation, certified by a Certified Public Accountant, of:
|
23.2.3.1 |
The relationship between PMPM Payments and capital, with the optimal relationship being 10:1, in order to prove capacity to assume risk;
|
23.2.3.2 |
A debt level of less than seventy-five percent (75%).and
|
23.2.3.3 |
Relationship of current assets to total liabilities shall be, at least, 80%.
|
143. |
Section 23.3.3 shall be amended and replaced in its entirety as follows:
|
23.3.3
|
The Contractor shall establish a stop-loss limit amount that is in compliance with the limits specified in 42 CFR 422.208(f). The limit shall be activated when the expense of providing Covered Services to an Enrollee, including all outpatient and inpatient expenses, reaches this sum. The Contractor shall have mechanisms in place to identify the stop loss once it is reached for an Enrollee, and shall establish monthly reports to inform PMGs of Enrollees who have reached the stop-loss limit. The Contractor shall assume all losses exceeding the limit.
|
144. |
Section 23.6.1 shall be amended and replaced in its entirety as follows:
|
23.6.1
|
Any Physician Incentive Plans established by the Contractor shall comply with Federal and Puerto Rico regulations, including 42 CFR 422.208 and 422.210, and 42 CFR 438.3(i), and with the requirements in Section 10.7 of this Contract.
|
145. |
Section 23.7.4.1 shall be amended and replaced in its entirety as follows:
|
23.7.4.1
|
Definition of A Party in Interest – As defined in Section 1318(b) of the Public Health Service Act, a party in interest is:
|
23.7.4.1.1 |
(i) Any director, officer, partner, or employee responsible for management or administration of the Contractor; (ii) any person or legal entity that is directly or indirectly the beneficial owner of more than five percent (5%) of the equity of the Contractor; (iii) any person or legal entity that is the beneficial owner of a mortgage, deed of trust, note, or other interest secured by, and valuing more than five percent (5%) of the Contractor; or, (iv) in the case of a Contractor organized as a nonprofit corporation, an incorporator or enrollee of such corporation under applicable Commonwealth corporation law;
|
23.7.4.1.2 |
Any organization in which a person or a legal entity described in Section 23.7.4.1.1 is director, officer or partner; has directly or indirectly a beneficial interest of more than five percent (5%) of the equity of the Contractor; or has a mortgage, deed of trust, note, or other interest valuing more than five percent (5%) of the assets of the Contractor;
|
23.7.4.1.3 |
Any person directly or indirectly controlling, controlled by, or under common control with the Contractor; or
|
23.7.4.1.4 |
Any spouse, child, or parent of an individual described in Sections 23.7.4.1.1-23.7.4.1.3.
|
146. |
Section 23.7.4.4 shall be amended and replaced in its entirety as follows:
|
23.7.4.4
|
As per 42 CFR 455.105 the Contractor, within thirty-five (35) Calendar Days of the date of request by the HHS Secretary, ASES or the Commonwealth Medicaid agency, and on an annual basis to ASES and the Commonwealth Medicaid agency, shall report full and complete information about:
|
23.7.4.4.1 |
The ownership of any subcontractor with whom the provider has had business transactions totaling more than $25,000 during the 12-month period ending on the day of the request; and
|
23.7.4.4.2 |
Any significant business transactions between the provider and any wholly owned supplier, or between the provider and any subcontractor, during the five (5)-year period ending on the date of the request.
|
147. |
Immediately following Section 23.7.4.4.2, a new Section 23.7.4.5 shall be inserted stating as follows:
|
23.7.4.5
|
Disclosures of Information on Annual Business Transactions or other reports of transactions between the Contractor and parties in interest provided to ASES or other agencies must be made available to Enrollees upon reasonable request.
|
148. |
Section 29.1 shall be amended and replaced in its entirety as follows:
|
29.1
|
ASES is prohibited by law from entering into contracts with any person or entity that has been, or whose affiliated subsidiary companies, or any of its shareholders, partners, officers, principals, managing employees, subsidiaries, parent companies, officers, directors, board members, or ruling bodies have been, under investigation for, accused of, convicted of, or sentenced to imprisonment, in Puerto Rico, the other USA jurisdictions, or any other jurisdiction, for any crime involving corruption, fraud, embezzlement, or unlawful appropriation of public funds, pursuant to Act 458, as amended, and Act 84 of 2002
.
|
149. |
Section 30.1.4 shall be amended and replaced in its entirety as follows:
|
30.1.4
|
All contracts between the Contractor and Subcontractors must be in writing, must comply with all applicable Medicaid laws and regulations, including subregulatory guidance and provisions set forth in this Agreement, as applicable, and must specify the activities and responsibilities delegated to the Subcontractor containing terms and conditions consistent with this Contract. The contracts must also include provisions for revoking delegation or imposing other sanctions if the Subcontractor’s performance is inadequate. The Contractor and the Subcontractors must also make reference to a business associates agreement between the Parties.
|
150. |
Section 30.1.8 shall be amended and replaced in its entirety as follows:
|
30.1.8
|
ASES shall have the right to review all financial or business transactions between the Contractor and a Subcontractor at any time upon request. ASES, CMS, or Office of Inspector General may inspect, evaluate and audit the Subcontractor at any time if ASES, CMS or Office of Inspector General determines there is a reasonable possibility of fraud or similar risk. ASES shall also retain the right to review all criminal background checks for all employees of the Subcontractor, as referenced in Article 29, as well as any past exclusions from Federal programs.
|
151. |
Immediately following Section 30.1.11, a new Section 30.1.12 shall be inserted stating as follows, and the remaining Article 30.1 shall be renumbered accordingly, including any references thereto:
|
30.1.12
|
Pursuant to the requirements of 42 CFR 438.230(c)(3)(i) and 42 CFR 438.3(k), ASES, CMS, the Office of Inspector General, the Comptroller General, and their respective designees shall have the right at any time to inspect, evaluate, and audit any books, records, contractors, computer or other electronic systems of the Subcontractor, or of the Subcontractor’s contractor, that pertain to any aspect of services and activities performed or determination of amounts payable under this Agreement.
|
152. |
Original Section 30.1.12, renumbered by this Amendment as 30.1.13, shall be amended and replaced in its entirety as follows:
|
30.1.13
|
All Subcontractors must fulfill the requirements of 42 CFR 438.3, 438.6 and 438.230 as appropriate. Subcontractors shall also retain, as applicable, enrollee grievance and appeal records as per 42 CFR 438.416, base data for setting actuarially sound capitation rates as per 42 CFR 438.5(c), Medical Loss Ratio reports as per 42 CFR 438.8(k), and the data, information and documentation specified in 42 CFR 438.604, 438.606, 438.608, and 610 for a period of no less than ten (10) years, as set forth in Section 33.1.1.
|
153. |
Original Section 30.1.12 shall be deleted in its entirety, including any references thereto.
|
154. |
Section 30.2.1 shall be amended and replaced in its entirety as follows:
|
30.2.1
|
The Contractor shall submit to ASES, and shall require any Subcontractors hereunder to submit to ASES, cost or pricing Data for any subcontract to this Contract prior to award. The Contractor shall also certify that the information submitted by the Subcontractor is, to the best of the Contractor’s knowledge and belief, accurate, complete and current as of the date of agreement, or the date of the negotiated price of the Subcontract or amendment to the Contract. The Contractor shall insert the substance of this Section in each Subcontract hereunder.
|
155. |
Section 33.1.1 shall be amended and replaced in its entirety as follows:
|
33.1.1
|
The Contractor and its Subcontractors, if any, shall preserve and make available all of its records pertaining to the performance under this Contract for inspection or audit, as provided below, throughout the Contract Term, for a period of ten (10) years from the date of final payment under this Contract, and for such period, if any, as is required by applicable statute or by any other section of this Contract. If the Contract is completely or partially terminated, the records relating to the work terminated shall be preserved and made available for period of ten (10) years from the Termination Date of the Contract or of any resulting final settlement. The Contractor is responsible to preserve all records pertaining to its performance under this Contract, and to have them available and accessible in a timely manner, and in a reasonable format that assures their integrity. Records that relate to Appeals, litigation, or the settlements of Claims arising out of the performance of this Contract, or costs and expenses of any such agreements as to which exception has been taken by the Contractor or any of its duly Authorized Representatives, shall be retained by Contractor until such Appeals, litigation, Claims or exceptions have been disposed of.
|
156. |
Section 33.2.3 shall be amended and replaced in its entirety as follows:
|
33.2.3
|
Pursuant to the requirements of 42 CFR 434.6(a)(5) and 42 CFR 434.38, ASES, CMS, the Office of Inspector General, the Comptroller General, and their respective designees shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents of the Contractor and Subcontractors, and may inspect the premises, physical facilities, equipment, computers or other electronic systems where activities or work related to the GHP program is conducted. The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later. Any records requested hereunder shall be produced Immediately for on-site review or sent to the requesting authority by mail within fourteen (14) Calendar Days following a request. All records shall be provided at the sole cost and expense of the Contractor. ASES shall have unlimited rights to use, disclose, and duplicate all Information and Data in any way relating to this Contract in accordance with applicable Puerto Rico and Federal laws and regulations.
|
157. |
Immediately following Section 38.2.2, a new Section 38.2.3 shall be inserted stating as follows, and the remaining Article 38 shall be renumbered accordingly, including any references thereto:
|
38.2.3
|
At the request of either party, ASES will evaluate any enacted Federal, state or local legislative or regulatory changes with applicability to the GHIP program that materially impact the PMPM Payment. If after a process of actuarial evaluation, using credible data, ASES determines that the enacted legislative and/or regulatory changes materially impact the PMPM Payment, ASES will adjust the PMPM rates for Metro North and West Service Regions to reflect the above-referenced changes after the adjusted rates are approved by CMS. Any revisions to the PMPM Payments under this Section would be applicable only from January 1, 2018 until June 30, 2018, or from the effective date of any new law or regulation, whichever is later. “Materially impact” shall mean that a recalculation of current PMPM Payments is required in order to remain actuarially sound.
|
158. |
Section 40.1 shall be amended and replaced in its entirety as follows:
|
40.1
|
This Contract shall be governed in all respects by the laws of Puerto Rico. Any lawsuit or other action brought against ASES or the Commonwealth based upon or arising from this Contract shall be brought in a court of competent jurisdiction in Puerto Rico.
|
159. |
Section 54.1 shall be amended and replaced in its entirety as follows:
|
54.1
|
The Contractor and Subcontractors shall disclose, and ASES shall review, financial statements for each person or corporation with an ownership or control interest of five percent (5%) or more of its entity. For the purposes of this Section, a person or corporation with an ownership or control interest shall mean a person or corporation:
|
54.1.1 |
That owns directly or indirectly five percent (5%) or more of the Contractor’s/Subcontractor’s capital or stock or received five percent (5%) or more of its profits;
|
54.1.2 |
That has an interest in any mortgage, deed of trust, note, or other obligation secured in whole or in part by the Contractor/Subcontractor or by its property or assets, and that interest is equal to or exceeds five percent (5%) of the total property and assets of the Contractor/Subcontractor; and
|
54.1.3 |
That is an officer or director of the Contractor/Subcontractor (if it is organized as a corporation) or is a partner in the Contractor’s/ Subcontractor’s organization (if it is organized as a partnership).
|
160. |
Section 55.2 shall be amended and replaced in its entirety as follows:
|
55.2
|
ASES reserves the authority to seek an amendment to this Contract at any time if such an amendment is necessary in order for the terms of this Contract to comply with Federal law, the laws of Puerto Rico or the Government of Puerto Rico Fiscal Plan as certified by the Financial Oversight and Management Board for Puerto Rico pursuant to the Puerto Rico Oversight, Management and Economic Stability Act of 2016. The Contractor shall consent to any such amendment.
|
161. |
The following amended attachments, copies of which are included, are substituted in this Agreement as follows:
|
a. |
ATTACHMENT 5: FORMULARY OF MEDICATIONS COVERED AND LIST OF MEDICATIONS BY EXCEPTION
|
b. |
ATTACHMENT 8: COST-SHARING
|
c. |
ATTACHMENT 9: ENROLLMENT MANUAL
|
d. |
ATTACHMENT 11: PER MEMBER PER MONTH PAYMENTS
|
e. |
ATTACHMENT 19: QUALITY INCENTIVE PROGRAM MANUAL
|
IV. |
RATIFICATION
|
V. |
EFFECT;CMS APPROVAL
|
VI. |
AMENDMENT EFFECTIVE DATE
|
VII. |
ENTIRE AGREEMENT
|
/s/ Angela M. Avila Marrero
|
|||
12/26/2017
|
|||
Ms. Angela M. Avila Marrero, Executive Director
|
Date
|
||
EIN:
66-0500678
|
|||
TRIPLE-S SALUD, INC.
|
|||
/s/ Madeline Hernandez Urquiza
|
|||
12/26/2017
|
|||
Ms. Madeline Hernandez Urquiza, President
|
Date
|
Therapeutic Category [Categoría Terapéutica]
|
Therapeutic
Class [Clase Terapéutica]
|
Drug
Description
[Descripción de
la Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
|
Stimulants - Misc.
|
Modafinil Oral Tablet 100 MG
|
Y
|
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
|
Stimulants - Misc.
|
Modafinil Oral Tablet 200 MG
|
Y
|
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
|
Stimulants - Misc.
|
Provigil Oral Tablet 100 MG
|
Y
|
ADHD/ANTI-NARCOLEPSY/ANTIOBESITY/ANOREXIANTS
|
Stimulants - Misc.
|
Provigil Oral Tablet 200 MG
|
Y
|
ANALGESICS - ANTIINFLAMMATORY
|
Interleukin-1 Receptor Antagonist (IL-1Ra)
|
Kineret Subcutaneous Solution Prefilled Syringe 100 MG/0.67ML
|
Y
|
ANTHELMINTICS
|
ANTHELMINTICS
|
Albenza Oral Tablet 200 MG
|
Y
|
ANTHELMINTICS
|
ANTHELMINTICS
|
Ivermectin Oral Tablet 3 MG
|
Y
|
ANTHELMINTICS
|
ANTHELMINTICS
|
Stromectol Oral Tablet 3 MG
|
Y
|
ANTIDOTES AND SPECIFIC ANTAGONISTS
|
Antidotes - Chelating Agents
|
Exjade Oral Tablet Soluble 125 MG
|
Y
|
ANTIDOTES AND SPECIFIC ANTAGONISTS
|
Antidotes -
Chelating Agents
|
Exjade Oral Tablet Soluble 250 MG
|
Y
|
Therapeutic Category [Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Aprepitant Oral Capsule 125 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Emend Oral Capsule 80 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Emend Oral Capsule 125 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Aprepitant Oral Capsule 40 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Emend Oral Capsule 40 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Emend Oral Capsule 80 & 125 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Emend Oral Suspension Reconstituted 125 MG
|
Y
|
ANTIEMETICS
|
Substance P/Neurokinin 1 (NK1) Receptor Antagonists
|
Aprepitant Oral Capsule 80 & 125 MG
|
Y
|
ANTI-INFECTIVE AGENTS - MISC.
|
Antiprotozoal Agents
|
Mepron Oral Suspension 750 MG/5ML
|
Y
|
ANTI-INFECTIVE AGENTS - MISC.
|
Antiprotozoal Agents
|
Atovaquone Oral Suspension 750 MG/5ML
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Alkylating Agents
|
Cyclophosphamide Oral Capsule 25 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Alkylating Agents
|
Cyclophosphamide Oral Capsule 50 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Antibiotics
|
Novantrone Intravenous Concentrate 20 MG/10ML
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Antibiotics
|
Mitoxantrone HCl Intravenous Concentrate 25 MG/12.5ML
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Antibiotics
|
Mitoxantrone HCl Intravenous Concentrate 20 MG/10ML
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Antibiotics
|
Mitoxantrone HCl Intravenous Concentrate 30 MG/15ML
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Tarceva Oral Tablet 100 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Tarceva Oral Tablet 150 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Bosulif Oral Tablet 500 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Bosulif Oral Tablet 100 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Afinitor Disperz Oral Tablet Soluble 2 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Afinitor Disperz Oral Tablet Soluble 3 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Afinitor Disperz Oral Tablet Soluble 5 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Tafinlar Oral Capsule 50 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Tafinlar Oral Capsule 75 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Mekinist Oral Tablet 0.5 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Mekinist Oral Tablet 2 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Imbruvica Oral Capsule 140 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Zelboraf Oral Tablet 240 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ibrance Oral Capsule 75 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ibrance Oral Capsule 100 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ibrance Oral Capsule 125 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Cotellic Oral Tablet 20 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ninlaro Oral Capsule 2.3 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ninlaro Oral Capsule 3 MG
|
Y
|
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES
|
Antineoplastic Enzyme Inhibitors
|
Ninlaro Oral Capsule 4 MG
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Benzisoxazoles
|
Risperdal Consta Intramuscular Suspension Reconstituted 12.5 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Benzisoxazoles
|
Risperdal Consta Intramuscular Suspension Reconstituted 37.5 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Benzisoxazoles
|
Risperdal Consta Intramuscular Suspension Reconstituted 50 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Benzisoxazoles
|
Risperdal Consta Intramuscular Suspension Reconstituted 25 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 200 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 300 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 400 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 50 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 150 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Clozaril Oral Tablet 100 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Clozaril Oral Tablet 25 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Clozapine Oral Tablet 100 MG
|
Y
|
ANTIPSYCHOTICS/ANTIMANIC AGENTS
|
Dibenzapines
|
Clozapine Oral Tablet 25 MG
|
Y
|
ANTIVIRALS
|
Hepatitis Agents
|
Hepsera Oral Tablet 10 MG
|
Y
|
ANTIVIRALS
|
Hepatitis Agents
|
Adefovir Dipivoxil Oral Tablet 10 MG
|
Y
|
ANTIVIRALS
|
Hepatitis Agents
|
Entecavir Oral Tablet 0.5 MG
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ANTIVIRALS
|
Hepatitis Agents
|
Entecavir Oral Tablet 1 MG
|
Y
|
ANTIVIRALS
|
Hepatitis Agents
|
Baraclude Oral Tablet 0.5 MG
|
Y
|
ANTIVIRALS
|
Hepatitis Agents
|
Baraclude Oral Tablet 1 MG
|
Y
|
CORTICOSTEROIDS
|
Glucocorticosteroid s
|
Entocort EC Oral Capsule Delayed Release Particles 3 MG
|
Y
|
CORTICOSTEROIDS
|
Glucocorticosteroid s
|
Budesonide Oral Capsule Delayed Release Particles 3 MG
|
Y
|
DERMATOLOGICALS
|
Antipsoriatics
|
Tazorac External Gel 0.05 %
|
Y
|
DERMATOLOGICALS
|
Antipsoriatics
|
Tazorac External Gel 0.1 %
|
Y
|
DERMATOLOGICALS
|
Antipsoriatics
|
Tazorac External Cream 0.05 %
|
Y
|
DERMATOLOGICALS
|
Antipsoriatics
|
Tazorac External Cream 0.1 %
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Forteo Subcutaneous Solution 600 MCG/2.4ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Reclast Intravenous Solution 5 MG/100ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Zoledronic Acid Intravenous Solution 5 MG/100ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Pamidronate Disodium Intravenous Solution 30 MG/10ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Pamidronate Disodium Intravenous Solution 90 MG/10ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Pamidronate Disodium Intravenous Solution 6 MG/ML
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Alendronate Sodium Oral Tablet 40 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Fosamax Oral Tablet 40 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Bone Density Regulators
|
Prolia Subcutaneous Solution 60 MG/ML
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Hormone Receptor Modulators
|
Raloxifene HCl Oral Tablet 60 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Hormone Receptor Modulators
|
Evista Oral Tablet 60 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Growth Hormone Receptor Antagonists
|
Somavert Subcutaneous Solution Reconstituted 10 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Growth Hormone Receptor Antagonists
|
Somavert Subcutaneous Solution Reconstituted 15 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Growth Hormone Receptor Antagonists
|
Somavert Subcutaneous Solution Reconstituted 20 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Growth Hormone Receptor Antagonists
|
Somavert Subcutaneous Solution Reconstituted 25 MG
|
Y
|
ENDOCRINE AND METABOLIC AGENTS - MISC.
|
Growth Hormone Receptor Antagonists
|
Somavert Subcutaneous Solution Reconstituted 30 MG
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Feiba NF Intravenous Solution Reconstituted
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Feiba VH Immuno Intravenous Solution Reconstituted
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Feiba Intravenous Solution Reconstituted
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 250 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 500 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 750 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 1000 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 1500 UNIT
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 2000 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Antihemophilic Products
|
Eloctate Intravenous Solution Reconstituted 3000 UNIT
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Platelet Aggregation Inhibitors
|
Effient Oral Tablet 5 MG
|
Y
|
HEMATOLOGICAL AGENTS - MISC.
|
Platelet Aggregation Inhibitors
|
Effient Oral Tablet 10 MG
|
Y
|
MISCELLANEOUS THERAPEUTIC CLASSES
|
Immunosuppressive Agents
|
Zortress Oral Tablet 0.25 MG
|
Y
|
MISCELLANEOUS THERAPEUTIC CLASSES
|
Immunosuppressive Agents
|
Zortress Oral Tablet 0.75 MG
|
Y
|
MISCELLANEOUS THERAPEUTIC CLASSES
|
Immunosuppressive Agents
|
Zortress Oral Tablet 0.5 MG
|
Y
|
MISCELLANEOUS THERAPEUTIC CLASSES
|
Systemic Lupus Erythematosus Agents
|
Benlysta Intravenous Solution Reconstituted 120 MG
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard S/D Intravenous Solution Reconstituted 10 GM
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard S/D Less IgA Intravenous Solution Reconstituted 5 GM
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard S/D Less IgA Intravenous Solution Reconstituted 10 GM
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gamunex-C Injection Solution 1 GM/10ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gamunex-C Injection Solution 2.5 GM/25ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gamunex-C Injection Solution 5 GM/50ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gamunex-C Injection Solution 20 GM/200ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gamunex-C Injection Solution 10 GM/100ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammaked Injection Solution 1 GM/10ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammaked Injection Solution 2.5 GM/25ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammaked Injection Solution 5 GM/50ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammaked Injection Solution 10 GM/100ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammaked Injection Solution 20 GM/200ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 1 GM/10ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 2.5 GM/25ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 5 GM/50ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 10 GM/100ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 20 GM/200ML
|
Y
|
PASSIVE IMMUNIZING AND TREATMENT AGENTS
|
Immune Serums
|
Gammagard Injection Solution 30 GM/300ML
|
Y
|
Therapeutic Category
[Categoría Terapéutica]
|
Therapeutic Class
[Clase Terapéutica]
|
Drug Description
[Descripción de la
Droga]
|
Preautorization
[Preautorización]
Y=Yes
|
RESPIRATORY AGENTS - MISC.
|
Cystic Fibrosis Agents
|
Pulmozyme Inhalation Solution 1 MG/ML
|
Y
|
TETRACYCLINES
|
TETRACYCLINES
|
Tetracycline HCl Oral Capsule 250 MG
|
Y
|
TETRACYCLINES
|
TETRACYCLINES
|
Tetracycline HCl Oral Capsule 500 MG
|
Y
|
TETRACYCLINES
|
TETRACYCLINES
|
Demeclocycline HCl Oral Tablet 150 MG
|
Y
|
TETRACYCLINES
|
TETRACYCLINES
|
Demeclocycline HCl Oral Tablet 300 MG
|
Y
|
TETRACYCLINES
|
TETRACYCLINES
|
Declomycin Oral Tablet 300 MG
|
Y
|
VASOPRESSORS
|
Anaphylaxis Therapy Agents
|
Epinephrine Injection Solution Auto-injector 0.15 MG/0.3ML
|
Y
|
VASOPRESSORS
|
Anaphylaxis Therapy Agents
|
Epinephrine Injection Solution Auto-injector 0.15 MG/0.15ML
|
Y
|
VASOPRESSORS
|
Anaphylaxis Therapy Agents
|
Epinephrine Injection Solution Auto-injector 0.3 MG/0.3ML
|
Y
|
VIH-SIDA
|
|
VIH-SIDA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg cap,
300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
|
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp
, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
|
BICILLIN L-A 600000 unit/ml im susp
|
3
|
Non-Preferred
|
||
penicillin g procaine 600000 unit/ml im susp
|
3
|
Non-Preferred
|
BICILLIN LA
|
|
BICILLIN L-A 1200000 unit/2ml im susp
|
4
|
Non-Preferred
|
||
BICILLIN L-A 2400000 unit/4ml im susp
|
5
|
Non-Preferred
|
||
Quinolones [Quinolonas]
|
||||
ciprofloxacin hcl 250 mg tab,
500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
VIH-SIDA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfadiazine 500 mg tab
|
4
|
Preferred
|
SULFADIAZINE
|
|
Tetracyclines [Tetraciclinas]
|
||||
minocycline hcl
100 mg cap, 50 mg cap, 75 mg cap
|
1
|
Preferred
|
MINOCIN
|
|
doxycycline monohydrate 50 mg cap, 100 mg cap
|
2
|
Non-Preferred
|
MONODOX
|
|
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
|
||||
Antituberculars [Antituberculosos]
|
||||
isoniazid 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ISONIAZID
|
|
rifampin 150 mg cap
|
1
|
Preferred
|
RIFADIN
|
|
ethambutol hcl 100 mg tab
|
2
|
Non-Preferred
|
MYAMBUTOL
|
|
pyrazinamide 500 mg tab
|
2
|
Non-Preferred
|
PYRAZINAMIDE
|
|
rifampin 300 mg cap
|
2
|
Preferred
|
RIFADIN
|
|
ethambutol hcl 400 mg tab
|
3
|
Non-Preferred
|
MYAMBUTOL
|
|
isoniazid 50 mg/5ml syr
|
5
|
Non-Preferred
|
ISONIAZID
|
|
rifabutin 150 mg cap
|
MYCOBUTIN
|
Puerto Rico Health
Department
Tuberculosis
Control
Program
|
||
cycloserine 250 mg cap
|
SEROMYCIN
|
|||
RIFAMATE 50-300 mg cap
|
||||
TRECATOR 250 mg tab
|
||||
CAPASTAT 1 gm inj
|
VIH-SIDA
|
|
Drug Name [Nombre
del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ketoconazole 200 mg tab
|
1
|
Preferred
|
NIZORAL
|
|
terbinafine hcl 250 mg tab
|
1
|
Preferred
|
LAMISIL
|
|
fluconazole 40 mg/ml susp
|
2
|
Preferred
|
DIFLUCAN
|
|
voriconazole 40 mg/ml susp
|
4
|
Preferred
|
VFEND
|
|
itraconazole 100 mg cap
|
5
|
Preferred
|
SPORANOX
|
|
SPORANOX 10 mg/ml soln
|
6
|
Preferred
|
||
voriconazole 50 mg tab
|
8
|
Preferred
|
VFEND
|
|
voriconazole 200 mg tab
|
10
|
Preferred
|
VFEND
|
|
ANTIPARASITICS [ANTIPARASITARIOS]
|
||||
Anthelmintics [Antihelmínticos]
|
||||
ALBENZA 200 mg tab
|
9
|
Preferred
|
||
Antimalarials [Antimaláricos]
|
||||
DARAPRIM 25 mg tab
|
7
|
Non-Preferred
|
PA
|
|
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
|
||||
NEBUPENT 300 mg inh soln
|
4
|
Preferred
|
||
atovaquone 750 mg/5ml susp
|
9
|
Non-Preferred
|
MEPRON
|
|
ANTIVIRALS [ANTIVIRALES]
|
||||
Anti-Cytomegalovirus (CMV) Agents [Agentes Anti-Citomegalovirus]
|
||||
valganciclovir hcl 450 mg
tab
|
13
|
Non-Preferred
|
VALCYTE
|
VIH-SIDA
|
|
Antiherpetic Agents [Agentes Antiherpéticos]
|
||||
acyclovir 200 mg cap, 400
mg tab, 800 mg tab
|
1
|
Preferred
|
ZOVIRAX
|
|
acyclovir 200 mg/5ml susp
|
2
|
Preferred
|
ZOVIRAX
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors [Inhibidores No Nucleósidos De La Transciptasa Reversa]
|
||||
nevirapine 200 mg tab
|
1
|
Preferred
|
VIRAMUNE
|
|
nevirapine 50 mg/5ml susp
|
5
|
Non-Preferred
|
VIRAMUNE
|
|
RESCRIPTOR 200 mg tab
|
6
|
Non-Preferred
|
||
SUSTIVA 200 mg cap
|
6
|
Preferred
|
P
|
|
nevirapine er 100 mg tab er 24 hr, 400 mg tab er 24 hr
|
7
|
Non-Preferred
|
VIRAMUNE XR
|
|
SUSTIVA 50 mg cap, 600 mg tab
|
7
|
Preferred
|
P
|
|
zidovudine 300 mg tab
|
2
|
Non-Preferred
|
RETROVIR
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos De La Transcriptasa Reversa]
|
||||
stavudine 1 mg/ml soln, 15
mg cap, 20 mg cap, 30 mg cap, 40 mg cap
|
3
|
Preferred
|
ZERIT
|
|
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr
|
4
|
Non-Preferred
|
VIDEX EC
|
|
lamivudine
10 mg/ml soln
|
4
|
Preferred
|
EPIVIR
|
|
lamivudine 150 mg tab
|
4
|
Preferred
|
EPIVIR
|
|
zidovudine 100 mg cap, 50 mg/5ml syr
|
4
|
Non-Preferred
|
RETROVIR
|
|
abacavir sulfate 300 mg tab
|
5
|
Non-Preferred
|
ZIAGEN
|
|
didanosine 400 mg cap dr
|
5
|
Non-Preferred
|
VIDEX EC
|
|
lamivudine 300 mg tab
|
5
|
Preferred
|
EPIVIR
|
|
VIDEX 2 gm soln
|
5
|
Non-Preferred
|
||
lamivudine 100 mg tab
|
6
|
Preferred
|
EPIVIR
|
PA
|
lamivudine-zidovudine 150300 mg tab
|
6
|
Preferred
|
COMBIVIR
|
|
ZIAGEN 20 mg/ml soln
|
6
|
Non-Preferred
|
abacavir-lamivudinezidovudine 300-150-300 mg tab
|
10
|
Non-Preferred
|
TRIZIVIR
|
VIH-SIDA
|
|
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
|
||||
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
|
||||
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
|
1
|
Preferred
|
PA, P
|
|
PROCRIT 3000 unit/ml inj soln
|
5
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
|
6
|
Preferred
|
PA, P
|
|
PROCRIT 10000 unit/ml inj soln
|
6
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
|
7
|
Preferred
|
PA, P
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
|
8
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
|
9
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
PROCRIT 40000 unit/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
Iron [Hierro]
|
||||
iron 325 (65 fe) mg tab
|
1
|
Preferred
|
IRON
|
VIH-SIDA
|
|
CHEMOTHERAPIES [QUIMIOTERAPIAS]
|
||||
Antineoplastic Progestins [Antineoplásicos De Progestina]
|
||||
megestrol acetate 20 mg
tab, 40 mg tab
|
1
|
Preferred
|
MEGACE
|
|
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
|
2
|
Preferred
|
MEGACE
|
|
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
|
||||
leucovorin calcium 5 mg tab
|
3
|
Preferred
|
LEUCOVORIN
|
|
leucovorin calcium 10 mg tab, 15 mg tab
|
4
|
Preferred
|
LEUCOVORIN
|
|
leucovorin calcium 25 mg tab
|
9
|
Preferred
|
LEUCOVORIN
|
|
leucovorin calcium 50 mg inj, 100 mg inj, 200 mg inj, 350 mg inj, 500 mg inj
|
9
|
Non-Preferred
|
LEUCOVORIN
|
|
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
|
||||
Antifungals [Antifungales]
|
||||
clotrimazole 10 mg
mouth/throat lozenge, 10 mg mouth/throat troche
|
1
|
Preferred
|
MYCELEX
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
nystatin 100000 unit/ml mouth/throat susp
|
1
|
Preferred
|
MYCOSTATIN
|
|
HORMONAL AGENTS [AGENTES HORMONALES]
|
||||
Mineralocorticoids [Mineralocorticoides]
|
||||
fludrocortisone acetate 0.1
mg tab
|
1
|
Preferred
|
FLORINEF
|
VIH-SIDA
|
|
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
|
||||
Glucocorticosteroids [Glucocorticoides]
|
||||
dexamethasone 0.5 mg tab,
0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
|
1
|
Preferred
|
DECADRON
|
|
MEDROL 2 mg tab
|
1
|
Preferred
|
methylprednisolone 32 mg tab, 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
methylprednisolone (pak) 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
|
1
|
Preferred
|
PRELONE
|
|
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
prednisone (pak) 10 mg tab, 5 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
|
2
|
Preferred
|
CORTEF
|
|
methylprednisolone 16 mg tab, 8 mg tab
|
2
|
Preferred
|
MEDROL
|
NEFROLOGIA
|
|
NEFROLOGIA
|
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ERYPED 400 400 mg/5ml susp
|
6
|
Preferred
|
||
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp,
200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
|
BICILLIN L-A 600000 unit/ml im susp
|
3
|
Non-Preferred
|
||
penicillin g procaine 600000 unit/ml im susp
|
3
|
Non-Preferred
|
BICILLIN LA
|
|
BICILLIN L-A 1200000 unit/2ml im susp
|
4
|
Non-Preferred
|
||
BICILLIN L-A 2400000 unit/4ml im susp
|
5
|
Non-Preferred
|
||
Quinolones [Quinolonas]
|
||||
ciprofloxacin hcl 250 mg tab,
500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
NEFROLOGIA
|
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
|
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
|
||||
cefaclor 250 mg cap, 500
mg cap
|
2
|
Preferred
|
CECLOR
|
|
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
|
2
|
Preferred
|
CEFZIL
|
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
|
||||
cefdinir 125 mg/5ml susp,
300 mg cap
|
2
|
Preferred
|
OMNICEF
|
|
cefdinir 250 mg/5ml susp
|
3
|
Preferred
|
OMNICEF
|
|
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
|
||||
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
|
||||
acarbose 100 mg tab, 25 mg
tab, 50 mg tab
|
2
|
Preferred
|
PRECOSE
|
|
Biguanides [Biguanidas]
|
||||
metformin hcl 1000 mg tab,
500 mg tab, 850 mg tab
|
1
|
Preferred
|
GLUCOPHAGE
|
|
metformin hcl er 500 mg tab er 24 hr, 750 mg tab er 24 hr
|
1
|
Preferred
|
GLUCOPHAGE XR
|
|
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
|
||||
KOMBIGLYZE XR 2.5
-1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr
|
3
|
Preferred
|
ST, P
|
|
ONGLYZA 2.5 mg tab, 5 mg tab
|
3
|
Preferred
|
ST, P
|
|
Insulin Mixtures [Mezclas De Insulinas]
|
||||
HUMULIN 70/30 (70
-30) 100 unit/ml sc susp
|
2
|
Preferred
|
P
|
NEFROLOGIA
|
|
NEFROLOGIA
|
|
Sulfonylureas [Sulfonilureas]
|
||||
glimepiride 1 mg tab, 2 mg
tab, 4 mg tab
|
1
|
Preferred
|
AMARYL
|
|
glipizide 10 mg tab, 5 mg tab
|
1
|
Preferred
|
GLUCOTROL
|
|
ANTIEMETICS [ANTIEMÉTICOS]
|
||||
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
NEFROLOGIA
|
|
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
|
1
|
Preferred
|
CARDIZEM
|
|
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
DILACOR XR
|
|
diltiazem hcl er beads 120 mg cap er 24 hr
|
1
|
Preferred
|
TIAZAC
|
|
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
CARDIZEM CD
|
|
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
DILACOR XR
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
nifedipine er osmotic 30 mg tab er 24 hr
|
1
|
Preferred
|
PROCARDIA XL
|
|
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
|
1
|
Preferred
|
CALAN
|
|
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er
|
1
|
Preferred
|
CALAN SR
|
|
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg cap er 24 hr
|
2
|
Preferred
|
TIAZAC
|
|
diltiazem hcl er coated beads 300 mg cap er 24 hr
|
2
|
Preferred
|
CARDIZEM CD
|
|
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr
|
2
|
Preferred
|
PROCARDIA XL
|
|
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
|
||||
atenolol 100 mg tab, 25 mg
tab, 50 mg tab
|
1
|
Preferred
|
TENORMIN
|
NEFROLOGIA
|
|
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
|
1
|
Preferred
|
LOPRESSOR
|
|
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
LOPRESSOR
|
|
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
|
2
|
Preferred
|
LOPRESSOR
|
|
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
|
||||
atenolol
-chlorthalidone 10025 mg tab, 50-25 mg tab
|
1
|
Preferred
|
TENORETIC
|
|
metoprolol- hydrochlorothiazide 50-25 mg tab
|
2
|
Non-Preferred
|
LOPRESSOR HCT
|
|
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab
|
3
|
Non-Preferred
|
LOPRESSOR HCT
|
NEFROLOGIA
|
|
chlorthalidone 25 mg tab, 50 mg tab
|
1
|
Non-Preferred
|
HYGROTON
|
|
DIURIL 250 mg/5ml susp
|
1
|
Preferred
|
||
hydrochlorothiazide 25 mg tab, 50 mg tab
|
1
|
Preferred
|
MICROZIDE
|
|
metolazone 2.5 mg tab, 5 mg tab
|
1
|
Non-Preferred
|
ZAROXOLYN
|
|
chlorthalidone 100 mg tab
|
2
|
Non-Preferred
|
HYGROTON
|
|
metolazone 10 mg tab
|
2
|
Non-Preferred
|
ZAROXOLYN
|
|
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
|
||||
carvedilol 12.5 mg tab, 25
mg tab, 3.125 mg tab, 6.25 mg tab
|
1
|
Preferred
|
COREG
|
|
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
|
||||
Alpha 1-Adrenoceptor Antagonists [Bloqueadores Alfa1-Adrenérgicos]
|
||||
tamsulosin hcl 0.4 mg cap
|
1
|
Preferred
|
FLOMAX
|
NEFROLOGIA
|
|
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
|
7
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
|
8
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
|
9
|
Preferred
|
PA, P
|
|
PROCRIT 20000 unit/ml inj soln
|
9
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
PROCRIT 40000 unit/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
Folates [Folatos]
|
||||
folic acid 1 mg tab, 400 mcg
tab, 800 mcg tab
|
1
|
Preferred
|
FOLIC ACID
|
OTC
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Iron [Hierro]
|
||||
iron 325 (65 fe) mg tab
|
1
|
Preferred
|
IRON
|
|
DEXFERRUM 50 mg/ml inj soln
|
5
|
Non-Preferred
|
||
INFED 50 mg/ml inj soln
|
5
|
|||
CHEMOTHERAPIES [QUIMIOTERAPIAS]
|
||||
Antineoplastic Progestins [Antineoplásicos De Progestina]
|
||||
megestrol acetate 20 mg
tab, 40 mg tab
|
1
|
Preferred
|
MEGACE
|
|
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
|
2
|
Preferred
|
MEGACE
|
|
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
|
||||
Needles & Syringes [Agujas Y Jeringuillas]
|
||||
insulin syringe/needle
|
1
|
Preferred
|
.
|
NEFROLOGIA
|
|
DYSLIPIDEMICS [DISLIPIDÉMICOS]
|
||||
Bile Acid Sequestrants [Secuestradores De Acidos Biliares]
|
||||
cholestyramine 4 gm pckt, 4
gm/dose oral pwdr
|
3
|
Preferred
|
QUESTRAN
|
|
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
|
||||
gemfibrozil 600 mg tab
|
1
|
Preferred
|
LOPID
|
|
Hmg Coa Reductase Inhibitors [Inhibidores De La Reductasa De Hmg Coa]
|
||||
atorvastatin calcium 10 mg
tab, 20 mg tab, 40 mg tab, 80 mg tab
|
1
|
Preferred
|
LIPITOR
|
|
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab
|
1
|
Non-Preferred
|
PRAVACHOL
|
|
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab
|
1
|
Preferred
|
ZOCOR
|
|
pravastatin sodium 40 mg tab
|
2
|
Non-Preferred
|
PRAVACHOL
|
|
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
|
||||
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
|
||||
famotidine
20 mg tab, 40 mg tab
|
1
|
Preferred
|
PEPCID
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
|
1
|
Preferred
|
ZANTAC
|
|
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
|
||||
Phosphate Binder Agents [Enlazadores De Fosfato]
|
||||
RENVELA 0.8 gm pckt
|
6
|
Preferred
|
PA, P
|
|
RENVELA 2.4 gm pckt, 800 mg tab
|
7
|
Preferred
|
PA, P
|
NEFROLOGIA
|
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
cyclosporine 25 mg cap
|
4
|
Preferred
|
SANDIMMUNE
|
PA
|
cyclosporine modified 100 mg cap, 100 mg/ml soln
|
4
|
Preferred
|
NEORAL
|
PA
|
cyclosporine 100 mg cap
|
5
|
Preferred
|
SANDIMMUNE
|
PA
|
NEFROLOGIA
|
|
cyclosporine modified 100 mg cap
|
5
|
Preferred
|
NEORAL
|
PA, P
|
NEORAL 100 mg cap
|
5
|
Preferred
|
PA, P
|
|
cyclosporine 100 mg cap, 25 mg cap
|
6
|
Preferred
|
SANDIMMUNE
|
PA, P
|
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap
|
6
|
Preferred
|
PA, P
|
|
cyclosporine modified 100 mg/ml soln
|
7
|
Preferred
|
NEORAL
|
PA, P
|
NEORAL 100 mg/ml soln
|
7
|
Preferred
|
PA, P
|
|
Glucocorticosteroids [Glucocorticoides]
|
||||
dexamethasone 0.5 mg tab
, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
|
1
|
Preferred
|
DECADRON
|
|
MEDROL 2 mg tab
|
1
|
Preferred
|
||
methylprednisolone 32 mg tab, 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
methylprednisolone (pak) 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
|
1
|
Preferred
|
PRELONE
|
|
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
prednisone (pak) 10 mg tab, 5 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
|
2
|
Preferred
|
CORTEF
|
|
methylprednisolone 16 mg tab, 8 mg tab
|
2
|
Preferred
|
MEDROL
|
|
Organ Transplant Agents [Agentes Para Trasplantes]
|
||||
azathioprine 50 mg tab
|
1
|
Preferred
|
IMURAN
|
NEFROLOGIA
|
|
Drug Name [Nombre del
Medicamento]
|
Net Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
mycophenolate mofetil 250 mg cap, 500 mg tab
|
2
|
Preferred
|
CELLCEPT
|
PA
|
tacrolimus 0.5 mg cap
|
3
|
Non-Preferred
|
PROGRAF
|
PA
|
MYFORTIC
180 mg tab dr
|
4
|
Preferred
|
PA, P
|
|
tacrolimus 1 mg cap
|
4
|
Non-Preferred
|
PROGRAF
|
PA
|
mycophenolic acid 180 mg tab dr
|
5
|
Preferred
|
MYFORTIC
|
PA
|
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
|
5
|
Non-Preferred
|
RAPAMUNE
|
PA
|
MYFORTIC
360 mg tab dr
|
6
|
PA, P
|
||
tacrolimus 5 mg cap
|
6
|
Non-Preferred
|
PROGRAF
|
PA
|
mycophenolic acid 360 mg tab dr
|
7
|
Preferred
|
MYFORTIC
|
PA
|
RAPAMUNE 1 mg/ml soln
|
8
|
Non-Preferred
|
PA
|
|
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
|
||||
Calcium Regulating Agents [Agentes Reguladores De Calcio]
|
||||
calcitriol 0.25 mcg cap
|
1
|
Preferred
|
ROCALTROL
|
|
calcitriol 0.5 mcg cap
|
2
|
Preferred
|
ROCALTROL
|
|
calcitriol 1 mcg/ml soln
|
5
|
Preferred
|
ROCALTROL
|
|
Electrolytes/Minerals Replacement [Reemplazo De Electrolitos/Minerales]
|
||||
potassium chloride 20
meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln
|
1
|
Preferred
|
KAY-CIEL
|
|
potassium chloride crys er 10 meq tab er, 20 meq tab er
|
1
|
Preferred
|
KLOR-CON
|
|
potassium chloride er 10 meq tab er, 8 meq tab er
|
1
|
Preferred
|
KLOR-CON
|
|
potassium chloride er 10 meq cap er, 8 meq cap er
|
2
|
Preferred
|
MICRO-K
|
|
potassium chloride 40 meq/15ml (20%) oral liquid
|
4
|
Preferred
|
KAON CL
|
|
Potassium Removing Resins [Resinas Removedoras De Potasio]
|
||||
kalexate oral pwdr
|
3
|
Preferred
|
KAYEXALATE
|
|
sodium polystyrene sulfonate oral pwdr, 15 gm/60ml susp
|
3
|
Preferred
|
KAYEXALATE
|
NEFROLOGIA
|
|
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANALGESICS [ANALG
ÉSICOS]
|
||||
Nonsteroidal Anti-Inflammatory Agents (NSAIDS) [Anti-Inflamatorios No Esteroidales]
|
||||
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL=15 días No refills
|
nabumetone 500 mg tab, 750 mg tab
|
1
|
Preferred
|
RELAFEN
|
|
naproxen 250 mg tab, 375 mg tab, 500 mg tab
|
1
|
Preferred
|
NAPROSYN
|
QL=15 días No refills
|
naproxen dr 375 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
NAPROSYN
|
QL=15 días No refills
|
sulindac 150 mg tab, 200 mg tab
|
1
|
Preferred
|
CLINORIL
|
|
meloxicam7.5 mg tab, 15 mg tab
|
1
|
Preferred
|
MOBIC
|
QL=15 días No refills
|
indomethacin 25 mg cap, 50 mg cap
|
1
|
Non-Preferred
|
INDOCIN
|
|
Opioid Analgesics, Long-Acting [Analgésicos Opiodes, Larga Duración]
|
||||
fentanyl 25 mcg/hr td patch
72 hr
|
2
|
Preferred
|
DURAGESIC
|
|
oxycodone hcl 10 mg tab
|
2
|
Preferred
|
DAZIDOX
|
QL=15 días No refills
|
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr
|
3
|
Preferred
|
DURAGESIC
|
|
morphine sulfate er 15 mg tab er
|
3
|
Preferred
|
MORPHINE
|
|
oxycodone hcl 20 mg tab
|
3
|
Preferred
|
DAZIDOX
|
QL=15 días No refills
|
fentanyl 100 mcg/hr td patch 72 hr
|
4
|
Preferred
|
DURAGESIC
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/ Límites]
|
morphine sulfate er 30 mg tab er
|
4
|
Preferred
|
MORPHINE
|
|
morphine sulfate er 60 mg tab er
|
5
|
Preferred
|
MORPHINE
|
|
morphine sulfate er 100 mg tab er
|
6
|
Preferred
|
MORPHINE
|
|
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
|
||||
acetaminophen
-codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=15 días No refills
|
acetaminophen-codeine #2 300-15 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=15 días No refills
|
acetaminophen-codeine #3 300-30 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=15 días No refills
|
acetaminophen-codeine #4 300-60 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=15 días No refills
|
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln
|
1
|
Preferred
|
VICODIN
|
QL=15 días No refills
|
hydromorphone hcl 2 mg tab, 4 mg tab
|
1
|
Preferred
|
DILAUDID
|
|
meperidine hcl 50 mg/ml inj soln
|
1
|
Preferred
|
DEMEROL
|
|
morphine sulfate 15 mg tab, 30 mg tab
|
1
|
Preferred
|
MORPHINE
|
|
oxycodone-acetaminophen 5-325 mg tab
|
1
|
Preferred
|
PERCOCET
|
QL=15 días No refills
|
tramadol hcl 50 mg tab
|
1
|
Preferred
|
ULTRAM
|
|
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab
|
2
|
Preferred
|
CODEINE
|
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
|
2
|
Preferred
|
BIAXIN
|
|
clarithromycin 250 mg/5ml susp
|
3
|
Preferred
|
BIAXIN
|
|
ERY-TAB 500 mg tab dr
|
3
|
Preferred
|
||
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
|
3
|
Preferred
|
ERY-TAB
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
erythromycin ethylsuccinate 400 mg tab
|
3
|
Preferred
|
E.E.S.
|
|
ERYTHROCIN STEARATE 250 mg tab
|
4
|
Non-Preferred
|
||
E.E.S. GRANULES 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 200 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 400 400 mg/5ml susp
|
6
|
Preferred
|
||
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp,
200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
amoxicillin-pot clavulanate, 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
|
BICILLIN L-A 600000 unit/ml im susp
|
3
|
Non-Preferred
|
||
penicillin g procaine 600000 unit/ml im susp
|
3
|
Non-Preferred
|
BICILLIN LA
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
BICILLIN L-A 1200000 unit/2ml im susp
|
4
|
Non-Preferred
|
||
BICILLIN L-A 2400000 unit/4ml im susp
|
5
|
Non-Preferred
|
||
Quinolones [Quinolonas]
|
||||
ciprofloxacin hcl 250 mg tab,
500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
|
Sulfonamides [Sulfonamidas]
|
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfadiazine 500 mg tab
|
4
|
Preferred
|
SULFADIAZINE
|
|
ANTICONVULSANTS [ANTICONVULSIVANTES]
|
||||
Anticonvulsants [Anticonvulsivantes
|
||||
gabapentin 100 mg cap, 300
mg cap, 400 mg cap, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
NEURONTIN
|
|
DILANTIN 30 mg cap
|
2
|
Preferred
|
||
gabapentin 250 mg/5ml soln
|
2
|
Preferred
|
NEURONTIN
|
|
phenytoin 125 mg/5ml susp, 50 mg tab chew
|
2
|
Preferred
|
DILANTIN
|
|
phenytoin sodium extended 100 mg cap
|
2
|
Preferred
|
DILANTIN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ANTIEMETICS [ANTIEMÉTICOS]
|
||||
5-Hydroxytryptamine 3 (5-HT3) Antagonists [Antagonistas De 5-HT3]
|
||||
ondansetron 4 mg odt, 8 mg
odt
|
1
|
Preferred
|
ZOFRAN ODT
|
|
ondansetron hcl 24 mg tab, 4 mg tab, 8 mg tab
|
1
|
Preferred
|
ZOFRAN
|
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
|
promethazine hcl 25 mg/ml inj soln, 50 mg/ml inj soln
|
1
|
Preferred
|
PHENERGAN
|
|
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
|
1
|
Preferred
|
PHENERGAN
|
|
trimethobenzamide hcl 300 mg cap
|
1
|
Preferred
|
TIGAN
|
|
Phenothiazines [Fenotiazinas]
|
||||
prochlorperazine edisylate 5
mg/ml inj soln
|
1
|
Preferred
|
COMPAZINE
|
|
prochlorperazine maleate 10 mg tab, 5 mg tab
|
1
|
Preferred
|
COMPAZINE
|
|
prochlorperazine 25 mg rect supp
|
4
|
Non-Preferred
|
COMPAZINE
|
|
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
|
||||
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
|
||||
dapsone 100 mg tab, 25 mg
tab
|
2
|
Preferred
|
DAPSONE
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Cost
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
|
6
|
Preferred
|
PA, P
|
|
PROCRIT 10000 unit/ml inj soln
|
6
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln
|
7
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
|
8
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
|
9
|
Preferred
|
PA, P
|
|
PROCRIT 20000 unit/ml inj soln
|
9
|
Preferred
|
PA, P
|
|
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
PROCRIT 40000 unit/ml inj soln
|
11
|
Preferred
|
PA, P
|
|
Folates [Folatos] | ||||
folic acid 1 mg tab, 400 mcg
tab, 800 mcg tab
|
1
|
Preferred
|
FOLIC ACID
|
OTC
|
Iron [Hierro] | ||||
iron 325 (65 fe) mg tab
|
1
|
Preferred
|
IRON
|
|
DEXFERRUM 50 mg/ml inj soln
|
5
|
Non-Preferred
|
||
INFED 50 mg/ml inj soln
|
5
|
Preferred
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
CHEMOTHERAPIES [QUIMIOTERAPIAS] | ||||
Alkylating Agents [Agentes Alquilantes] | ||||
lomustine 10 mg cap
|
3
|
Non-Preferred
|
CEENU
|
|
ALKERAN 2 mg tab
|
4
|
Non-Preferred
|
||
temozolomide 5 mg cap
|
4
|
Non-Preferred
|
TEMODAR
|
PA
|
lomustine 40 mg cap
|
5
|
Non-Preferred
|
CEENU
|
|
LEUKERAN 2 mg tab
|
6
|
Non-Preferred
|
||
lomustine 100 mg cap
|
6
|
Non-Preferred
|
CEENU
|
|
MYLERAN 2 mg tab
|
7
|
Preferred
|
||
temozolomide 20 mg cap
|
9
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 250 mg cap
|
11
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 140 mg cap
|
13
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 100 mg cap, 180 mg cap
|
14
|
Non-Preferred
|
TEMODAR
|
PA
|
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
|
||||
STIVARGA 40 mg tab
|
21
|
Preferred
|
PA, P
|
|
Antiandrogens [Antiandrógenos]
|
||||
bicalutamide 50 mg tab
|
2
|
Preferred
|
CASODEX
|
|
flutamide 125 mg cap
|
4
|
Non-Preferred
|
EULEXIN
|
PA
|
Antiestrogens [Antiestrógenos]
|
||||
tamoxifen citrate 10 mg tab,
20 mg tab
|
1
|
Preferred
|
NOLVADEX
|
|
Antimetabolites [Antimetabolitos]
|
||||
hydroxyurea 500 mg cap
|
2
|
Preferred
|
HYDREA
|
|
mercaptopurine 50 mg tab
|
2
|
Preferred
|
PURINETHOL
|
|
methotrexate 2.5 mg tab
|
2
|
Preferred
|
METHOTREXATE
|
|
capecitabine 150 mg tab
|
7
|
Preferred
|
XELODA
|
PA
|
capecitabine 500 mg tab
|
11
|
Preferred
|
XELODA
|
PA
|
Antineoplastic Enzyme Inhibitors [Antineoplásicos Inhibidores De Enzimas]
|
||||
SPRYCEL 20 mg tab
|
10
|
Preferred
|
PA, P
|
|
SPRYCEL 50 mg tab
|
13
|
Preferred
|
PA, P
|
|
imatinib
100 mg tab
|
13
|
Non-Preferred
|
GLEEVEC
|
PA
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
SPRYCEL 70 mg tab
|
14
|
Preferred
|
PA, P
|
|
TASIGNA 200 mg cap
|
15
|
Preferred
|
PA, P
|
|
SPRYCEL 80 mg tab
|
17
|
Preferred
|
PA, P
|
|
TASIGNA 150 mg cap
|
18
|
Preferred
|
PA, P
|
|
SPRYCEL 100 mg tab
|
19
|
Preferred
|
PA, P
|
|
AFINITOR 2.5 mg tab
|
20
|
Preferred
|
PA, P
|
|
NEXAVAR 200 mg tab
|
20
|
Preferred
|
PA, P
|
|
SPRYCEL 140 mg tab
|
20
|
Preferred
|
PA, P
|
|
AFINITOR 10 mg tab, 5 mg tab, 7.5 mg tab
|
21
|
Preferred
|
PA, P
|
|
imatinib 400 mg tab
|
23
|
Non-Preferred
|
GLEEVEC
|
PA
|
Antineoplastic Progestins [Antineoplásicos De Progestina]
|
||||
megestrol acetate 20 mg
tab, 40 mg tab
|
1
|
Preferred
|
MEGACE
|
|
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp
|
2
|
Preferred
|
MEGACE
|
|
Aromatase Inhibitors [Inhibidores De La Aromatasa]
|
||||
anastrozole 1 mg tab
|
1
|
Preferred
|
ARIMIDEX
|
|
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
|
||||
leucovorin calcium 5 mg tab
|
3
|
Preferred
|
LEUCOVORIN
|
|
leucovorin calcium 10 mg tab, 15 mg tab
|
4
|
Preferred
|
LEUCOVORIN
|
leucovorin calcium 25 mg tab
|
9
|
Preferred
|
LEUCOVORIN
|
Luteinizing Hormone-Releasing (Lhrh) Analogs [Análogos De Lhrh]
|
||||
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit
|
6
|
Preferred
|
PA, P
|
|
LUPRON DEPOT-PED 11.25 mg im kit, 15 mg im kit, 7.5 mg im kit
|
8
|
Preferred
|
PA, P
|
|
LUPRON DEPOT 22.5 mg im kit, 30 mg im kit
|
9
|
Preferred
|
PA, P
|
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
|
||||
Dermatological Skin Cancer Agents [Dermatológicos Para Cáncer De La Piel]
|
||||
fluorouracil 2 % soln, 5 %
soln
|
3
|
Preferred
|
EFUDEX
|
|
fluorouracil 5 % crm
|
4
|
Non-Preferred
|
EFUDEX
|
|
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
|
||||
Anti-Ulcer Agents [Agentes Anti-Ulceras]
|
||||
misoprostol 100 mcg tab,
200 mcg tab
|
1
|
Preferred
|
CYTOTEC
|
|
sucralfate 1 gm tab
|
1
|
Preferred
|
CARAFATE
|
|
CARAFATE 1 gm/10ml susp
|
3
|
Non-Preferred
|
||
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
|
||||
famotidine
20 mg tab, 40 mg tab
|
1
|
Preferred
|
PEPCID
|
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
|
||||
Cyclosporine Analogs [Análogos De Ciclosporina]
|
||||
NEORAL
25 mg cap
|
3
|
Preferred
|
PA, P
|
|
cyclosporine modified 25 mg cap, 50 mg cap
|
3
|
Preferred
|
NEORAL
|
PA
|
cyclosporine 25 mg cap
|
4
|
Preferred
|
SANDIMMUNE
|
PA
|
cyclosporine modified 100 mg cap, 100 mg/ml soln
|
4
|
Preferred
|
NEORAL
|
PA
|
cyclosporine 100 mg cap
|
5
|
Preferred
|
SANDIMMUNE
|
PA
|
NEORAL 100 mg cap
|
5
|
Preferred
|
PA, P
|
|
cyclosporine 100 mg cap, 25 mg cap
|
6
|
Preferred
|
SANDIMMUNE
|
PA
|
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap
|
6
|
Preferred
|
PA, P
|
|
NEORAL 100 mg/ml soln
|
7
|
Preferred
|
PA, P
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Glucocorticosteroids [Glucocorticoides]
|
||||
dexamethasone 0.5 mg tab,
0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
|
1
|
Preferred
|
DECADRON
|
|
MEDROL 2 mg tab
|
1
|
Preferred
|
||
methylprednisolone 32 mg tab, 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
methylprednisolone (pak) 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
|
1
|
Preferred
|
PRELONE
|
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
prednisone (pak) 10 mg tab, 5 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
|
2
|
Preferred
|
CORTEF
|
|
methylprednisolone 16 mg tab, 8 mg tab
|
2
|
Preferred
|
MEDROL
|
|
Organ Transplant Agents [Agentes Para Trasplantes]
|
||||
azathioprine 50 mg tab
|
1
|
Preferred
|
IMURAN
|
|
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab
|
2
|
Preferred
|
CELLCEPT
|
PA
|
tacrolimus 0.5 mg cap
|
3
|
Non-Preferred
|
PROGRAF
|
PA
|
MYFORTIC
180 mg tab dr
|
4
|
Preferred
|
PA, P
|
|
tacrolimus 1 mg cap
|
4
|
Non-Preferred
|
PROGRAF
|
PA
|
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
|
5
|
Non-Preferred
|
RAPAMUNE
|
PA
|
MYFORTIC
360 mg tab dr
|
6
|
Preferred
|
PA, P
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
tacrolimus 5 mg cap
|
6
|
Non-Preferred
|
PROGRAF
|
PA
|
RAPAMUNE 1 mg/ml soln
|
8
|
Non-Preferred
|
PA
|
|
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
|
||||
Calcium Regulating Agents [Agentes Reguladores De Calcio]
|
||||
calcitriol
0.25 mcg cap
|
1
|
Preferred
|
ROCALTROL
|
|
calcitriol 0.5 mcg cap
|
2
|
Preferred
|
ROCALTROL
|
Revisado: 5 de mayo de 2017
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
E.E.S. GRANULES 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 200 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 400 400 mg/5ml susp
|
6
|
Preferred
|
||
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg cap,
300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
|
MACRODANTIN 25 mg cap
|
1
|
Preferred
|
||
metronidazole 250 mg tab, 500 mg tab
|
1
|
Preferred
|
FLAGYL
|
|
nitrofurantoin macrocrystal 50 mg cap
|
1
|
Preferred
|
MACRODANTIN
|
|
nitrofurantoin macrocrystal 100 mg cap
|
2
|
Preferred
|
MACRODANTIN
|
|
nitrofurantoin monohyd macro 100 mg cap
|
2
|
Preferred
|
MACROBID
|
|
nitrofurantoin oral
suspension 25 MG/5ML
|
6
|
Non-Preferred
|
FURADANTIN
|
|
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp
, 200 mg/5ml susp, 250 mg cap, , 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
|
BICILLIN L-A 600000 unit/ml im susp
|
3
|
Non-Preferred
|
||
penicillin g procaine 600000 unit/ml im susp
|
3
|
Non-Preferred
|
BICILLIN LA
|
|
BICILLIN L-A 1200000 unit/2ml im susp
|
4
|
Non-Preferred
|
||
BICILLIN L-A 2400000 unit/4ml im susp
|
5
|
Non-Preferred
|
||
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
|
||||
cefaclor 250 mg cap, 500
mg cap
|
2
|
Preferred
|
CECLOR
|
|
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
|
2
|
Preferred
|
CEFZIL
|
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
|
||||
cefdinir 125 mg/5ml susp,
300 mg cap
|
2
|
Preferred
|
OMNICEF
|
|
cefdinir 250 mg/5ml susp
|
3
|
Preferred
|
OMNICEF
|
|
Vaginal Antibiotics [Antibióticos Vaginales]
|
||||
metronidazole 0.75 % vag
gel
|
2
|
Preferred
|
VANDAZOLE
|
Rapid-Acting Insulins [Insulinas De Rápida Duración]
|
||||
HUMALOG 100 unit/ml sc
soln
|
4
|
Preferred
|
P
|
|
Short-Acting Insulins [Insulinas De Corta Duración]
|
||||
HUMULIN R 100 unit/ml inj
soln
|
2
|
Preferred
|
P
|
|
ANTIEMETICS [ANTIEMÉTICOS]
|
||||
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
|
trimethobenzamide hcl 300 mg cap
|
1
|
Preferred
|
TIGAN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Phenothiazines [Fenotiazinas]
|
||||
prochlorperazine edisylate 5
mg/ml inj soln
|
1
|
Preferred
|
COMPAZINE
|
|
prochlorperazine maleate 10 mg tab, 5 mg tab
|
1
|
Preferred
|
COMPAZINE
|
|
prochlorperazine 25 mg rect supp
|
4
|
Non-Preferred
|
COMPAZINE
|
|
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
|
||||
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
|
||||
methyldopa 250 mg tab, 500
mg tab
|
1
|
Preferred
|
ALDOMET
|
|
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
|
||||
atenolol 100 mg tab, 25
mg tab, 50 mg tab
|
1
|
Preferred
|
TENORMIN
|
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
|
1
|
Preferred
|
LOPRESSOR
|
|
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
LOPRESSOR
|
|
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
|
2
|
Preferred
|
LOPRESSOR
|
|
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
|
||||
atenolol
-chlorthalidone 10025 mg tab, 50-25 mg tab
|
1
|
Preferred
|
TENORETIC
|
|
metoprolol-hydrochlorothiazide 50-25 mg tab
|
2
|
Non-Preferred
|
LOPRESSOR HCT
|
|
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab
|
3
|
Non-Preferred
|
LOPRESSOR HCT
|
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
|
||||
Antituberculars [Antituberculosos]
|
||||
isoniazid 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ISONIAZID
|
|
rifampin 150 mg cap
|
1
|
Preferred
|
RIFADIN
|
|
ethambutol hcl 100 mg tab
|
2
|
Non-Preferred
|
MYAMBUTOL
|
|
rifampin 300 mg cap
|
2
|
Preferred
|
RIFADIN
|
|
ethambutol hcl 400 mg tab
|
3
|
Non-Preferred
|
MYAMBUTOL
|
|
isoniazid 50 mg/5ml syr
|
5
|
Non-Preferred
|
ISONIAZID
|
|
rifabutin 150 mg cap
|
6
|
Preferred
|
MYCOBUTIN
|
Puerto Rico Health
Department
Tuberculosis
Control Program
|
RIFAMATE 50-300 mg cap
|
||||
TRECATOR 250 mg tab
|
||||
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
|
||||
dapsone 100 mg tab, 25 mg
tab
|
2
|
Preferred
|
DAPSONE
|
|
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
|
||||
Vaginal Antifungals [Antifungales Vaginales]
|
||||
terconazole 0.4 % vag crm, 0.8 % vag crm
|
2
|
Preferred
|
TERAZOL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
|
||||
Glucocorticosteroids [Glucocorticoides]
|
||||
dexamethasone 0.5 mg tab,
0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
|
1
|
Preferred
|
DECADRON
|
|
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln
|
1
|
Preferred
|
DECADRON
|
|
KENALOG 10 mg/ml inj susp
|
1
|
Non-Preferred
|
||
MEDROL 2 mg tab
|
1
|
Preferred
|
||
methylprednisolone 32 mg tab, 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
methylprednisolone (pak) 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
|
1
|
Preferred
|
PRELONE
|
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
prednisone (pak) 10 mg tab, 5 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
|
2
|
Preferred
|
CORTEF
|
|
methylprednisolone 16 mg tab, 8 mg tab
|
2
|
Preferred
|
MEDROL
|
|
KENALOG 40 mg/ml inj susp
|
5
|
Non-Preferred
|
||
Immune Globulins [Immunoglobulinas]
|
||||
RHOGAM ultra-filtered plus im soln 1500 unit
|
4
|
Preferred
|
ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 25050 mcg/dose inh aer pwdr
|
4
|
Preferred
|
QL = 1 pompa / 30 días, ST, P
|
|
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer
|
4
|
Preferred
|
QL = 1 pompa / 30 días, ST, P
|
|
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,
|
4
|
Non-Preferred
|
PULMICORT
|
AL ≤ 12 años
|
budesonide 1mg/2ml inh susp
|
8
|
Non-Preferred
|
PULMICORT
|
AL ≤ 12 años
|
FLOVENT HFA 220 mcg/act inh aer
|
4
|
Preferred
|
QL = 1 pompa / 30 días, P
|
|
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr
|
5
|
Preferred
|
QL = 1 pompa / 30 días, ST, P
|
|
ADVAIR HFA 230-21 mcg/act inh aer
|
5
|
Preferred
|
QL = 1 pompa / 30 días, ST, P
|
|
Nonsedating Histamine1 Blocking Agents [Bloqueadores De Histamina1 No-Sedantes]
|
||||
loratadine 10 mg tab
|
1
|
Preferred
|
CLARITIN
|
OTC
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
|
||||
promethazine hcl 12.5 mg
tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
|
1
|
Preferred
|
PHENERGAN
|
|
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
|
||||
albuterol sulfate (2.5
mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln
|
1
|
Preferred
|
ALBUTEROL
|
|
terbutaline sulfate 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
BRETHINE
|
VENTOLIN HFA 108 (90 base) mcg/act inh aer
|
1
|
Preferred
|
QL = 1 pompa / 30 días, P
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANALGESICS [ANA
LGÉSICOS]
|
||||
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
|
||||
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL=15 días No refills
|
indomethacin 25 mg cap, 50 mg cap
|
1
|
Non-Preferred
|
INDOCIN
|
|
nabumetone 500 mg tab, 750 mg tab
|
1
|
Preferred
|
RELAFEN
|
|
naproxen 250 mg tab, 375 mg tab, 500 mg tab
|
1
|
Preferred
|
NAPROSYN
|
QL=15 días No refills
|
naproxen dr 375 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
NAPROSYN
|
QL=15 días No refills
|
salsalate 500 mg tab, 750 mg tab
|
1
|
Preferred
|
DISALCID
|
|
sulindac 150 mg tab, 200 mg tab
|
1
|
Preferred
|
CLINORIL
|
|
meloxicam7.5 mg tab, 15 mg tab
|
1
|
Preferred
|
MOBIC
|
QL=15 días No refills
|
Long-Acting Opioid Analgesics [Analgésicos Opiodes de Larga Duración]
|
||||
fentanyl 25 mcg/hr td patch
72 hr
|
2
|
Preferred
|
DURAGESIC
|
|
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr
|
3
|
Preferred
|
DURAGESIC
|
|
morphine sulfate er 15 mg tab er
|
3
|
Preferred
|
MORPHINE
|
|
fentanyl 100 mcg/hr td patch 72 hr
|
4
|
Preferred
|
DURAGESIC
|
|
morphine sulfate er 30 mg tab er
|
4
|
Preferred
|
MORPHINE
|
|
morphine sulfate er 60 mg tab er
|
5
|
Preferred
|
MORPHINE
|
|
morphine sulfate er 100 mg tab er
|
6
|
Preferred
|
MORPHINE
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
methadone hcl oral tablet 10 mg
|
Preferred
|
METHADONE
|
ASSMCA
|
|
methadone hcl oral solution 10 mg/ 5ml
|
Preferred
|
METHADONE
|
ASSMCA
|
|
Short-Acting Opioid Analgesics [Analgésicos Opiodes de Corta Duración]
|
||||
test
|
||||
acetaminophen-codeine 120-12 mg/5ml soln, 30015 mg tab, 300-30 mg tab,
300-60 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=15 días No refills
|
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln
|
1
|
Preferred
|
VICODIN
|
QL=15 días No refills
|
hydromorphone hcl 2 mg tab, 4 mg tab
|
1
|
Preferred
|
DILAUDID
|
|
meperidine hcl 50 mg/ml inj soln
|
1
|
Preferred
|
DEMEROL
|
|
morphine sulfate 15 mg tab, 30 mg tab
|
1
|
Preferred
|
MORPHINE
|
|
oxycodone-acetaminophen 5-325 mg tab
|
1
|
Preferred
|
OXYCODONE APAP
|
QL=15 días No refills
|
tramadol hcl 50 mg tab
|
1
|
Preferred
|
ULTRAM
|
|
butalbital-apap-caffeine 50325-40 mg cap, 50-325-40 mg tab
|
2
|
Preferred
|
FIORICET
|
QL=15 días No refills
|
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab
|
2
|
Preferred
|
CODEINE
|
|
meperidine hcl 100 mg/ml inj soln
|
2
|
Preferred
|
DEMEROL
|
|
morphine sulfate 10 mg/5ml soln
|
2
|
Preferred
|
MORPHINE
|
|
morphine sulfate (concentrate) 100 mg/5ml soln, 20 mg/ml soln
|
2
|
Preferred
|
MORPHINE
|
|
hydromorphone hcl 8 mg tab
|
3
|
Preferred
|
DILAUDID
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
|
hydroxyzine pamoate 100
mg cap, 25 mg cap, 50 mg cap
|
1
|
Preferred
|
VISTARIL
|
|
ANTIBACTERIALS [ANTIBACTERIANOS]
|
||||
Aminoglycosides [Aminoglucósidos]
|
||||
tobramycin 300 mg/5ml inh neb soln
|
18
|
Non-Preferred
|
TOBI
|
PA
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
First Generation Cephalosporins [Cefalosporinas de Primera Generación]
|
||||
cephalexin 125 mg/5ml
susp, 250 mg cap, 500 mg cap
|
1
|
Preferred
|
KEFLEX
|
|
cefadroxil 250 mg/5ml susp
|
2
|
Non-Preferred
|
DURICEF
|
AL ≤ 12 años
|
cephalexin 250 mg/5ml susp
|
2
|
Preferred
|
KEFLEX
|
|
cefadroxil 500 mg/5ml susp
|
3
|
Non-Preferred
|
DURICEF
|
AL ≤ 12 años
|
Macrolides [Macrólidos]
|
||||
azithromycin 250 mg tab,
500 mg tab
|
1
|
Preferred
|
ZITHROMAX
|
|
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
|
2
|
Preferred
|
ZITHROMAX
|
|
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
|
2
|
Preferred
|
BIAXIN
|
SALUD FÍSICA
|
|
clarithromycin 250 mg/5ml susp
|
3
|
Preferred
|
BIAXIN
|
|
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
|
3
|
Preferred
|
ERY-TAB
|
|
erythromycin ethylsuccinate 400 mg tab
|
3
|
Preferred
|
E.E.S.
|
|
ERYTHROCIN STEARATE 250 mg tab
|
4
|
Non-Preferred
|
||
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg
cap, 300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
|
MACRODANTIN 25 mg cap
|
1
|
Preferred
|
||
metronidazole 250 mg tab, 500 mg tab
|
1
|
Preferred
|
FLAGYL
|
|
nitrofurantoin macrocrystal 50 mg cap
|
1
|
Preferred
|
MACRODANTIN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
nitrofurantoin macrocrystal 100 mg cap
|
2
|
Preferred
|
MACRODANTIN
|
|
nitrofurantoin monohyd macro 100 mg cap
|
2
|
Preferred
|
MACROBID
|
|
nitrofurantoin oral suspension 25 MG/5ML
|
6
|
Non-Preferred
|
FURADANTIN
|
|
vancomycin hcl 125 mg cap
|
9
|
Non-Preferred
|
VANCOCIN
|
|
vancomycin hcl 250 mg cap
|
10
|
Non-Preferred
|
VANCOCIN
|
SALUD FÍSICA
|
|
Penincillinis [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 400-57 mg/5ml susp, 500125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
|
BICILLIN L-A 600000 unit/ml im susp
|
3
|
Non-Preferred
|
||
penicillin g procaine 600000 unit/ml im susp
|
3
|
Non-Preferred
|
BICILLIN LA
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
BICILLIN L-A 1200000 unit/2ml im susp
|
4
|
Non-Preferred
|
||
BICILLIN L-A 2400000 unit/4ml im susp
|
5
|
Non-Preferred
|
||
Quinolones [Quinolonas]
|
||||
ciprofloxacin hcl 250 mg
tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
SALUD FÍSICA
|
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
|
Second Generation Cephalosporins [Cefalosporinas de Segunda Generación]
|
||||
cefaclor 250 mg cap, 500
mg cap
|
2
|
Preferred
|
CECLOR
|
|
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
|
2
|
Preferred
|
CEFZIL
|
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
|
sulfadiazine 500 mg tab
|
4
|
Preferred
|
SULFADIAZINE
|
|
Tetracyclines [Tetraciclinas]
|
||||
minocycline hcl 100 mg
cap, 50 mg cap, 75 mg cap
|
1
|
Preferred
|
MINOCIN
|
|
doxycycline monohydrate 50 mg cap, 100 mg cap
|
2
|
Non-Preferred
|
MONODOX
|
|
Third Generation Cephalosporins [Cefalosporinas de Tercera Generación]
|
||||
cefdinir 125 mg/5ml susp,
300 mg cap
|
2
|
Preferred
|
OMNICEF
|
|
cefdinir 250 mg/5ml susp
|
3
|
Preferred
|
OMNICEF
|
Drug Name
[Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Vaginal Antibiotics [Antibióticos Vaginales]
|
||||
metronidazole 0.75 % vag
gel
|
2
|
Preferred
|
VANDAZOLE
|
clindamycin phosphate 2 % vag crm
|
3
|
Non-Preferred
|
CLEOCIN
|
SALUD FÍSICA
|
|
ANTICONVULSANTS [ANTICONVULSIVANTES]
|
||||
Anticonvulsants [Anticonvulsivantes]
|
||||
carbamazepine 100 mg tab
chew, 200 mg tab
|
1
|
Preferred
|
TEGRETOL
|
|
clonazepam 0.5 mg tab, 1 mg tab, 2 mg tab
|
1
|
Preferred
|
KLONOPIN
|
|
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
DEPAKOTE
|
|
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
NEURONTIN
|
|
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
|
1
|
Preferred
|
LAMICTAL
|
|
lamotrigine chew tab 5 mg, 25 mg
|
3
|
Non-Preferred
|
LAMICTAL
|
|
levetiracetam 250 mg tab, 500 mg tab
|
1
|
Preferred
|
KEPPRA
|
|
levetiracetam er 24 hrs 500 mg tab, 750 mg
|
3
|
Non-Preferred
|
KEPPRA XR
|
|
oxcarbazepine 150 mg tab
|
1
|
Preferred
|
TRILEPTAL
|
|
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
|
1
|
Preferred
|
PHENOBARBITAL
|
|
primidone 250 mg tab, 50 mg tab
|
1
|
Preferred
|
MYSOLINE
|
|
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
TOPAMAX
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
valproic acid 250 mg cap, 250 mg/5ml syr
|
1
|
Preferred
|
DEPAKENE
|
|
zonisamide 50 mg cap
|
1
|
Preferred
|
ZONEGRAN
|
|
DILANTIN 30 mg cap
|
2
|
Preferred
|
||
gabapentin 250 mg/5ml soln
|
2
|
Preferred
|
NEURONTIN
|
|
levetiracetam 100 mg/ml soln, 1000 mg tab, 750 mg tab
|
2
|
Preferred
|
KEPPRA
|
|
oxcarbazepine 300 mg tab, 600 mg tab
|
2
|
Preferred
|
TRILEPTAL
|
|
phenytoin 125 mg/5ml susp, 50 mg tab chew
|
2
|
Preferred
|
DILANTIN
|
|
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
|
2
|
Preferred
|
DILANTIN
|
|
zonisamide 100 mg cap, 25 mg cap
|
2
|
Preferred
|
ZONEGRAN
|
|
carbamazepine er 200 mg tab er 12 hr
|
3
|
Preferred
|
TEGRETOL
|
|
ethosuximide 250 mg cap, 250 mg/5ml soln
|
3
|
Preferred
|
ZARONTIN
|
|
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
|
3
|
Preferred
|
PHENOBARBITAL
|
|
carbamazepine 100 mg/5ml susp
|
4
|
Preferred
|
TEGRETOL
|
|
carbamazepine er 400 mg tab er 12 hr
|
4
|
Preferred
|
TEGRETOL
|
|
oxcarbazepine 300 mg/5ml susp
|
4
|
Preferred
|
TRILEPTAL
|
|
VIMPAT 10 mg/ml soln,100 mg tab, 150 mg tab,50 mg tab
|
5
|
Preferred
|
PA, C
|
|
VIMPAT 200 mg tab, 200 mg/20ml iv soln
|
6
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Intermediate-Acting Insulins [Insulinas de Duración Intermedia]
|
||||
HUMULIN N
100 unit/ml sc susp
|
2
|
Preferred
|
C
|
|
Long-Acting Insulins [Insulinas de Larga Duración]
|
||||
LANTUS SOLOSTAR 100
unit/ml subcutaneous solution pen-injector
|
2
|
Preferred
|
C
|
SALUD FÍSICA
|
|
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
|
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr, 25 mg/ml inj soln, 50 mg/ml inj soln
|
1
|
Preferred
|
PHENERGAN
|
|
trimethobenzamide hcl 300 mg cap
|
1
|
Preferred
|
TIGAN
|
|
Phenothiazines [Fenotiazinas]
|
||||
prochlorperazine edisylate
5 mg/ml inj soln
|
1
|
Preferred
|
COMPAZINE
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
prochlorperazine maleate 10 mg tab, 5 mg tab
|
1
|
Preferred
|
COMPAZINE
|
|
prochlorperazine 25 mg rect supp
|
4
|
Non-Preferred
|
COMPAZINE
|
|
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
|
||||
Antigout Agents [Agentes Antigota]
|
||||
allopurinol 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ZYLOPRIM
|
|
colchicine 0.6 mg cap
|
3
|
Preferred
|
MITIGARE
|
PA
|
colchicine 0.6 mg tab
|
3
|
Non-Preferred
|
COLCRYS
|
QL= 3 tab, 15días
|
Uricosurics [Uricosúricos]
|
||||
probenecid 500 mg tab
|
1
|
Preferred
|
BENEMID
|
|
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
|
||||
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
|
||||
clonidine hcl 0.1 mg tab, 0.2 mg tab, 0.3 mg tab
|
1
|
Preferred
|
CATAPRESS
|
SALUD FÍSICA
|
|
methyldopa 250 mg tab, 500 mg tab
|
1
|
Preferred
|
ALDOMET
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
lisinopril-hydrochlorothiazide 1012.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
|
1
|
Preferred
|
ZESTORETIC
|
|
Calcium Channel Blocking Agents [Bloqueadores de Canales de Calcio]
|
||||
amlodipine besylate 10 mg
tab, 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
NORVASC
|
|
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
|
1
|
Preferred
|
CARDIZEM
|
|
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
DILACOR XR
|
SALUD FÍSICA
|
|
diltiazem hcl er beads 120 mg cap er 24 hr
|
1
|
Preferred
|
TIAZAC
|
|
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
CARDIZEM CD
|
|
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr
|
1
|
Preferred
|
DILACOR XR
|
|
nifedipine er osmotic 30 mg tab er 24 hr
|
1
|
Preferred
|
PROCARDIA XL
|
|
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
|
1
|
Preferred
|
CALAN
|
|
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er
|
1
|
Preferred
|
CALAN SR
|
|
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg er 24 hr
|
2
|
Preferred
|
TIAZAC
|
|
diltiazem hcl er coated beads 300 mg cap er 24 hr
|
2
|
Preferred
|
CARDIZEM CD
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr
|
2
|
Preferred
|
PROCARDIA XL
|
|
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores de Anhidrasa Carbónica]
|
||||
acetazolamide 125 mg tab,
250 mg tab
|
3
|
Preferred
|
DIAMOX
|
|
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
|
||||
atenolol 100 mg tab, 25 mg
tab, 50 mg tab
|
1
|
Preferred
|
TENORMIN
|
|
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
|
1
|
Preferred
|
TOPROL XL
|
SALUD FÍSICA
|
|
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
LOPRESSOR
|
|
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr
|
2
|
Non-Preferred
|
TOPROL XL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
|
||||
propranolol hcl 10 mg tab,
20 mg tab, 20 mg/5ml soln,
40 mg tab, 40 mg/5ml soln,
80 mg tab
|
1
|
Preferred
|
INDERAL
|
|
propranolol hcl 60 mg tab
|
2
|
Non-Preferred
|
INDERAL
|
|
Potassium-Sparing Diuretics [Diuréticos Conservadores de Potasio]
|
||||
spironolactone 100 mg tab,
25 mg tab, 50 mg tab
|
1
|
Preferred
|
ALDACTONE
|
|
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab
|
1
|
Preferred
|
MAXZIDE
|
SALUD FÍSICA
|
|
Thiazide Diuretics [Diuréticos Tiazidas]
|
||||
chlorothiazide 250 mg tab,
500 mg tab
|
1
|
Preferred
|
DIURIL
|
|
chlorthalidone 25 mg tab, 50 mg tab
|
1
|
Non-Preferred
|
HYGROTON
|
|
DIURIL 250 mg/5ml susp
|
1
|
Preferred
|
||
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
MICROZIDE
|
|
indapamide 1.25 mg tab,2.5 mg tab
|
1
|
Preferred
|
LOZOL
|
|
metolazone 2.5 mg tab, 5 mg tab
|
1
|
Non-Preferred
|
ZAROXOLYN
|
|
chlorthalidone 100 mg tab
|
2
|
Non-Preferred
|
HYGROTON
|
|
metolazone 10 mg tab
|
2
|
Non-Preferred
|
ZAROXOLYN
|
|
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
|
||||
carvedilol 12.5 mg tab, 25
mg tab, 3.125 mg tab, 6.25 mg tab
|
1
|
Preferred
|
COREG
|
|
Vasodilators [Vasodilatadores]
|
||||
hydralazine hcl 10 mg tab,
100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
APRESOLINE
|
|
minoxidil 10 mg tab, 2.5 mg tab
|
1
|
Preferred
|
LONITEN
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /Límites]
|
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
|
||||
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
|
||||
divalproex sodium 125 mg
tab dr, 250 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
DEPAKOTE
|
SALUD FÍSICA
|
|
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
TOPAMAX
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
pramipexoledihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab,1.5 mg tab
|
1
|
Preferred
|
MIRAPEX
|
|
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab
|
1
|
Preferred
|
REQUIP
|
|
ropinirole hcl 2 mg tab
|
2
|
Preferred
|
REQUIP
|
|
amantadine hcl 100 mg cap
|
3
|
Preferred
|
SYMMETREL
|
|
bromocriptine mesylate 2.5 mg tab
|
3
|
Preferred
|
PARLODEL
|
|
carbidopa-levodopaentacapone 18.75-75-200 mg tab
|
4
|
Non-Preferred
|
STALEVO
|
|
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab,37.5-150-200 mg tab, 50200-200 mg tab
|
5
|
Non-Preferred
|
STALEVO
|
|
Dopamine Precursors [Precursores de Dopamina]
|
||||
carbidopa
-levodopa 10-
100 mg tab, 25-100 mg tab
|
1
|
Preferred
|
SINEMET
|
|
carbidopa-levodopa 25250 mg tab
|
2
|
Preferred
|
SINEMET
|
|
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er
|
2
|
Preferred
|
SINEMET CR
|
|
Monoamine Oxidase B (MAO-B) Inhibitors [Inhibidores de MAO-B]
|
||||
selegiline hcl 5 mg tab
|
3
|
Non-Preferred
|
CARBEX
|
SALUD FÍSICA
|
|
ANTIVIRALS [ANTIVIRALES]
|
||||
Anti-Influenza Agents [Age
ntes Anti-Infuenza]
|
||||
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg cap
|
4
|
Preferred
|
TAMIFLU
|
|
TAMIFLU 6 mg/ ml susp
|
13
|
Non-Preferred
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
INTELENCE
200 mg tab
|
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
|
|||
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos de la
Transcriptasa Reversa]
|
||||
zidovudine 300 mg tab
|
2
|
Non-Preferred
|
RETROVIR
|
|
stavudine 1 mg/ml soln, 15 mg cap, 20 mg cap, 30 mg cap, 40 mg cap
|
3
|
Preferred
|
ZERIT
|
|
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr
|
4
|
Non-Preferred
|
ZIAGEN
|
|
lamivudine
10 mg/ml soln
|
5
|
Preferred
|
EPIVIR
|
|
lamivudine 150 mg tab
|
4
|
Preferred
|
EPIVIR
|
|
zidovudine 100 mg cap, 50 mg/5ml syr
|
4
|
Non-Preferred
|
RETROVIR
|
|
abacavir sulfate 300 mg tab
|
5
|
Preferred
|
ZIAGEN
|
|
didanosine 400 mg cap dr
|
5
|
Non-Preferred
|
ZIAGEN
|
|
lamivudine 300 mg tab
|
5
|
Preferred
|
EPIVIR
|
|
VIDEX 2 gm soln
|
5
|
Non-Preferred
|
||
lamivudine 100 mg tab
|
6
|
Preferred
|
EPIVIR
|
PA
|
lamivudine-zidovudine 150-300 mg tab
|
6
|
Preferred
|
COMBIVIR
|
|
abacavir-lamivudinezidovudine 300-150-300 mg tab
|
10
|
Non-Preferred
|
TRIZIVIR
|
|
EMTRIVA 200 mg cap
|
CENTROS DE
PREVENCIÓN Y
TRATAMIENTO
- CLÍNICAS DE
IMMUNOLOGÍA
|
|||
VIREAD 300 mg tab
|
||||
TRUVADA 200-300 mg tab
|
TRUVADA
|
SALUD FÍSICA
|
|
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA
BENIGNA]
|
||||
5-Alpha Reductase Inhibitors [Inhibidores de 5-Alfa Reductasa]
|
||||
finasteride 5 mg tab
|
1
|
Preferred
|
PROSCAR
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
|
||||
tamsulosin hcl 0.4 mg cap
|
1
|
Preferred
|
FLOMAX
|
|
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap
|
1
|
Preferred
|
HYTRIN
|
|
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
|
||||
Anticoagulants [Anticoagulantes]
|
||||
warfarin sodium 1 mg tab,
10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab,
7.5 mg tab
|
1
|
Preferred
|
COUMADIN
|
|
heparin sodium (porcine) 1000 unit/ml inj soln
|
2
|
Preferred
|
HEPARIN
|
|
heparin sodium (porcine)10000 unit/ml inj soln,5000 unit/ml inj soln
|
3
|
Preferred
|
HEPARIN
|
|
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln
|
3
|
Preferred
|
HEPARIN
|
|
heparin sodium (porcine) 2000 unit/ml iv soln
|
8
|
Preferred
|
HEPARIN
|
SALUD FÍSICA
|
|
Cobalamins [Cobalaminas]
|
||||
cyanocobalamin 1000
mcg/ml inj soln
|
1
|
Preferred
|
VIT B-12
|
|
Colony Stimulating Factors [Estimulantes Mieloides]
|
||||
NEUPOGEN 300 mcg/0.5ml inj soln, 300 mcg/ml inj soln, 480 mcg/1.6ml inj soln
|
10
|
Preferred
|
PA, C
|
|
NEULASTA 6 mg/0.6ml sc soln
|
15
|
Preferred
|
PA, C
|
|
NEULASTA DELIVERYKIT6 mg/0.6ml sc soln
|
15
|
Preferred
|
PA, C
|
|
NEUPOGEN 480mcg/0.8ml inj soln
|
12
|
Preferred
|
PA, C
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Erythropoiesis-Stimulating Agents [Agentes Estimulantes de Eritropoiesis]
|
||||
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln
|
1
|
Preferred
|
PA, C
|
|
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln
|
6
|
Preferred
|
PA, C
|
|
ARANESP (ALBUMINFREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln
|
6
|
Preferred
|
PA, C
|
|
PROCRIT 10000 unit/ml inj soln
|
7
|
Preferred
|
PA, C
|
|
ARANESP (ALBUMINFREE) 40 mcg/0.4ml inj soln
|
7
|
Preferred
|
PA, C
|
|
ARANESP (ALBUMINFREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln
|
8
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
ARANESP (ALBUMINFREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln
|
9
|
Preferred
|
PA, C
|
|
PROCRIT 20000 unit/ml inj soln
|
9
|
Preferred
|
PA, C
|
|
ARANESP (ALBUMIN
FREE) 100 mcg/ml inj soln
|
11
|
Preferred
|
PA, C
|
|
PROCRIT 40000 unit/ml inj soln
|
10
|
Preferred
|
PA, C
|
|
Factor Xa Inhibitors [Inhibidores Del Factor Xa]
|
||||
ELIQUIS 2.5 mg tab
|
4
|
Preferred
|
PA, C
|
|
ELIQUIS 5 mg tab
|
4
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
enoxaparin sodium 100 mg/ml sc soln
|
9
|
Non-Preferred
|
LOVENOX
|
PA
|
enoxaparin sodium 120 mg/0.8ml sc soln
|
10
|
Non-Preferred
|
LOVENOX
|
PA
|
enoxaparin sodium 150 mg/ml sc soln
|
14
|
Non-Preferred
|
LOVENOX
|
PA
|
Platelet Modifying Agents [Modificadores de Plaquetas]
|
||||
aspirin 325 mg tab, 325 mg
tab dr, 81 mg tab dr
|
1
|
Preferred
|
ASPIRIN
|
OTC
|
aspirin low dose 81 mg tab, 81 mg tab dr
|
1
|
Preferred
|
ASPIRIN
|
OTC
|
cilostazol 100 mg tab, 50 mg tab
|
1
|
Preferred
|
PLETAL
|
|
clopidogrel bisulfate 75 mg tab
|
1
|
Preferred
|
PLAVIX
|
|
BONE DENSITY REGULATORS [REGULADORES DE DENSIDAD ÓSEA]
|
||||
Bisphosphonates [Bifosfonatos]
|
||||
alendronate sodium 10 mg
tab, 35 mg tab, 5 mg tab, 70 mg tab
|
1
|
Preferred
|
FOSAMAX
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
|
||||
Antiarrhythmics Class II [Antiarrítmicos Clase II]
|
||||
propranolol hcl 10 mg tab,
20 mg tab, 40 mg tab, 80 mg tab
|
1
|
Preferred
|
INDERAL
|
|
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab
|
1
|
Preferred
|
BETAPACE
|
|
propranolol hcl 60 mg tab
|
2
|
Preferred
|
INDERAL
|
|
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
|
||||
quinidine sulfate 200 mg
tab, 300 mg tab
|
1
|
Preferred
|
QUINIDINE SULFATE
|
|
quinidine gluconate er 324 mg tab er
|
2
|
Preferred
|
QUINAGLUTE
|
|
quinidine sulfate er 300 mg tab er
|
2
|
Preferred
|
QUINIDINE SULFATE
|
SALUD FÍSICA
|
|
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
|
||||
mexiletine hcl 150 mg cap
|
2
|
Preferred
|
MEXITIL
|
|
mexiletine hcl 200 mg cap
|
3
|
Preferred
|
MEXITIL
|
|
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
|
||||
flecainide acetate 100 mg
tab, 50 mg tab
|
1
|
Preferred
|
TAMBOCOR
|
|
propafenone hcl 150 mg tab, 225 mg tab
|
1
|
Preferred
|
RYTHMOL
|
|
flecainide acetate 150 mg tab
|
2
|
Preferred
|
TAMBOCOR
|
|
propafenone hcl 300 mg tab
|
3
|
Preferred
|
RYTHMOL
|
|
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
|
||||
amiodarone hcl 200 mg tab
|
1
|
Preferred
|
CORDARONE
|
|
Intermittent Claudication Agents [Agentes Para La Claudicación Intermitente]
|
||||
pentoxifylline er 400 mg
tab er
|
1
|
Preferred
|
TRENTAL
|
|
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
|
||||
digox 125 mcg tab, 250
mcg tab
|
2
|
Preferred
|
LANOXIN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
digoxin 0.05 mg/ml soln, 125 mcg tab, 250 mcg tab
|
2
|
Preferred
|
LANOXIN
|
|
Pulmonary Hypertension Agents [Agentes Para Hipertensión Pulmonar]
|
||||
sildenafil citrate 20 mg tab
|
3
|
Preferred
|
REVATIO
|
PA
|
ADEMPAS 0.5 mg tab
|
15
|
Preferred
|
PA, C
|
|
ADEMPAS 1 mg tab, 1.5 mg tab, 2 mg tab
|
18
|
Preferred
|
PA, C
|
|
ADEMPAS 2.5 mg tab
|
20
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
Vasodilators [Vasodilatadores]
|
||||
isosorbide mononitrate 10
mg tab, 20 mg tab
|
1
|
Preferred
|
IMDUR
|
|
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr
|
1
|
Preferred
|
IMDUR
|
|
nitroglycerin 0.2 mg/hr td patch 24hr
|
1
|
Preferred
|
NITRODUR
|
|
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl
|
1
|
Preferred
|
||
nitroglycerin 0.1 mg/hr td patch 24hr, 0.4 mg/hr td patch 24hr, 0.6 mg/hr td patch 24hr
|
2
|
Non-Preferred
|
NITRODUR
|
|
CENTRAL NERVOUS SYSTEM AGENTS [AGENTES SISTEMA NERVIOSO CENTRAL]
|
||||
Multiple Sclerosis Agents [Agentes para Esclerosis Múltiple]
|
||||
AMPYRA
10 tab er 12hr
|
9
|
Preferred
|
PA, C
|
|
COPAXONE 20 mg/ml sc kit
|
17
|
Preferred
|
PA, C
|
|
COPAXONE 40 mg/ml subcutaneous solution prefilled syringe
|
14
|
Preferred
|
PA, C
|
|
AVONEX 30 mcg im kit
|
13
|
Preferred
|
PA, C
|
|
AVONEX PEN 30 mcg/0.5ml im kit
|
13
|
Preferred
|
PA, C
|
|
AVONEX PREFILLED 30 mcg/0.5ml im kit
|
13
|
Preferred
|
PA, C
|
|
GILENYA 0.5 mg cap
|
15
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
TYSABRI intravenous concentrate 300 mg/15ml
|
15
|
Preferred
|
PA, C
|
TECFIDERA 120 mg cap dr
|
14
|
Preferred
|
PA, C
|
|
TECFIDERA 240 mg cap dr
|
14
|
Preferred
|
PA, C
|
|
TECFIDERA 120-240 MG misc
|
14
|
Preferred
|
PA, C
|
|
BETASERON 0.3 mg sc kit
|
13
|
Preferred
|
PA, C
|
|
CHEMOTHERAPIES [QUIMIOTERAPIAS]
|
||||
Alkylating Agents [Agentes Alquilantes]
|
||||
lomustine 10 mg cap
|
3
|
Non-Preferred
|
CEENU
|
|
ALKERAN 2 mg tab
|
4
|
Non-Preferred
|
||
temozolomide 5 mg cap
|
4
|
Non-Preferred
|
TEMODAR
|
PA
|
lomustine 40 mg cap
|
5
|
Non-Preferred
|
CEENU
|
|
LEUKERAN 2 mg tab
|
6
|
Non-Preferred
|
||
lomustine 100 mg cap
|
6
|
Non-Preferred
|
CEENU
|
|
MYLERAN 2 mg tab
|
7
|
Non-Preferred
|
||
temozolomide 20 mg cap
|
9
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 250 mg cap
|
11
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 140 mg cap
|
13
|
Non-Preferred
|
TEMODAR
|
PA
|
temozolomide 100 mg cap, 180 mg cap
|
14
|
Non-Preferred
|
TEMODAR
|
PA
|
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
|
||||
STIVARGA 40 mg tab
|
15
|
Preferred
|
PA, C
|
|
Antiandrogens [Antiandrógenos]
|
||||
bicalutamide 50 mg tab
|
2
|
Preferred
|
CASODEX
|
|
flutamide 125 mg cap
|
4
|
Non-Preferred
|
EULEXIN
|
|
Antiestrogens [Antiestrógenos]
|
||||
tamoxifen
citrate 10 mg tab, 20 mg tab
|
1
|
Preferred
|
NOLVADEX
|
|
Vaginal Estrogens [Estrógenos Vaginal]
|
||||
VAGIFEM 10 mcg vag tab
|
3
|
Non-Preferred
|
||
Antimetabolites [Antimetabolitos]
|
||||
hydroxyurea 500 mg cap
|
2
|
Preferred
|
HYDREA
|
|
mercaptopurine 50 mg tab
|
2
|
Preferred
|
PURINETHOL
|
|
methotrexate 2.5 mg tab
|
2
|
Preferred
|
METHOTREXATE
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Luteinizing Hormone-Releasing (LHRH) Analogs [Análogos De LHRH]
|
||||
LUPRON DEPOT 45 mg im kit
|
2
|
Preferred
|
PA, C
|
|
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit
|
6
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
|
Antifungals [Antifungales]
|
||||
clotrimazole 10 mg
mouth/throat lozenge, 10 mg mouth/throat troche
|
1
|
Preferred
|
MYCELEX
|
|
nystatin 100000 unit/ml mouth/throat susp
|
1
|
Preferred
|
MYCOSTATIN
|
|
Oral Antiseptics [Antisépticos Orales]
|
||||
chlorhexidine gluconate
0.12 % mouth/throat soln
1
Preferred PERIDEX
|
||||
Xerostomia [Xerostomía]
|
||||
pilocarpine 5 mg tab
|
3
|
Preferred
|
SALAGEN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
|
||||
Acne Antibiotics [Antibióticos para Acné]
|
||||
sulfacetamide sodium
sulfur 10-5 % external emulsion
|
1
|
Preferred
|
SULFACET R
|
|
clindamycin phosphate 1 % soln
|
2
|
Preferred
|
CLEOCIN T
|
|
erythromycin 2 % gel, 2 % soln
|
2
|
Preferred
|
ERYGEL
|
|
Acne Products [Productos para el Acné]
|
||||
tretinoin 0.05 % crm,
|
2
|
Preferred
|
RETIN A
|
AL < 21 años
|
isotretinoin 10 mg cap, 20 mg cap, 30 mg cap
|
6
|
Preferred
|
Zenatane
|
|
Antihistamines [Antihistamínicos]
|
||||
hydroxyzine hcl 10 mg tab,
10 mg/5ml soln, 10 mg/5ml syr, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
ATARAX
|
|
Antipsoriatics [Antipsoriáticos]
|
||||
methoxsalen 10 m cap
|
Preferred
|
Oxsoralen
|
||
Antiseborrheic Products [Productos Antiseborrea]
|
||||
selenium sulfide 2.5 % lot
|
1
|
Preferred
|
SELSUN
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab
|
1
|
Non-Preferred
|
PRAVACHOL
|
|
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab
|
1
|
Preferred
|
ZOCOR
|
|
pravastatin sodium 40 mg tab
|
2
|
Non-Preferred
|
PRAVACHOL
|
|
GASTROINTESTINAL AGENTS [AGENTESGASTROINTESTINALES]
|
||||
Antispasmodics [Antiespasmódicos]
|
||||
dicyclomine hcl 10 mg cap,
20 mg tab
|
1
|
Preferred
|
BENTYL
|
SALUD FÍSICA
|
|
dicyclomine hcl 10 mg/5ml soln
|
2
|
Preferred
|
BENTYL
|
Anti-Ulcer Agents [Agentes Anti-Ulceras]
|
||||
misoprostol 100 mcg tab,
200 mcg tab
|
1
|
Preferred
|
CYTOTEC
|
|
sucralfate 1 gm tab
|
1
|
Preferred
|
CARAFATE
|
|
1 gm/10ml susp
|
3
|
Non-Preferred
|
||
Digestive Enzymes [Enzimas Digestivas]
|
||||
CREON 12000 unit cap dr
prt, 6000 unit cap dr prt
|
3
|
Preferred
|
C
|
|
CREON 24000 unit cap dr prt, 36000 unit cap dr prt, 3000-9500 unit cap dr prt
|
5
|
Preferred
|
C
|
|
Histamine2 (H2) Receptor Antagonists [Antagonistas del Receptor de H2]
|
||||
famotidine
20 mg tab, 40 mg tab
|
1
|
Preferred
|
PEPCID
|
|
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr
|
1
|
Preferred
|
ZANTAC
|
|
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
|
||||
ursodiol 300 mg cap
|
4
|
Preferred
|
ACTIGALL
|
PA
|
cromolyn sodium 100 mg/5ml oral conc
|
6
|
Non-Preferred
|
GASTROCROM
|
PA
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Proton Pump Inhibitors [Inhibidores de la Bomba de Protones]
|
||||
omeprazole 10 mg cap dr, 20 mg cap dr,40 mg cap dr
|
1
|
Preferred
|
PRILOSEC
|
QL=180 caps/ 365 días
|
Rectal Anti-Inflammatories [Anti-Inflamatorios Rectales]
|
||||
hydrocortisone ace
pramoxine 1-1 % rect crm,
2.5-1 % rect crm
|
2
|
Preferred
|
ANALPRAM-HC
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
ALPHANATE/VWF COMPLEX/HUMAN 250 unit iv soln, 500 unit iv soln, 1000 unit iv soln, 1500 unit iv soln, 2000 unit iv soln
|
25
|
Non-Preferred
|
PA
|
SALUD FÍSICA
|
|
KOGENATE FS 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit
|
25
|
Preferred
|
PA, C
|
|
KOGENATE FS BIO-SET 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit
|
25
|
Preferred
|
PA, C
|
|
BENEFIX 250 unit intravenous kit, 500 unit intravenous kit, 1000 unit intravenous kit, 2000 unit intravenous kit, 3000 unit intravenous kit
|
25
|
Preferred
|
PA, C
|
|
ANTIINHIBITOR COAGULANT COMPLEX for inj
|
25
|
Non-Preferred
|
PA
|
|
ANTIHEMOPHILIC FACTOR VIII for inj.
|
25
|
Non-Preferred
|
PA
|
|
Hemostatics [Hemostáticos]
|
||||
tranexamic acid 650 mg tab, 1000 mg/ ml IV soln
|
4
|
Non-Preferred
|
LYSTEDA
|
PA
|
AMICAR 500 mg tab,
0.25 gm/ml oral soln
|
5
|
Non-Preferred
|
PA
|
|
AMICAR 0.25 gm/ml oral soln
|
8
|
Non-Preferred
|
PA
|
|
tranexamic acid
100 mg/ml IV soln
|
Non-Preferred
|
CYKLOKAPRON
|
PA
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name [Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /Límites]
|
Thyroid Hormones [Hormona Tiroidea]
|
||||
levothyroxine sodium 100
mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
|
1
|
Preferred
|
SYNTHROID
|
|
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
|
1
|
Preferred
|
C
|
|
Vasopressin Analogs [Análogos de Vasopresina]
|
||||
desmopressin
acetate 4 mcg/ml inj soln
|
2
|
Non-Preferred
|
DDAVP
|
|
desmopressin acetate 0.2 mg tab
|
3
|
Non-Preferred
|
DDAVP
|
|
desmopressin ace rhinal tube 0.01 % nasal soln
|
4
|
Non-Preferred
|
DDAVP
|
|
desmopressin ace spray refrig 0.01 % nasal soln
|
4
|
Non-Preferred
|
DDAVP
|
|
desmopressin acetate 0.1 mg tab
|
4
|
Non-Preferred
|
DDAVP
|
|
desmopressin acetate spray 0.01 % nasal soln
|
4
|
Non-Preferred
|
DDAVP
|
|
STIMATE 1.5 mg/ml nasal soln
|
7
|
Non-Preferred
|
SALUD FÍSICA
|
|
IMMUNOLOGICAL AGENTS [AGENTES INMUNOLÓGICOS]
|
||||
Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
|
||||
ENBREL
25 mg sc kit, 25mg/0.5ml sc sol
|
9
|
Preferred
|
PA, C
|
|
ENBREL 50mg/ml sc soldermat
|
9
|
Preferred
|
PA, C
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
HUMIRA 10 mg/0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
|
9
|
Preferred
|
PA, C
|
|
REMICADE 100 mg iv soln
|
16
|
Preferred
|
PA, C
|
|
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
|
||||
Organ Transplant Agents
|
||||
cyclosporine modified 25
mg cap, 50 mg cap
|
3
|
Preferred
|
NEORAL
|
a
PA
|
cyclosporine modified 25 mg cap, 50 mg cap
|
3
|
Preferred
|
NEORAL
|
aPA
|
NEORAL 25 mg cap
|
4
|
Preferred
|
aPA, C
|
|
cyclosporine 25 mg cap
|
4
|
Preferred
|
SANDIMMUNE
|
aPA
|
cyclosporine modified 100 mg cap, 100 mg/ml soln
|
4
|
Preferred
|
NEORAL
|
aPA
|
cyclosporine 100 mg cap
|
5
|
Preferred
|
SANDIMMUNE
|
aPA
|
cyclosporine modified 100 mg cap
|
5
|
Preferred
|
NEORAL
|
aPA
|
NEORAL 100 mg cap
|
5
|
Preferred
|
aPA, C
|
|
cyclosporine 100 mg cap, 25 mg cap
|
6
|
Preferred
|
SANDIMMUNE
|
aPA
|
SANDIMMUNE 100 mg
cap, 100 mg/ml soln, 25 mg cap
|
6
|
Preferred
|
aPA, C
|
|
cyclosporine modified 100 mg/ml soln
|
7
|
Preferred
|
NEORAL
|
aPA
|
NEORAL 100 mg/ml soln
|
8
|
Preferred
|
aPA, C
|
SALUD FÍSICA
|
|
Glucocorticosteroids [Glucocorticoides]
|
||||
dexamethasone 0.5 mg
tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab
|
1
|
Preferred
|
DECADRON
|
|
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln
|
1
|
Preferred
|
DECADRON
|
OB-GYN
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
KENALOG 10 mg/ml inj susp
|
1
|
Preferred
|
||
MEDROL 2 mg tab
|
1
|
Preferred
|
||
methylprednisolone 32 mg tab, 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
methylprednisolone (pak) 4 mg tab
|
1
|
Preferred
|
MEDROL
|
|
prednisolone 15 mg/5ml soln, 15 mg/5ml syr
|
1
|
Preferred
|
PRELONE
|
|
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
prednisone (pak) 10 mg tab, 5 mg tab
|
1
|
Preferred
|
DELTASONE
|
|
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab
|
2
|
Preferred
|
CORTEF
|
|
methylprednisolone 16 mg tab, 8 mg tab
|
2
|
Preferred
|
MEDROL
|
|
cortisone acetate 25 mg tab
|
3
|
Non-Preferred
|
CORTISONE
|
|
KENALOG 40 mg/ml inj susp
|
5
|
Non-Preferred
|
||
betamethasone sod phos & acet 6 mg/ml inj susp
|
2
|
Preferred
|
CELESTONE SOLUSPAN
|
OB-GYN
|
Organ Transplant Agents [Agentes para Trasplantes]
|
||||
azathioprine 50 mg tab
|
1
|
Preferred
|
IMURAN
|
|
AZASAN 75 mg, 100 mg
|
Non-Preferred
|
|||
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab
|
2
|
Preferred
|
CELLCEPT
|
aPA
|
tacrolimus 0.5 mg cap
|
3
|
Non-Preferred
|
PROGRAF
|
aPA
|
MYFORTIC 180 mg tab dr
|
4
|
Preferred
|
aPA, C
|
|
tacrolimus 1 mg cap
|
4
|
Non-Preferred
|
PROGRAF
|
aPA
|
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab
|
5
|
Non-Preferred
|
RAPAMUNE
|
aPA
|
MYFORTIC
360 mg tab dr
|
6
|
Preferred
|
aPA, C
|
|
tacrolimus 5 mg cap
|
6
|
Non-Preferred
|
PROGRAF
|
aPA
|
RAPAMUNE 1 mg/ml soln
|
8
|
Non-Preferred
|
aPA
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
|
||||
Aminosalicylates [Aminosalicilatos]
|
||||
mesalamine
rectal enema 4 gm
|
4
|
Preferred
|
ROWASA
|
|
DELZICOL 400 mg cap dr
|
5
|
Preferred
|
C
|
|
ASACOL HD 800 mg tab dr
|
6
|
Preferred
|
C
|
|
Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
|
||||
ENBREL
25 mg sc kit, 25mg/0.5ml sc sol
|
8
|
Preferred
|
PA, C
|
|
ENBREL 50mg/ml sc sol
|
9
|
Preferred
|
PA, C
|
|
HUMIRA 10 mg/0.2 ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
HUMIRA PEDIATRIC CROHNS START 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
HUMIRA PEN 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
HUMIRA PEN-CROHNS STARTER 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
HUMIRA PEN-PSORIASIS STARTER 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
REMICADE 100 mg iv soln
|
13
|
Preferred
|
PA, C
|
SALUD FÍSICA
|
|
Intrarectal Low Potency Glucocorticoids [Glucocorticoides Intrarectales de Baja Potencia]
|
||||
hydrocortisone 100
mg/60ml rect enema
|
2
|
Preferred
|
COLOCORT
|
|
Sulfonamides [Sulfonamidas]
|
||||
sulfasalazine 500 mg tab,
500 mg tab dr
|
1
|
Preferred
|
AZULFIDINE
|
|
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
|
||||
Calcium Regulating Agents [Agentes Reguladores de Calcio]
|
||||
calcitriol 0.25 mcg cap
|
1
|
Preferred
|
ROCALTROL
|
|
calcitriol 0.5 mcg cap
|
2
|
Preferred
|
ROCALTROL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Carnitine Deficiency [Deficiencia de Carnitina]
|
||||
levocarnitine 1 gm/10ml soln, 330 mg tab
|
3
|
Preferred
|
CARNITOR
|
|
Chelating Agents [Agentes Quelantes]
|
||||
DEPEN TITRATABS
250 mg tab
|
25
|
Preferred
|
PA
|
|
Electrolytes/Minerals Replacement [Reemplazo de Electrolitos/Minerales]
|
||||
potassium chloride 20
meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln
|
1
|
Preferred
|
KAY-CIEL
|
|
potassium chloride crys er 10 meq tab er, 20 meq tab er
|
1
|
Preferred
|
KLOR-CON
|
|
potassium chloride er 10 meq cap er, 8 meq cap er
|
2
|
Preferred
|
MICRO-K
|
|
potassium chloride 40 meq/15ml (20%) oral solution
|
4
|
Preferred
|
KAON CL
|
|
Potassium Removing Resins [Resinas Removedoras de Potasio]
|
||||
sodium polystyrene
sulfonate 15 gm/60ml susp
|
3
|
Preferred
|
KAYEXALATE
|
SALUD FÍSICA
|
|
Prenatal Vitamins [Vitaminas Prenatales]
|
||||
classic
prenatal 28-0.8 mg tab
|
1
|
Preferred
|
PRENATAL VITAMINS
|
OB-GYN
|
prenatal 27-0.8 mg tab, 271 mg tab, 28-0.8 mg tab
|
1
|
Preferred
|
PREPLUS
|
OB-GYN
|
prenatal 19 tab chew, tab, 29-1 mg tab chew, 29-1 mg tab
|
1
|
Preferred
|
PRENATAL VITAMINS
|
OB-GYN
|
prenatal formula 28-0.8 mg tab
|
1
|
Preferred
|
PRENATAL VITAMINS
|
OB-GYN
|
prenatal low iron 27-0.8 mg tab, 27-1 mg tab
|
1
|
Preferred
|
PREPLUS
|
OB-GYN
|
prenatal plus iron 29-1 mg tab
|
1
|
Preferred
|
PRENATABS
|
OB-GYN
|
prenatal vitamins 0.8 mg tab, 28-0.8 mg tab
|
1
|
Preferred
|
PRENATAL VITAMINS
|
OB-GYN
|
SALUD FÍSICA
|
|
Nasal Steroids [Esteroides Nasales]
|
||||
fluticasone propionate 50
mcg/act nasal susp
|
1
|
Preferred
|
FLONASE
|
QL = 1 pompa / 30 días
|
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
|
||||
Antiglaucoma Agents [Agentes Antiglaucoma]
|
||||
brimonidine tartrate 0.2 %
ophth soln
|
1
|
Preferred
|
ALPHAGAN
|
|
dorzolamide hcl 2 % ophth soln
|
1
|
Preferred
|
TRUSOPT
|
|
levobunolol hcl 0.25 % ophth soln, 0.5 % ophth soln
|
1
|
Preferred
|
BETAGAN
|
|
timolol maleate 0.25 % ophth soln, 0.5 % ophth soln
|
1
|
Preferred
|
TIMOPTIC
|
|
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml
|
1
|
Preferred
|
COSOPT
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
betaxolol hcl 0.5 % ophth soln
|
2
|
Non-Preferred
|
BETOPTIC
|
|
Miotics [Mióticos]
|
||||
pilocarpine hcl 1 % ophth
soln, 2 % ophth soln, 4 % ophth soln
|
3
|
Preferred
|
ISOPTOCARPINE
|
|
Mydriatics [Midriáticos]
|
||||
atropine sulfate 1 % ophth
oint, 1 % ophth soln
|
1
|
Preferred
|
ISO-ATROPINE
|
|
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
|
||||
diclofenac sodium 0.1 %
ophth soln
|
1
|
Preferred
|
VOLTAREN
|
QL = max 30 días / 365 días
|
ketorolac tromethamine 0.5 % ophth soln
|
1
|
Preferred
|
ACULAR
|
QL = max 30 días / 365 días
|
SALUD FÍSICA
|
|
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
|
ciprofloxacin hcl 0.3 %
ophth soln
|
1
|
Preferred
|
CILOXAN
|
|
gentamicin sulfate 0.3 % ophth oint, 0.3 % ophth soln
|
1
|
Preferred
|
GARAMYCIN
|
|
ofloxacin 0.3 % ophth soln
|
1
|
Preferred
|
OCUFLOX
|
|
polymyxin b-trimethoprim 10000-0.1 unit/ml-% ophth soln
|
1
|
Preferred
|
POLYTRIM
|
|
tobramycin 0.3 % ophth soln
|
1
|
Preferred
|
TOBREX
|
|
bacitracin 500 unit/gm ophth oint
|
3
|
Non-Preferred
|
BACITRACIN
|
|
Ophthalmic Antivirals [Antivirales Oftálmicos]
|
||||
trifluridine 1 % ophth soln
|
4
|
Non-Preferred
|
VIROPTIC
|
PA
|
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
|
||||
latanoprost 0.005 % ophth
soln
|
1
|
Preferred
|
XALATAN
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Ophthalmic Steroids [Esteroides Oftálmicos]
|
||||
neomycin
-polymyxindexamethasone 3.5-
10000-0.1 ophth oint, 3.5- 10000-0.1 ophth susp
|
1
|
Preferred
|
MAXITROL
|
|
prednisolone acetate 1 % ophth susp
|
2
|
Preferred
|
PRED FORTE
|
|
prednisolone sodium phosphate 1 % ophth soln
|
2
|
Preferred
|
INFLAMASE
|
|
fluorometholone 0.1 % ophth susp
|
3
|
Preferred
|
FML LIQUIFILM
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Inhaled Corticosteroids [Corticosteroides Inhalados]
|
||||
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr
|
3
|
Preferred
|
QL = 1 pompa / 30 días, C
|
SALUD FÍSICA
|
|
FLOVENT HFA 110 mcg/act inh aer, 44 mcg/act inh aer
|
3
|
Preferred
|
QL = 1 pompa / 30 días, C
|
|
ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 250-50 mcg/dose inh aer pwdr
|
4
|
Preferred
|
QL= 1 pompa / 30 días, ST, C
|
|
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer
|
4
|
Preferred
|
QL= 1 pompa / 30 días, ST, C
|
|
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp
|
4
|
Non-Preferred
|
PULMICORT
|
AL ≤ 12 años
|
budesonide 1mg/2ml inh susp
|
8
|
Non-Preferred
|
PULMICORT
|
AL ≤ 12 años
|
FLOVENT HFA 220 mcg/act inh aer
|
4
|
Preferred
|
QL= 1 pompa / 30 días, C
|
|
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr
|
5
|
Preferred
|
QL= 1 pompa / 30 días, ST, C
|
|
ADVAIR HFA 230-21 mcg/act inh aer
|
5
|
Preferred
|
QL= 1 pompa / 30 días, ST, C
|
|
Nonsedating Histamine1 Blocking Agents [Bloqueadores de Histamina1 No-Sedantes]
|
||||
cetirizine HCl oral soln 1 MG/ML (5 MG/5ML)
|
1
|
Preferred
|
ZYRTEC
|
OTC
|
loratadine 5 mg/5ml soln, 5 mg/5ml syr
|
1
|
Preferred
|
CLARITIN
|
OTC
|
loratadine 10 mg tab
|
1
|
Preferred
|
CLARITIN
|
OTC
|
Phosphodiesterase Inhibitors [Inhibidores de la Fosfodiesterasa]
|
||||
theophylline er 100 mg tab
er 12 hr, 200 mg tab er 12 hr, 300 mg tab er 12 hr, 450 mg tab er 12 hr
|
1
|
Preferred
|
THEO-DUR
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos
/Límites]
|
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
|
||||
albuterol sulfate (2.5
mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
|
1
|
Preferred
|
ALBUTEROL
|
|
terbutaline sulfate 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
BRETHINE
|
|
VENTOLIN HFA 108 (90 base) mcg/act inh aer
|
2
|
Preferred
|
QL = 1 pompa / 30 días, C
|
|
RHEUMATOID ARTHRITIS AGENTS [AGENTES PARA ARTRITIS REUMATOIDE]
|
||||
Immunomodulators (TNF And Non-TNF) [Inmunomoduladores (TNF Y No-TNF)]
|
||||
ENBREL
25 mg sc kit, 25mg/0.5ml sc sol
|
8
|
Preferred
|
PA, C
|
|
ENBREL 50mg/ml sc sol
|
9
|
Preferred
|
PA, C
|
|
ORENCIA 125 mg/ml subcutaneous solution prefilled syringe, 125 mg/ml ClickJect sc sol Autoinjector
|
10
|
Preferred
|
PA, C
|
|
HUMIRA 10 mg/ 0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit
|
11
|
Preferred
|
PA, C
|
|
REMICADE 100 mg iv soln
|
13
|
Preferred
|
PA, C
|
|
Non-Biologic Agents [Agentes No-Biológicos]
|
||||
methotrexate 2.5 mg tab
|
2
|
Preferred
|
METHOTREXATE
|
|
leflunomide 10 mg tab, 20 mg tab
|
4
|
Non-Preferred
|
ARAVA
|
PA
|
DEPEN TITRATABS 250 mg tab
|
25
|
Preferred
|
PA
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANTI-ADDICTION AGENTS [AGENTES
CONTRA LA ADDICIÓN]
|
||||
Opioid Antagonist [Antagonistas De Opioides]
|
||||
buprenorphine hcl 2 mg tab
subl, 8 mg tab subl
|
3
|
Preferred
|
SUBUTEX
|
PA
|
SUBOXONE subl film 2-0.5 mg, 8-2 mg, 4-1 mg, 12-3 mg
|
4
|
Preferred
|
PA, C
|
|
Detox Treatment [Tratamiento De Detox]
|
||||
b-1 100 mg tab
|
1
|
Preferred
|
THIAMINE
|
QL
|
clonidine hcl 0.1 mg tab
|
1
|
Preferred
|
CATAPRESS
|
|
folic acid 1 mg tab
|
1
|
Preferred
|
FOLIC ACID
|
QL
|
ibuprofen 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL
|
loperamide hcl 2 mg cap
|
1
|
Preferred
|
IMODIUM
|
QL
|
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
|
||||
Benzodiazepines [Benzodiazepinas]
|
||||
clonazepam 0.5 mg tab, 1
mg tab, 2mg tab
|
1
|
Preferred
|
KLONOPIN
|
|
diazepam 10 mg tab, 2 mg tab, 5 mg tab
|
1
|
Preferred
|
VALIUM
|
|
lorazepam 0.5 mg tab, 1 mg tab
|
1
|
Preferred
|
ATIVAN
|
|
diazepam 1 mg/ml soln
|
2
|
Non-Preferred
|
VALIUM
|
|
DIAZEPAM INTENSOL 5 mg/ml oral conc
|
2
|
Non-Preferred
|
||
lorazepam 2 mg/ml oral conc
|
2
|
Non-Preferred
|
ATIVAN
|
|
Sedating Histamine 1 Blocking Agents [Sedantes Bloqueadores Histamine 1]
|
||||
hydroxyzine pamoate 100
mg cap, 25 mg cap, 50 mg cap
|
1
|
Preferred
|
VISTARIL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
|
||||
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
|
||||
bupropion hcl 75 mg tab
|
1
|
Preferred
|
WELLBUTRIN
|
|
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr
|
1
|
Preferred
|
WELLBUTRIN SR
|
|
escitalopram oxalate 5mg tab, 10 mg tab, 20 mg tab
|
1
|
Preferred
|
LEXAPRO
|
|
mirtazapine 15 mg tab, 30 mg tab, 45 mg tab, 7.5 mg tab
|
1
|
Preferred
|
REMERON
|
|
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab
|
1
|
Preferred
|
DESYREL
|
|
bupropion hcl 100 mg tab
|
2
|
Non-Preferred
|
WELLBUTRIN
|
|
bupropion hcl er (xl) 150 mg tab er 24 hr, 300 mg tab er 24 hr
|
2
|
Non-Preferred
|
WELLBUTRIN XL
|
|
mirtazapine 15 mg odt, 30 mg odt, 45 mg odt
|
3
|
Non-Preferred
|
REMERON
|
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o Norepinefrina]
|
||||
citalopram hydrobromide
10 mg tab, 20 mg tab, 40 mg tab
|
1
|
Preferred
|
CELEXA
|
|
fluoxetine hcl 10 mg cap, 20 mg cap
|
1
|
Preferred
|
PROZAC
|
|
paroxetine hcl 10 mg tab, 20 mg tab, 30 mg tab, 40 mg tab
|
1
|
Preferred
|
PAXIL
|
|
sertraline hcl 100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
ZOLOFT
|
|
sertraline hcl oral concentrate 20 mg/ml
|
2
|
Non-Preferred
|
ZOLOFT
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
venlafaxine hcl 100mg tab, 25mg tab, 37.5mg tab, 50mg tab, 75mg tab
|
1
|
Preferred
|
EFFEXOR
|
|
venlafaxine hcl er 150 mg cap er 24 hr, 37.5 mg cap er 24 hr, 75 mg cap er 24 hr
|
1
|
Preferred
|
EFFEXOR XR
|
|
duloxetine 20 mg cap, 30 mg cap, 60 mg cap
|
2
|
Non-Preferred
|
CYMBALTA
|
|
Tricyclic Agents [Tricíclicos]
|
||||
amitriptyline hcl 10 mg tab,
100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab
|
1
|
Preferred
|
ELAVIL
|
|
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap
|
1
|
Preferred
|
SINEQUAN
|
|
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
TOFRANIL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
|
1
|
Preferred
|
RISPERDAL
|
|
quetiapine fumarate 50 mg tab
|
2
|
Preferred
|
SEROQUEL
|
|
risperidone 1 mg/ml soln
|
2
|
Preferred
|
RISPERDAL
|
|
quetiapine fumarate 100 mg tab
|
3
|
Preferred
|
SEROQUEL
|
|
LATUDA 120 mg tab, 20 mg tab, 40 mg tab, 60 mg tab, 80 mg tab
|
4
|
Preferred
|
PA
|
PA, P
|
quetiapine fumarate 200 mg tab
|
4
|
Preferred
|
SEROQUEL
|
|
quetiapine fumarate 300 mg tab
|
5
|
Preferred
|
SEROQUEL
|
|
quetiapine fumarate 400 mg tab
|
6
|
Preferred
|
SEROQUEL
|
|
aripriprazole 2 mg tab, 5 mg tab, 10 mg tab, 15 mg tab, 20 mg tab, 30 mg tab
|
7
|
Non-Preferred
|
ABILIFY
|
PA
|
aripiprazole 1 mg/ml soln
|
10
|
Non-Preferred
|
ABILIFY
|
PA
|
Typical - First Generation [Típicos - Primera Generación]
|
||||
fluphenazine hcl 1 mg tab,
10 mg tab, 2.5 mg tab, 5
mg tab
|
1
|
Preferred
|
PROLIXIN
|
|
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab, 2 mg/ml oral conc
|
1
|
Preferred
|
HALDOL
|
|
thioridazine hcl 10 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
MELLARIL
|
|
thiothixene 1 mg cap, 2 mg cap, 5 mg cap
|
1
|
Preferred
|
NAVANE
|
|
trifluoperazine hcl mg tab, 2 mg tab, 5 mg tab, 10 mg tab
|
2
|
Preferred
|
STELAZINE
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
chlorpromazine hcl 25 mg tab
|
2
|
Preferred
|
THORAZINE
|
|
haloperidol 5 mg tab
|
2
|
Preferred
|
HALDOL
|
|
haloperidol decanoate 50 mg/ml im soln
|
2
|
Preferred
|
HALDOL DECANOATE
|
thioridazine hcl 100 mg tab
|
2
|
Preferred
|
MELLARIL
|
|
thiothixene 10 mg cap
|
2
|
Preferred
|
NAVANE
|
|
chlorpromazine hcl 100 mg tab, 50 mg tab
|
3
|
Preferred
|
THORAZINE
|
|
haloperidol 10 mg tab
|
3
|
Preferred
|
HALDOL
|
|
haloperidol decanoate 100 mg/ml im soln
|
3
|
Preferred
|
HALDOL DECANOATE
|
|
chlorpromazine hcl 200 mg tab
|
4
|
Preferred
|
THORAZINE
|
|
haloperidol 20 mg tab
|
4
|
Preferred
|
HALDOL
|
|
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
|
||||
Bipolar Agents [Agentes Para Bipolaridad]
|
||||
divalproex sodium 125 mg
tab dr, 250 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
DEPAKOTE
|
|
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
|
1
|
Preferred
|
LAMICTAL
|
|
lamotrigine chew tab 5 mg, 25 mg
|
3
|
Non-Preferred
|
LAMICTAL
|
|
lithium carbonate 150 mg cap, 300 mg cap, 300 mg tab, 600 mg cap
|
1
|
Preferred
|
LITHIUM
|
|
lithium carbonate er 300 mg tab er, 450 mg tab er
|
1
|
Preferred
|
LITHIUM
|
|
olanzapine 10 mg tab, 15 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
|
1
|
Preferred
|
ZYPREXA
|
|
quetiapine fumarate 25 mg tab
|
1
|
Preferred
|
SEROQUEL
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
|
1
|
Preferred
|
RISPERDAL
|
|
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
|
1
|
Preferred
|
DEPAKENE
|
|
quetiapine fumarate 50 mg tab
|
2
|
Preferred
|
SEROQUEL
|
|
risperidone 1 mg/ml soln
|
2
|
Preferred
|
RISPERDAL
|
|
quetiapine fumarate 100 mg tab
|
3
|
Preferred
|
SEROQUEL
|
|
quetiapine fumarate 200 mg tab
|
4
|
Preferred
|
SEROQUEL
|
|
quetiapine fumarate 300 mg tab
|
5
|
Preferred
|
SEROQUEL
|
|
quetiapine fumarate 400 mg tab
|
6
|
Preferred
|
SEROQUEL
|
|
aripriprazole 10 mg tab, 15 mg tab, 2 mg tab, 5 mg tab, 20 mg tab, 30 mg tab
|
7
|
Non-Preferred
|
ABILIFY
|
PA
|
aripiprazole 1 mg/ml soln
|
10
|
Non-Preferred
|
ABILIFY
|
PA
|
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
|
||||
ADHD Amphetamines [Anfetaminas ADHD]
|
||||
amphetamine
-
dextroamphetamine 15 mg tab, 30 mg tab
|
2
|
Preferred
|
ADDERALL
|
AL 4-20años
|
amphetamine- dextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
|
3
|
Preferred
|
ADDERALL
|
AL 4-20 años
|
dextroamphetamine sulfate 10 mg tab, 5 mg tab
|
3
|
Preferred
|
DEXEDRINE
|
AL 4-20 años
|
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr
|
4
|
Non-Preferred
|
DEXEDRINE SR
|
AL 4-20 años
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
dextroamphetamine sulfate er 15 mg cap er 24 hr
|
5
|
Non-Preferred
|
DEXEDRINE SR
|
AL 4-20 años
|
DYANAVEL XR oral susp.er 2.5 mg/ mL
|
4
|
Non-Preferred
|
DYANAVEL XR
|
PA, AL 6-20 años
|
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
|
||||
clonidine hcl 0.1 mg tab
|
1
|
Preferred
|
CATAPRESS
|
|
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab
|
2
|
Preferred
|
FOCALIN
|
AL 6-20 años
|
methylphenidate hcl 5 mg tab
|
2
|
Preferred
|
RITALIN
|
AL 6-20 años
|
dexmethylphenidate hcl 10 mg tab
|
3
|
Preferred
|
FOCALIN
|
AL 6-20 años
|
methylphenidate hcl 10 mg tab, 20 mg tab
|
3
|
Preferred
|
RITALIN
|
AL 6-20 años
|
methylphenidate soln 5mg/5ml, 10 mg/5ml
|
Non-Preferred
|
METHYLIN
|
||
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap
|
4
|
Preferred
|
PA, AL 6-20 años, P
|
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
|
||||
Benzodiazepines [Benzodiazepinas]
|
||||
flurazepam hcl 15 mg cap,
30 mg cap
|
1
|
Preferred
|
DALMANE
|
|
temazepam 15 mg cap, 30 mg cap
|
1
|
Preferred
|
RESTORIL
|
|
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
|
||||
doxepin hcl 10 mg cap, 10
mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap
|
1
|
Preferred
|
SINEQUAN
|
|
zolpidem tartrate 10 mg tab, 5 mg tab
|
1
|
Preferred
|
AMBIEN
|
SALUD MENTAL
|
|
SALUD MENTAL
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANALGESICS [ANALG
ÉSICOS]
|
||||
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
|
||||
ibuprofen 400 mg tab, 600
mg tab
|
1
|
Preferred
|
MOTRIN
|
QL=5 días
|
nabumetone 500 mg tab, 750 mg tab
|
1
|
Preferred
|
RELAFEN
|
QL=5 días
|
naproxen 250 mg tab, 375 mg tab, 500 mg tab
|
1
|
Preferred
|
NAPROSYN
|
QL=15 días No repeticiones
|
salsalate 500 mg tab, 750 mg tab
|
1
|
Preferred
|
DISALCID
|
QL=5 días
|
indomethacin 25 mg cap, 50 mg cap
|
1
|
Non-Preferred
|
INDOCIN
|
|
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
|
||||
acetaminophen
-codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=5 días
|
acetaminophen-codeine #2 300-15 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=5 días
|
acetaminophen-codeine #3 300-30 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=5 días
|
acetaminophen-codeine #4 300-60 mg tab
|
1
|
Preferred
|
TYLENOL-CODEINE
|
QL=5 días
|
butalbital-apap-caffeine 50325-40 mg tab
|
1
|
Preferred
|
FIORICET
|
QL=5 días
|
tramadol hcl 50 mg tab
|
1
|
Preferred
|
ULTRAM
|
QL=5 días
|
butalbital-apap-caffeine 50325-40 mg cap
|
2
|
Preferred
|
FIORICET
|
QL=5 días
|
margesic 50-325-40 mg cap
|
2
|
Preferred
|
FIORICET
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ANESTHETICS [ANESTÉSICOS]
|
||||
Local Anesthetics [Anestésicos Locales]
|
||||
lidocaine viscous 2 % mouth/throat soln
|
1
|
Preferred
|
XYLOCAINE
|
QL=5 días
|
ANTIBACTERIALS [ANTIBACTERIANOS]
|
||||
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
|
||||
cephalexin 125 mg/5ml
susp, 250 mg cap, 500 mg cap
|
1
|
Preferred
|
KEFLEX
|
QL=5 días
|
cefadroxil 250 mg/5ml susp
|
2
|
Non-Preferred
|
DURICEF
|
QL=5 días, AL 012 años
|
cephalexin 250 mg/5ml susp
|
2
|
Preferred
|
KEFLEX
|
QL=5 días
|
cefadroxil 500 mg/5ml susp
|
3
|
Non-Preferred
|
DURICEF
|
QL=5 días, AL 0-12 años
|
Macrolides [Macrólidos]
|
||||
azithromycin 250 mg tab,
500 mg tab
|
1
|
Preferred
|
ZITHROMAX
|
QL=5 días
|
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
|
2
|
Preferred
|
ZITHROMAX
|
QL=5 días
|
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
|
2
|
Preferred
|
BIAXIN
|
QL=5 días
|
clarithromycin 250 mg/5ml susp
|
3
|
Preferred
|
BIAXIN
|
QL=5 días
|
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
|
3
|
Preferred
|
ERY-TAB
|
QL=5 días
|
erythromycin ethylsuccinate 400 mg tab
|
3
|
Preferred
|
E.E.S.
|
QL=5 días
|
ERYTHROCIN STEARATE 250 mg tab
|
4
|
Non-Preferred
|
QL=5 días
|
|
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg cap,
300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
QL=5 días
|
MACRODANTIN 25 mg cap
|
1
|
Preferred
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
metronidazole 250 mg tab, 500 mg tab
|
1
|
Preferred
|
FLAGYL
|
QL=5 días
|
nitrofurantoin macrocrystal 50 mg cap
|
1
|
Preferred
|
MACRODANTIN
|
QL=5 días
|
nitrofurantoin macrocrystal 100 mg cap
|
2
|
Preferred
|
MACRODANTIN
|
QL=5 días
|
nitrofurantoin monohyd macro 100 mg cap
|
2
|
Preferred
|
MACROBID
|
QL=5 días
|
Penicillins [Penicilinas] | ||||
amoxicillin 125 mg/5ml susp,
200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
QL=5 días
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
QL=5 días
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
QL=5 días
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
QL=5 días
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
QL=5 días
|
Quinolones [Quinolonas] | ||||
ciprofloxacin hcl 250 mg tab,
500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
QL=5 días
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
QL=5 días
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
QL=5 días
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
|
||||
cefaclor 250 mg cap, 500
mg cap
|
2
|
Preferred
|
CECLOR
|
QL=5 días
|
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
|
2
|
Preferred
|
CEFZIL
|
QL=5 días
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
QL=5 días
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
QL=5 días
|
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
|
||||
cefdinir 125 mg/5ml susp,
300 mg cap
|
2
|
Preferred
|
OMNICEF
|
QL=5 días
|
cefdinir 250 mg/5ml susp
|
3
|
Preferred
|
OMNICEF
|
QL=5 días
|
ANTICONVULSANTS [ANTICONVULSIVANTES]
|
||||
Anticonvulsants [Anticonvulsivantes]
|
||||
carbamazepine 100 mg tab
chew, 200 mg tab
|
1
|
Preferred
|
TEGRETOL
|
QL=5 días
|
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
NEURONTIN
|
QL=5 días
|
levetiracetam 250 mg tab, 500 mg tab
|
1
|
Preferred
|
KEPPRA
|
QL=5 días
|
oxcarbazepine 150 mg tab
|
1
|
Preferred
|
TRILEPTAL
|
QL=5 días
|
SALUD FÍSICA
|
|
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
|
1
|
Preferred
|
PHENOBARBITAL
|
QL=5 días
|
primidone 250 mg tab, 50 mg tab
|
1
|
Preferred
|
MYSOLINE
|
QL=5 días
|
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
TOPAMAX
|
QL=5 días
|
DILANTIN 30 mg cap
|
2
|
Preferred
|
QL=5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
levetiracetam 1000 mg tab, 750 mg tab
|
2
|
Preferred
|
KEPPRA
|
QL=5 días
|
oxcarbazepine 300 mg tab, 600 mg tab
|
2
|
Preferred
|
TRILEPTAL
|
QL=5 días
|
phenytoin 125 mg/5ml susp, 50 mg tab chew
|
2
|
Preferred
|
DILANTIN
|
QL=5 días
|
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
|
2
|
Preferred
|
DILANTIN
|
QL=5 días
|
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
|
2
|
Preferred
|
DILANTIN
|
QL=5 días
|
ethosuximide 250 mg cap, 250 mg/5ml soln
|
3
|
Preferred
|
ZARONTIN
|
QL=5 días
|
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
|
3
|
Preferred
|
PHENOBARBITAL
|
QL=5 días
|
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
|
||||
Cholinesterase Inhibitors [Inhibidores De Colinesterasa]
|
||||
donepezil hcl 10 mg tab, 5
mg tab
|
1
|
Preferred
|
ARICEPT
|
QL=5 días
|
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap
|
3
|
Preferred
|
EXELON
|
QL=5 días
|
SALUD FÍSICA
|
|
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
|
||||
Monoamine Oxidase (Mao) Inhibitors [Inhibidores De Mao]
|
||||
selegiline
hcl 5 mg tab
|
3
|
Non-Preferred
|
CARBEX
|
QL=5 días
|
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
|
||||
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
|
||||
acarbose 100 mg tab, 25 mg
tab, 50 mg tab
|
2
|
Preferred
|
PRECOSE
|
QL=5 días
|
Biguanides [Biguanidas]
|
||||
metformin hcl 1000 mg tab,
500 mg tab, 850 mg tab
|
1
|
Preferred
|
GLUCOPHAGE
|
QL=5 días
|
SALUD FÍSICA
|
|
ANTIEMETICS [ANTIEMÉTICOS]
|
||||
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 5 mg tab, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
QL=5 días
|
trimethobenzamide hcl 300 mg cap
|
1
|
Preferred
|
TIGAN
|
QL=5 días
|
Phenothiazines [Fenotiazinas]
|
||||
prochlorperazine maleate 10
mg tab, 5 mg tab
|
1
|
Preferred
|
COMPAZINE
|
QL=5 días
|
prochlorperazine 25 mg rect supp
|
4
|
Non-Preferred
|
COMPAZINE
|
QL=5 días
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name [Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/ Límites]
|
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
|
||||
Antigout Agents [Agentes Antigota]
|
||||
allopurinol 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ZYLOPRIM
|
QL=5 días
|
colchicine 0.6 mg cap
|
3
|
Preferred
|
MITIGARE
|
PA
|
colchicine 0.6 mg tab
|
3
|
Non-Preferred
|
COLCRYS
|
QL= 3 tab, 15días
|
Uricosurics [Uricosúricos]
|
||||
probenecid 500 mg tab
|
1
|
Preferred
|
BENEMID
|
QL=5 días
|
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
|
||||
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
|
||||
clonidine hcl 0.2 mg tab, 0.3
mg tab
|
1
|
Preferred
|
CATAPRESS
|
QL=5 días
|
methyldopa 250 mg tab, 500 mg tab
|
1
|
Preferred
|
ALDOMET
|
QL=5 días
|
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
|
||||
terazosin hcl 1 mg cap, 10
mg cap, 2 mg cap, 5 mg cap
|
1
|
Preferred
|
HYTRIN
|
QL=5 días
|
SALUD FÍSICA
|
|
Angiotensin II Receptor Blockers (Arb) [Antagonistas Del Receptor Angiotensina II]
|
||||
losartan potassium
100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
COZAAR
|
QL=5 días
|
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
|
1
|
Preferred
|
HYZAAR
|
QL=5 días
|
Angiotensin-Converting Enzyme (Ace) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensin]
|
||||
lisinopril 10 mg tab, 2.5 mg
tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
|
1
|
Preferred
|
ZESTRIL
|
QL=5 días
|
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
|
1
|
Preferred
|
ZESTORETIC
|
QL=5 días
|
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
|
||||
amlodipine besylate 10 mg
tab, 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
NORVASC
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Potassium-Sparing Diuretics [Diuréticos Conservadores De Potasio]
|
||||
spironolactone 100 mg tab,
25 mg tab, 50 mg tab
|
1
|
Preferred
|
ALDACTONE
|
QL=5 días
|
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab
|
1
|
Preferred
|
MAXZIDE
|
QL=5 días
|
Thiazide Diuretics [Diuréticos Tiazidas]
|
||||
chlorothiazide 250 mg tab,
500 mg tab
|
1
|
Preferred
|
DIURIL
|
QL=5 días
|
chlorthalidone 25 mg tab, 50 mg tab
|
1
|
Preferred
|
HYGROTON
|
QL=5 días
|
DIURIL 250 mg/5ml susp
|
1
|
Preferred
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name [Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/ Límites]
|
pyridostigmine bromide
180 mg tab er
|
6
|
Non-Preferred
|
MESTINON
|
|
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
|
||||
Antituberculars [Antituberculosos]
|
||||
isoniazid 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ISONIAZID
|
QL=5 días
|
rifampin 150 mg cap
|
1
|
Preferred
|
RIFADIN
|
QL=5 días
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
bromocriptine mesylate 2.5 mg tab
|
3
|
Preferred
|
PARLODEL
|
QL=5 días
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab
|
1
|
Preferred
|
BETAPACE
|
QL=5 días
|
sotalol hcl (af) 120 mg tab, 160 mg tab, 80 mg tab
|
1
|
Preferred
|
BETAPACE
|
QL=5 días
|
propranolol hcl 60 mg tab
|
2
|
Preferred
|
INDERAL
|
QL=5 días
|
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
|
||||
quinidine sulfate 200
mg tab, 300 mg tab
|
1
|
Preferred
|
QUINIDINE SULFATE
|
QL=5 días
|
quinidine gluconate er 324 mg tab er
|
2
|
Preferred
|
QUINAGLUTE
|
QL=5 días
|
quinidine sulfate er 300 mg tab er
|
2
|
Preferred
|
QUINIDINE SULFATE
|
QL=5 días
|
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
|
||||
mexiletine hcl 150 mg cap
|
2
|
Preferred
|
MEXITIL
|
QL=5 días
|
mexiletine hcl 200 mg cap
|
3
|
Preferred
|
MEXITIL
|
QL=5 días
|
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
|
||||
flecainide acetate 100 mg
tab, 50 mg tab
|
1
|
Preferred
|
TAMBOCOR
|
QL=5 días
|
propafenone hcl 150 mg tab, 225 mg tab
|
1
|
Preferred
|
RYTHMOL
|
QL=5 días
|
flecainide acetate 150 mg tab
|
2
|
Preferred
|
TAMBOCOR
|
QL=5 días
|
propafenone hcl 300 mg tab
|
3
|
Preferred
|
RYTHMOL
|
QL=5 días
|
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
|
||||
amiodarone hcl 200 mg tab
|
1
|
Preferred
|
CORDARONE
|
QL=5 días
|
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
|
||||
digox 125 mcg tab, 250 mcg
tab
|
2
|
Preferred
|
LANOXIN
|
QL=5 días
|
digoxin 125 mcg tab, 250 mcg tab
|
2
|
Preferred
|
LANOXIN
|
QL=5 días
|
Vasodilators [Vasodilatadores]
|
||||
isosorbide mononitrate 10
mg tab, 20 mg tab
|
1
|
Preferred
|
ISORDIL
|
QL=5 días
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
SALUD FÍSICA
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
|
||||
promethazine hcl 12.5 mg
tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
|
1
|
Preferred
|
PHENERGAN
|
QL=5 días
|
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
|
||||
albuterol sulfate (2.5
mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
|
1
|
Preferred
|
PROVENTIL
|
QL=5 días
|
terbutaline sulfate 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
BRETHINE
|
QL=5 días
|
VENTOLIN HFA 108 (90 base) mcg/act inh aer
|
1
|
Preferred
|
QL=1 frasco / 30 días, P
|
SALUD FÍSICA
|
|
SUB MENTAL
|
|
SUB MENTAL
|
|
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o
Norepinefrina]
|
||||
citalopram hydrobromide 10 mg tab, 20 mg tab, 40 mg tab
|
1
|
Preferred
|
CELEXA
|
QL=30 días
|
fluoxetine hcl 10 mg cap, 20 mg cap
|
1
|
Preferred
|
PROZAC
|
QL=30 días
|
SUB MENTAL
|
|
SUB MENTAL
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
DETOX TREATMENT [TRATAMIENTO DE DETOX]
|
||||
Detox Treatment [Tratamiento De Detox]
|
||||
clonidine hcl 0.1 mg tab
|
1
|
Preferred
|
CATAPRESS
|
QL=7 días
|
folic acid 1 mg tab
|
1
|
Preferred
|
FOLIC ACID
|
QL=7 días
|
ibuprofen 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL=7 días
|
loperamide hcl 2 mg cap
|
1
|
Preferred
|
IMODIUM
|
QL=7 días
|
vitamin b-1 100 mg tab
|
1
|
Preferred
|
THIAMINE
|
QL=7 días
|
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
|
||||
Bipolar Agents [Agentes Para Bipolaridad]
|
||||
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
DEPAKOTE
|
QL=30 días
|
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
|
1
|
Preferred
|
LAMICTAL
|
QL=30 días
|
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
|
1
|
Preferred
|
DEPAKENE
|
QL=30 días
|
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
|
||||
ADHD Amphetamines [Anfetaminas ADHD]
|
||||
amphetamine- dextroamphetamine 15 mg tab, 30 mg tab
|
2
|
Preferred
|
ADDERALL
|
QL=30 días, AL 4-20 años, PA ≥ 21 años
|
SUB MENTAL
|
|
amphetaminedextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab
|
3
|
Preferred
|
ADDERALL
|
QL=30 días, AL 4-20 años, PA ≥ 21 años
|
dextroamphetamine sulfate 10 mg tab, 5 mg tab
|
3
|
Preferred
|
DEXEDRINE
|
QL=30 días, AL 4-20 años, PA ≥ 21 años
|
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr
|
4
|
Non-Preferred
|
DEXEDRINE SR
|
QL=30 días, AL 4-20 años, PA ≥ 21 años
|
dextroamphetamine sulfate er 15 mg cap er 24 hr
|
5
|
Non-Preferred
|
DEXEDRINE SR
|
QL=30 días, AL 4-20 años, PA ≥ 21 años
|
DYANAVEL XR oral susp. er 2.5 mg/ mL
|
4
|
Non-Preferred
|
DYANAVEL XR
|
PA, AL 6-20 años
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
|
||||
clonidine hcl 0.1 mg tab
|
1
|
Preferred
|
CATAPRESS
|
QL=7 días
|
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab
|
2
|
Preferred
|
FOCALIN
|
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
|
methylphenidate hcl 5 mg tab
|
2
|
Preferred
|
RITALIN
|
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
|
dexmethylphenidate hcl 10 mg tab
|
3
|
Preferred
|
FOCALIN
|
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
|
methylphenidate hcl 10 mg tab, 20 mg tab
|
3
|
Preferred
|
RITALIN
|
QL=30 días,
AL 6-20 años,
PA ≥ 21 años
|
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap
|
4
|
Preferred
|
PA, QL=30 días, AL 6-20
años, PA ≥ 21 años, P
|
SUB MENTAL
|
|
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
|
||||
Benzodiazepines [Benzodiazepinas]
|
||||
flurazepam hcl 15 mg cap, 30 mg cap
|
1
|
Preferred
|
DALMANE
|
QL=5 días
|
temazepam 15 mg cap, 30 mg cap
|
1
|
Preferred
|
RESTORIL
|
QL=5 días
|
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
|
||||
zolpidem tartrate 10 mg tab, 5 mg tab
|
1
|
Preferred
|
AMBIEN
|
QL=5 días
|
DENTAL
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANALGESICS [ANALGÉSICOS]
|
||||
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [Anti-Inflamatorios No Esteroidales]
|
||||
ibuprofen 400 mg tab, 600
mg tab, 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL=7 días
|
naproxen 250 mg tab, 375 mg tab, 500 mg tab
|
1
|
Preferred
|
NAPROSYN
|
QL=7 días
|
naproxen dr 375 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
NAPROSYN
|
QL=7 días
|
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
|
||||
acetaminophen
-codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL=7 días
|
acetaminophen-codeine #2 300-15 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL=7 días
|
acetaminophen-codeine #3 300-30 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL=7 días
|
acetaminophen-codeine #4 300-60 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL=7 días
|
hydrocodone- acetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab
|
1
|
Preferred
|
VICODIN
|
QL=7 días
|
ANTIBACTERIALS [ANTIBACTERIANOS]
|
||||
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
|
||||
cephalexin 125 mg/5ml
susp, 250 mg cap, 500 mg cap
|
1
|
Preferred
|
KEFLEX
|
|
cefadroxil 250 mg/5ml susp
|
2
|
Non-Preferred
|
DURICEF
|
AL ≤ 12 años
|
cephalexin 250 mg/5ml susp
|
2
|
Preferred
|
KEFLEX
|
|
cefadroxil 500 mg/5ml susp
|
3
|
Non-Preferred
|
DURICEF
|
AL ≤ 12 años
|
Macrolides [Macrólidos]
|
||||
ERY
-TAB 500 mg tab dr
|
3
|
Preferred
|
DENTAL
|
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos/ Límites]
|
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
|
3
|
Preferred
|
ERY-TAB
|
|
erythromycin ethylsuccinate 400 mg tab
|
3
|
Preferred
|
E.E.S.
|
|
ERYTHROCIN STEARATE 250 mg tab
|
4
|
Non-Preferred
|
||
E.E.S. GRANULES 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 200 200 mg/5ml susp
|
5
|
Preferred
|
||
ERYPED 400 400 mg/5ml susp
|
6
|
Preferred
|
||
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg cap,
300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
|
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp,
200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
DENTAL
|
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
|
||||
Therapeutic Class [Clase Terapéutica]
|
||||
ANALGESICS [ANALG ÉSICOS]
|
||||
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [
Anti-Inflamatorios No Esteroidales]
|
||||
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
MOTRIN
|
QL = 5 días
|
indomethacin 25 mg cap, 50 mg cap
|
1
|
Non-Preferred
|
INDOCIN
|
QL = 5 días
|
nabumetone 500 mg tab, 750 mg tab
|
1
|
Preferred
|
RELAFEN
|
QL = 5 días
|
naproxen 250 mg tab, 375 mg tab, 500 mg tab
|
1
|
Preferred
|
NAPROSYN
|
QL = 5 días
|
naproxen sodium 275 mg tab, 550 mg tab
|
1
|
Preferred
|
ANAPROX
|
QL = 5 días
|
salsalate 500 mg tab, 750 mg tab
|
1
|
Preferred
|
DISALCID
|
QL = 5 días
|
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
|
||||
acetaminophen
-codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-
60 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL = 5 días
|
acetaminophen-codeine #2 300-15 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL = 5 días
|
acetaminophen-codeine #3 300-30 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL = 5 días
|
acetaminophen-codeine #4 300-60 mg tab
|
1
|
Preferred
|
TYLENOL- CODEINE
|
QL = 5 días
|
butalbital-apap-caffeine 50325-40 mg tab
|
1
|
Preferred
|
FIORICET
|
QL = 5 días
|
tramadol hcl 50 mg tab
|
1
|
Preferred
|
ULTRAM
|
QL = 5 días
|
butalbital-apap-caffeine 50325-40 mg cap
|
2
|
Preferred
|
FIORICET
|
QL = 5 días
|
Drug Name [Nombre
del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
ANESTHETICS [ANESTÉSICOS]
|
||||
Local Anesthetics [Anestésicos Locales]
|
||||
lidocaine viscous 2 %
mouth/throat soln
|
1
|
Preferred
|
XYLOCAINE
|
QL = 5 días
|
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
|
||||
Benzodiazepines [Benzodiazepinas]
|
||||
clonazepam 0.5 mg tab, 1
mg tab, 2mg tab
|
1
|
Preferred
|
KLONOPIN
|
QL = 5 días
|
diazepam 10 mg tab, 2 mg tab, 5 mg tab
|
1
|
Preferred
|
VALIUM
|
QL = 5 días
|
lorazepam 0.5 mg tab, 1 mg tab
|
1
|
Preferred
|
ATIVAN
|
QL = 5 días
|
temazepam 15 mg cap, 30 mg cap
|
1
|
Preferred
|
RESTORIL
|
QL = 5 días
|
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
|
||||
hydroxyzine pamoate 100
mg cap, 25 mg cap, 50 mg cap
|
1
|
Preferred
|
VISTARIL
|
QL = 5 días
|
ANTIBACTERIALS [ANTIBACTERIANOS]
|
||||
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
|
||||
cephalexin 125 mg/5ml
susp, 250 mg cap, 500 mg cap
|
1
|
Preferred
|
KEFLEX
|
QL = 5 días
|
cefadroxil 250 mg/5ml susp
|
2
|
Non-Preferred
|
DURICEF
|
QL = 5 días, AL ≤ 12
|
cephalexin 250 mg/5ml susp
|
2
|
Preferred
|
KEFLEX
|
QL = 5 días
|
cefadroxil 500 mg/5ml susp
|
3
|
Non-Preferred
|
DURICEF
|
QL = 5 días, AL ≤ 12
|
Macrolides [Macrólidos]
|
||||
azithromycin 250 mg tab,
500 mg tab
|
1
|
Preferred
|
ZITHROMAX
|
QL = 5 días
|
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab
|
2
|
Preferred
|
ZITHROMAX
|
QL = 5 días
|
Drug Name [Nombre
del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab
|
2
|
Preferred
|
BIAXIN
|
QL = 5 días
|
clarithromycin 250 mg/5ml susp
|
3
|
Preferred
|
BIAXIN
|
QL = 5 días
|
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab
|
3
|
Preferred
|
ERY-TAB
|
QL = 5 días
|
erythromycin ethylsuccinate 400 mg tab
|
3
|
Preferred
|
E.E.S.
|
QL = 5 días
|
ERYTHROCIN STEARATE 250 mg tab
|
4
|
Non-Preferred
|
QL = 5 días
|
|
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
|
||||
clindamycin hcl 150 mg cap,
300 mg cap, 75 mg cap
|
1
|
Preferred
|
CLEOCIN
|
QL = 5 días
|
MACRODANTIN 25 mg cap
|
1
|
Preferred
|
QL = 5 días
|
metronidazole 250 mg tab, 500 mg tab
|
1
|
Preferred
|
FLAGYL
|
QL = 5 días
|
nitrofurantoin macrocrystal 50 mg cap
|
1
|
Preferred
|
MACRODANTIN
|
QL = 5 días
|
nitrofurantoin macrocrystal 100 mg cap
|
2
|
Preferred
|
MACRODANTIN
|
QL = 5 días
|
nitrofurantoin oral
suspension 25 MG/5ML
|
6
|
Non-Preferred
|
FURADANTIN
|
|
nitrofurantoin monohyd macro 100 mg cap
|
2
|
Preferred
|
MACROBID
|
QL = 5 días
|
Penicillins [Penicilinas]
|
||||
amoxicillin 125 mg/5ml susp,
200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab
|
1
|
Preferred
|
AMOXIL
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab
|
1
|
Preferred
|
AUGMENTIN
|
QL = 5 días
|
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap
|
1
|
Preferred
|
PRINCIPEN
|
QL = 5 días
|
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab
|
1
|
Preferred
|
VEETIDS
|
QL = 5 días
|
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp
|
3
|
Preferred
|
AUGMENTIN
|
QL = 5 días
|
Quinolones [Quinolonas]
|
||||
ciprofloxacin hcl 250 mg tab,
500 mg tab, 750 mg tab
|
1
|
Preferred
|
CIPRO
|
QL = 5 días
|
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab
|
1
|
Preferred
|
LEVAQUIN
|
QL = 5 días
|
ciprofloxacin 500 mg/5ml (10%) susp
|
3
|
Preferred
|
CIPRO
|
QL = 5 días
|
ciprofloxacin 250 mg/5ml (5%) susp
|
4
|
Preferred
|
CIPRO
|
QL = 5 días
|
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
|
||||
cefaclor 250 mg cap, 500
mg cap
|
2
|
Preferred
|
CECLOR
|
QL = 5 días
|
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab
|
2
|
Preferred
|
CEFZIL
|
QL = 5 días
|
Sulfonamides [Sulfonamidas]
|
||||
sulfamethoxazole
-tmp ds 800-160 mg tab
|
1
|
Preferred
|
SEPTRA
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab
|
1
|
Preferred
|
SEPTRA
|
QL = 5 días
|
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
|
||||
cefdinir 125 mg/5ml susp,
300 mg cap
|
2
|
Preferred
|
OMNICEF
|
QL = 5 días
|
cefdinir 250 mg/5ml susp
|
3
|
Preferred
|
OMNICEF
|
QL = 5 días
|
ANTICONVULSANTS [ANTICONVULSIVANTES]
|
||||
Anticonvulsants [Anticonvulsivantes]
|
||||
carbamazepine 100 mg tab
chew, 200 mg tab
|
1
|
Preferred
|
TEGRETOL
|
QL = 5 días
|
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab
|
1
|
Preferred
|
KLONOPIN
|
QL = 5 días
|
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr
|
1
|
Preferred
|
DEPAKOTE
|
QL = 5 días
|
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab
|
1
|
Preferred
|
NEURONTIN
|
QL = 5 días
|
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab
|
1
|
Preferred
|
LAMICTAL
|
QL = 5 días
|
lamotrigine chew tab 5 mg, 25 mg
|
3
|
Non-Preferred
|
LAMICTAL
|
|
levetiracetam 250 mg tab, 500 mg tab
|
1
|
Preferred
|
KEPPRA
|
QL = 5 días
|
levetiracetam er 24 hrs 500 mg tab, 750 mg
|
3
|
Non-Preferred
|
KEPPRA XR
|
|
oxcarbazepine 150 mg tab
|
1
|
Preferred
|
TRILEPTAL
|
QL = 5 días
|
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab
|
1
|
Preferred
|
PHENOBARBITAL
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
primidone 250 mg tab, 50 mg tab
|
1
|
Preferred
|
MYSOLINE
|
QL = 5 días
|
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
TOPAMAX
|
QL = 5 días
|
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr
|
1
|
Preferred
|
DEPAKENE
|
QL = 5 días
|
zonisamide 50 mg cap
|
1
|
Preferred
|
ZONEGRAN
|
QL = 5 días
|
DILANTIN 30 mg cap
|
2
|
Preferred
|
QL = 5 días
|
|
levetiracetam 1000 mg tab, 750 mg tab
|
2
|
Preferred
|
KEPPRA
|
QL = 5 días
|
oxcarbazepine 300 mg tab, 600 mg tab
|
2
|
Preferred
|
TRILEPTAL
|
QL = 5 días
|
phenytoin 125 mg/5ml susp, 50 mg tab chew
|
2
|
Preferred
|
DILANTIN
|
QL = 5 días
|
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap
|
2
|
Preferred
|
DILANTIN
|
QL = 5 días
|
zonisamide 100 mg cap, 25 mg cap
|
2
|
Preferred
|
ZONEGRAN
|
QL = 5 días
|
ethosuximide 250 mg cap, 250 mg/5ml soln
|
3
|
Preferred
|
ZARONTIN
|
QL = 5 días
|
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln
|
3
|
Preferred
|
PHENOBARBITAL
|
QL = 5 días
|
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
|
||||
Cholinesterase Inhibitors [Inhibidores De Colinesterasa
|
||||
donepezil hcl 10 mg tab, 5
mg tab
|
1
|
Preferred
|
ARICEPT
|
QL = 5 días
|
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap
|
3
|
Preferred
|
EXELON
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Sulfonylureas [Sulfonilureas]
|
||||
glimepiride 1 mg tab, 2 mg
tab, 4 mg tab
|
1
|
Preferred
|
AMARYL
|
QL = 5 días
|
glipizide 10 mg tab, 5 mg tab
|
1
|
Preferred
|
GLUCOTROL
|
QL = 5 días
|
ANTIEMETICS [ANTIEMÉTICOS]
|
||||
Miscellaneous Antiemetics [Antieméticos Misceláneos]
|
||||
metoclopramide hcl 10 mg
tab, 5 mg tab, 5 mg/ml inj soln
|
1
|
Preferred
|
REGLAN
|
QL = 5 días
|
ormir 50 mg cap
|
1
|
Preferred
|
BENADRYL
|
QL = 5 días
|
pharbedryl 50 mg cap
|
1
|
Preferred
|
BENADRYL
|
QL = 5 días
|
trimethobenzamide hcl 300 mg cap
|
1
|
Preferred
|
TIGAN
|
QL = 5 días
|
Phenothiazines [Fenotiazinas]
|
||||
prochlorperazine maleate 10
mg tab, 5 mg tab
|
1
|
Preferred
|
COMPAZINE
|
QL = 5 días
|
prochlorperazine 25 mg rect supp
|
4
|
Non-Preferred
|
COMPAZINE
|
QL = 5 días
|
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
|
||||
Antigout Agents [Agentes Antigota]
|
||||
allopurinol 100 mg tab, 300
mg tab
|
1
|
Preferred
|
ZYLOPRIM
|
QL = 5 días
|
colchicine 0.6 mg cap
|
3
|
Preferred
|
MITIGARE
|
PA
|
COLCRYS 0.6 mg tab
|
4
|
Non-Preferred
|
QL= 3 tab, 15días
|
|
Uricosurics [Uricosúricos]
|
||||
probenecid 500 mg tab
|
1
|
Preferred
|
BENEMID
|
QL = 5 días
|
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
|
||||
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
|
||||
clonidine hcl 0.1 mg tab, 0.2
mg tab, 0.3 mg tab
|
1
|
Preferred
|
CATAPRESS
|
QL = 5 días
|
methyldopa 250 mg tab, 500 mg tab
|
1
|
Preferred
|
ALDOMET
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
|
||||
terazosin hcl 1 mg cap, 10
mg cap, 2 mg cap, 5 mg cap
|
1
|
Preferred
|
HYTRIN
|
QL = 5 días
|
Angiotensin II Receptor Blockers (ARB) [Antagonistas Del Receptor Angiotensina II]
|
||||
losartan potassium 100 mg
tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
COZAAR
|
QL = 5 días
|
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab
|
1
|
Preferred
|
HYZAAR
|
QL = 5 días
|
Angiotensin-Converting Enzyme (ACE) Inhibitors [Inhibidores De La Enzima Convertidora
De Angiotensina]
|
||||
lisinopril 10 mg tab, 2.5 mg
tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab
|
1
|
Preferred
|
ZESTRIL
|
QL = 5 días
|
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab
|
1
|
Preferred
|
ZESTORETIC
|
QL = 5 días
|
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
|
||||
amlodipine besylate 10 mg
tab, 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
NORVASC
|
QL = 5 días
|
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab
|
1
|
Preferred
|
CARDIZEM
|
QL = 5 días
|
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab
|
1
|
Preferred
|
CALAN
|
QL = 5 días
|
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores De Anhidrasa Carbónica]
|
||||
acetazolamide 125 mg tab, 250 mg tab
|
3
|
Preferred
|
DIAMOX
|
QL = 5 días
|
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
|
||||
atenolol 100 mg tab, 25 mg
tab, 50 mg tab
|
1
|
Preferred
|
TENORMIN
|
QL = 5 días
|
Drug Name [Nombre del Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr
|
1
|
Preferred
|
LOPRESSOR
|
QL = 5 días
|
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab
|
1
|
Preferred
|
LOPRESSOR
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
MESTINON 60 mg/5ml syr
|
4
|
Non-Preferred
|
QL = 5 días
|
|
pyridostigmine bromide
180 mg tab er
|
6
|
Non-Preferred
|
MESTINON
|
QL = 5 días
|
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
|
||||
Antituberculars [Antituberculosos]
|
||||
CAPASTAT SULFATE 1 gm
inj soln
|
QL = 5 días
Puerto Rico
Department
Tuberculosis
Control Program
|
|||
cycloserine 250 mg cap
|
SEROMYCIN
|
|||
RIFAMATE 150-300 mg cap
|
||||
TRECATOR 250 mg tab
|
||||
rifabutin 150 mg cap
|
7
|
MYCOBUTIN
|
||
isoniazid 100 mg tab, 300 mg tab
|
1
|
Preferred
|
ISONIAZID
|
QL = 5 días
|
rifampin 150 mg cap
|
1
|
Preferred
|
RIFADIN
|
QL = 5 días
|
ethambutol hcl 100 mg tab
|
2
|
Non-Preferred
|
MYAMBUTOL
|
QL = 5 días
|
pyrazinamide 500 mg tab
|
2
|
Non-Preferred
|
PYRAZINAMIDE
|
QL = 5 días
|
rifampin 300 mg cap
|
2
|
Preferred
|
RIFADIN
|
QL = 5 días
|
ethambutol hcl 400 mg tab
|
3
|
Non-Preferred
|
MYAMBUTOL
|
QL = 5 días
|
isoniazid 50 mg/5ml syr
|
5
|
Non-Preferred
|
ISONIAZID
|
QL = 5 días
|
ANTIPARASITICS [ANTIPARASITARIOS]
|
||||
Antimalarials [Antimaláricos]
|
||||
chloroquine phosphate 250
mg tab, 500 mg tab
|
1
|
Preferred
|
ARALEN
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab
|
1
|
Preferred
|
MIRAPEX
|
QL = 5 días
|
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab
|
1
|
Preferred
|
REQUIP
|
QL = 5 días
|
ropinirole hcl 2 mg tab
|
2
|
Preferred
|
REQUIP
|
QL = 5 días
|
amantadine hcl 100 mg cap
|
3
|
Preferred
|
SYMMETREL
|
QL = 5 días
|
bromocriptine mesylate 2.5 mg tab
|
3
|
Preferred
|
PARLODEL
|
QL = 5 días
|
carbidopa-levodopaentacapone 18.75-75-200 mg tab
|
4
|
Non-Preferred
|
STALEVO
|
QL = 5 días
|
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5150-200 mg tab, 50-200-200 mg tab
|
5
|
Non-Preferred
|
STALEVO
|
QL = 5 días
|
Dopamine Precursors [Precursores De Dopamina]
|
||||
carbidopa
-levodopa 10-100 mg tab, 25-100 mg tab
|
1
|
Preferred
|
SINEMET
|
QL = 5 días
|
carbidopa-levodopa 25-250 mg tab
|
2
|
Preferred
|
SINEMET
|
QL = 5 días
|
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er
|
2
|
Preferred
|
SINEMET CR
|
QL = 5 días
|
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
|
||||
Atypical - Second Generation [Atípicos - Segunda Generación]
|
||||
risperidone 0.25 mg tab, 0.5
mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab
|
1
|
Preferred
|
RISPERDAL
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Typical - First Generation [Típicos - Primera Generación]
|
||||
haloperidol 0.5 mg tab, 1 mg
tab, 2 mg tab
|
1
|
Preferred
|
HALDOL
|
QL = 5 días
|
haloperidol 5 mg tab
|
2
|
Preferred
|
HALDOL
|
QL = 5 días
|
haloperidol 10 mg tab
|
3
|
Preferred
|
HALDOL
|
QL = 5 días
|
haloperidol 20 mg tab
|
4
|
Preferred
|
HALDOL
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
|
||||
mexiletine hcl 150 mg cap
|
2
|
Preferred
|
MEXITIL
|
QL = 5 días
|
mexiletine hcl 200 mg cap
|
3
|
Preferred
|
MEXITIL
|
QL = 5 días
|
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
|
||||
flecainide acetate 100 mg
tab, 50 mg tab
|
1
|
Preferred
|
TAMBOCOR
|
QL = 5 días
|
propafenone hcl 150 mg tab, 225 mg tab
|
1
|
Preferred
|
RYTHMOL
|
QL = 5 días
|
flecainide acetate 150 mg tab
|
2
|
Preferred
|
TAMBOCOR
|
QL = 5 días
|
propafenone hcl 300 mg tab
|
3
|
Preferred
|
RYTHMOL
|
QL = 5 días
|
Antiarrhythmics Type Iii [Antiarrítmicos Tipo Iii]
|
||||
amiodarone hcl 200 mg tab
|
1
|
Preferred
|
CORDARONE
|
QL = 5 días
|
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
|
||||
digoxin 125
mcg tab, 250 mcg tab
|
2
|
Preferred
|
LANOXIN
|
QL = 5 días
|
Vasodilators [Vasodilatadores]
|
||||
isosorbide mononitrate 10
mg tab, 20 mg tab
|
1
|
Preferred
|
ISORDIL
|
QL = 5 días
|
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr
|
1
|
Preferred
|
IMDUR
|
QL = 5 días
|
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl
|
1
|
Preferred
|
QL = 5 días
|
|
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
|
||||
Antifungals [Antifungales]
|
||||
clotrimazole 10 mg
mouth/throat lozenge, 10 mg mouth/throat troche
|
1
|
Preferred
|
MYCELEX
|
QL = 5 días
|
nystatin 100000 unit/ml mouth/throat susp, 100000 unit/ml crm
|
1
|
Preferred
|
NYSTATIN
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
|
||||
omeprazole 10 mg cap dr, 20 mg cap dr, 40 mg cap dr
|
1
|
Preferred
|
PRILOSEC
|
QL=180 caps/ 365 días
|
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
|
||||
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
|
phenazopyridine hcl 100 mg
tab, 200 mg tab
|
1
|
Preferred
|
PYRIDIUM
|
QL = 3 días
|
HORMONAL AGENTS [AGENTES HORMONALES]
|
||||
Antithyroid Agents [Agentes Antitiroide]
|
||||
methimazole 10 mg tab, 5
mg tab
|
1
|
Preferred
|
TAPAZOLE
|
QL = 5 días
|
propylthiouracil 50 mg tab
|
2
|
Preferred
|
PROPYLTHIOURA CIL
|
QL = 5 días
|
Calcimimetic Agents [Agentes Calcimiméticos]
|
||||
SENSIPAR 30
mg tab
|
7
|
Preferred
|
PA, QL = 5 días
|
|
SENSIPAR 60 mg tab
|
9
|
Preferred
|
PA, QL = 5 días
|
|
SENSIPAR 90 mg tab
|
10
|
Preferred
|
PA, QL = 5 días
|
|
Dopamine Agonists [Agonistas De Dopamina]
|
||||
bromocriptine mesylate 2.5
mg tab
|
3
|
Preferred
|
PARLODEL
|
QL = 5 días
|
Thyroid Hormones [Hormona Tiroidea]
|
||||
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab
|
1
|
Preferred
|
QL = 5 días, P
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
Ophthalmic Steroids [Esteroides Oftálmicos]
|
||||
neomycin
-polymyxindexamethasone 3.5-100000.1 ophth oint, 3.5-100000.1 ophth susp
|
1
|
Preferred
|
MAXITROL
|
QL = 1Frasco 5ML/5 días
|
prednisolone acetate 1 % ophth susp
|
2
|
Preferred
|
PRED FORTE
|
QL = 1 Frasco 5 ML/5 días
|
OTIC AGENTS [AGENTES OTICOS]
|
||||
Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
|
||||
acetic acid 2 % otic soln
|
2
|
Preferred
|
VOSOL
|
QL = 1 Frasco 15 ML/10 días
|
Otic Antibiotics [Antibióticos Oticos]
|
||||
neomycin
-polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp
|
2
|
Preferred
|
CORTISPORIN
|
QL = 1 Frasco 10 ML/10 días
|
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
|
||||
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
|
||||
ipratropium bromide 0.02 %
inh soln
|
1
|
Non-Preferred
|
ATROVENT
|
QL = 5 días
|
Drug Name [Nombre del
Medicamento]
|
Net
Cost
[Costo
Neto]
|
Tier [Tier]
|
Reference Name
[Nombre de
Referencia]
|
Requirements/
Limits
[Requerimientos /
Límites]
|
FLOVENT HFA 110 mcg/act inh aer
|
3
|
Preferred
|
QL = 1 Inh 12 EA/30 días, P
|
|
FLOVENT HFA 44 mcg/act inh aer
|
3
|
Preferred
|
QL = 1 Inh 10.6 EA/30 días, P
|
|
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,
1mg/2ml inh susp
|
4
|
Non-Preferred
|
PULMICORT
|
AL </=12
|
budesonide 1mg/2ml inh susp
|
8
|
Non-Preferred
|
PULMICORT
|
AL </=12
|
FLOVENT HFA 220 mcg/act inh aer
|
4
|
Preferred
|
QL = 1 Inh 12EA/30 días, P
|
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
|
||||
promethazine hcl 12.5 mg
tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr
|
1
|
Preferred
|
PHENERGAN
|
QL = 5 días
|
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
|
||||
albuterol sulfate (2.5
mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr
|
1
|
Dl
|
ALBUTEROL
|
QL = 5 días
|
terbutaline sulfate 2.5 mg tab, 5 mg tab
|
1
|
Preferred
|
BRETHINE
|
QL = 5 días
|
VENTOLIN HFA 108 (90 base) mcg/act inh aer
|
1
|
Preferred
|
QL = 1 Inh 18 EA/30 días, P
|
|
|
1.
|
The Social Security Act (SSA), Sections 1916 and 1916A.
|
2.
|
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation.
|
3.
|
The Puerto Rico State Plan Amendment (SPA) for Cost Sharing.
|
4.
|
The New Cost Sharing (Copayment) Structure for Medicaid and CHIP Beneficiaries.
|
42 CFR §447.51
|
Definitions.
|
42 CFR §447.52 | Cost sharing. |
42 CFR §447.53 | Cost sharing for drugs. |
42 CFR §447.54 | Cost sharing for services furnished in a hospital emergency department. |
42 CFR §447.55
|
Premiums. |
42 CFR §447.56 | Limitations on premiums and cost sharing. |
42 CFR §447.57 | Beneficiary and public notice requirements. |
1.
|
Medicaid beneficiaries are only subject to copayments and to no other form of cost sharing, such as coinsurances or deductibles.
|
2.
|
CHIP beneficiaries (Children Health Insurance Program or Medicaid Optional Targeted Low-Income Children) do not pay cost sharing or any other form of cost sharing, such as coinsurances or deductibles.
|
3.
|
Certain beneficiaries and services are exempt from any cost sharing, which mean that no copayment will be charged in these instances.
|
4.
|
Copayment amounts can vary by coverage codes and
by
the type of covered health care service.
|
5.
|
This Policy does not apply to individuals eligible for the Government Health Plan (GHP) as State or Commonwealth beneficiary.
|
1.
|
The Cost Sharing (Copagos) Structure, coverage codes, and copayment amounts applied to all Medicaid and CHIP beneficiaries, were effective from November 1, 2011 through June 30, 2016.
|
2.
|
The coverage codes were determined on the basis of the beneficiary Eligibility Monthly Income and the number of Members in the Family Unit. For example: if the Eligibility Income of a Medicaid beneficiary is $300 per month and the Members in the Family Unit is two (2), the coverage code assigned is 110. The evaluation uses Table I as follows:
|
a.
|
Eligibility Monthly Income = $300;
|
b.
|
Members in Family Unit = 2;
|
c.
|
Position on the row for Members in Family Unit of 2;
|
d.
|
Determine in which column of Coverage Codes on the row the Eligibility Monthly Income of $300 fits;
|
e.
|
The eligibility monthly income of $300 fits in range $249-UP which is under column 110; and
|
f.
|
Therefore, the beneficiary is assigned coverage code 110.
|
3.
|
It does not apply to anyone who is eligible as a State or Commonwealth beneficiary.
|
1.
|
Table I - Medicaid Coverage Codes, determined on the basis of eligibility monthly income and the number of members in the beneficiary’s family unit.
|
2.
|
Table II - CHIP Coverage Codes, determined on the basis of eligibility monthly income and the number of members in the beneficiary’s family unit.
|
3.
|
Table III - Medicaid and CHIP Coverage Codes and the applicable copayment amounts for each service.
|
TABLE I
|
||
Medicaid Cost Sharing (Copayments) Structure Prior to July 1
st
, 2016
Coverage Codes and Its Determination
|
||
Members in Family Unit
|
Eligibility Monthly Income Range by Coverage Code
|
|
100
|
110
|
|
1
|
$0-$200
|
$201-UP
|
2
|
$0-$248
|
$249-UP
|
3
|
$0-$295
|
$296-UP
|
4
|
$0-$343
|
$344-UP
|
5
|
$0-$390
|
$391-UP
|
6
|
$0-$438
|
$439-UP
|
7
|
$0-$485
|
$486-UP
|
8
|
$0-$533
|
$534-UP
|
9
|
$0-$580
|
$581-UP
|
10
|
$0-$628
|
$629-UP
|
11
|
$0-$675
|
$676-UP
|
12
|
$0-$723
|
$724-UP
|
13
|
$0-$770
|
$771-UP
|
14
|
$0-$818
|
$819-UP
|
15
|
$0-$865
|
$866-UP
|
TABLE II | |
CHIP Cost Sharing Structure (Copayments) Prior to July 1
st
, 2016
Coverage Codes and Its Determination
|
|
Members in Family Unit
|
Eligibility Monthly Income Range by Coverage Code
|
230
|
|
1
|
$551-$1,100
|
2
|
$551-$1,300
|
3
|
$551-$1,500
|
4
|
$551-$1,700
|
5
|
$551-$1,900
|
6
|
$551-$2,100
|
7
|
$551-$2,300
|
8
|
$551-$2,500
|
9
|
$551-$2,700
|
10
|
$551-$2,900
|
11
|
$551-$3,100
|
12
|
$551-$3,300
|
13
|
$551-$3,500
|
14
|
$551-$3,700
|
15
|
$551-$3,900
|
TABLE III
|
|||
Medicaid and CHIP Cost Sharing (Copayments) Structure Prior to July 1
st
, 2016 Applicable
Copayment Amounts for Each Service by Coverage Code
|
|||
Service
|
Coverage Codes and Copayments Amounts
|
||
Medicaid
|
CHIP
|
||
100
|
110
|
230
|
|
Hospital Admission, (per entire stay)
|
$0.00
|
$3.00
|
$0.00
|
Non-emergency Services Provided in a Hospital Emergency Room (ER), (per visit)
|
$3.80
|
$3.80
|
$0.00
|
Visit to Primary Care Physician (PCP), (per visit)
|
$0.00
|
$1.00
|
$0.00
|
Visit to Specialist, (per visit)
|
$0.00
|
$1.00
|
$0.00
|
Visit to Sub-Specialist, (per visit)
|
$0.00
|
$1.00
|
$0.00
|
High-Tech Laboratories, (per procedure)
|
$0.00
|
$0.50
|
$0.00
|
TABLE III
|
|||
Medicaid and CHIP Cost Sharing (Copayments) Structure Prior to July 1
st
, 2016 Applicable
Copayment Amounts for Each Service by Coverage Code
|
|||
Service
|
Coverage Codes and Copayments Amounts
|
||
Medicaid
|
CHIP
|
||
100
|
110
|
230
|
|
Clinical Laboratories, (per procedure)
|
$0.00
|
$0.50
|
$0.00
|
X-Rays, (per procedure)
|
$0.00
|
$0.50
|
$0.00
|
Special Diagnostic Test, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Therapy - Physical, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Therapy - Respiratory, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Therapy - Occupational, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Dental - Preventative, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Dental - Restorative, (per procedure)
|
$0.00
|
$1.00
|
$0.00
|
Pharmacy - Generic, (per drug)
|
$1.00
|
$1.00
|
$0.00
|
Pharmacy - Brand, (per drug)
|
$3.00
|
$3.00
|
$0.00
|
All Other Services or Items Not Specified Above
|
$0.00
|
$0.00
|
$0.00
|
1.
|
Be effective on July 1
st
, 2016; except for those Medicaid dual beneficiaries with Medicare Part A and B and who are enrolled in a Medicare Advantage (MA) Plan contracted with ASES, commonly known as Platino Plan. In Platino Plans, the New Cost Sharing Structure will be implemented on January 1
st
, 2017.
|
2.
|
Assign the Medicaid and CHIP Coverage Codes on the basis of:
|
a.
|
MAGI: Obamacare provides a new method for determining eligibility of individuals for Medicaid and CHIP, based on what is called Modified Adjusted Gross Income (MAGI).
|
b.
|
At July 1, 2016 and until implementation of MAGI Methodologies for determining Medicaid and CHIP eligibility, the Medicaid Program will continue assigning Medicaid and CHIP Coverage Codes for a beneficiary on the basis of the eligibility monthly income and the number of members in the family unit of the beneficiary, as illustrates on Tables I and II.
|
c.
|
On and after implementation of MAGI Methodologies for determining Medicaid and CHIP eligibility:
|
(1)
|
The Medicaid Program will be assigned the Medicaid and CHIP Coverage Codes for an individual on the basis of MAGI Monthly Income and MAGI Household Size of the individual.
|
(2)
|
Coverage Codes vary by household monthly income ranges.
|
(3)
|
Medicaid and CHIP Coverage Codes are based on ranges of MAGI Monthly Income as a percentage of the Puerto Rico Poverty Level (PRPL) in effect.
|
(4)
|
Example: if the MAGI Monthly Income of a Medicaid beneficiary is $300 per month with a MAGI household size of two (2) the coverage code assigned is 110. The evaluation uses Table IV as follows:
|
(a)
|
MAGI Monthly Income = 300;
|
(b)
|
MAGI household size = 2;
|
(c)
|
Position on the row for MAGI Household Size of 2;
|
(d)
|
Determine in which column of Coverage Code 100, 110, 120 ó 130 on the row, the MAGI Monthly Income of $300 fits;
|
(e)
|
MAGI Monthly Income of $300 fits in range $272-$542 which is under column 110; and,
|
(f)
|
Therefore, the beneficiary is assigned coverage code 110.
|
3.
|
Expand the number of coverage codes:
|
a.
|
The new coverage codes 120, 130, and 220 and the copayments amounts associate with these codes will be implemented on and after MAGI eligibility evaluation system go-lives.
|
b.
|
The new coverage codes will be assigned on the basis of MAGI Monthly Income and MAGI Household Size of the individual.
|
4.
|
Revise some copayments amounts on existing coverage codes, and establish copayment amounts on new coverage codes.
|
a.
|
Starting on July 1
st
, 2016:
|
(1)
|
All Medicaid beneficiaries with the coverage codes 100 or 110 will pay the new the copayments amounts associate with these codes, as illustrate on Table VI.
|
(2)
|
All CHIP beneficiaries with the coverage code 230 will continue paying the copayments amounts associate with this code, which remains as zero ($0) as illustrate on Table VI.
|
b.
|
On and after the implementation of MAGI methodologies for determining Medicaid or CHIP eligibility:
|
(1)
|
All Medicaid beneficiaries assigned the new coverage codes 120 and 130 will pay the copayment amounts associate with these codes, as illustrate on Table VI.
|
(2)
|
All CHIP beneficiaries with the coverage code 220 will pay the copayments amounts associate with this codes, which is zero ($0) as illustrate on Table VI.
|
5.
|
Copayment amount vary by coverage codes and by service.
|
1.
|
Table IV - Medicaid Coverage Codes, determined on the basis of MAGI Monthly Income and the MAGI Household Size of the individual. Coverage codes are assigned according to monthly income ranges defines as a percentage of the PRPL.
|
2.
|
Table V - CHIP Coverage Codes, determined on the basis of MAGI Monthly Income and the MAGI Household Size of the individual. Coverage codes are assigned according to income ranges defines as a percentage of the PRPL.
|
3.
|
Table VI - Medicaid and CHIP Coverage Codes and the applicable copayment amounts for each service.
|
TABLE IV
|
|||||
Medicaid Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
|
|||||
MAGI Household Size
|
Puerto Rico
Poverty Level
(PRPL)
|
MAGI Monthly Income Range by Coverage Code
|
|||
100
|
110
|
120
|
130
|
||
Percentage of PRPL
|
|||||
0%-50%
|
51%-100%
|
101%-150%
|
151%-UP
|
||
1
|
$0-$459
|
$0-$230
|
$231-$459
|
$460-$689
|
$690-UP
|
2
|
$0-$542
|
$0-$271
|
$272-$542
|
$543-$813
|
$814-UP
|
3
|
$0-$626
|
$0-$313
|
$314-$626
|
$627-$939
|
$940-UP
|
4
|
$0-$709
|
$0-$355
|
$356-$709
|
$710-$1,064
|
$1,065-UP
|
5
|
$0-$792
|
$0-$396
|
$397-$792
|
$793-$1,188
|
$1,189-UP
|
6
|
$0-$876
|
$0-$438
|
$438-$876
|
$877-$1,314
|
$1,315-UP
|
7
|
$0-$959
|
$0-$480
|
$481-$959
|
$960-$1,439
|
$1,440-UP
|
8
|
$0-$1,043
|
$0-$522
|
$523-$1,043
|
$1,044-$1,565
|
$1,566-UP
|
9
|
$0-$1,126
|
$0-$563
|
$564-$1,126
|
$1,127-$1,689
|
$1,690-UP
|
10
|
$0-$1,210
|
$0-$605
|
$606-$1,210
|
$1,211-$1,815
|
$1,816-UP
|
11
|
$0-$1,293
|
$0-$647
|
$648-$1,293
|
$1,294-$1,940
|
$1,941-UP
|
12
|
$0-$1,377
|
$0-$689
|
$690-$1,377
|
$1,378-$2,066
|
$2,067-UP
|
13
|
$0-$1,460
|
$0-$730
|
$731-$1,460
|
$1,461-$2,190
|
$2,191-UP
|
TABLE IV
|
|||||
Medicaid Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
|
|||||
MAGI Household Size
|
Puerto Rico
Poverty Level
(PRPL)
|
MAGI Monthly Income Range by Coverage Code
|
|||
100
|
110
|
120
|
130
|
||
Percentage of PRPL
|
|||||
0%-50%
|
51%-100%
|
101%-150%
|
151%-UP
|
||
14
|
$0-$1,544
|
$0-$772
|
$773-$1,544
|
$1,545-$2,316
|
$2,317-UP
|
15
|
$0-$1,627
|
$0-$814
|
$815-$1,627
|
$1,628-$2,441
|
$2,442-UP
|
TABLE V
|
|||
CHIP Cost Sharing Structure (Copayments) to be Effective On and After July 1, 2016
Coverage Codes and Its Determination
|
|||
MAGI Household Size
|
Puerto Rico Poverty Level (PRPL)
|
MAGI Monthly Income Range by Coverage Code
|
|
220
|
230
|
||
Percentage of PRPL
|
|||
0%-150%
|
151%-UP
|
||
1
|
$0-$459
|
$0-$689
|
$690-UP
|
2
|
$0-$542
|
$0-$813
|
$814-UP
|
3
|
$0-$626
|
$0-$939
|
$940-UP
|
4
|
$0-$709
|
$0-$1,064
|
$1,065-UP
|
5
|
$0-$792
|
$0-$1,188
|
$1,189-UP
|
6
|
$0-$876
|
$0-$1,314
|
$1,315-UP
|
7
|
$0-$959
|
$0-$1,439
|
$1,440-UP
|
8
|
$0-$1,043
|
$0-$1,565
|
$1,566-UP
|
9
|
$0-$1,126
|
$0-$1,689
|
$1,690-UP
|
10
|
$0-$1,210
|
$0-$1,815
|
$1,816-UP
|
11
|
$0-$1,293
|
$0-$1,940
|
$1,941-UP
|
12
|
$0-$1,377
|
$0-$2,066
|
$2,067-UP
|
13
|
$0-$1,460
|
$0-$2,190
|
$2,191-UP
|
14
|
$0-$1,544
|
$0-$2,316
|
$2,317-UP
|
15
|
$0-$1,627
|
$0-$2,441
|
$2,442-UP
|
1.
|
Performs a Medicaid beneficiary determination or redetermination on a beneficiary who enrolls in, or is enrolled in, a Platino Plan, and
|
2.
|
The beneficiary is assigned a coverage 120 or 130,
|
3.
|
The MAO will treat that beneficiary as if the coverage code was assigned as 110.
|
1.
|
The MAOs will implement the New Cost Sharing Structure, as indicated in Tables IV, VI, and VI.
|
2.
|
The MAOs will issue to each beneficiary a new ID Card with (i) the coverage code assigned by the Medicaid Program and (ii) copayments amount applicable to such code, as indicated in Table VI.
|
4.
|
The beneficiary will discard the old ID Card and use the new ID Card.
|
5.
|
The beneficiary will only be liable to pay the Table VI's copayments amount as a maximum.
|
1.
|
Children from 0 to less than 21 years of age.
|
2.
|
Pregnant women, during pregnancy and the post-partum period. The post-partum period begins on the last day of pregnancy and extends through the end of the month in which a 60-day period following the last day of pregnancy ends. Example: If March 3 is the last day of pregnancy, May 2 is the end of the 60-days, and May 31 is the last day of the month in which post-partum ends.
|
3.
|
Institutionalized Individuals, such as a nursing home.
|
4.
|
Beneficiaries receiving hospice care. As defined in Section 1905(o) of the Social Security Act, hospice care means the care furnished by a hospice program to a terminally ill individual who has voluntarily elected to have payment made for hospice care.
|
5.
|
American Indians and Alaskan Natives (AI/AN).
|
1.
|
Emergency services, (including ambulatory, hospital, and post-stabilization services), as defined at Section 1932(b)(2) of the Social Security Act and in the federal regulation, 42 CFR §438.114(a).
|
2.
|
Family planning services and supplies as described in Section 1905(a)(4)(C) of the Social Security Act, including contraceptives and pharmaceuticals for which the Puerto Rico claims or could claim Federal match at the enhanced rate under Section 1903(a)(5) of the Social Security Act for family planning services and supplies.
|
3.
|
Preventive services provided to children under 18 years of age, as described in the federal regulation at 42 CFR §457.520 of chapter D.
|
4.
|
Pregnancy-related services, including those services as defined in the federal regulation, 42 CFR §440.210(a)(2) and 42 CFR §440.250(p), and counseling services and drugs for cessation of tobacco use. All services provided to pregnant women, during pregnancy and the 60-day post-partum period, will be considered as pregnancy-related.
|
5.
|
Provider-preventable services as defined in the federal regulation, 42 CFR §447.26(b).
|
1.
|
The Preferred Provider Network is a subset of providers within the MCO General Network of Providers. The objectives of the Preferred Provider model are to:
|
a.
|
Increase access to Providers and needed services;
|
b.
|
Improve timely receipt of services;
|
c.
|
Improve the quality of beneficiary care;
|
d.
|
Enhance continuity of care; and
|
e.
|
Facilitate effective exchange of personal health information between providers and the MCO.
|
2.
|
Copayments do not apply to any service provided to a Medicaid beneficiary by a provider participating in the Preferred Provider Network.
|
3.
|
A provider who is a member of the Preferred Provider Network provides services to beneficiaries without the requirement for referrals and copayments.
|
4.
|
The MCO’s contracts with a provider who is a member of the Preferred Provider Network shall prohibit the provider from collecting copayments from Medicaid beneficiary.
|
5.
|
The Medicaid beneficiary is not required to use the Preferred Provider Network. But, if the Medicaid beneficiary chooses a provider from the MCO General Network of Providers, he/she is subject to the applicable copayments amount.
|
6.
|
If the Medicaid beneficiary needs a covered service and cannot have access to a specialist within the Preferred Provider Network within thirty (30) calendar days, the beneficiary shall have access to the specialist within the MCO General Network of Providers, without the imposition of copayments, but shall return to the PPN specialist once the PPN specialist is available to treat the beneficiary.
|
7.
|
Dentists and Pharmacies are not part of the Preferred Provider Network.
|
8.
|
For a Platino Plan, MAOs have to be in compliance with this exemption, if they operate a Preferred Provider Network model.
|
1.
|
The Puerto Rico Medicaid State Plan does not allow charging copayment for non-emergency services provided in a hospital emergency room to a Medicaid or CHIP beneficiary when the beneficiary:
|
a.
|
Calls the MCO Medical Advice Service Line, prior to visiting the hospital emergency room;
|
b.
|
Receives a code or an identification number;
|
c.
|
Presents such number at the time of the visit to the hospital emergency room; and
|
d.
|
The hospital emergency room will waive the beneficiary copayment for non-emergency services provided in a hospital emergency room.
|
2.
|
Regardless of whether the beneficiary uses or does not use the MCO Medical Advice Service Line, under no circumstance will a copayment be imposed on a Medicaid or CHIP Beneficiary for the treatment of an Emergency Medical Condition or Psychiatric Emergency provided.
|
3.
|
For a Platino Plan, MAOs will comply with the "Medical Advice Service Line Copayment Exemption", as described herein.
|
1.
|
High-Tech Laboratories.
|
2.
|
Clinical Laboratories.
|
3.
|
X-Rays.
|
4.
|
Special Diagnostic Test.
|
1.
|
Emergency medical condition means a medical condition manifesting itself by acute symptoms of sufficient severity (including severe pain) that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in the following:
|
a.
|
Placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy;
|
b.
|
Serious impairment to bodily functions; and
|
c.
|
Serious dysfunction of any bodily organ or part.
|
2.
|
Emergency services means covered inpatient and outpatient services that are:
|
a.
|
Furnished by a provider that is qualified to furnish these services under 42 CFR §438.114 and
|
b.
|
Needed to evaluate or stabilize an emergency medical condition.
|
3.
|
Post-Stabilization care services means covered services, related to an emergency medical condition that are provided after an enrollee is stabilized in order to maintain the stabilized condition, or to improve or resolve the enrollee's condition.
|
1.
|
To Medicaid beneficiary when he/she:
|
a.
|
Calls the MCO Medical Advice Service Line, previous to visit the hospital emergency room,
|
b.
|
Receives a code or an identification number, and
|
c.
|
Presents such number at the time of the visit to the hospital emergency room. In this instance, the copayment is waived.
|
2.
|
To Medicaid exempted groups of individuals listed in this Cost Sharing Policy under section "Copayments Are Not Charged To The Following Beneficiaries".
|
3.
|
Copayments do not apply to any service provided to a Medicaid beneficiary by a hospital emergency room participating in the Preferred Provider Network (PPN).
|
4.
|
For Medicaid beneficiaries with a Platino Plan, MAOs have to be in compliance with the "Preferred Provider Network (PPN) Copayment Exemption" and the "Medical Advice Service Line Copayment Exemption", as described under section "Other Copayments Exemptions".
|
1.
|
First, conducts an appropriate medical screening to determine
|
a.
|
Whether or not an emergency medical condition exists as required under 42 CFR §489.24 subpart G and b. That the individual does not need emergency services.
|
2.
|
Second, if not an emergency medical condition exists and before providing non-emergency services and imposing cost sharing for such services, the hospital's emergency room:
|
a.
|
Informs the beneficiary of the amount of his or her copayment obligation for non-emergency services provided in the hospital emergency room;
|
b.
|
Provides the beneficiary with the name and location of an available and accessible alternative non-emergency services provider;
|
c.
|
Determines that the alternative provider can provide services to the individual in a timely manner with the imposition of a lesser copayment amount or no copayment if the beneficiary is otherwise exempt from copayment; and
|
d.
|
Provides a referral to coordinate scheduling for treatment by the alternative provider.
|
3.
|
The federal regulation, 42 CFR §447.51, defines
Alternative Non-Emergency Services Provider
as a Medicaid provider, such as a physician's office, health care clinic, community health center, hospital outpatient department, or similar provider that can provide clinically appropriate services in a timely manner.
|
4.
|
Therefore, the hospital emergency room cannot charge the copayment if it does not follow and comply with the process as described herein.
|
1.
|
Before providing non-emergency services and imposing the applicable copayment for such services the hospital's emergency room will comply with the above mentioned requirements.
|
2.
|
There is a process in place to identify hospital emergency room services as non-emergency's room services for purposes of imposing cost sharing. This process does not:
|
a.
|
Limit hospital's obligations for screening and stabilizing treatment of an emergency medical condition under section 1867 of the Social Security Act (EMTALA); or
|
b.
|
Modify any obligations under either state or federal standards relating to the application of a prudentlayperson standard for payment or coverage of emergency medical services by any MCO (MAO for a Platino Plan).
|
3.
|
As part of the New Cost Sharing Structure, all participating hospital emergency rooms located in Puerto Rico will have their payments reduced by the copayment amount for non-emergency services provided at the hospital emergency room.
|
4.
|
Contracts between ASES and MCOs and MAOs include the non-emergency hospital emergency room copayment rules. MCOs and MAOs are required by contract to make these rules know to beneficiaries and providers. Compliance with these cost sharing rules will be monitored by ASES.
|
1.
|
All generic drugs, except for:
|
a.
|
Those with a significantly higher cost compared to their therapeutic alternatives, in which case they are classified as non-preferred drugs.
|
b.
|
Those with a low safety profile compared to their therapeutic alternatives, in which case they are classified as non-preferred drugs.
|
2.
|
Branded drugs that:
|
a.
|
Have no generic available and their net cost does not exceed a certain limit, otherwise they are classified as non-preferred.
|
b.
|
Their generic drug alternative is more expensive.
|
c.
|
Are contracted by ASES.
|
3.
|
Specialty drugs contracted by ASES.
|
1.
|
Branded drugs, except for:
|
a.
|
Those that have no generic drug available and their cost does not exceed a certain limit, in which case they are classified as preferred drug.
|
b.
|
Those with a more expensive generic (net cost), in which case they are classified as preferred drug.
|
c.
|
Are contracted by ASES, in which case they are classified as preferred drugs.
|
2.
|
Generic drugs that their established safety, efficacy, and cost profile (cost-effectiveness) are low compared to their therapeutic alternatives.
|
3.
|
Specialty drugs not contracted by ASES.
|
1.
|
To Medicaid beneficiaries exempted groups of individuals listed in this Cost Sharing (Copayments) Policy under section Beneficiaries Copayments Exemptions
|
2.
|
To Medicaid exempted services as described in this Cost Sharing (Copayments) Policy under section Health Care Services Copayments Exemptions, such as contraceptives for family planning services and drugs for cessation of tobacco use.
|
3.
|
For Platino Plans, MAOs will comply with this rule on January 1
st
, 2017.
|
1.
|
The beneficiary's prescribing provider determines based on medical necessity that:
|
a.
|
A Formulary non-preferred drug can be covered when a Formulary preferred drug for treatment of the same health condition either: (i) is less effective for the beneficiary health condition, (ii) has adverse effects for the beneficiary, or (iii) both.
|
b.
|
A non-Formulary drug can be covered when a Formulary preferred or non-preferred drug for treatment of the same health condition either: (i) is less effective for the beneficiary health condition, (ii) has adverse effects for the beneficiary, or (iii) both.
|
2.
|
The MCOs and the provider follow the usual pre-authorization procedure to consider these cases.
|
a.
|
The exception process is utilized when there is an indication that there is a medically necessary reason to cover a non-preferred drug or non-Formulary drug.
|
b.
|
When an exception is requested by the beneficiary, the MCO will do a clinical evaluation to consider and review the justification given by the prescribing provider, beneficiary's medical records, and any other relevant documentation to determine medical necessity based on the following criteria:
|
(1)
|
Contraindications to the medication listed in the Formulary.
|
(2)
|
History of adverse reactions to the medication listed in the Formulary.
|
(3)
|
Therapeutic failure of all available alternatives in the Formulary.
|
(4)
|
Non-existence of alternative therapy in the Formulary.
|
c.
|
If the documents and information provided supports the exception, the preauthorization is granted.
|
d.
|
The beneficiary has the right to file an appeal and request a fair hearing to review the determination that has been notified by the MCO.
|
3.
|
If the authorization is granted, the Medicaid Program and ASES have a timely process in place in which the pharmacy only charges to the Medicaid beneficiary the copayment applicable to a preferred drug, which is: $1 to beneficiaries with coverage code 110, $2 with coverage code 120, and $3 with coverage code 130.
|
4.
|
According with the federal regulation, 42 CFR §447.53(e), the Medicaid Program and ASES certify that in such cases the reimbursement to the pharmacy is based on the appropriate copayment amount.
|
5.
|
For Platino Plans, MAOs will comply with this rule on January 1
st
, 2017.
|
1.
|
In the event a beneficiary needs a drug or medicine that is not included in Puerto Rico Medicaid Formulary, the MCOs and providers will follow the usual pre-authorization procedure to allow beneficiaries to obtain drugs not included in the Formulary.
|
2.
|
The use of bioequivalent medications and drugs approved by the FDA and local regulations is authorized, unless contraindicated for the beneficiary by the physician or dentist who prescribed the medication.
|
3.
|
The absence of bioequivalent medications and drugs in stock does not exonerate the pharmacist from dispensing the medication nor does it entail the payment of additional surcharges by beneficiaries.
|
4.
|
Brand name drugs will be dispensed if the bioequivalent is not available at the pharmacy.
|
5.
|
All prescriptions shall be filled and dispensed at a participating pharmacy properly licensed under the laws of Puerto Rico freely chosen by the beneficiary.
|
6.
|
Pharmacies and Dentists are not part of the Preferred Provider Network.
|
7.
|
The MCO and/or provider cannot establish a different drug formulary nor limit in any way the drugs and medications included in the Puerto Rico Medicaid Formulary.
|
1.
|
At July 1
st
, 2016 and until implementation of MAGI Methodologies for determining Medicaid & CHIP eligibility, the Medicaid Program will continue determining the 5% cap on total copayments per quarter for a beneficiary on the basis of the eligibility monthly income and the number of members in the family unit of the beneficiary.
|
2.
|
On and after implementation of MAGI Methodologies for determining Medicaid & CHIP eligibility, the Medicaid Program will determine the 5% cap on total copayments per quarter for a beneficiary on the basis of his/her MAGI Monthly Income and his/her MAGI Household Size.
|
3.
|
For example: if a beneficiary Monthly Income is $300 per month, his/her quarterly copayment limit will be $45 ($300 x 3 months = $900 x 5% = $45).
|
1.
|
Increase or decrease in income.
|
2.
|
Increase or decrease in household size.
|
1.
|
The reimbursement requests must be submitted no later than two (2) calendar months after the end of the quarter.
|
2.
|
Reimbursement requests must include all minimum mandatory information, as instructed on the reimbursement request form, and can be submitted:
|
a.
|
In person: at ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico 00926-2712) or in any of the Medicaid Local Offices throughout the Island;
|
b.
|
By mail, to following postal address: ASES Client Services, PO Box 195661, San Juan, PR, 00919-5661; or
|
c.
|
By Facsimile (Fax), to ASES Fax number: 787-474-3347.
|
3.
|
ASES will conduct an investigation to evaluate reimbursement requests which will be completed no later than four (4) months from the end of the quarter for which the reimbursement request is made. The results of the investigation of any reimbursement request will be notified to the beneficiary no later than fifteen (15) calendar days from the limit date for the investigation. ASES will send a written communication to the beneficiary explaining the results of the reimbursement process investigation, and:
|
a.
|
If the amount to be reimbursed is five dollars ($5) or more, ASES will issue a reimbursement and will send a written communication to the beneficiary explaining the results of the reimbursement process investigation.
|
b.
|
If the amount to be reimbursed is less than five dollars ($5), the amount will be kept as a credit for a two
|
4.
|
The individual has the right to file an appeal and request a fair hearing to review the determination that has been notified by ASES. The appeal must be presented in writing and within a period of thirty (30) days, counting from the date of the ASES' notice. The appeal may be submitted:
|
a.
|
In person: at the ASES Central Office (physical address: #1549 Calle Alda, Urbanización Caribe, Río Piedras, Puerto Rico, 00926-2712);
|
b.
|
By mail, to following postal address: ASES Client Services, PO Box 195661, San Juan, PR, 00919-5661; or
|
c.
|
By Facsimile (Fax), to ASES Fax number: 787-474-3347.
|
5.
|
The determination will be final if the individual does not appeal within the term of thirty (30) days.
|
1.
|
Beneficiaries with an eligibility monthly income at or below 100 percent (100%) of the PRPL:
|
a.
|
When copayment charge is allowed or the beneficiary is not part of an otherwise exempt group, the provider, including a pharmacy or dentist, may request the applicable copayment amount, but cannot not deny services to a beneficiary on account of the his/her inability to pay the copayment amount at the time of receiving a service.
|
b.
|
The beneficiary will receive the health care service without paying the cost sharing at the time of receiving the service.
|
c.
|
Although services may not be denied, the beneficiary is still obligated to pay the cost sharing unless it is waived by the provider.
|
d.
|
If the copayment is not waived, the provider may ask the beneficiary for outstanding copayments amount the next time the beneficiary comes in for a service and/or send a bill to the beneficiary.
|
e.
|
In these cases, a hospital can charge the applicable copayment for non-emergency services furnished in its emergency room, if the conditions under 42 CFR 447.54(d) and the copayment rules for this service have been satisfied.
|
f.
|
Nothing prohibits a provider from choosing to reduce or to waive the copayment on a case-by-case basis.
|
g.
|
Medicaid beneficiaries identified by coverage code 100:
|
(1)
|
Prior MAGI Implementation and as illustrate on Table VII, all Medicaid beneficiaries identified by coverage code 100 have an Eligibility Monthly Income unit below 100% of the PRPL.
|
(2)
|
On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 100 have a MAGI household monthly income below 100% of the PRPL.
|
h.
|
Medicaid beneficiaries identified by coverage code 110:
|
(1)
|
Prior MAGI Implementation and as illustrate on Table VII, there are some Medicaid beneficiaries identified by coverage code 110 have an Eligibility Monthly Income at or below 100% of the PRPL.
|
(2)
|
On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 110 have a MAGI household monthly income at or below 100% of the PRPL.
|
2.
|
Beneficiaries with MAGI household monthly income above 100 percent (100%) of the PRPL:
|
a.
|
When copayment charge is allowed or the beneficiary is not part of an otherwise exempt group, the provider, including a pharmacy and a dentist, may request the applicable copayment amount as a condition for receiving the service.
|
b.
|
In these cases, a hospital can charge the applicable copayment for non-emergency services furnished in its emergency room, if the conditions under 42 CFR 447.54(d) and the copayment rules for this service have been satisfied.
|
c.
|
Nothing prohibits a provider from choosing to reduce or to waive the copayment on a case-by-case basis.
|
d.
|
Medicaid beneficiaries identified by coverage code 110: Prior MAGI Implementation and as illustrate on Table VII, there are some Medicaid beneficiaries identified by coverage code 110 have an Eligibility Monthly Income above 100% of the PRPL.
|
e.
|
Medicaid beneficiaries identified by coverage code 120 or 130: On and After MAGI Implementation and as illustrate on Table VIII, all Medicaid beneficiaries identified by coverage code 120 or 130 have a MAGI household monthly income above 100% of the PRPL.
|
3.
|
The following tables show Puerto Rico Poverty Level (PRPL) for Medicaid and CHIP and the coverage codes:
|
a.
|
Table VII: Puerto Rico Poverty Level (PRPL) Prior MAGI Implementation.
|
b.
|
Table VIII: Puerto Rico Poverty Level (PRPL) On and After MAGI Implementation.
|
TABLE VII
|
|||||
Puerto Rico Poverty Level (PRPL) Prior MAGI Implementation
|
|||||
Member in
Family Unit
|
Puerto Rico Poverty Level (PRPL)
|
Eligibility Monthly Income Ranges by Coverage Codes
|
|||
At or Below 100% of the PRPL
|
Above 100% of the PRPL
|
||||
100
|
110
|
Ranges Above 100% PRPL
|
110
|
||
1
|
$0-$413.53
|
$0-$200
|
$201-$413.53
|
$413.54-UP
|
$413.54-$550
|
2
|
$0-$488.72
|
$0-$248
|
$249-$488.72
|
$488.73-UP
|
$488.73-$650
|
3
|
$0-$563.91
|
$0-$295
|
$296-$563.91
|
$563.92-UP
|
$563.92-$750
|
4
|
$0-$639.10
|
$0-$343
|
$344-$639.10
|
$639.11-UP
|
$639.11-$850
|
5
|
$0-$714.29
|
$0-$390
|
$391-$714.29P
|
$714.30-UP
|
$714.30-$950
|
6
|
$0-$789.47
|
$0-$438
|
$439-$789.47
|
$789.48-UP
|
$789.48-$1,050
|
7
|
$0-$864.66
|
$0-$485
|
$486-$864.66
|
$864.67-UP
|
$864.67-$1,150
|
8
|
$0-$939.85
|
$0-$533
|
$534-$939.85
|
$939.86-UP
|
$939.86-$1,250
|
9
|
$0-$1,015.04
|
$0-$580
|
$581-$1,015.04
|
$1,015.05-UP
|
$1,015.05-$1,350
|
10
|
$0-$1,090.23
|
$0-$628
|
$629-$1,090.23
|
$1,090.24-UP
|
$1,090.24-$1,450
|
11
|
$0-$1,165.41
|
$0-$675
|
$676-$1,165.41
|
$1,165.42-UP
|
$1,165.42-$1,550
|
12
|
$0-$1,240.60
|
$0-$723
|
$724-$1,240.60
|
$1,240.61-UP
|
$1,240.61-$1,650
|
13
|
$0-$1,315.79
|
$0-$770
|
$771-$1,315.79
|
$1,315.79-UP
|
$1,315.79-$1,750
|
14
|
$0-$1,390.98
|
$0-$818
|
$819-$1,390.98
|
$1,390.98-UP
|
$1,390.98-$1,850
|
15
|
$0-$1,466.17
|
$0-$865
|
$866-$1,466.17
|
$1,466.17-UP
|
$1,466.17-$1,950
|
TABLE VIII
|
|||||
Puerto Rico Poverty Level (PRPL) To Be Effective Implemented On and After MAGI Implementation
|
|||||
MAGI Household
Size
|
Puerto Rico
Poverty Level
(PRPL)
|
MAGI Monthly Income Range by Coverage Code
|
|||
100
|
110
|
120
|
130
|
||
At or Below 100% of the PRPL
|
Above 100% of the PRPL
|
||||
0%-50%
|
51%-100%
|
101%-150%
|
151%-UP
|
||
1
|
$0-$459
|
$0-$230
|
$231-$459
|
$460-$689
|
$690-UP
|
2
|
$0-$542
|
$0-$271
|
$272-$542
|
$543-$813
|
$814-UP
|
3
|
$0-$626
|
$0-$313
|
$314-$626
|
$627-$939
|
$940-UP
|
TABLE VIII
|
|||||
Puerto Rico Poverty Level (PRPL) To Be Effective Implemented On and After MAGI Implementation
|
|||||
MAGI Household
Size
|
Puerto Rico
Poverty Level
(PRPL)
|
MAGI Monthly Income Range by Coverage Code
|
|||
100
|
110
|
120
|
130
|
||
At or Below 100% of the PRPL
|
Above 100% of the PRPL
|
||||
0%-50%
|
51%-100%
|
101%-150%
|
151%-UP
|
||
4
|
$0-$709
|
$0-$355
|
$356-$709
|
$710-$1,064
|
$1,065-UP
|
5
|
$0-$792
|
$0-$396
|
$397-$792
|
$793-$1,188
|
$1,189-UP
|
6
|
$0-$876
|
$0-$438
|
$438-$876
|
$877-$1,314
|
$1,315-UP
|
7
|
$0-$959
|
$0-$480
|
$481-$959
|
$960-$1,439
|
$1,440-UP
|
8
|
$0-$1,043
|
$0-$522
|
$523-$1,043
|
$1,044-$1,565
|
$1,566-UP
|
9
|
$0-$1,126
|
$0-$563
|
$564-$1,126
|
$1,127-$1,689
|
$1,690-UP
|
10
|
$0-$1,210
|
$0-$605
|
$606-$1,210
|
$1,211-$1,815
|
$1,816-UP
|
11
|
$0-$1,293
|
$0-$647
|
$648-$1,293
|
$1,294-$1,940
|
$1,941-UP
|
12
|
$0-$1,377
|
$0-$689
|
$690-$1,377
|
$1,378-$2,066
|
$2,067-UP
|
13
|
$0-$1,460
|
$0-$730
|
$731-$1,460
|
$1,461-$2,190
|
$2,191-UP
|
14
|
$0-$1,544
|
$0-$772
|
$773-$1,544
|
$1,545-$2,316
|
$2,317-UP
|
15
|
$0-$1,627
|
$0-$814
|
$815-$1,627
|
$1,628-$2,441
|
$2,442-UP
|
1.
|
In the Eligibility and Enrollment System;
|
2.
|
In the Eligibility Verification System; and
|
3.
|
On the Beneficiary Identification Card.
|
1.
|
The Social Security Act (SSA), Sections 1916 and 1916A.
|
2.
|
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation.
|
3.
|
The Puerto Rico Medicaid and CHIP State Plans.
|
4.
|
Cost Sharing Policy (Copayments) for Medicaid and CHIP Beneficiaries.
|
5.
|
The New Cost Sharing (Copayment) Structure for Medicaid and CHIP Beneficiaries.
|
1.
|
ASES has contracted with more than one MCO (MAO for a Platino Plan) to deliver the health care services establish under Puerto Rico Medicaid State Plan.
|
2.
|
ASES provides assurance that it calculates the payments to MCOs (MAOs for a Platino Plan) to take into account the copayments established under the Medicaid State Plan for beneficiaries or services not exempt from copayment, regardless of whether the MCO (MAO for a Platino Plan) imposes the copayment or the copayment is collected by the providers.
|
3.
|
Any MCO, MAO, or PBM contracted by ASES is allowed to impose copayments on beneficiaries up to the amounts specified in this Cost Sharing (Copagos) Policy, but such MCO, MAO, or PBM cannot exceed the copayment amounts established under the Puerto Rico Medicaid State Plan, as shown in this Policy.
|
4.
|
Contracts between ASES and MCOs, MAOs, and PBMs shall include this Cost Sharing Policy.
|
5.
|
MCOs and PBMs are required by contract:
|
a.
|
To make these rules know to beneficiaries and providers.
|
b.
|
To comply with this Cost Sharing Policy and the Puerto Rico Medicaid State Plan.
|
6.
|
For Platino Plans, MAOs have to be in compliance with this rule on January 1
st
, 2017.
|
7.
|
ASES will monitor the compliance with this Cost Sharing Policy.
|
1.
|
Except as provided under federal regulation 42 CFR §§447.56(c)(2) and (c)(3), each MCO must reduce the payment it makes to a provider by the amount of a beneficiary's copayment obligation, regardless of whether the provider has collected the copayment or has waived the copayment. Where the MCO contracts a provider on a capitated basis, the beneficiary’s copayment obligation is taken into account in calculating capitated rates.
|
2.
|
Contracts between ASES and MCOs shall include this Cost Sharing (Copagos) Policy. ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.
|
3.
|
Contracts between ASES and MCOs and providers shall include this Cost Sharing Policy. MCOs will monitor the providers' compliance with this Cost Sharing Policy's requirement.
|
4.
|
For Platino Plans, MAOs have to be in compliance with this rule on January 1
st
, 2017. ASES will monitor the MCOs compliance with this Cost Sharing Policy's requirement.
|
1.
|
The Medicaid Program notifies the beneficiary the "Results of Cost Sharing Determination" through the MA-10 Form (Notification of Action Taken on Application and/or Recertification), which is provided after a determination or redetermination of eligibility or when the Results of Cost Sharing Determination
is revised.
|
2.
|
ASES notifies to the beneficiary the assign coverage code and the copayments amounts through the ID Card, which is provided by the MCO (MAO for a Platino Plan).
|
1.
|
In the Eligibility and Enrollment System;
|
2.
|
In the Eligibility Verification System; and
|
3.
|
On the Beneficiary Identification Card.
|
1.
|
In person: at any Puerto Rico Medicaid Program Local Office throughout the Island;
|
2.
|
By mail, to the following postal address: Medicaid Program, Puerto Rico Department of Health, P.O. Box 70184, San Juan, P.R. 00936-8184; or
|
3.
|
By Facsimile (Fax) to: (787) 759-8361.
|
1.
|
They administer the Medicaid and CHIP Cost Sharing (Copagos) Policy in accordance with:
|
a.
|
The Social Security Act (SSA), Sections 1916 and 1916A
|
b.
|
The federal regulation, 42 CFR §§447.50-447.57 (excluding 42 CFR §447.55) of the federal regulation,
|
c.
|
The Puerto Rico Medicaid and CHIP State Plan.
|
2.
|
The cost sharing amount established for each service is always less than the amount that is paid for the service.
|
3.
|
The contracts with the MCOs, MAOs, and PBMs provide that any copayment charges imposes on Medicaid or CHIP beneficiaries are in accordance with the Puerto Rico Medicaid State Plan and this Cost Sharing (Copayments) Policy.
|
1.
|
Issued a Public Notice, in English and Spanish, to inform the beneficiaries, applicants, providers, and general public of the Cost Sharing SPA that specifies, among other topics:
|
a.
|
The copayment amounts for each service by coverage code.
|
b.
|
The beneficiaries who are subject to the copayment charges.
|
c.
|
The consequences, if any, for a beneficiary who does not pay a copayment amount.
|
2.
|
Have provided a reasonable opportunity for stakeholder comments about the Medicaid SPA for the New Cost Sharing Structure.
|
Page #
|
||
I. |
INTRODUCTION
|
5 |
II. |
DEFINITIONS
|
7 |
III. |
ELIGIBILITY
|
16 |
1. ELIGIBILITY CONCEPTS
|
17 | ||
1.1 Eligibility Determination
|
|||
1.2 MA-10
|
|||
1.3 Eligibility Effective Date
|
|||
1.4 Certification Date and its Relation with the Effective Date
|
|||
1.5 Eligibility Effective Date in the Case of a Newborn
|
|||
2. MAGI ELIGIBILITY RULES
|
19 | ||
2.1 Transfer of Eligibility Files from Medicaid
|
|||
2.2 Medicaid Family Record Changes
|
|||
2.3 Medicaid Member Record Changes
|
|||
2.4 Eligibility Records Concerning Household
|
|||
2.5 Additional Health Insurance Record
|
|||
3. MEDICAID/CHIP RETROACTIVE ELIGIBILITY
|
23 | ||
3.1 Medicaid or CHIP’s Retroactive Eligibility Effective Date
|
|||
3.2 Group of Records for Retroactive Periods
|
|||
4.TERMINATION OF ELIGIBILITY AND RECERTIFICATION PROCESS
|
24
|
||
5. ELIGIBILITY PERIOD EXTENSION
|
23 | ||
5
.1
Appeals Process for Re-Certification
|
|||
5.2 Appealing a Certification
|
|||
5.3 Eligibility Extension Due to Pregnancy
|
|||
6. ELIGIBILITY PERIOD TERMINATION..
|
26 | ||
IV. ENROLLMENT PROCESSES
|
|||
7. DATA EXCHANGE
|
27 | ||
8. VALIDATION PROCESS
|
28 | ||
9. ENROLLMENT FILES
|
30 | ||
|
9.1
Enrollment Files (.sus)
|
|
|
9.2 Eligibility Files (.ref)
|
|||
9.3 Data Export Files (.exp)
|
|||
9.4 Rejected Enrollment File (.rjc)
|
9.5 Eligibility Query File (.query)
|
|||
9.6 Eligibility Query Response File (.res)
|
|||
10. GHIP PLAN BENEFICIARY ENROLLMENT
|
31 | ||
10.1 Effective Date of Enrollment
|
|||
10.2 Date of Enrollment in the Case of Newborns
|
|||
10.3 Date of Re-enrollment of Dependent Children in Pregnancy Status
|
|||
10.4 Date of Re-enrollment in Cases of Loss of Eligibility
|
|||
10.5 PCP/PMG Change Enrollment Effective Date
|
|||
10.6 Changes in Coverage Codes and Enrollment
|
|||
10.7 Process Date
|
|||
11. MEDICARE PLATINO ENROLLMENT PROCESS
|
32 | ||
11.1 Eligibility Query Preceding a Medicare Platino Enrollment
|
|||
11.2 Transfer of Beneficiaries to Platino Products
|
|||
11.3 Effective Date of Medicare Platino Enrollment
|
|||
11.4 Recovery of Eligibility and Prospective Enrollment
|
|||
12. RETROACTIVE ENROLLMENT | 34 | ||
12.1 Retroactive Enrollment for Federal and State Category
|
|||
12.2 Retroactive Enrollment for Platino Plans
|
|||
13. ENROLLMENT RECORD
|
36 | ||
14. ENROLLMENT RECORD FIELDS
|
37 | ||
15. REJECTION OF AN ENROLLMENT RECORD
|
43 | ||
16. REJECTED ENROLLMENTS MANAGEMENT
|
43 | ||
17. ERROR CODES
|
43 | ||
18. NEW ERROR CODES UNDER MAGI
|
44 | ||
19. ERROR CODES TABLE
|
44 | ||
20. DISENROLLMENT
|
55 | ||
20.1 Disenrollment under GHIP and Medicare Platino
|
|||
20.2 Effective Date of Disenrollment
|
|||
21. GHIP PLAN DISENROLLMENT
|
55 | ||
21.1 Disenrollment Made by ASES or Medicaid
|
|||
21.2 Effective Date of the Programmatic Disenrollment
|
|||
22. MEDICARE PLATINO DISENROLLMENT
|
57 | ||
22.1 Disenrollment by Beneficiary Request
|
|||
22.2 Automatic Disenrollment
|
|||
22.3 Retroactive Disenrollment
|
|||
23. UPDATES TO NEW ENROLLMENT AND ENROLLING OMITTED BENEFICIARIE
|
58 |
24. CARRIERS RESPONSIBILITIES IN THE ENROLLMENT PROCESSES
|
59 | ||
V. PREMIUM PAYMENT
|
61 | ||
25 PREMIUM PAYMENTS GENERAL
|
62 | ||
26. TYPES OF PAYMENT
|
62 | ||
26.1 Monthly Payments
|
|||
26.2 Prorated Payments
|
|||
26.3 Retroactive Payments
|
|||
26.4 Prorated-retroactive payment
|
|||
26.5 Adjustments
|
|||
26.6 Special Adjustments
|
|||
26.7 Reasons why ASES will not execute a premium payment
|
|||
26.8 EDI 820 Payment File
|
|||
VI. SYSPREM: ENROLLMENT IN HISTORICAL DATA
|
65 | ||
27. ENROLLMENT IN HISTORICAL DATA
|
65 | ||
27.1 SYSPREM Functionality
|
|||
27.2 Carrier’s Eligibility File
|
|||
27.3 Premium Payment for SYSPREM
|
|||
27.4 SYSPREM Error Codes
|
I.
|
INTRODUCTION
|
I. INTRODUCTION
|
II.
|
DEFINITIONS
|
II. DEFINITIONS
|
III.
|
ELIGIBILITY
|
1. ELIGIBILITY CONCEPTS
|
2. MAGI ELIGIBILITY RECORDS CHANGES
|
FIELD
|
DESCRIPTION
|
Record_type
|
It is labeled with the letter “F” in the
Record_type
column
.
|
Family Code
|
The last 11 digits of the MPI Number will be included in the family code column.
|
Tran_id
|
New values (‘1’, ‘2’, ‘3’) were added to the
Tran_id
column to identify retroactive eligibility periods. This will be explained further below, in the MAGI Retroactive Eligibility Period Section.
|
Contact last name 1
|
P
aternal surname of the contact person.
Required
.
|
Contact last name 2
|
M
aternal surname of the contact person.
Required.
|
Contact first name
|
F
irst name of the contact person.
Required.
|
Residence-zip
|
Postal zone of the physical address.
Required
.
|
Residence-zip4
|
Additional digits for the postal zone.
|
PCT-of-poverty-level
|
This field will not be used. It must be filled with zeroes.
|
Deductible-level-code
|
This field will not be used. It must be filled with zeroes.
|
ELA_errors
|
This field will not be used. It must be fill with zeroes.
|
Mancomunado
|
This field will not be used. It must be fill with zeroes.
|
Application Number [new field]
|
This number corresponds to a unique number, linked to the way people fill out in the Medicaid Office, when they request the GHIP or when a recertification occurs. This number changes each time the "Family" group is to be re-certified.
|
FIELD
|
DESCRIPTION
|
Record Type
|
This record is identified with the letter "M" in this column.
|
Member suffix
|
The content of the
Member suffix
column will always be “01”.
|
Tran_id
|
New values (‘1’, ‘2’, ‘3’) were added to the
Tran_id
column to identify retroactive eligibility periods. This will be explained further below.
|
Contact Member
|
New field.
The MPI number of the contact member will be included in this field. If the contact person or guardian does not belong to the medically indigent population, Medicaid will assign him/her a number. This field is tied to the contact name in the family record.
|
Relationship
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Place-of-Birth
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Category
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Category-2
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Condition
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Med-ins-code
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Policy
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Class
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Class-2
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Denial-cat
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Denial-cat 2
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Pilot-cat
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Pilot-class
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Pilot-denial
|
This field will not be used. Its content will consist of zeroes or spaces.
|
Cost-Sharing Flag
|
New Field. The accepted values are:
N
= No exception,
C
= Child,
P
= Pregnant,
A
= American Indian,
I
= Institutionalized,
H
= Hospice. For the moment, this piece of information will remain informational in nature.
|
Max-copay
|
New field. This is the maximum co-pay amount that a beneficiary can pay within a given period. For the moment, this piece of information will remain informational in nature.
|
Extension-Flag
|
New field. Its content will be:
N
= Not undergoing an appeals process
A
= Currently undergoing an appeals process
U
= Close of the appeal
P
= Extension due to pregnancy
X
= Extension due to other reasons
The appeals process will be explained further below (See Section 8.1).
|
Spend Down Flag
|
New field. This field indicates whether or not “S” (“Spend-down”) records are included. If it does not contain this type of record, this field will show the letter “N”. If it does contain this type of record, it will show the letter “S”.
|
FIELD
|
DESCRIPTION
|
Record_type
|
It is labeled with the letter “O”.
|
Tran_id
|
This field will have the same content as the Family and Member records.
|
Process_date
|
Will have the same date contained in the Family and Member records.
|
MPI_1 al MPI_18
|
These are the MPIs of each member related to the member in the
Member_id
field at the time during which the eligibility evaluation is being carried out at
Medicaid
’s Offices.
|
FIELD
|
DESCRIPTION
|
Record_type
|
It is labeled with the letter “I”.
|
Tran_id
|
New values (‘1’, ‘2’, ‘3’) were added to the
Tran_id
column to identify retroactive eligibility periods. This will be explained further below in Medicaid or CHIP Retroactive Eligibility Record.
|
3. MEDICAID /CHIP’S RETROACTIVE ELIGIBILITY
|
4. TERMINATION OF ELIGIBILITY AND RECERTIFICATION PROCESS
|
5. ELIGIBILITY PERIOD EXTENSION
|
6. ELIGIBILITY PERIOD TERMINATION
|
IV.
|
ENROLLMENT PROCESSES
|
7. DATA EXCHANGE
|
8. VALIDATION PROCESS
|
9. ENROLLMENT FILES
|
9.1 ENROLLMENT FILE [CCYYMMDD.sus]
|
a. CC = Carrier Code
|
b. YY = Year
|
c. MM = Month
|
d. DD = Day
|
e. .SUS = Identifies the file as an enrollment file. The enrollment file may contain records
belonging to any of the regions contracted by the carrier.
|
Notes:
✓
Files received at 9:00 am are entered in the ASES daily cycle.
✓
If a file is received after 9:00 am, it will be entered in the next day's cycle.
|
9.2 ELIGIBILITY FILE [VYYMMDD.ref]
|
a. V = indicates that it is an eligibility file
|
b. YY = Year
|
c. MM = Month
|
d. DD = Day
|
e. .ref = Indicates that it is a file containing the records of the beneficiaries’ eligibility.
|
9.3 DATA EXPORT FILE [RRCCYYMMDD.exp]
|
a. RR = region code
|
b. CC = carrier code
|
c. YY = Year
|
d. MM = Month
|
e. DD = Day
|
f. .exp = Indicates that it is a file containing all the eligibility and enrollment transactions processed during the daily run.
|
9.4 REJECTED ENROLLMENTS FILE [*.rjc]
|
a. CC= Carrier Code
|
b. YY = Year
|
c. MM = Month
|
d. DD = Day
|
e. .rjc= Indicates that it is a file containing the records of the beneficiaries who have been rejected.
|
Notes: ASES runs a separate edition and update cycle for each contracted region. Enrollments are filtered through various editing and verification programs and identified as valid or rejected. This process produces a file (.rjc) that contains all the records that are rejected.
|
9.5 ELIGIBILITY QUERY FILE [CCYYMMDD.qry]
|
a. CC= Carrier Code
|
b. YY=Year
|
c. MM=Month
|
d. DD=Day
|
e. .qry =Indicates that is a file for eligibility verification.
|
Notes: A '.query' file is submitted by the carriers to verify a person's eligibility for the Medicare Platino Plan and the GHIP if necessary. Consequently, ASES generates a response in a '.res' (response) file with the requested information.
|
9.6 ELIGIBILITY QUERY RESPONSE FILE [CCYYMMDD.res]
|
a. CC=Carrier Code
|
b. YY=Year
|
c. MM=Month
|
d. DD=Day
|
e. .res = Indicates that it is a query response file.
|
Notes: This file is sent by ASES in response to a query file.
|
10. GHIP BENEFICIARY ENROLLMENT
|
11. MEDICARE PLATINO ENROLLMENT PROCESS
|
(1) |
Query:
through a file (".query"), the carrier requests a verification of a beneficiary’s eligibility for the Medicaid Office.
|
(2) |
Response:
ASES processes this query file and sends a response to the request in a file (.res). This file includes information regarding the beneficiary’s eligibility for the Medicaid Office, Medicaid Office specification for which the beneficiary is eligible (federal or local), and the data that identifies the beneficiary in the database, both at Medicaid Office and ASES.
|
(3) |
Platino Product Enrollment:
If the beneficiary is eligible for Medicaid coverage and has Medicare Part A and Part B benefits (dual-eligible beneficiary), the carrier will complete an enrollment record that will include data corresponding to the health plan under which the beneficiary is to be enrolled.
|
(4) |
Enrollment Update:
Subsequently, ASES will edit and update the data in the electronic enrollment record to identify the individual as a Platino Medicare beneficiary using CMS data file in monthly based. A daily eligibility file is then sent to the carrier that contains the data that shows the beneficiary's enrollment to Medicare Platino.
|
(5) |
Rejected Enrollments:
The enrollment records sended by carriers, are evaluated. If the enrolment file contain errors will be returned to the carriers for corresponding corrections.
|
12. RETROACTIVE ENROLLMENT
|
PLAN
|
RETROACTIVITY
|
|||
Eligibility
|
Enrollment
|
|||
Yes
|
No
|
Yes
|
No
|
|
Federal GHIP
(Medicaid and CHIP)
|
✓
(Up to Three (3) months)
|
✓
(3)
months
|
||
State GHIP
(State Population)
|
✓
|
✓
(3)
months
|
||
Platino
(65 years old, disabled, dual)
|
✓
(3)
months
|
✓
(6-18)
months
|
13. ENROLLMENT RECORD
|
Code
|
Plan
|
01
|
State (Commonwealth Population) y Federal (Medicaid or CHIP).
|
02
|
Platino SNP (Special Needs Plan).
|
14. ENROLLMENT RECORD FIELDS
|
TRAN_ID
|
CARRIER
|
Plan_Type
|
VERSION
|
Primary
Center
|
PCP1
|
PCP2
|
E
- New Enrollment
|
Y
|
Y
|
Y
|
Y
|
Y
|
O
|
C
- Change Carrier
|
Must be
different
from ASES DB
|
Y
|
Y
|
Y
|
Y
|
O
|
P
- Plan Change
|
Must be
the same
as in ASES DB
|
Must be
different
from ASES DB
|
Y
|
Y
|
Y
|
O
|
V
- Version Change
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
different
from ASES DB
|
Y
|
Y
|
O
|
I
- Change Primary Medical Group
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
different
from ASES DB
|
Y
|
O
|
1
- Change PCP1
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Y
|
N
|
2
- Change PCP2
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
N
|
Y
|
3
- Change PCP1 & PCP2
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Must be
the same
as in ASES DB
|
Y
|
Y
|
Region Name
|
Region Codes
Used in the Data
|
Region Codes
Used for the Filenames
|
North
|
A
|
AR
|
Metro-North
|
B
|
BA
|
East
|
E
|
ES
|
Northeast
|
F
|
FA
|
San Juan
|
J
|
SJ
|
Southeast
|
G
|
GU
|
Southwest
|
S
|
SO
|
Special
|
P
|
PX
|
West
|
Z
|
MA
|
a. |
Reject Identifier
- As a result of the validations, the record could be accepted or rejected. This field contains the codes that specify the result of said validation.
|
15. REJECTION OF AN ENROLLMENT RECORD
|
16. REJECTED ENROLLMENTS MANAGEMENT
|
(1)
|
Receipt of rejected enrollment records;
|
(2)
|
Evaluation of rejection codes received;
|
(3)
|
Identification of situations in which rejection is not clear for consultation with ASES;
|
(4)
|
Timely correction of identified errors;
|
(5)
|
Transfer of the corrected records to ASES in a 24 hour period.
|
17. ERROR CODES
|
18. NEW ERROR CODES UNDER MAGI
|
19. ERROR CODES TABLE
|
Error Code
|
Error Message
|
Additional Description
|
Possible Corrective Actions
|
011
(Record Type)
|
Invalid Record Type Code.
|
This field is required to be filled with code “E” in every case.
|
Fill with code “E”.
|
021
(Tran_ID)
|
Tran_ID field is blank.
|
This field is required to be filled with information about the type of transaction being processed.
|
Fill this field with the corresponding code.
|
022
(Tran_ID)
|
Invalid “Tran ID”.
|
An invalid transaction code has been identified.
|
Fill this field with a valid transaction code.
|
023
MAGI
|
If the field “Special Enroll” has been filled with code “T”, then the field “Tran_ID” should contain code “E” for new enrollments or code “C” if the transaction is about a carrier change.
|
For retroactive transactions (“T”), the field Tran_ID should be filled with code “E” or “C”, accordingly.
|
Verify and correct the information contained in the field.
|
031
(Process_ Date)
|
Process date field is blank.
|
||
032
(Process_Date)
|
Invalid process date.
|
||
033
(Process_Date)
|
Except for the cases about newborns, for GHIP transactions, the process date should be lesser or equal to the effective date of the new enrollment or the change that is notified and greater or equal to three months before the effective date.
|
For GHIP (Plan Type = 01) the process date should be lesser or equal to the effective date of the new enrollment or the change notified. The process date should fall within three (3) months before the effective date.
|
Compare the process date with the effective date of the new subscription or the change about the record notified.
|
082
(Member_SSN)
|
The beneficiary’s social security number does not contain nine (9) characters.
|
Verify this information and provide the beneficiary’s social security number.
|
091
(Member_Suffix)
|
The information related to the suffix that identifies the beneficiary is required and the corresponding field is blank.
|
Provide the suffix that identifies the beneficiary.
|
|
092
(Member_Suffix)
|
The suffix that identifies the beneficiary that was provided by the carrier does not contain two (2) characters.
|
Provide the two (2) characters suffix that identifies the beneficiary.
|
|
093
(Member_Suffix)
|
The suffix that identifies the beneficiary was not found in the ASES eligibility records databases under the region and family identifier specified.
|
A record for the beneficiary’s suffix was not found, under the region and family identifier specified, in the ASES database.
|
Verify that the suffix assigned in the carrier’s database concurs with the one registered in the ASES database. If the “Family_ID” contains an error this error code will appear.
|
101
(Effective_Date)
|
The effective date information is required and the field is blank.
|
Provide the effective date.
|
|
102
(Effective_Date)
|
Invalid Effective Date.
|
Provide a valid effective date.
|
|
103
(Effective_Date)
|
For new enrollments under a GHIP plan, the effective date should be before the daily run date (“Run Process Date”) at ASES.
|
For a new enrollment under the GHIP plan (Plan Type=01) and Tran_ID=E the effective date should be before the daily run date at ASES. It is presumed that a beneficiary has been enrolled with the carrier before the enrollment record has been sent to ASES. The new enrollments should not be sent with future effective dates.
|
Verify the dates and proceed to correct.
|
104
(Effective_Date)
|
For transactions related to the GHIP plan (Plan Type=01) which “Tran_ID” is not “1”, “2”, “3”, “E”, “O” o “D”,
the effective date should be after the enrollment process date and it should be on the first of the following month.
Only applies to GHIP plans and only when the transaction is not about a PCP change, a new enrollment or a disenroll (“D”).
|
For transactions related to the GHIP plan (Plan Type=01) which “Tran_ID” is not “1”, “2”, “3”, “E”, “O” o “D”, the effective date should be after the process date and it should be on the first of the following month after the process date at ASES.
|
Verify the dates and proceed to correct.
|
105
(Effective_Date)
|
The Platino plans enrollment effective date that does not have Tran_ID “1”, “2”, “3" or "D", should be on the first of the month of the beneficiary’s enrollment.
|
Verify that the Platino enrollment effective date is on the first of the month of the beneficiary’s enrollment.
|
|
106
(Effective_Date)
|
For a disenrollment transaction (TRAN_ID=”D”), the transaction effective date should be on the first of the following month.
|
||
107
(Effective_Date)
|
The enrollment effective date of the transaction sent should fall within the family group’s last eligibility period.
|
The eligibility of the family, to which the beneficiary corresponds, was cancelled after the effective date of the enrollment sent.
|
These cases will be submitted as candidates for enrollment in the historical data under the enrollment system (SYSPREM).
|
109
MAGI
(Effective_Date)
|
A code ‘T’ was not included in the ‘Special Enroll’ field and a SYSRETRO record, specifying an eligibility period that covers the enrollment effective date sent by the carrier, has been identified.
|
A code ‘T’ was not included in the ‘Special Enroll’ field for an enrollment that corresponds to a SYSRETRO period.
|
Verify if the transaction is about a retroactive enrollment under MAGI. If that is the case, include code “T” in the “Special Enroll” field.
|
10A
(Effective_Date)
Emergencias
|
If the field “Special_Enroll” =”E”, then,
for
GHIP beneficiaries funded through state funds
,
the effective date should be greater or equal than the Certification Date. For federally funded GHIP beneficiaries (Medicaid and CHIP), the Effective Date should be greater or equal than the Eligibility Effective Date.
|
For emergency cases the effective date cannot be before the certification date (State funded GHIP) or the eligibility effective date (Federally GHIP, Medicaid and CHIP).
|
Verify the effective dates and certification date and proceed to correct.
|
10B
(Effective_Date)
|
If the field “Special_Enroll” =”N”, the effective date should be greater or equal than the beneficiary’s birth date and it should not surpass the period of a year calculated from the birth date.
|
The newborn enrollments’ effective date cannot be before the birth date nor can it extend for more than one (1) year calculated from the birth date.
|
Verify that the effective date concurs with the birth date and that it does not surpass the period of one (1) year calculated from the birth date.
|
111
(Plan_Type)
|
The Plan Type code is required and the field is blank.
|
Include the required information related to the Plan Type.
|
|
112
(Plan _Type)
|
The provided Plan Type code does not contain two (2) characters.
|
Verify and provide the corresponding Plan Type code.
|
|
113
(Plan_Type)
|
The provided Plan Type, Carrier Code and Plan Version are incorrect.
|
The enrollment records are required to correspond with the Plan Type and Plan Version contracted with ASES by the carrier.
The Plan Version code, for Platino plans, should concur with the Plan Version code assigned by ASES; for GHIP plans, this code should equate to the coverage code assigned by the Medicaid Office.
|
Verify this information and correct.
|
114
(Plan_Type)
|
For disenrollment transactions (Tran_ID =”D”), code “01” (GHIP) should be included in the “Plan Type” field.
|
Verify the transaction type and include code 01 (GHIP) in the Plan Type field.
|
|
121
(Plan_Version)
|
The Plan Version code is required and the field is blank.
|
Include the information corresponding with the Plan Version.
|
|
122
(Plan_Version)
|
The Plan Version code does not contain three (3) characters.
|
Verify the information and provide the three (3) characters code corresponding to the Plan Version.
|
174
(PCP2_Effective Date)
|
Barring new enrollment transactions, the PCP2 effective date should concur with the first day of the month following the notification of the change.
|
For transactions about a PCP2 change, the PCP2 effective date should be on the first day of the month following the notification of the change.
|
Verify that the PCP2 effective date is on the first day of the month following the notification of the change.
|
175
(PCP2_Effective Date)
|
If the PCP2 field is not blank, the field corresponding with the PCP1 effective date should not be blank and vice versa.
|
When there is data in the PCP2 field, there should be a valid date in the PCP2 effective date field and vice versa.
|
Verify the related fields and proceed to include the missing information.
|
176
(PCP2_Effective Date)
|
If the transaction is about a disenrollment (Tran_ID=”D”), then the PCP2 effective date field should be blank.
|
Verify the transaction type and remove any PCP2 information that is not required.
|
|
177
(PCP2_Effective Date)
|
It has been identified that the beneficiary is already enrolled with another carrier for a date equal or after the Effective Date of the enrollment sent. This error applies to cases of new enrollment and carrier change.
|
The beneficiary is already enrolled at ASES with another carrier for a date equal or after the effective date of the enrollment sent.
|
Verify that the effective date sent to ASES corresponds with the appropriated date.
|
178
(PCP2_Effective Date)
|
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP2 field is not blank, the PCP2 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','2','3', in which the PCP2 field is not blank, the PCP2 effective date should be greater or equal than the existing enrollment effective date.
|
For enrollments having Tran_ID 'E','C' or 'I', in which the PCP2 field is not blank, the PCP2 effective date should be equal to the effective date of the enrollment to be applied. For enrollments having Tran_ID 'P','V','2','3', in which the PCP2 field is not blank, the PCP2 effective date should be greater or equal than the existing enrollment effective date.
|
Verify the provided PCP2 effective date.
|
181
(Family_Primary_
Center)
|
For GHIP plans, it is required to provide information about the Family Primary Medical Group.
|
For GHIP plans, the information about the Family Primary Medical Group is required.
|
Include the corresponding Primary Medical Group code for the corresponding Family.
|
182
(Family_Primary_
Center)
|
The transaction did not require information about the Family Primary Medical Group and information was provided for said field.
|
Verify the transaction type and remove the information not required from the corresponding field.
|
|
183
(Family_Primary_
Center)
|
If the transaction is about a disenrollment (Tran_ID=”D”), the Primary Medical Group field should be blank.
|
The transaction is about a disenrollment “D” and there is information in the Primary Medical Group field.
|
Verify the transaction type and remove the information not required from the PMG field.
|
20. DISENROLLMENT (Cancellation)
|
21. GHIP DISENROLLMENT (Cancellation)
|
GHIP Disenrollment Reason
|
GHIP Disenrollment Effective Date
|
Notified by ASES (not notified on the last business day of the month).
|
Date Specified in the ASES Disenrollment Notification.
|
Notified by ASES (on the last business day of the month).
|
First day of the following month.
|
Requested by Beneficiary or Carrier.
|
No later than the first day of the second month in which the Carrier or Beneficiary has requested disenrollment.
|
Death of the Beneficiary
|
Federal and state funded Commonwealth beneficiaries are disenrolled from the first day after death.
|
Move of the Beneficiary.
|
Since the contract covers all regions on the island any move within the island has no impact. If the move causes a change of region, then the effective date is the date notified by Medicaid.
|
Beneficiary moved outside of Puerto Rico.
|
Federal and state funded Commonwealth beneficiaries will be disenrolled as of the first day of ineligibility as notified by the Medicaid Office.
|
Incarceration of the Beneficiary
|
Federal and state funded Commonwealth beneficiaries will be disenrolled as of the first day of ineligibility as notified by the Medicaid Office.
|
After completing the pregnancy and post-natal care eligibility extension
|
If at re-certification a woman becomes ineligible for GHIP and is pregnant, the eligibility is extended for 60 days after the baby is born or after a pregnancy loss.
|
22. MEDICARE PLATINO DISENROLLMENT
|
Reason for Disenrollment
|
Effective Date of Disenrollment
|
Death of the Beneficiary
|
First day after death.
|
Incarceration of the Beneficiary
|
First day of ineligibility as notified by Medicaid.
|
Beneficiary enters or stated in a residential institution under circumstances which rendered the individual ineligible for enrollment in Medicare Advantage, including when an enrollee is admitted to the hospital that (1) is certified by Medicare as a long term care hospital and (2) has an average stay for all patients greater than ninety-five (95) days.
|
First day of ineligibility as notified by Medicaid.
|
Beneficiary enrollment while being eligible
|
Effective Date of Enrollment in the Platino Plan Carriers.
|
Move of the Beneficiary.
|
Since the contract covers all regions on the island any move within the island has no impact.
|
Beneficiary moved outside of Puerto Rico.
|
First day of ineligibility as notified by Medicaid.
|
Expedite Disenrollment: - Urgent Medical Need
|
First day of the next month after determination except where medical need requires an earlier disenrollment.
|
Expedite Disenrollment: - Non-consensual enrollment
|
Retroactive to the first day of the month
|
Expedite Disenrollment: - Disenrollment from the carrier Medicare Platino
|
Concurrent with the Effective Date of Disenrollment from the carrier Medicare Advantage Product.
|
23. UPDATES TO NEW ENROLLMENTS AND ENROLLING OMITTED BENEFICIARIES
|
24. CARRIERS RESPONSIBILITIES IN THE ENROLLMENT PROCESSES
|
V.
|
PREMIUM PAYMENT
|
25. PREMIUM PAYMENT
|
26. TYPES OF PAYMENT
|
(1)
|
If the beneficiary is not enrolled in the ASES databases on the first day of the month for which the payment transaction is being executed;
|
(2)
|
If the beneficiary is enrolled on a date after the date of payment;
|
(3)
|
If the enrollment had been rejected by ASES and a new enrollment was not submitted by the carrier with the relevant corrections (4) If from of the ASES eligibility data arises that the beneficiary had a cancellation or changed the carrier
|
VI.
|
SYSPREM ENROLLMENT IN HISTORICAL DATA
|
27. SYSPREM: ENROLLMENT IN HISTORICAL DATA
|
(1)
|
The month in which the beneficiary was enrolled with a different carrier,
|
(2)
|
The month in which the beneficiary is cancelled or
|
(3)
|
Until the date of current billing.
|
Code
|
Primary Error Description
|
107
|
Effective Date prior to the current family eligibility period.
|
108
|
Effective date prior to the current beneficiary eligibility period.
|
280
|
The family must be eligible in the current eligibility data.
|
281
|
The beneficiary must be eligible in the current eligibility data.
|
177
|
Enrolled with another carrier on or after the effective date.
|
Code
|
Secondary Error Description
|
083
|
Social Security Number Not Found.
|
093
|
Suffix not found.
|
132
|
MPI Not Found.
|
222
|
Currently enrolled with the same carrier
|
223
|
Currently enrolled with another carrier
|
225
|
Incorrect Social Security Number
|
226
|
Incorrect MPI Number
|
22F
|
Error found in other beneficiaries of the family (GHIP).
|
Code
|
New Error Codes Description
|
996
|
Sysprem record successfully inserted in history.
|
980
|
The Process Date of the enrollment record must be greater than the Process Date of the previous enrollment record for the beneficiary who appears previously enrolled for the month corresponding to the Effective Date of the enrollment.
|
981
|
The beneficiary must not have beneficiaries of his family with errors not acceptable by SYSPREM in the same enrollment file.
|
982
|
The enrollment record must not have an Effective Date prior to 01/01/2006.
|
983
|
Enrolled in history for the Effective Date of the enrollment record.
|
984
|
It is a New Enrollment, the Effective Date is not first of the month and the beneficiary is already subscribed in another carrier at the Effective Date specified.
|
985
|
It is a New Enrollment and the Effective Date should be at least as recent as the beneficiary’s Certification Date at the specified Effective Date.
|
986
|
For SYSPREM processing, the Enrollment Effective Date should be before the Effective Date of the current enrolled record at the ASES databases.
|
Enrollment Manual
|
67
|
Region
|
Contracted PMPM
|
|||
Metro-North
|
$
|
183.38
|
||
West
|
$
|
148.99
|
|
PUERTO RICO HEALTH INSURANCE ADMINISTRATION
COMMONWEALTH OF PUERTO RICO
PLANNING AND QUALITY AFFAIRS OFFICE
|
|
TABLE OF CONTENTS
|
I.
|
INTRODUCTION
|
1
|
II.
|
REPORTING TIMEFRAMES
|
2
|
III.
|
EVALUATION & POINT DISTRIBUTION
|
2
|
IV.
|
RETENTION FUND & COMPLIANCE PERCENTAGE
|
3
|
V.
|
DEFINITIONS
|
4
|
VI.
|
PERFORMANCE MEASURES
|
5
|
VII.
|
PREVENTIVE CLINICAL PROGRAMS
|
12
|
A.
|
DISEASE MANAGEMENT PROGRAM
|
12
|
B.
|
PHYSICIAN INCENTIVE PLAN
|
16
|
VIII.
|
ER QUALITY INITIATIVE PROGRAM
|
16
|
IX.
|
CONCLUSION
|
17
|
X.
|
APPENDIX A
|
18
|
I. |
INTRODUCTION
|
• |
Performance measures (Section 12.5.4.1)
|
• |
Preventive Clinical Programs (Section 12.5.4.2)
|
✓ |
Physician Incentive Program
|
✓ |
Disease Management Program
|
• |
Emergency Room Use Indicators (Section 12.5.4.3)
|
II.
|
REPORTING TIMEFRAMES
|
Quarter
|
Incurred Service Time Period
|
Payment as of:
|
Submission Date
|
Baseline Data Analysis: Calendar Year 2016*
|
August 30, 2017
|
||
Q1
|
7/1/2017 through 9/30/2017
|
December 31, 2017
|
January 30, 2018
|
Q2
|
10/1/2017 through 12/31/2017
|
March 31, 2018
|
April 30, 2018
|
Q3
|
1/1/2018 through 3/30/2018
|
June 30, 2018
|
July 30, 2018
|
Q4
|
4/1/2018 through 6/30/2018
|
September 30, 2018
|
October 30, 2018
|
III.
|
EVALUATION & POINT DISTRIBUTION
|
• |
2 Points = Full compliance with expected goal, meets or exceeds (90%-100%) expected goal as define in the QIP Manual.
|
• |
1 point = Partial compliance, results reported are 70% or over but less than 90% (70.00% - 89.99%) of the established goal.
|
• |
0 point = Fails; results reported are less than 70% (0% - 69.99%) of the established goal.
|
• |
1 Points = Full compliance with expected goal, meets or exceeds (90% - 100%) expected goal as define in the QIP Manual.
|
• |
O.5 point = Partial compliance, results reported are 70% or over but less than 90% (70.00% - 89.99%) of the established goal.
|
• |
0 point = Fails; results reported are less than 70% (0% - 69.99%) of the established goal.
|
Program
|
Points
|
Performance Measures
|
16
|
Preventive Clinical Programs
|
31
|
ER Quality Incentive Program
|
5
|
IV.
|
R
ETENTION FUND & COMPLIANCE PERCENTAGE
|
Compliance Percent
|
Disbursement Percentage of Monthly PM/PM
|
100-90%
|
100%
|
89.9-80%
|
75%
|
79.9-70%
|
50%
|
69.9 and below %
|
0%
|
V.
|
DEFINITIONS
|
1. |
Disease Management:
An administrative function comprised of a set of Enrollee-centered steps to provide coordinated care to Enrollees suffering from diseases listed in Section [7.8.3] of the Contract.
|
2. |
Hot Spotting:
The ability to identify in a timely manner heavy users of the systems and their patterns of utilization to provide targeted interventions and care through mapping data.
|
3. |
Incurred date
: Is the date in which the service was provided.
|
4. |
Intervention:
activities targeted at the achievement of client stability, wellness, and autonomy through advocacy, assessment, planning, communication, education, resource management, care coordination, collaboration, and service facilitation.
|
5. |
Performance measures
: periodic measurement of outcomes and results used to assess the effectiveness and efficiency of quality initiatives on selected indicators.
|
6. |
Per member per month payment (PMPM):
The fixed monthly amount that the MCO is paid by ASES for each enrollee to ensure that benefits under the Contract are provided. This payment is made regardless of whether the enrollee receives benefits during the period covered by the payment.
|
7. |
Preventive Services
: Health care services provided by a physician or other provider within the scope of his or her practice under Puerto Rico law to detect or prevent disease, disability, behavioral health conditions, or other health conditions; and to promote physical and behavioral health and efficiency.
|
8. |
Primary Care Physician:
A licensed medical doctor (MD) who is a provider and who, within the scope of practice and in accordance with Puerto Rico Certification and licensure requirements, is responsible for providing all required primary care to enrollees. The PCP is responsible for determining services required by enrollees, provides continuity of care, and provides referrals for enrollees when medically necessary. A PCP may be a general practitioner, family physician, internal medicine physician, obstetrician/gynecologist, or pediatrician.
|
9. |
Retention Fund
: The amount of withhold by ASES of the monthly Per Member
per
Month Payments otherwise payable to the MCO in order to incentivize the MCO to meet performance targets under the Quality Incentive Program described in Section [12.5.3]. This amount shall be
equal to
the percent of that portion of the total Per Member
per
Month Payment that is determined to be attributable to the MCO’s administration of the Quality Incentive Program described in Sections [12.5 and 22.3]. Amounts withheld will be reimbursed to the MCO in whole or in part (as set forth in Sections [12.5 and 22.3]) in the event of a determination by ASES that the MCO has complied with the quality standards and criteria established by Section [12.5].
|
10. |
Special Coverage:
A component of Covered Services provided by the MCO, described in Section [7.7], which are more extensive than the Basic Coverage services, and for which Enrollees are eligible only by “registering.” Registration for Special Coverage is based on intensive medical needs occasioned by serious illness.
|
11. |
Quality Incentive Program
: mechanism to improve the quality of services provided to Enrollees. The program shall consist of three (3) categories of performance indicators: performance measures, preventive clinical program measures and ER Utilization measures.
|
12. |
Active Member
: GHP member with
continuous
enrollment during the measurement quarter.
|
VI.
|
PERFORMANCE MEASURES
|
Page
5
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
Cervical Cancer
|
|
Definition for Baseline
|
Total of women 21–64 years of age who were not screened for cervical cancer the year prior to the
measurement year
.
|
Numerator
|
The number of active women in the denominator with a cervical cancer screening during the measurement year.
|
Denominator
|
Indicate the number of active women without a Cervical cancer screening the year prior to the measurement period for whom the screening has not been performed during previous quarters.
|
Codes
|
ICD-10-CM Diagnosis: Z12.4
CPT CODES: 88141-88143, 88147, 88148, 88150, 88152-88154, 88164-88167, 88174, 88175
HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
|
Cholesterol Management
|
|
Definition for Baseline
|
Total members 18-75 years with a high risk diagnose who have not had a LDL-C test during year prior to the measurement period.
|
Numerator
|
Numerator 1: Indicate the number of active members in the denominator with Diabetes Mellitus and a LDL-C test done during the measurement period.
Numerator 2: Indicate the number of active members in the denominator with a Cardiovascular Condition and a LDL-C test done during the measurement period.
Numerator 3: Indicate the number of active members in the denominator with Arterial Hypertension and a LDL-C test done during the measurement year.
|
Denominator
|
Denominator 1: Indicate the number of active members with Diabetes Mellitus and without a LDL-C test done the year prior to the measurement year
for whom the screening has not been performed during previous quarters.
Denominator 2: Indicate the number of active members with a Cardiovascular Condition and without a LDL-C test done the year prior to the measurement year for whom the screening has not been performed during previous quarters.
Denominator 3: Indicate the number of active members with Hypertension and without a LDL-C test done the year prior to the measurement year for whom the screening has not been performed during previous quarters.
|
Codes
|
ICD-10-CM Diagnosis: Z13.220 & Codes for DM (E10 y E11), CVD (I70, II75), HBP (I10, I11, I12, I13, I15)
CPT CODES: 80061 - Lipid Panel, 82465 Cholesterol, 83718 HDL Cholesterol, 83719 LDL, 83721 VLDL, 84478 Triglycerides , 83698 Lipoprotein Associated Phospholipase A2, 83700 Lipoprotein, blood; electrophoretic, 83704 quantitation of lipoprotein particle numbers and lipoprotein subclasses when measured.
|
Page
6
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
Access to Preventive Care Visits
|
|
Definition for Baseline
|
Total members who have not had at least one preventive care visit with a PCP
the year prior
during the measurement period.
|
Numerator
|
The number of active members in the denominator with a preventive care visit with a PCP during the measurement period.
|
Denominator
|
Indicate the number of active members without a preventive care visit with a PCP the year prior to the measurement period for whom the screening has not been performed during previous quarters.
|
Codes
|
ICD-10-CM Diagnosis
"General Medical Exam:Z00.00, Z00.01, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9 "
ICD-10-CM Procedure Other Exams: Z00.5, Z00.8, Z02.0, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9
CPT CODES: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 9938199387, 99391-99397, 99401-99404, 99411, 99412, 99214, 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
HCPCS G0402, G0438, G0439, G0463, T1015
|
Page
8
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
Follow up after Hospitalization for Mental Health
|
|
Definition for Baseline
|
Percent of members who were discharge of acute mental health care facility and were seen on an outpatient basis by a psychiatrist or a physician within thirty days after discharge.
|
Numerator
|
The number of discharges in the denominator followed by an outpatient encounter with a psychiatrist or a physician within thirty days after discharge. (This amount shall include visits performed 30 days after the end of the quarter.)
|
Denominator
|
The number of discharges from an acute mental health care facility during the quarter.
|
Codes
|
ICD-10 F32.0 – F32.4, F32.9, F33.0-F33.3, F33.41, F33.9
|
VII.
|
PREVENTIVE CLINICAL PROGRAMS
|
A.
|
DISEASE MANAGEMENT PROGRAM (7.8.3 OF THE CONTRACT)
|
a. |
Improve the health of persons with specific chronic conditions and
|
b. |
Reduce health care service use and costs associated with avoidable complications, such as emergency room visits and hospitalizations.
|
Page
12
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
DM Condition
|
Baseline
|
Numerator
|
Denominator
|
DM1. Asthma (Bronchial Asthma)
|
Calendar year 2016 Members with the diagnosis of Asthma in the category of severe
|
Total number of active members with the diagnosis of Asthma in the category of severe who are participants of the DM Program in the measurement period.
|
Number of active members with the diagnosis of Asthma in the category of severe as identified in the baseline.
|
DM2. Diabetes Mellitus (Type 1 or 2)
|
Calendar year 2016 Members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe
|
Total number of active members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe who are participants of the
DM
Program
in the
measurement period
|
Number of active members with the diagnosis of Diabetes Mellitus (Type 1 or 2) in the category of severe as identified in the baseline.
|
DM3. Congestive Heart Failure
|
Calendar year 2016 Members with the diagnosis of Congestive Heart Failure in the category of severe
|
Total number of active members with the diagnosis of Congestive Heart Failure in the category of severe who are participants of the DM Program in the measurement period
|
Number of active members with the diagnosis of Congestive Heart Failure in the category of severe as identified in the baseline.
|
DM4. Arterial Hypertension
|
Calendar year 2016 Members with the diagnosis of Arterial Hypertension in the category of severe
|
Total number of active members with the diagnosis of Arterial Hypertension in the category of severe who are participants of the DM Program in the measurement period
|
Number of active members with the diagnosis of Arterial Hypertension in the category of severe as identified in the baseline.
|
DM5. Major Depression (DEP)
|
Calendar year 2016 Members with the diagnosis of Major Depression in the category of severe
|
Total number of active members with the diagnosis of Major Depression in the category of severe who are participants of the DM Program in the measurement period.
|
Number of active members with the diagnosis of Major Depression in the category of severe as identified in the baseline.
|
Page
13
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
B.
|
UM Metrics
|
• |
Improve the delivery of care to members for preventive services and chronic conditions • Align with national quality measures such as those of the Centers for Medicare & Medicaid Services (CMS) and National Committee for Quality Assurance (NCQA).
|
• |
Improve patient Care coordination
|
• |
Electronic Health Record (EHR)
|
1. |
Evaluate 100% of the PCPs (with 100 lives as minimum) through Medical Record Review for compliance with clinical and administrative performance measures identified by the Health Plan.
|
§ |
The MCO will submit quarterly the reports on the number of PCP eligible by region and those scores obtained on the reported quarter.
|
2. |
The MCO shall ensure at a minimum seventy percent (70%) of PCP will be in compliance with eighty percent (80%) scorecard on those indicators approved by ASES and included in the Health Plan Audit during the Contract year.
|
§ |
MCO will provide a list by PMG and by region of the certified PCP eligible for the financial incentive that received the preventive services auditing with the percentage of compliance for each PCP evaluated during the reporting period.
|
VIII.
|
ER QUALITY INITIATIVE PROGRAM
|
1. |
Educational campaign to educate consumers about healthcare options available to them when a primary care physician isn’t available. The intent of the campaign is to let consumers know the emergency room is not the only alternative when seeking treatment. Options include retail health clinics, walk-in doctor's offices and urgent care centers – all of which, officials say, can provide the same care in less time and less out-of-pocket expense than an ER visit.
|
2. |
One on One Care management interventions
|
3. |
PCPs interventions on identifying high users or potential high users of ER services.
|
4. |
Changes on access to urgent care at PCP offices with extended hours or urgent clinics.
|
1. |
Through a timely and accurate Hot Spotting Report all MCOs will provide ASES the demographic characteristics and PMG information of identified High ER Utilizers by severity level (1 point):
|
Severity Criteria ER Visits
|
|
Level 1: Mild
|
3-6 visits a year
|
Level 2: Moderate
|
7-11 visits a year
|
Level 3: Severe
|
12 or more visits a year
|
2. |
Ambulatory Visits Rate (2 points):
|
• |
Total Number of Non-Emergency Ambulatory Visits incurred by Active Severe ER Utilizers / Total members on Active Severe ER Utilizers
|
3. |
Annualized ER Rate on frequent ER users (2 points):
|
• |
Total Number of ER Visits incurred by members with 7 or more ER Visits / Total members with 7 or more ER Visits x 1,000
|
• |
Baseline: Calendar year 2016: Annual rate per thousand of ER visits of members in moderate and severe categories
|
IX
|
CONCLUSION
|
X
|
APPENDIX A
|
1. |
Asthma (Bronchial Asthma) Member Identification Criteria:
|
Page
18
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
Severity
|
Hospital
Admissions
|
ER Visits
|
Outpatient
|
Pharmacy
(Therapeutic categories)
|
Mild:
Comply with all of the following:
|
0
|
1
|
0-3
|
1
|
Moderate:
Comply with two of the following:
|
1
|
2
|
4-5
|
2
|
Severe:
Comply with at least one of the following:
|
≥2
|
≥3
|
≥6
|
≥3
combined categories at least any three months during the baseline year
|
Patients with emphysema, COPD, Chronic Bronchitis, Cystic Fibrosis and Acute Respiratory Failure
|
2. |
Diabetes Mellitus (Type 1 and 2) Member Identification Criteria
|
Diagnostic Codes
|
Medical encounters with any of the following ICD10: E10, E11, E13
|
Age
|
0-75
|
With at least one of the following events:
|
|
Medications
|
1 or more
|
ER Visits
|
1 or more
|
Hospital Admission
|
At least one hospital admission
|
Outpatient Visits
|
2 or more
|
Severity
|
Hospital
Admissions
|
ER Visits
|
Pharmacy
(Therapeutic categories)
|
Complications*
|
Mild:
Comply with all of the following:
|
0
|
0
|
1
|
0
|
Moderate:
Comply with two of the following:
|
0
|
1 o 2
|
2
|
1-2
|
Severe:
Comply with at least two of the following:
|
≥1
|
≥3
|
≥3
|
≥ 3
|
3. |
Congestive Heart Failure Member Identification:
|
Severity
|
Hospital
Admissions
|
ER Visits
|
Pharmacy
(Therapeutic categories)
|
Complications*
|
Mild:
Comply with all of the following:
|
0
|
0-1
|
0-1
|
0
|
Moderate:
Comply with two of the following:
|
1
|
2
|
2
|
1-2
|
Severe:
Comply with at least two of the following:
|
≥ 2
|
≥ 3
|
≥3
|
≥ 3
|
4. |
Arterial Hypertension Member Identification
|
Patients with I11.0, I13.0, I13.2
|
Page
22
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
5. |
Major Depression
|
Severity
|
Hospital
Admissions
|
ER
Visits
|
Pharmacy
(Therapeutic
Categories)
|
Complications*
|
Mild:
Comply with all of the following:
|
0
|
1
|
1
|
0
|
Moderate:
Comply with two of the following:
|
1
|
2
|
2
|
1-2
|
Severe:
Comply with at least one of the following:
|
≥ 2
|
≥ 3
|
≥3
|
≥ 3
|
Page
23
|
Definition reference in this manual are from the Puerto Rico Health Insurance
Administration Contract and NCQA (National Committee for Quality Assurance)
|
· |
Triple-S Salud, Inc. (“TSS”), a wholly-owned subsidiary of TSM.
|
·
|
Triple-S Advantage, Inc. (“TSA”), a wholly-owned subsidiary of TSS.
|
· |
Triple-S Vida, Inc., a wholly-owned subsidiary of TSM.
|
· |
Triple-S Propiedad, Inc., a wholly-owned subsidiary of TSM.
|
* |
Pursuant to Item 601(b)(21)(ii) of Regulation S-K, the names of other subsidiaries of Triple-S Management Corporation are omitted because, considered in the aggregate, they would not constitute a significant subsidiary as of the end of the year covered by this report.
|
1. |
I have reviewed this Annual Report on Form 10-K of Triple-S Management Corporation (“the registrant”);
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date:
|
March 7, 2018
|
By:
|
/s/
Roberto García-Rodríguez
|
|
Roberto García-Rodríguez
|
||||
President and Chief Executive Officer
|
1. |
I have reviewed this Annual Report on Form 10-K of Triple-S Management Corporation (“the registrant”);
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date:
|
March 7, 2018
|
By:
|
/s/
Juan J. Román-Jiménez
|
|
Juan J. Román-Jiménez
|
||||
Executive Vice President and Chief Financial Officer
|
a) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
b) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date:
|
March 7, 2018
|
By:
|
/s/
Roberto García-Rodríguez
|
|
Roberto García-Rodríguez
|
||||
President and Chief Executive Officer
|
a) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
b) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date:
|
March 7, 2018
|
By:
|
/s/
Juan J. Román-Jiménez
|
|
Juan J. Román-Jiménez
|
||||
Executive Vice President and Chief Financial Officer
|